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© (54) Title: GENERAL DETECTION AND ISOLATION OF SPECIFIC CELLS BY BINDING OF LABELED MOLECULES
(57) Abstract: The present invention relates to detection molecules comprising at least one binding molecule, at least one linker and
at least one label, and detection methods making use of same. The invention provides a high-throughput method for detection, isola
tion and/or identification of specific entities or cells.
General detection and isolation of specific cells by binding of labeled molecules
The application claims priority from PA 2014 0031 1 filed 13-06-2014, PA 2014 00322
filed 18-06-2014 and PA 2014 00453 filed 16-08-2014. All patent and non-patent
references cited in the present application, are hereby incorporated by reference in
their entirety.
Field of invention
The present invention relates to detection molecules comprising at least one binding
molecule, at least one linker and at least one label, and detection methods making use
of same. The invention provides a high-throughput method for detection, isolation
and/or identification of specific entities or cells.
Background of invention
The adaptive immune system is directed through specific interactions between immune
cells and antigen-presenting cells (e.g. dendritic cells, B-cells, monocytes and
macrophages) or target cells (e.g. virus infected cells, bacteria infected cells or cancer
cells). In important field in immunology relates to the understanding of the molecular
interaction between an immune cell and the target cell.
Specifically for T-lymphocytes (T-cells), this interaction is mediated through binding
between the T-cell receptor (TCR) and the Major Histocompatibility Complex (MHC)
class I or class II. The MHC molecules carries a peptide cargo, and this peptide in
decisive for T-cell recognition. The understanding of T-cell recognition experienced a
dramatic technological breakthrough when Atman et al. (1) in 1996 discovered that
multimerization of single peptide-MHC molecules into tetramers would allow sufficient
binding-strength (avidity) between the peptide-MHC molecules and the TCR to
determine this interaction through a fluorescence label attached to the MHC-multimer.
Such fluorescent-labelled MHC multimers (of both class I and class I I molecules) are
now widely used for determining the T-cell specificity. The MHC multimer associated
fluorescence can be determined by e.g. flow cytometry or microscopy, or T-cells can be
selected based on this fluorescence label through e.g. flow cytometry or bead-based
sorting. However, a limitation to this approach relates to the number of different
fluorescence labels available, as each fluorescence label serve as a specific signature
for the peptide-MHC in question.
Thus, this strategy is poorly matching the enormous diversity in T-cell recognition. For
the most predominant subset of T-cells (the αβ TCR T-cells), the number of possible
distinct αβ TCRs has been estimated at 10 15 (2) although the number of distinct
TCRs in an individual human is probably closer to 107(3). Therefore, much effort has
attempted to expand the complexity of the T-cell determination, with the aim to enable
detection of multiple different T-cell specificities in a single sample. A more recent
invention relates to multiplex detection of antigen specific T-cells is the use of
combinatorial encoded MHC multimers. This technique uses a combinatorial
fluorescence labelling approach that allows for the detection of 28 different T-cell
populations in a single sample when first published (4,5), but has later been extended
through combination with novel instrumentation and heavy metal labels to allow
detection of around 100 different T-cell populations in a single sample (6).
The requirement for new of technologies that allow a more comprehensive analysis of
antigen-specific T-cell responses is underscored by the fact that several groups have
tried to develop so-called MHC microarrays. In these systems, T-cell specificity is not
encoded by fluorochromes, but is spatially encoded (7,8). In spite of their promise,
MHC microarrays have not become widely adopted, and no documented examples for
its value in the multiplexed measurement of T-cell responses, for instance epitope
identification, are available.
Considering the above, there remains a need for a high-throughput method in the art of
detection, isolation and/or identification of specific antigen responsive cells, such as
antigen specific T-cells.
Further, there remains a need for a high-throughput method in the art of detection,
isolation and/or identification of specific entities or cells, which cells can be detected via
a binding molecule specific for said entity or cell.
Further, there remains a need in the art, considering the often limited amounts of
sample available, for methods allowing detection, isolation and/or identification of
multiple species of specific entities or cells, such as specific antigen responsive cells,
such as T-cells, in a single sample.
Summary of invention
The present invention provides a detection molecule comprising a binding molecule
(BM), a linker (Li) and a label (La). Said detection molecule can be used in various
methods, such as methods comprising one or more steps of recognizing at least one
entity or cell, binding at least one entity or cell, detecting at least one entity/cell-
detection molecule complex, isolating at least one entity/cell-detection molecule
complex and/or identifying one or more detection molecules bound to at least one
entity/cell.
It is an aspect of the invention to provide a detection method comprising the steps of
1. Combining a sample with at least one detection molecule; wherein the detection
molecule comprises a binding molecule (BM), a linker (Li), and a label (La); and
wherein said sample comprises at least one cell and/or entity,
2 . Incubating the at least one detection molecule and the sample;
3 . Isolating and/or detecting the at least one detection molecule of step b), and
4 . Optionally determining the identity of the at least one detection molecule of step
c).
A binding molecule is a molecule that specifically associates covalently or non-
covalently with a structure belonging to or associated with an entity in a sample. The
defined structure in sample bound by a binding molecule is also called the target
structure or target of the binding molecule.
The label comprised in the detection molecule of the present invention is any molecule,
atom or signal the identity of which can be found or determined by any means. The
label is unique and specific for a certain detection molecule, or set of detection
molecules, and enables the isolation, detection and/or identification of the identity of
said detection molecules (or cell-detection molecule complexes). In a particular
embodiment the label is a nucleic acid label, such as a DNA label,
The linker comprised in the detection molecule of the present invention is a molecular
entity and/or bond that connect the binding molecule and the label of the detection
molecule.
The present invention describes the use of labels, preferably nucleic acid labels
(comprising a barcode sequence) as specific labels for binding molecules such as
MHC multimers to determine e.g. the antigen responsiveness in biological samples.
After cellular selection the barcode sequence of the label can be revealed by e.g.
sequencing. This technology allows for detection of multiple (potentially >1000)
different antigen-specific cells in a single sample.
Description of Drawings
Figure 1. Structure of detection molecules. (A) Structure of a detection molecule, in
which the "binding molecule" comprises n pMHC complexes, where n can be any
integer between 1 and 1000. (B) Structure of a detection molecule, comprising
"binding molecule", label and the linker connecting the binding molecule and the label.
The lower half of the figure shows the symbols representing the DNA tag (also called
the oligonucleotide or oligonucleotide tag), the linker connecting binding molecule and
label, MHC (major histocompatibility complex), peptide or other molecule (that binds to
the MHC complex), pMHC (peptide-major histocompatibility complex), and the binding
molecule (BM).
Figure 2 . Isolation and detection of detection molecules capable of binding to cells. The
different steps of the method is outlined. In the depicted method the label of the
detection molecule is an oligonucleotide. In Step 1 cells and "molecule library" (2 -1015
detection molecules) is mixed. In Step 2 the cells and detection molecules are
incubated, allowing none, some or all of the detection molecules to bind cells, and vice
versa, allowing none, some or all of the cells to bind detection molecules. In step 3 the
cell-detection molecule complexes are isolated, enriched for or detected. In the
depicted approach, cells are spun down, having the effect of spinning detection
molecules bound to the cells down as well. In Step 4 the detection molecules that
bound to cells in step 3 (and therefore were co-precipitated with the cells) are
identified. In the example the label consists of an oligonucleotide. Therefore, by PCR
amplification of the oligonucleotide labels, followed by e.g. polyacrylamide gel
electrophoresis to distinguish labels with different migration in the gel, the labels may
be identified and thereby the detection molecules (and the identity of the corresponding
binding molecules) can be identified. Alternatively, the oligonucleotide labels are
identified by sequencing, directly from the precipitate of step 3 , or following
amplification of the oligonucleotides in the precipitate by e.g. PCR.
Figure 3 . Generation of barcode-labeled MHC multimers.
Figure 3 describes how peptide-MHC molecules, nucleic acid (DNA)-barcodes and
(optional) fluorescent labels are assembled to form a library of MHC multimers each
holding a DNA-barcode specific for the given peptide-MHC molecule involved. Figure
3A: The barcode is designed to have a unique sequence that can be determined
through DNA sequencing. Also the barcode have shared amplification ends, enabling
amplification of all DNA-barcodes simultaneously in a PCR reaction. DNA-barcodes are
attached to the MHC-multimerization backbone (e.g. via a biotin linker binding to
streptavidin on the multimer backbone). Figure 3B: Represents the multimer
backbone. This may be any backbone that allow multimerization of macro-molecules.
The backbone may (optionally) hold a fluorescence label (illustrated by the asterisk) to
track the total pool of MHC multimer binding cells irrespectively of the peptide-MHC
multimer specificity. Fig 3C: Represents the peptide-MHC molecule of interest,
carrying a specific peptide cargo (horizontal line). Figure 3D: Represents the
assembled peptide-MHC mulitimers carrying the DNA barcode.
Figure 4 . Generation of a library of barcode labelled MHC multimers (Composition).
Fig 4 illustrates the generation of a full barcode library. Fig 4A: This library is
composed of multiple, potentially more than 1000 different peptide-MHC multimers,
each with a specific DNA-barcode. Such that barcode#1 codes for peptide-MHC
complex#1 , barcode#2 codes for peptide-MHC complex#2, barcode#3 codes for
peptide-MHC complex#3, and so on until the possible mixture of thousands different
specificities each with a specific barcode. Fig 4B: Represents the final reagent, which
is a mixture of numerous different MHC-multimers each carrying a specific DNA
barcode as a label for each peptide-MHC specificity.
Figure 5 . Detection of antigen responsive cells in a single sample.
Method for detecting antigen responsive cells in a sample. In Fig. 5 it is illustrated how
this library can be used for staining of antigen responsive cells in a single sample. Fig
5A: Cells in single cell suspension (may e.g., but not exclusive, originate from
peripheral blood, tissue biopsies or other body fluids) are mixed with the peptide-library
represented in fig 4B. Fig 5B: After staining, cells are sequentially washed and spun to
remove residual MHC multimers that are not bound to a cellular surface. Specific cell
populations, e.g. T-cells (CD8 or CD4 restricted), other immune cells or specifically
MHC multimer binding T-cells may be sorted by flow cytometry or others means of cell
sorting/selection. Fig 5C: The DNA-barcode oligonucleotide sequences isolated from
the cell population is amplified by PCR. Fig 5D: This amplification product is
sequenced by deep sequencing (providing 10-1 00.000s of reads). The sequencing will
reveal the specific barcode sequence of DNA barcodes attached to cells in the
specimen after selection, as these will appear more frequent than sequences
associated to the background of non-specific attachment of MHC multimers. The
"signal-to-noise" is counteracted by the fact that any unspecific MHC multimer event
will have a random association of 1/1000 different barcodes (dependent of the size of
the library), making it even more sensitive than normal multimer staining.
Figure 6 . Describes the possibility of linking the antigen specificity (tracked by the
barcode) to other properties. Use of a multimeric major histocompatibility complex.
In Fig 6 , it is illustrated how this technology can be used to link different properties to
the antigen specificity of a cell population.
Fig 6A: Illustrates how cells after binding to a barcode labeled MHC multimer library
may be exposed to a certain stimuli. Cell populations can be selected based on the
functional response to this stimuli (e.g., but not exclusive, cytokine secretion,
phosphorylation, calcium release or numerous other measures). After selecting the
responsive or non-responsive population (following the steps of Fig 5), the DNA
barcodes can be sequenced to decode the antigen responsiveness, and thereby
determining the antigen-specificities involved in a given response.
Fig 6B: Illustrates how cells can be selected based on phenotype, to link a certain set
of phenotypic characteristics to the antigen-responsiveness.
Fig 6C: Represents the possibility for single-cell sorting of MHC-multimer binding cells
based on the co-attached fluorescence label on the MHC multimer. Through single-cell
sorting the antigen-specificity of the given cell can be determined on a single cell level
through sequencing of the associated barcode label. This can be linked to the TCR that
can also be sequenced on a single cell level, as recently described ( 10). Hereby, this
invention will provide a link between the TCR sequence, or other single-cell properties
and the antigen specificity, and may through the use of barcode labeled MHC multimer
libraries enable definition of antigen-specific TCRs in a mixture of thousands different
specificities.
Fig 6D illustrates the use of barcode labeled MHC multimer libraries for the quantitative
assessment of MHC multimer binding to a given T-cell clone or TCR transduced/
transfected cells. Since sequencing of the barcode label allow several different labels
to be determined simultaneously on the same cell population, this strategy can be used
to determine the avidity of a given TCR relative to a library of related peptide-MHC
multimers. The relative contribution of the different DNA-barcode sequences in the final
readout is determined based on the quantitative contribution of the TCR binding for
each of the different peptide-MHC multimers in the library. Via titration based analyses
it is possible to determine the quantitative binding properties of a TCR in relation to a
large library of peptide-MHC multimers. All merged into a single sample. For this
particular purpose the MHC multimer library may specifically hold related peptide
sequences or alanine-substitution peptide libraries.
Figure 7 . Experimental data for attaching a DNA-barcode to a MHC multimer and
amplify the specific sequences following T-cell staining. Fig 7A: Shows the staining of
cytomegalovirus (CMV) specific T-cells in a peripheral blood samples. The specific
CMV-derived peptide-MHC multimers was labeled with a barcode (barcode#1) and
mixed with an irrelevant/non-specific peptide-MHC multimer (HIV) labeled with
barcode (barcode#2) and mixed with 998 other non-barcode labeled non-specific MHC
multimers. Data here shows the feasibility for staining of CMV-specific T-cells in a
mixture of 1000 other MHC multimers. Data is shown for three different staining
protocols (A, B, C). Fig 7B: Shows the readout of the specific barcode sequences by
quantative PCR. Barcode#1 (CMV) determining the CMV specific T-cell in detected for
all three staining protocols, whereas the irrelevant/non-specific barcode signal,
barcode#2 (HIV) is undetectable.
Figure 8 : Stability of single-stranded and double-stranded oligonucleotides in blood
preparations, cf. Example A.
Figure 9 : A schematic presentation of the Label systems applied; the 10S and 20S
DNA-barcode systems. A . The 10S system comprised of single stranded
oligonucleotides which were applied as a DNA barcodes. 10S structure: A -80
nucleotide sequence. Biotin is attached at the 5'end where it accommodates easy
attachment via a streptavidin binding site. The nucleotide sequence consists of a 20-
25nt forward primer followed by a random incorporation of 6 nt (N6), a short 3nt linker
and 25nt that comprise the diverse barcode-identity. This is followed by 20-25nt
reverse primer region. B. The 20S system are generated from annealing and
elongation of two partially complementary oligonucleotides-nucleotide sequences,
Oligo A and Oligo B, producing a fully double-stranded unique DNA sequences, which
are used as DNA-barcodes. Oligo A corresponds largely to the 10 S DNA-barcodes,
i.e. biotin is coupled to the 5'-end which begins with a forward primer region that is
followed by a N6 segment and the unique oligonucleotide-sequence that will constitute
one half of the barcode identity. After the unique sequence the reverse primer region of
the 10S system is replaced by a 16 nt sequence that is complementary to the 3'-end of
Oligo B. Oligo B is described from the 3'-end where it anneals with Oligo A with a 16 nt
complementary binding region followed by the unique oligonucleotide-sequence that
will constitute the other half of the barcode identity. Hereafter comes a N6 region,
which is followed by what is actually a forward primer region (since it lies in the 5'-end)
but its complementary region will constitute the reverse priming region of the 20S-DNA
barcodes. Thus the primary differences between 10S and 20S barcodes are revealed
in a greater length of the 20S barcode, which is required to encompass two unique
barcode regions, an annealing-site and an additional N6 region nearest the 3'-end. This
adds up to 130 nts. C. Through PCR amplification of enriched DNA-barcode Labels
these are appointed a sample identification barcode (6-8nt), which is part of the forward
primer design. Additionally both the forward and reverse primers hold adaptors for the
Ion Torrent sequencing (A-key and P1-key respectively). Primers and keys for the 10S
and the 20S barcode were of a similar design (here showing a 20S barcode).
Asterisk=biotin, nt=nucleotide.
Figure 10 : Detection of a CMV specificity amongst negative control Detection
Molecules (cf Example 1) . A unique 20S DNA-barcode was associated with the CMV
positive Detection Molecules in 1. , while another unique 20S DNA-barcode was
associated with the CMV positive control Detection Molecules in 2 . The spare DNA-
barcode in each sample incubation was associated with the HIV negative control
Detection Molecule. A. Representative dot plot showing the PE positive population
after staining with CMV and HIV Detection Molecules carrying separate 20S DNA-
barcodes. B. Ct values from multiplex qPCR of the sorted PE-pMHC-dextramer
positive cells. Cells were stained with 1. and 2 . respectively. Detection Molecules
associated with a positive control (CMV) 20S barcode and a negative control (HIV)
20S barcode were present during staining, but the negative control (HIV) Detection
Molecule was evidently washed out. The results obtained from two individual
experiments are presented in separate bars. Approximately 200 cells were applied in
each PCR. QPCR was run in duplicates and Ct values are shown as mean ±range of
duplicates.
Figure 11: Detection of a CMV specificity amongst negative control Detection
Molecules (cf. Example 2). A unique 10S DNA-barcode was associated with the
positive control Detection Molecules in 1, while another unique barcode was associated
with the positive control reagents in 2 . The spare barcode in each experiment was
associated with a HIV negative Detection Molecules. In addition 998x unlabeled (i.e.
lacking a DNA-barcode) negative control Detection Molecules were present in both 1.
and 2 . A, Ct values from multiplex qPCR of the sorted PE-pMHC-dextramer positive
cells. Cells were stained with 1. and 2 . respectively. Detection Molecules associated
with a positive control (CMV) 10S barcode and a negative control (HIV) 10S barcode
were present during staining, but the negative control (HIV) Detection Molecules were
evidently washed out. Approximatly 575 cells were analyzed in each qPCR. B. The
estimated number of barcodes bound per cell relative to the obtained Ct-values (as
calculated from a standard curve of 10S barcode). It is evident that there were some
differences in the Ct values shown in B, even though the same number of cells was
present in all qPCRs. This is however leveled when the values are normalized in
respect to their specific probes. QPCR was run in duplicates, here showing mean ±
range of duplicates.
Figure 12 : Schematic presentations of the number of specific 10S DNA-barcode reads
mapped to seven different samples as identified by their respective sample- ID
barcodes (cf. Example 3). A BC sample containing a 5% HLA-B0702 CMV pp65 TPR T
cell response (corresponding Detection Molecule encoded by barcode 88) were spiked
into a HLA-B0702 negative BC in fivefold dilutions, creating seven samples with
theoretic frequencies of 5%, 1%, 0.2%, 0.04%, 0.008%, 0.0016% and 0.00032% of
these T cells. The BC that these cells were spiked into contained -0.1% HLA-A1 101
EBV-EBNA4 specific T cells (corresponding Detection Molecule encoded by barcode
4). Samples were stained with the same library comprised of 110 different 10S-labeled
Detection Molecules. Each panel, named according to the theoretic frequency of the
HLA-B0702 CMV response, represents the respective reads mapped to that given
sample-ID barcode. The bars indicate reads mapped to a given 10S barcode (vertical
lines) after normalization in respect to the Detection Molecule-input reads mapped to
that same 10S barcode. Experiments were performed in duplicate. Here showing
mean.
Figure 13 : Schematic presentations of the number of specific 20S DNA-barcode reads
mapped to seven different samples as identified by their respective sample- ID
barcodes (cf. Example 4). A BC sample containing a 5% HLA-B0702 CMV pp65 TPR T
cell response (corresponding Detection Molecule encoded by barcode A3B18) were
spiked into a HLA-B0702 negative BC in fivefold dilutions, creating seven samples with
theoretic frequencies of 5%, 1%, 0.2%, 0.04%, 0.008%, 0.0016% and 0.00032% of
these T cells. The BC that these cells were spiked into contained -1% HLA-A1 10 1
EBV-EBNA4 specific T cells (corresponding Detection Molecule encoded by barcode
A 1B4). Samples were stained with the same library comprised of 110 different 20S-
labeled Detection Molecules. Each panel, named according to the theoretic frequency
of the HLA-B0702 CMV response, represents the respective reads mapped to that
given sample-ID barcode. The bars indicate reads mapped to a given 20S barcode
(vertical lines) after normalization in respect to the Detection Molecule-input reads
mapped to that same 20S barcode. Experiments were performed in duplicate. Here
showing mean.
Figure 14: Schematic presentations of the number of specific 10 S barcode reads
mapped to six different samples as identified by their respective sample-ID barcodes
(cf. Example 5). Six BCs were stained with the same library comprised of 110 different
10S-labeled Detection Molecules. Each panel, named according to the donor BC
number, represents the respective reads mapped to that given sample-ID barcode. The
bars indicate reads mapped to a given 10 S barcode (vertical lines) after normalization
in respect to the Detection Molecule-input reads mapped to that same 10S barcode.
Figure 15 : Schematic presentations of the number of specific 20S barcode reads
mapped to six different samples as identified by their respective sample-ID barcodes
(cf. Example 6). Six BCs were stained with the same library comprised of 110 different
20S-labeled Detection Molecules. Each panel, named according to the donor BC
number, represents the respective reads mapped to that given sample-ID barcode. The
bars indicate reads mapped to a given 20S barcode (vertical lines) after normalization
in respect to the Detection Molecule-input reads mapped to that same 20S barcode.
Figure 16 : Schematic presentations of the number of specific 20S barcode reads
mapped to 13 different TIL samples as identified by their respective sample-ID
barcodes along with the reads mapped to the Detection Molecule-input sample (lower
panel) (cf. Example 7). 11 TIL samples were stained with the same library comprised of
175 different 20S-labeled Detection Molecules. Each panel represents the respective
reads mapped to that given sample-ID barcode, which corresponds to TILs from
resected tumor of a given malignant melanoma patient or to the Detection Molecule-
input sample. Panel 1-7 and 9-1 1 represents the reads obtained from a singular
amplification and sequencing of enriched Detection Molecules, i.e. 20S barcodes, with
individual patient samples. Panel 10k corresponds to the mean reads obtained from
three separate amplification-rounds (with individual sample-IDs) of equivalent to 10.000
sorted cells (enriched Detection Molecule) from the same patient-sample (TIL sample
8). Panel 1K corresponds to the reads obtained from amplification of equivalent to 1000
sorted cells (enriched Detection Molecule) and panel 100 corresponds to the mean
reads obtained from three separate amplification-rounds (with individual sample- IDs) of
equivalent to 100 sorted cells (enriched Detection Molecule) from the same patient-
sample (TIL sample 8). The bars indicate reads mapped to a given 20S barcode
(vertical lines). The reads were not normalized in respect to the input sample (here
mean of triplicate PCRs with unique sample-IDs), since only a total of -5600 reads
were obtained in the sequencing reaction (samples are being resequenced). Even so,
the results are encouraging, with 20S sequences mapping to most of the barcode
identities present in the Detection Molecule library (input) and a trend showing
preferential enrichment of certain, but different, 20S barcodes across the patient
samples. Furthermore, the replicates of sample 8 , based on different cell numbers,
shows comparable results. The number of reads of each barcode is reduced in
clonality in respect to their N6 sequence.
Definitions and abbreviations
As used everywhere herein, the term "a", "an" or "the" is meant to be one or more, i . e.
at least one.
'Aff.' is an abbreviation for affinity.
An "amino acid residue" can be a natural or non-natural amino acid residue linked
peptide bonds or bonds different from peptide bonds. The amino acid residues can be
in D-configuration or L-configuration. An amino acid residue comprises an amino
terminal part (NH2) and a carboxy terminal part (COOH) separated by a central part
comprising a carbon atom, or a chain of carbon atoms, at least one of which comprises
at least one side chain or functional group. NH2 refers to the amino group present at
the amino terminal end of an amino acid or peptide, and COOH refers to the carboxy
group present at the carboxy terminal end of an amino acid or peptide. The generic
term amino acid comprises both natural and non-natural amino acids. Natural amino
acids of standard nomenclature as listed in J. Biol. Chem., 243:3552-59 (1969) and
adopted in 37 C.F.R., section 1.822(b)(2) belong to the group of amino acids listed in
the table herein below. Non-natural amino acids are those not listed in the Table below.
Examples of non-natural amino acids are those listed e.g. in 37 C.F.R. section
1.822(b)(4), all of which are incorporated herein by reference. Also, non-natural amino
acid residues include, but are not limited to, modified amino acid residues, L-amino
acid residues, and stereoisomers of D-amino acid residues.
The terms "amino-terminal" and "carboxyl-terminal" are used herein to denote positions
within polypeptides. Where the context allows, these terms are used with reference to a
particular sequence or portion of a polypeptide to denote proximity or relative position.
For example, a certain sequence positioned carboxyl-terminal to a reference sequence
within a polypeptide is located proximal to the carboxyl terminus of the reference
sequence, but is not necessarily at the carboxyl terminus of the complete polypeptide.
Adjuvant: adjuvants are drugs that have few or no pharmacological effects by
themselves, but can increase the efficacy or potency of other drugs when given at the
same time. In another embodiment, an adjuvant is an agent which, while not having
any specific antigenic effect in itself, can stimulate the immune system, increasing the
response to a vaccine.
Agonist: agonist as used herein is a substance that binds to a specific receptor and
triggers a response in the cell. It mimics the action of an endogenous ligand that binds
to the same receptor.
Antagonist: antagonist as used herein is a substance that binds to a specific receptor
and blocks the response in the cell. It blocks the action of an endogenous ligand that
binds to the same receptor.
Antibodies: As used herein, the term "antibody" means an isolated or recombinant
binding agent that comprises the necessary variable region sequences to specifically
bind an antigenic epitope. Therefore, an antibody is any form of antibody or fragment
thereof that exhibits the desired biological activity, e.g., binding the specific target
antigen. Antibodies can derive from multiple species. For example, antibodies include
rodent (such as mouse and rat), rabbit, sheep, camel, and human antibodies.
Antibodies can also include chimeric antibodies, which join variable regions from one
species to constant regions from another species. Likewise, antibodies can be
humanized, that is constructed by recombinant DNA technology to produce
immunoglobulins which have human framework regions from one species combined
with complementarity determining regions (CDR's) from a another species'
immunoglobulin. The antibody can be monoclonal or polyclonal. Antibodies can be
divided into isotypes (IgA, IgG, IgM, IgD, IgE, lgG1 , lgG2, lgG3, lgG4, lgA1 , lgA2,
lgM1 , lgM2)
Antibodies: In another embodiment the term "antibody" refers to an intact antibody, or a
fragment of an antibody that competes with the intact antibody for antigen binding. In
certain embodiments, antibody fragments are produced by recombinant DNA
techniques. In certain embodiments, antibody fragments are produced by enzymatic or
chemical cleavage of intact antibodies. Exemplary antibody fragments include, but are
not limited to, Fab, Fab', F(ab')2, Fv, and scFv. Exemplary antibody fragments also
include, but are not limited to, domain antibodies, nanobodies, minibodies ((scFv-
C.sub.H3).sub.2), maxibodies ((scFv-C.sub.H2-C. sub. H3).sub.2), diabodies
(noncovalent dimer of scFv).
Antigen presenting cell: An antigen-presenting cell (APC) as used herein is a cell that
displays foreign antigen complexed with MHC on its surface.
Antigenic peptide: Used interchangeably with binding peptide. Any peptide molecule
that is bound or able to bind into the binding groove of either MHC class 1 or MHC
class 2 molecules.
Antigenic polypeptide: Polypeptide that contains one or more antigenic peptide
sequences.
APC: Antigen presenting cell
Aptamer: the term aptamer as used herein is defined as oligonucleic acid or peptide
molecules that bind a specific target molecule. Aptamers are usually created by
selecting them from a large random sequence pool, but natural aptamers also exist.
Aptamers can be divided into DNA aptamers, RNA aptamers and peptide aptamers.
Avidin: Avidin as used herein is a glycoprotein found in the egg white and tissues of
birds, reptiles and amphibians. It contains four identical subunits having a combined
mass of 67,000-68,000 daltons. Each subunit consists of 128 amino acids and binds
one molecule of biotin.
Binding molecule (BM): The binding molecule comprised in the detection molecule of
the present invention is any molecule that can specifically associate with, recognize
and/or bind to a cell or any other entity, such as another molecule, a surface or a
biological cell or other type of cellular entity (e.g. micelle). Example binding molecules
are antibodies, MHC-and MHC-peptide complexes, peptides, small organic molecules,
oligonucleotides, any kind of aptamer, proteins, multicomponent complexes comprising
2 , 3 , 4 , 5 , 6 , 7 , 8 , or more subunits, and supramolecular structures.
Biologically active molecule: A biologically active molecule is a molecule having itself a
biological activity/effect or is able to induce a biological activity/effect when
administered to a biological system. Biologically active molecules include adjuvants,
immune targets (e.g. antigens), enzymes, regulators of receptor activity, receptor
Iigands, immune potentiators, drugs, toxins, cytotoxic molecules, co-receptors, proteins
and peptides in general, sugar moieties, lipid groups, nucleic acids including siRNA,
nanoparticles, small molecules.
Bioluminescent: Bioluminescence, as used herein, is the production and emission of
light by a living organism as the result of a chemical reaction during which chemical
energy is converted to light energy.
Biotin: Biotin, as used herein, is also known as vitamin H or B7. Niotin has the chemical
formula C 0H 6N2O3S.
Bispecific antibodies: The term bispecific antibodies as used herein is defined as
antibodies that have binding specificities for at least two different antigens. The
antibody can also be trispecific or multispecific.
Bispecific capture molecule: Molecule that have binding specificities for at least two
different antigens. The molecule can also be trispecific or multispecific.
Carrier/linker (Li): Carrier and linker may be used interchangeably herein, whereby a
carrier is one type of a linker according to the present invention. A carrier as used
herein can be any type of molecule that is directly or indirectly associated with the
binding molecule such as a MHC peptide complex. In this invention, a carrier will
typically refer to a functionalized polymer (e.g. dextran) that is capable of reacting with
a binding molecule such as MHC-peptide complexes, thus covalently attaching the
binding molecule to the carrier, or that is capable of reacting with scaffold molecules
(e.g. streptavidin), thus covalently attaching streptavidin to the carrier; the streptavidin
then may bind MHC-peptide complexes. Carrier and scaffold may also be used
interchangeably herein where scaffold typically refers to smaller molecules of a linker
or multimerization domain and carrier typically refers to larger molecule and/or cell like
structures.
Cell-detection molecule complex: A complex comprising at least one detection
molecule according to the invention and at least one cell.
Chelating chemical compound: Chelating chemical compound, as used herein, is the
process of reversible bindingof a ligand to a metal ion, forming a metal complex.
Chemiluminescent: Chemiluminescence, as used herein, is the emission of light
(luminescence) without emission of heat as the result of a chemical reaction.
Chromophore: A chromophore, as used herein, is the part of a visibly coloured
molecule responsible for light absorption over a range of wavelengths thus giving rise
to the colour. By extension the term can be applied to uv or ir absorbing parts of
molecules.
Coiled-coil polypeptide: Used interchangeably with coiled-coil peptide and coiled-coil
structure. The term coiled-coil polypeptide as used herein is a structural motif in
proteins, in which 2-7 alpha-helices are coiled together like the strands of a rope
Complement protein: Protein of the complement system.
Counting beads: Beads or particles countable in a flow cytometry experiment. They can
be used as internal control beads enabling absolute cell count in a sample.
Covalent binding: The term covalent binding is used herein to describe a form of
chemical bonding that is characterized by the sharing of pairs of electrons between
atoms. Attraction-to-repulsion stability that forms between atoms when they share
electrons is known as covalent bonding.
Crosslinking is the process of chemically joining two or more molecules by a covalent
bond. Crosslinking reagents contain reactive ends to specific functional groups
(primary amines, sulfhydryls, etc.) on proteins or other molecules.
Detection molecule: A molecule comprising a binding molecule (BM), a label (La) and a
linker (Li), wherein 'a' is meant to comprise at least one, or one or more.
Diagnosis: The act or process of identifying or determining the nature and cause of a
disease or injury through evaluation
Diabodies: The term "diabodies" refers to small antibody fragments with two antigen-
binding sites, which fragments comprise a heavy-chain variable domain (VH)
connected to a light-chain variable domain (VL) in the same polypeptide chain (VH-VL).
By using a linker that is too short to allow pairing between the two domains on the
same chain, the domains are forced to pair with the complementary domains of another
chain and create two antigen-binding sites.
Dendritic cell: The term dendritic cell as used herein is a type of immune cells. Their
main function is to process antigen material and present it on the surface to other cells
of the immune system, thus functioning as antigen-presenting cells.
Detection: In this invention detection means any method capable of measuring, or
determining the presence of, one molecule alone or bound to another molecule.
Dextran: the term dextran as used herein is a complex, branched polysaccharide made
of many glucose molecules joined into chains of varying lengths. The straight chain
consists of a 1->6 glycosidic linkages between glucose molecules, while branches
begin from a1->3 linkages (and in some cases, a1->2 and a1->4 linkages as well).
Diabodies: The term "diabodies" refers to small antibody fragments with two antigen-
binding sites, which fragments comprise a heavy-chain variable domain (VH)
connected to a light-chain variable domain (VL) in the same polypeptide chain (VH-VL).
By using a linker that is too short to allow pairing between the two domains on the
same chain, the domains are forced to pair with the complementary domains of another
chain and create two antigen-binding sites.
Direct detection of T cells: Direct detection of T cells is used herein interchangeably
with direct detection of TCR and direct detection of T cell receptor. As used herein
direct detection of T cells is detection directly of the binding interaction between a
specific T cell receptor and a MHC multimer.
DNA: The term DNA (Deoxyribonucleic acid) duplex as used herein is a polymer of
simple units called nucleotides, with a backbone made of sugars and phosphate atoms
joined by ester bonds. Attached to each sugar is one of four types of molecules called
bases.
DNA duplex: In living organisms, DNA does not usually exist as a single molecule, but
instead as a tightly-associated pair of molecules. These two long strands entwine like
vines, in the shape of a double helix.
Electrophilic: electrophile, as used herein, is a reagent attracted to electrons that
participates in a chemical reaction by accepting an electron pair in order to bond to a
nucleophile.
Entity-detection molecule complexes: A complex comprising at least one detection
molecule according to the invention and at least one entity.
Enzyme label: enzyme labelling, as used herein, involves a detection method
comprising a reaction catalysed by an enzyme.
Entity: An entity according to the present invention is capable of being recognized
and/or bound by a detection molecule comprising a binding molecule as defined herein,
to form a complex comprising the entity and the detection molecule.
Epitope-focused antibody: Antibodies also include epitope-focused antibodies, which
have at least one minimal essential binding specificity determinant from a heavy chain
or light chain CDR3 from a reference antibody, methods for making such epitope-
focused antibodies are described in U.S. patent application Ser. No. 11/040,1 59, which
is incorporated herein by reference in its entirety.
Flow cytometry: The analysis and/or sorting of single cells using a flow cytometer.
Flow cytometer: Instrument that measures cell size, granularity and flourescence due
to bound fluorescent molecules as single cells pass in a stream past photodectors. A
flow cytometer carry out the measurements and/or sorting of individual cells.
Fluorescent: the term fluorescent as used herein is to have the ability to emit light of a
certain wavelength when activated by light of another wavelength.
Fluorochromes: Fluorochrome, as used herein, is any fluorescent compound used as a
dye to mark e.g. protein with a fluorescent label.
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Fluorophore: A fluorophore, as used herein, is a component of a molecule which
causes a molecule to be fluorescent.
Folding: In this invention folding means in vitro or in vivo folding of proteins in a tertiery
structure.
Fusion antibody: As used herein, the term "fusion antibody" refers to a molecule in
which an antibody is fused to a non-antibody polypeptide at the N- or C-terminus of the
antibody polypeptide.
Glycosylated: Glycosylation, as used herein, is the process or result of addition of
saccharides to proteins and lipids.
Hapten: A residue on a molecule for which there is a specific molecule that can bind,
e.g. an antibody.
Heteroconjugate antibodies are composed of two covalently joined antibodies. Such
antibodies have, for example, been proposed to target immune system cells to
unwanted cells.
IgG: IgG as used herein is a monomeric immunoglobulin, built of two heavy chains and
two light chains. Each molecule has two antigen binding sites.
Isolated antibody: The term "isolated" antibody as used herein is an antibody which has
been identified and separated and/or recovered from a component of its natural
environment.
Immunoconjugates: The invention also pertains to immunoconjugates comprising an
antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g.,
an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments
thereof), or a radioactive isotope (i.e., a radioconjugate). Enzymatically active toxins
and fragments thereof that can be used include diphtheria A chain, nonbinding active
fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin
A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins,
dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica
charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin,
restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides
are available for the production of radioconjugated antibodies. Conjugates of the
antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling
agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane
(IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active
esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido
compounds (such as bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives
(such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene
2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-
dinitrobenzene).
Immune monitoring: Immune monitoring of the present invention refers to testing of
immune status in the diagnosis and therapy of diseases like but not limited to cancer,
immunoproliferative and immunodeficiency disorders, autoimmune abnormalities, and
infectious disease. It also refers to testing of immune status before, during and after
vaccination and transplantation procedures.
Immune monitoring process: a series of one or more immune monitoring analyses
Indirect detection of T cells: Indirect detection of T cells is used interchangeably herein
with indirect detection of TCR and indirect detection of T cell receptor. As used herein
indirect detection of T cells is detection of the binding interaction between a specific T
cell receptor and a MHC multimer by measurement of the effect of the binding
interaction.
lonophore: ionophore, as used herein, is a lipid-soluble molecule usually synthesized
by microorganisms capable of transporting ions.
Label (La). The label comprised in the detection molecule of the present invention is
any molecule, atom or signal the identity of which can be found or determined by any
means. The label of a detection molecule specifies the binding molecule that is linked
to the label. Example labels are nucleic acid labels including oligonucleotides such as
DNA, RNA, PNA, LNA; antibodies; any of the elements such as zinc, iron, magnesium,
any of the lanthanides; peptides; proteins; and any type of organic molecules. The
identity of the label can be determined by any appropriate method for the specific type
of label, including but not limited to mass spectrometry, sequencing (e.g. DNA
sequencing, peptide sequencing), gel electrophoresis, gel filtration, and many other
methods.
Labelling: Labelling herein means attachment of a label to a molecule.
Lanthanide: lanthanide, as used herein, series comprises the 15 elements with atomic
numbers 57 through 7 1 , from lanthanum to lutetium.
LDA: limiting dilution assay
A ligand is a molecule capable of binding to and forming a complex with a biomolecule
to serve a biological purpose.
Linker (Li). The linker comprised in the detection molecule of the present invention is a
molecular entity and/or bond that connect the binding molecule and the label of the
detection molecule. The linker can be of any length, such as length 1-10.000 A
(Angstrom), and can have any composition, including for example an oligonucleotide,
peptide, organic molecule, and more. A linker according to the present invention
comprises, or is identical to, a carrier molecule (or carrier), a multimerization domain, a
scaffold, a connector and/or a backbone, and may equally be referred to as such
herein. The linker in one embodiment comprises any linker, carrier or carrier molecule,
multimerization domain or backbone, to which the binding molecule and the label are
attached. The attachment may be direct or indirect, and may comprise a covalent or
non-covalent binding.
Liposomes: The term liposome as used herein is defined as a spherical vesicle with a
membrane composed of a phospholipid and cholesterol bilayer. Liposomes, usually but
not by definition, contain a core of aqueous solution; lipid spheres that contain no
aqueous material are called micelles.
Immunoliposomes: The antibodies disclosed herein can also be formulated as
immunoliposomes. Liposomes comprising the antibody are prepared by methods
known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA 82:
3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77: 4030 (1980); and U.S. Pat.
Nos. 4,485,045 and 4,544,545. Particularly useful liposomes can be generated by the
reverse-phase evaporation method with a lipid composition comprising
phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine
(PEG-PE).
Immuno-profiling: Immuno profiling as used herein defines the profiling of an
individual's antigen-specific T-cell repertoire
MHC: Major histocompatibility complex.
MHC I is used interchangeably herein with MHC class I and denotes the major
histocompatibility complex class I .
MHC I I is used interchangeably herein with MHC class I I and denotes the major
histocompatibility complex class I .
MHC molecule: a MHC molecule as used everywhere herein is defined as any MHC
class I molecule or MHC class I I molecule as defined herein.
A "MHC Class I molecule" as used everywhere herein is used interchangeably with
MHC I molecule and is defined as a molecule which comprises 1-3 subunits, including
a MHC I heavy chain, a MHC I heavy chain combined with a MHC I beta2microglobulin
chain, a MHC I heavy chain combined with MHC I beta2microglobulin chain through a
flexible linker, a MHC I heavy chain combined with an antigenic peptide, a MHC I
heavy chain combined with an antigenic peptide through a linker, a MHC I heavy chain/
MHC I beta2microglobulin dimer combined with an antigenic peptide, and a MHC I
heavy chain/ MHC I beta2microglobulin dimer combined with an antigenic peptide
through a flexible linker to the heavy chain or beta2microglobulin. The MHC I molecule
chains can be changed by substitution of single or by cohorts of native amino acids, or
by inserts, or deletions to enhance or impair the functions attributed to said molecule.
MHC Class I like molecules (including non-classical MHC Class I molecules) include
CD1d, HLA E, HLA G, HLA F, HLA H, MIC A , MIC B, ULBP-1 , ULBP-2, and ULBP-3.
A "MHC Class I I molecule" as used everywhere herein is used interchangeably with
MHC I I molecule and is defined as a molecule which comprises 2-3 subunits including
a MHC I I alpha-chain and a MHC I I beta-chain (i.e. a MHC I I alpha/beta-dimer), an
MHC I I alpha/beta dimer with an antigenic peptide, and an MHC I I alpha/beta dimer
combined with an antigenic peptide through a flexible linker to the MHC I I alpha or
MHC I I beta chain, a MHC I I alpha/beta dimer combined through an interaction by
affinity tags e.g. jun-fos, a MHC I I alpha/beta dimer combined through an interaction by
affinity tags e.g. jun-fos and further combined with an antigenic peptide through a
flexible linker to the MHC I I alpha or MHC I I beta chain. The MHC I I molecule chains
can be changed by substitution of single or by cohorts of native amino acids, or by
inserts, or deletions to enhance or impair the functions attributed to said molecule.
Under circumstances where the MHC I I alpha-chain and MHC I I beta-chain have been
fused, to form one subunit, the "MHC Class I I molecule" can comprise only 1 subunit or
2 subunits if antigenic peptide is also included.
MHC Class I I like molecules (including non-classical MHC Class I I molecules) include
HLA DM, HLA DO, l-A beta2, and l-E beta2.
"MHC complexes", "MHC molecules" and "MHC constructs" are used interchangeably
herein, and - if not further specified - comprises MHCs loaded with or bound to
peptides as well as empty MHCs (not loaded with peptides).
MHC-peptide complex defines any MHC I and/or MHC I I molecule combined with
antigenic peptide.
A "peptide free MHC Class I molecule" is used interchangeably herein with "peptide
free MHC I molecule" and as used everywhere herein is meant to be a MHC Class I
molecule as defined above with no peptide.
A "peptide free MHC Class I I molecule" is used interchangeably herein with "peptide
free MHC I I molecule" and as used everywhere herein is meant to be a MHC Class I I
molecule as defined above with no peptide.
Such peptide free MHC Class I and I I molecules are also called "empty" MHC Class I
and I I molecules.
The MHC molecule may suitably be a vertebrate MHC molecule such as a human, a
mouse, a rat, a porcine, a bovine or an avian MHC molecule. Such MHC complexes
from different species have different names. E.g. in humans, MHC complexes are
denoted HLA. The person skilled in the art will readily know the name of the MHC
complexes from various species.
In general, the term "MHC molecule" is intended to include all alleles. By way of
example, in humans e.g. HLA A, HLA B, HLA C, HLA D, HLA E, HLA F, HLA G, HLA
H, HLA DR, HLA DQ and HLA DP alleles are of interestshall be included, and in the
mouse system, H-2 alleles are of interestshall be included. Likewise, in the rat system
RT1 -alleles, in the porcine system SLA-alleles, in the bovine system BoLA, in the avian
system e.g. chicken-B alleles, are of interestshall be included.
By the terms "MHC complexes" and "MHC multimers" as used herein are meant such
complexes and multimers thereof, which are capable of performing at least one of the
functions attributed to said complex or multimer. The terms include both classical and
non-classical MHC complexes. The meaning of "classical" and "non-classical" in
connection with MHC complexes is well known to the person skilled in the art. Non-
classical MHC complexes are subgroups of MHC-like complexes. The term "MHC
complex" includes MHC Class I molecules, MHC Class I I molecules, as well as MHC-
like molecules (both Class I and Class II), including the subgroup non-classical MHC
Class I and Class I I molecules.
MHC multimer: The terms MHC multimer, MHC-multimer, MHCmer and MHC'mer
herein are used interchangeably, to denote a complex comprising more than one MHC-
complex and/or MHC-peptide complex, held together by covalent or non-covalent
bonds. .In one embodiment a MHC multimer comprises 2 copies (dimer), 3 copies
(trimer), 4 copies (tetramer), 5 copies, (pentamer), 6 copies (hexamer), 7 copies
(heptamer), 8 copies (octamer), 9 copies (nonamer), 10 copies (decamer), 11 copies,
12 copies, 13 copies, 14 copies, 15 copies, 16 copies, 17 copies, 18 copies, 19 copies
or 20 copies,
Monoclonal antibodies: Monoclonal antibodies, as used herein, are antibodies that are
identical because they were produced by one type of immune cell and are all clones of
a single parent cell.
Monovalent antibodies: The antibodies in the present invention can be monovalent
antibodies. Methods for preparing monovalent antibodies are well known in the art. For
example, one method involves recombinant expression of immunoglobulin light chain
and modified heavy chain. The heavy chain is truncated generally at any point in the Fc
region so as to prevent heavy chain crosslinking. Alternatively, the relevant cysteine
residues are substituted with another amino acid residue or are deleted so as to
prevent crosslinking. In vitro methods are also suitable for preparing monovalent
antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab
fragments, can be accomplished using routine techniques known in the art.
Multimerization domain: A multimerization domain is a type of linker according to the
present invention. It may also be used as a synonym to linker. It defines a molecule, a
complex of molecules, or a solid support, to which one or more binding molecules,
such as MHC or MHC-peptide complexes, can be attached. A multimerization domain
consist of one or more carriers and/or one or more scaffolds and may also contain one
or more scaffold molecules (or connectors) connecting carrier to scaffold, carrier to
carrier, scaffold to scaffold. The multimerization domain may also contain one or more
scaffold molecules that can be used for attachment of binding molecules and/or other
molecules to the multimerization domain. Multimerization domains thus comprises IgG,
streptavidin, streptactin, micelles, cells, polymers, beads and other types of solid
support, and small organic molecules carrying reactive groups or carrying chemical
motifs that can bind binding molecules such as MHC complexes and other molecules.
Nanobodies: Nanobodies as used herein is a type of antibodies derived from camels,
and are much smaller than traditional antibodies.
Neutralizing antibodies: neutralizing antibodies as used herein is an antibody which, on
mixture with the homologous infectious agent, reduces the infectious titer.
NMR: NMR (Nuclear magnetic resonance), as used herein, is a physical phenomenon
based upon the quantum mechanical magnetic properties of an atom's nucleus. NMR
refers to a family of scientific methods that exploit nuclear magnetic resonance to study
molecules.
Non-covalent: The term non-covalent bond as used herein is a type of chemical bond
that does not involve the sharing of pairs of electrons, but rather involves more
dispersed variations of electromagnetic interactions.
Nucleic acid duplex: A nucleic acid is a complex, high-molecular-weight biochemical
macromolecule composed of nucleotide chains that convey genetic information. The
most common nucleic acids are deoxyribonucleic acid (DNA) and ribonucleic acid
(RNA).
Nucleophilic: a nucleophile, as used herein, is a reagent that forms a chemical bond to
its reaction partner (the electrophile) by donating both bonding electrons.
"One or more" as used everywhere herein is intended to include one and a plurality i.e.
more than one.
Pegylated: pegylated, as used herein, is conjugation of Polyethylene glycol (PEG) to
proteins.
Peptide or protein: Any molecule composed of at least two amino acids. Peptide
normally refers to smaller molecules of up to around 30 amino acids and protein to
larger molecules containing more amino acids.
Phosphorylated; phosphorylated, as used herein, is is the addition of a phosphate
(P0 4) group to a protein molecule or a small molecule.
PNA: PNA (Peptide nucleic acid) as used herein is a chemical similar to DNA or RNA.
DNA and RNA have a deoxyribose and ribose sugar backbone, respectively, whereas
PNA's backbone is composed of repeating N-(2-aminoethyl)-glycine units linked by
peptide bonds. The various purine and pyrimidine bases are linked to the backbone by
methylene carbonyl bonds. PNAs are depicted like peptides, with the N-terminus at the
first (left) position and the C-terminus at the right.
"A plurality" as used everywhere herein should be interpreted as two or more.
This applies i.a. to the MHC complex and the binding entity. When a plurality of MHC
complexes is attached to the multimerization domain, such as a scaffold or a carrier
molecule, the number of MHC complexes need only be limited by the capacity of the
multimerization domain.
Polyclonal antibodies: a polyclonal antibody as used herein is an antibody that is
derived from different B-cell lines. They are a mixture of immunoglobulin molecules
secreted against a specific antigen, each recognising a different epitope.
Polymer: the tern polymer as used herein is defined as a compound composed of
repeating structural units, or monomers, connected by covalent chemical bonds.
Polypeptide: Peptides are the family of short molecules formed from the linking, in a
defined order, of various a-amino acids. The link between one amino acid residue and
the next is an amide bond and is sometimes referred to as a peptide bond. Longer
peptides are reffered to as proteins or polypeptide.
Polysaccharide: The term polysaccharide as used herein is defined as polymers made
up of many monosaccharides joined together by glycosidic linkages.
Radicals: radicals, as used herein, are atomic or molecular species with unpaired
electrons on an otherwise open shell configuration. These unpaired electrons are
usually highly reactive, so radicals are likely to take part in chemical reactions.
Radioactivity: Radioactive decay is the process in which an unstable atomic nucleus
loses energy by emitting radiation in the form of particles or electromagnetic waves.
RNA: RNA (Ribonucleic acid) as used herein is a nucleic acid polymer consisting of
nucleotide monomers that plays several important roles in the processes that translate
genetic information from deoxyribonucleic acid (DNA) into protein products.
RNA: RNA (Ribonucleic acid) as used herein is a nucleic acid polymer consisting of
nucleotide monomers that plays several important roles in the processes that translate
genetic information from deoxyribonucleic acid (DNA) into protein products
Scaffold: A scaffold is typically an organic molecule carrying reactive groups, capable
of reacting with reactive groups on a MHC- or MHC-peptide complex. Particularly small
organic molecules of cyclic structure (e.g. functionalized cycloalkanes or functionalized
aromatic ring structures) are termed scaffolds. Scaffold and carrier are used
interchangeably herein where scaffold typically refers to smaller molecules of a
multimerization domain and carrier typically refers to larger molecule and/or cell like
structures. Both scaffold, carrier and multimerization domain are types of linkers
according to the present invention.
Sequencing. In the present aspect it is understood that sequencing encompasses all
types of sequencing of a given nucleic acid sequence, including also e.g. deep-
sequencing or next-generation sequencing, in which amplified barcode sequences of a
nucleic acid label (the PCR product) is sequenced a large number of repetitive time
(number of total reads, e.g. 100.000s of reads). The number of reads for the individual
barcode sequence will relate to their quantitative presence in the amplification product,
which again represents their quantitative presence before amplification, since all DNA-
barcodes have similar amplification properties. Thus, the number of reads for a specific
barcode sequence compared to the total number of reads will correlate to the presence
of antigen responsive cells in the test-sample.
Staining: In this invention staining means specific or unspecific labelling of cells by
binding labeled molecules to defined proteins or other structures on the surface of cells
or inside cells. The cells are either in suspension or part of a tissue. The labeled
molecules can be MHC multimers, antibodies or similar molecules capable of binding
specific structures on the surface of cells.
Streptavidin: Streptavidin as used herein is a tetrameric protein purified from the
bacterium Streptomyces avidinii. Streptavidin is widely use in molecular biology
through its extraordinarily strong affinity for biotin.
Sugar: Sugars as used herein include monosaccharides, disaccharides, trisaccharides
and the oligosaccharides - comprising 1, 2 , 3 , and 4 or more monosaccharide units
respectively.
TCR: T-cell receptor
Therapy: Treatment of illness or disability
Vaccine: A vaccine is an antigenic preparation used to establish immunity to a disease
or illness and thereby protect or cure the body from a specific disease or illness.
Vaccines are either prophylactic and prevent disease or therapeutic and treat disease.
Vaccines may contain more than one type of antigen and is then called a combined
vaccine.
Vaccination: The introduction of vaccine into the body of human or animals for the
purpose of inducing immunity.
Detailed description of the invention
The present invention provides a detection molecule comprising a binding molecule
(BM), a linker (Li) and a label (La). Said detection molecule can be used in various
methods, such as detection methods as outlined herein.
The binding molecules of the invention are capable of specifically associating with,
such as recognizing and/or binding to, a target entity or cell.
The present invention provides a means for detecting detection molecules capable of
binding to - and/or bound to - individual cells or to a subset of cells.Alternatively, the
present invention provides a means for detecting the presence and/or abundance of
cells capable of binding to detection molecules.
The present invention is in one embodiment used for epitope discovery, analytical
studies, diagnosis, and therapy, and may be used in vivo (e.g. in animals) or in vitro
(e.g. in any kind of cell samples such as blood, synovial fluid or bone marrow).
The present invention is in one embodiment used to characterize cells for their ability to
bind certain detection molecules. The present invention is in one embodiment used to
detect the presence of certain cell types, identified by their detection molecule-binding
pattern.
In another embodiment, the technology is used for T-cell epitope mapping, immune-
recognition discovery, or measuring immune reactivity after vaccination or immune-
related therapies.
COMPOSITION
It is an aspect of the present invention to provide a detection molecule comprising
a . a binding molecule (BM),
b. a linker (Li), and
c . a label (La).
The components of the detection molecule namely binding molecule, linker and label
are defined herein elsewhere. It is understood that 'a' in the present context include at
least one, or one or more, of each of said components. A binding molecule can thus be
a monomeric or a multimeric binding molecule.
The present invention thus provides a detection molecule comprising at least one
binding molecule (BM), at least one linker (Li) and at least one label (La).
It is understood that each component of the detection molecule, namely the binding
molecule, the linker and the label, individually can be selected from any of the binding
molecules, linkers and labels disclosed herein throughout. Thus, any combination of
binding molecules, linkers and labels are encompassed within the present disclosure
and invention.
It is also an aspect of the present invention to provide an entity-detection molecule
complex, wherein said complex comprises
a . at least one detection molecule comprising a binding molecule (BM), a linker
(Li) and a label (La), and
b. at least one entity.
It is also an aspect of the present invention to provide a cell-detection molecule
complex, wherein said complex comprises
c . at least one detection molecule comprising a binding molecule (BM), a linker
(Li) and a label (La), and
d . at least one cell.
In one embodiment the cell-detection molecule complexes comprises a cell, such as an
immune cell, associated with or bound to a detection molecule having a binding
molecule specific for the immune cell.
In one embodiment one or more components of the detection molecule; that is one or
more of the binding molecule, the linker and the label are each as described in WO
2002/072631 , WO 2009/106073 or WO 2009/003492, which are hereby incorporated
by reference in their entirety.
In a particular embodiment the detection molecule has one or more characteristics as
the detection molecules described in, and/or is prepared as described in, WO
2009/003492; European Journal of Immunology, vol. 3 1, pp 32-38, January 2001
(Hansen et al); or Journal of Immunological Methods, vol. 241 , issues 1-2, 3 1 July 2000
(Le Doussal et al).
In an aspect of the present invention the label will serve as a specific label for
identifying a given binding molecule.
In an aspect of the present invention the label, such as a nucleic acid label, will serve
as a specific label for a given binding molecule, such as a MHC molecule or peptide-
MHC molecule that is multimerized to form a MHC multimer.
In one embodiment the present invention provides a detection molecule comprising
a . a monomeric or a multimeric major histocompatibility complex (MHC) molecule,
such as a monomeric or multimeric peptide MHC complex,
b. a linker comprising a multimerization domain and optionally one or more
connectors, and
c . a nucleic acid label.
In one embodiment the present invention provides a detection molecule comprising
a . a monomeric or a multimeric major histocompatibility complex (MHC) molecule,
such as a monomeric or multimeric peptide MHC complex,
b. a linker comprising a multimerization domain and optionally one or more
connectors, and
c . a peptide label.
In one embodiment the present invention provides a detection molecule comprising
a . an anti-target molecule capable of associating with, recognizing and/or binding
to a predetermined marker molecule (or target) on a cell type, wherein said
marker molecule is specific for a certain cell type
b. a linker (Li) comprising a multimerization domain and optionally one or more
connectors, and
c . a nucleic acid label.
Anti-target molecules are defined in more detail herein below.
In one embodiment the present invention provides a detection molecule comprising
a . CD1 , wherein said CD1 is selected from the group consisting of CD1 CD1 a ,
CD1 b, CD1c, CD1d and CD1 e,
b. a linker comprising a multimerization domain and optionally one or more
connectors, and
c . a nucleic acid label.
In one the linker of the detection molecule comprises a multimerization domain, such
as a polysaccharide such as dextran, and optionally further comprises streptavidin or
avidin whereby the binding molecule and/or the label comprises biotin.
In one embodiment the invention relates to a multimeric major histocompatibility
complex (MHC) comprising
a . two or more MHC molecules linked by a backbone molecule (linker); and
b. at least one nucleic acid molecule (label) linked to said backbone, wherein said
nucleic acid molecule comprises a central stretch of nucleic acids (barcode
region) designed to be amplified by e.g. PCR.
In one embodiment the invention relates to a major histocompatibility complex (MHC)
comprising
a . one MHC molecule
b. a backbone molecule (linker); and
c . at least one nucleic acid molecule (label) linked to said backbone, wherein said
nucleic acid molecule comprises a central stretch of nucleic acids (barcode
region) designed to be amplified by e.g. PCR.
The invention provides a composition comprising one detection molecule, or one set of
identical detection molecules.
Also provided is a composition comprising two or more different detection molecules, or
two or more sets of different detection molecules, each detection molecule comprising
at least one binding molecule (BM), at least one linker (Li) and at least one label (La)
as defined herein,
wherein each of the two or more detection molecules, or two or more sets of detection
molecules, comprises a label which is unique to and specific for the binding molecule of
each of said two or more different detection molecules.
In one embodiment said composition comprising two or more different detection
molecules, or two or more sets of different detection molecules, comprises 2 to
1,000,000 different detection molecules, such as 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11, 12 , 13 ,
14, 15 , 16, 17 , 18, 19 , 20, 2 1 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 3 1, 32, 33, 34, 35, 36,
37, 38, 39, 40 different detection molecules; for example 1-3, 3-5, 5-1 0 , 10-15, 15-20,
20-25, 25-30, 30-35, 35-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-1 00, 100-1 10 , 110-
120, 120-1 30, 130-140, 140-150, 150-175, 175-200, 200-250, 250-300, 300-400, 400-
500, 500-600, 600-700, 700-800, 800-900, 900-1000, 1000-1500, 1500-2000, 2000-
3000, 3000-4000, 4000-5000, 5000-7500, 7500-1 0,000, 10,000-20,000, 20,000-
50,000, 50,000-100,000, 100,000-200,000, 200,000-500,000, 500,000-1 ,000,000
different detection molecules, or sets of different detection molecules.
The term 'different detection molecules' as used herein means that one or more of the
binding molecule and/or label of each of the two or more detection molecules, or two or
more sets of detection molecules, are different. Thus, the different detection molecules
have different binding specificities (targets) and/or have different labels.
Another embodiment of the present invention relates to a composition comprising a
subset of multimeric major histocompatibility complexes (MHC's) according to the
invention, wherein each set of MHC's has a different peptide decisive for T cell
recognition and a unique "barcode" region in the nucleic acid label (such as a DNA
molecule).
Ratio of binding molecule/Label
In oneembodiment there is a one-to-one relation between the label and the binding
molecule, i.e. only one specific label (e.g. a specific oligonucleotide sequence) is
attached to a specific binding molecule (e.g. a specific antibody). In other words,
identifying the label (e.g. by sequencing an oligonucleotide label) will unambiguously
identify the binding molecule attached to the label.
In another embodiment there is a one-to-one relation between the label and a group of
binding molecules, i.e. only one specific label (e.g. a specific oligonucleotide sequence)
is attached to a specific set of binding molecules (e.g. twenty different antibodies). In
other words, identifying the label (e.g. by sequencing an oligonucleotide label) will
unambiguously identify the group of binding molecule that may be attached to the label;
identifying the label, however, will not identify the specific binding molecule that is
attached to this particular copy of the label.
In yet another embodiment there is a one-to-one relation between a group of labels and
a group of binding molecules, i.e. the label chosen for a specific detection molecule is
chosen from a a set of labels (e.g. twenty different oligonucleotide sequences) and the
binding molecule chosen for a specific detection molecule is chosen from a set of
binding molecules (e.g. twenty different antibodies). In other words, identifying the label
of a detection molecule (e.g. by sequencing an oligonucleotide label) will
unambiguously identify the group of binding molecule that may be attached to the label;
identifying the label, however, will not identify the specific binding molecule that is
attached to this particular copy of the label.
In another embodiment there is a one-to-one relation between a group of labels and a
binding molecule, i.e. the label chosen for a specific detection molecule is chosen from
a set of labels (e.g. twenty different oligonucleotide sequences). In other words,
identifying the label of a detection molecule (e.g. by sequencing an oligonucleotide
label) will unambiguously identify the binding molecule attached to the label; identifying
the binding molecule, however, will not identify the specific label that is attached to this
particular copy of the label. In cases where a certain label itself binds to the cells (and
thus might lead to the wrong conclusion that the attached binding molecule binds to the
cell), using several labels to encode the same binding molecule will allow the operator
to distinguish binding of the binding molecule from binding of the label to the cell. Using
several labels for the same binding molecule, or using several binding molecules for
the same label can thus be used as internal controls.
Label
The label comprised in the detection molecule of the present invention is any molecule,
atom or signal the identity of which can be found or determined by any means. The
label of a detection molecule specifies the identity of the binding molecule that is linked
to the label. The identity of the label can be determined by any appropriate method for
the specific type of label.
In one embodiment there is provided a detection molecule comprising one or more
binding molecules, one or more linkers, and one or more labels. The one or more
labels may be connected with the other components of the detection molecule in any
manner. In one embodiment, one or more labels are connected to the linker (or one of
the linkers, or both or all of the multiple linkers) of the detection molecule. In one
embodiment one or more labels are connected to the binding molecule (or one of the
binding molecules, or both or all of the multiple binding molecules) of the detection
molecule.
In one embodiment each detection molecule comprises one label. In another
embodiment the detection molecule comprises two or more labels, such as 3 , 4 , 5 , 6 , 7 ,
8 , 9 , 10 , 11, 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 labels. In one embodiment the detection
molecule comprises 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-1 0 , 10-15, 15-20, 20-25, 25-
30, 30-40, 40-50, 50-75, 75-1 00, 100-1 50, 150-200, 200-250, 250-500, 500-750, 750-
1000 labels.
In one embodiment each of said labels are identical to each other. In another
embodiment each of said labels are different from each other. In yet another
embodiment two or more of said labels are different with respect to each other.
In one embodiment the label linked to a given detection molecule is different from the
label linked to other detection molecules used in the same assay.
In another embodiment the detection molecule comprises two different types of labels,
such as 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11, 1 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 different types of
labels.
Labeling molecules
Labelling molecules are molecules that can be detected in a certain analysis, i.e. the
labelling molecules provide a signal detectable by the used method. Label and labelling
molecules are used interchangeably herein.
The labelling molecule may be any labelling molecule suitable for direct or indirect
detection. By the term "direct" is meant that the labelling molecule can be detected per
se without the need for a secondary molecule, i.e. is a "primary" labelling molecule. By
the term "indirect" is meant that the labelling molecule can be detected by using one or
more "secondary" molecules, i.e. the detection is performed by the detection of the
binding of the secondary molecule(s) to the primary molecule.
In one embodiment the labelling molecule is attached to the linker
In one embodiment the labelling molecule is attached to the binding molecule.
The labelling molecule in one embodiment comprises a suitable linker or 'connector
molecule' for attachment to the linker. Linkers suitable for attachment to labelling
molecules would be readily known by the person skilled in the art and as described
elsewhere herein.
A label of the present invention is in one embodiment selected from the group
consisting of polymers, nucleic acids, oligonucleotides, peptides, fluorescent labels,
phosphorescent labels, enzyme labels, chemiluminescent labels, bioluminescent
labels, haptens, antibodies, dyes, nanoparticle labels, elements, metal particles, heavy
metal labels, isotope labels, radioisotopes, stable isotopes, chains of isotopes and
single atoms.
Labels may be organic or inorganic molecules or particles.
Organic molecules labels include ribonucleic acids (e.g. RNA, DNA or unnatural DNA,
RNA, and XNA (e.g. PNA, LNA, GNA, TNA) and mononucleotides, peptides and other
polyamides (e.g. peptides comprising β-amino acid residues), lipids, carbohydrates,
amino acids, and many other molecules.
Inorganic molecule labels include the elements (e.g. Lanthanum, Cerium,
Praseodymium, Neodymium, Promethium, Samarium, Europium, Gadolinium, Terbium,
Dysprosium, and the rest of the elements known). The elements may coupled to the
linker by way of chelates that coordinate the ions (interact non-covalently with the ions),
where the chelates are then linked to the linker (in cases such as Gadolinium where
the element can exist on ionic form), or the element may be contained in micelles. For
some applications, rare elements are particularly favorable. For other applications
heavy metals are particularly favorable.
Isotopes may also be used as labels (e.g. Carbon isotopes 2C, C and 4C).
Furthermore, label molecules comprising combinations of different isotopes and
elements may also be used.
Particle labels include quantum dots, nanoparticles, micelles (e.g. comprising different
fluorophores internally or in its membrane) and other particulate structures.
A molecule label may have a molecular weight of between 1 Da and several million Da.
In some instances a very low molecular weigth is preferred, such as a molecular weight
of 1- 10 Da, 11-50 Da, 50-250 Da, or 251 -500 Da. This may for example be the case
when mass spectrometry is used to detect the identity of element labels (e.g.
Gadolinium, Gd). In other cases a low molecular weight, e.g. 501-2000 Da, 2001-5000
Da, or 5001-10000 Da may be preferred. This may be the case when e.g. peptide
labels are used, where the petide label comprises around 10-40 amino acid residues.
In yet other cases, a high molecular weight of the molecule label is practical, and the
molecular weight of the molecule label may be 10001 -50000 Da, 50001-200000 Da, or
200000-1000000 Da. This may be the case e.g. in cases where a ribonucleic acid label
is used, where the coding region (also called the barcode region or barcode sequence)
is of significant length (e.g. 10-20 nucleotides) and where it is practical to have flanking
primer binding regions of each 10-20 nucleotides, plus other sequences of different
practical use. The resulting oligonucleotide label may in these cases be 30-1000 nt
long, corresponding to molecular weights of about 10000-600000 Da. Finally, multi-
molecule structures, such as in cases where a number of different fluorescent proteins
are ordered in an array by binding to specific regions in a template DNA, where the
total label sthus comprises a long oligonucletide to which is bound a number of
proteins, and the toal molecular weight of the label may thus be 50000-200000 Da,
200001-100000, or 1000001 - 10000000 Da.
In one embodiment the labels are fluorophores and other molecules that emit or absorb
radiation. The fluorophores and other molecules emitting or absorbing radiation may be
of organic or inorganic nature, and can be e.g. small molecules as well as large
proteins. In one embodiment, it is particularly favorable if all the fluorophores and other
molecules that emit or absorp radiation are within the same narrow range of emission
wavelength optimum, such as having wavelength optima in the range 1-10 nm, 11-30
nm, 3 1- 100 nm, 10 1-200 nm, 201-300 nm, 301-400 nm, 401-500 nm, 501-600 nm,
601-700 nm, 701-800 nm, 800-900 nm, 901-1200 nm, 1201-1500 nm, or larger than
1500 nm. As an example, if the instrument has a narrow range of wavelengths that can
be detected, it is advantageous that all labels fall within this range of detection. On the
other hand, if the instrument used to detect the radiation emitted by the labels has a
wide span of detectable wavelengths, it is desirable that the different labels used in an
experiment fall in several of the above-mentioned ranges, as this will result in little
overlap between emission of different labels, and therefore more accurate detection of
relative abundance of the different labels of an experiment. Emitted radiation may be
phosphorescence, luminescence, fluorescence and more.
The labelling compound may suitably be selected:
from fluorescent labels such as 5-(and 6)-carboxyfluorescein, 5- or 6-carboxy-
fluorescein, 6-(fluorescein)-5-(and 6)-carboxamido hexanoic acid, fluorescein isothio-
cyanate (FITC), rhodamine, tetramethylrhodamine, and dyes such as Cy2, Cy3, and
Cy5, optionally substituted coumarin including AMCA, PerCP, phycobiliproteins
including R-phycoerythrin (RPE) and allophycoerythrin (APC), Texas Red, Princeston
Red, Green fluorescent protein (GFP) and analogues thereof, and conjugates of R-
phycoerythrin or allophycoerythrin and e.g. Cy5 or Texas Red, and inorganic
fluorescent labels based on semiconductor nanocrystals (like quantum dot and Qdot™
nanocrystals), and time-resolved fluorescent labels based on lanthanides like Eu3+
and Sm3+,
from haptens such as DNP, biotin, and digoxiginin,
from enzymatic labels such as horse radish peroxidase (HRP), alkaline phosphatase
(AP), beta-galactosidase (GAL), glucose-6-phosphate dehydrogenase, beta-N-acetyl-
glucosaminidase, β-glucuronidase, invertase, Xanthine Oxidase, firefly luciferase and
glucose oxidase (GO),
from luminiscence labels such as luminol, isoluminol, acridinium esters, 1,2-dioxetanes
and pyridopyridazines,
from radioactivity labels such as incorporated isotopes of iodide, cobalt, selenium,
tritium, and phosphor, and
from single atoms such as zinc (Zn), iron (Fe), magnesium (Mg), any of the lanthanides
(Ln) including La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb and Lu;
scandium (Sc) and yttrium (Y).
Different principles of labelling and detection exist, based on the specific property of the
labelling molecule. Examples of different types of labelling are emission of radioactive
radiation (radionuclide, isotopes), absorption of light (e.g. dyes, chromophores),
emission of light after excitation (fluorescence from fluorochromes), NMR (nuclear
magnetic resonance form paramagnetic molecules) and reflection of light (scatter from
e.g. such as gold-, plastic- or glass -beads/particles of various sizes and shapes).
Alternatively, the labelling molecules can have an enzymatic activity, by which they
catalyze a reaction between chemicals in the near environment of the labelling
molecules, producing a signal, which include production of light (chemi-luminescence),
precipitation of chromophor dyes, or precipitates that can be detected by an additional
layer of detection molecules. The enzymatic product can deposit at the location of the
enzyme or, in a cell based analysis system, react with the membrane of the cell or
diffuse into the cell to which it is attached. Examples of labelling molecules and
associated detection principles are shown in the table below.
Labelling substance Effect Assay-principle
Fluorochromes emission of light having a "Photometry, Microscopy,
specific spectra spectroscopy
PMT, photographic film,
CCD's (Color-Capture Device
or Charge-coupled device).
Radionuclide irradiation, α , β or gamma Scintillation counting, GM-
□ rays tube, photographic film ,
excitation of phosphor-imager
screen
Enzyme; catalysis of H20 2 reduction "Photometry, Microscopy,
HRP,(horse reddish using luminol as Oxygen spectroscopy
peroxidase), acceptor, resulting in oxidized PMT, photographic film,
peroxidases in general luminal + light CCD's (Colour-Capture
catalysis of H20 2 reduction Device or Charge-coupled
using a soluble dye, or device),
molecule containing a hapten,
such as a biotin residue as Secondary label linked
Oxygen acceptor, resulting in antibody
precipitation . The habten can
be recognized by a detection
molecule.
Particles; gold , polystyrene Change of scatter, reflection Microscopy, cytometry,
beads, pollen and other and transparency of the electron microscopy
particles associated entity PMT's, light detecting
devices, flowcytometry scatter
AP (Alkaline Phosphatase) Catalyze a chemical "Photometry, Microscopy,
conversion of a non- spectroscopy
detectable to a precipitated
detectable molecule, such as Secondary label linked
a dye or a hapten antibody
lonophores or chelating Change in absorption and "Photometry, Cytometry,
chemical compounds binding emission spectrums when spectroscopy
to specific ions, e.g. Ca + binding.
Change in intensity
Lanthanides Fluorescence "photometry, cytometry,
Phosphorescence spectroscopy
Paramagnetic NMR (Nuclear magnetic
resonance)
DNA fluorescing stains Propidium iodide "Photometry, cytometry,
Hoechst stain spectroscopy
DAPI
AMC
DraQ5™
Acridine orange
7-AAD
Nucleic acid label Sequence, mass PCR amplification , sequening
Mass spec
Gel electrophoresis, PAGE
QPCR
Peptide label Sequence, mass Sequencing
Labelling substance Effect Assay-principle
Mass spec
Gel electrophoresis, PAGE
Labelling molecules can be attached to a given binding molecule by covalent linkage
as described for attachment of binding molecules to multimerization domains
elsewhere herein. The attachment can be directly between reactive groups in the
labelling molecule and reactive groups in the binding molecule or the attachment can
be through a linker covalently attached to labelling molecule and binding molecule.
When labelling MHC multimers the label can be attached either to the MHC complex
(heavy chain, β2ηι or peptide) or to the multimerization domain.
In particular,
one or more labelling molecules may be attached to the carrier molecule, or
one or more labelling molecules may be attached to one or more of the scaffolds, or
one or more labelling compounds may be attached to one or more of the binding
molecules, or one or more labelling compounds may be attached to the carrier
molecule and/or one or more of the scaffolds and/or one or more of the binding
molecules.
A single labelling molecule does not always generate sufficient signal intensity. The
signal intensity can be improved by assembling single label molecules into large multi-
labelling compounds, containing two or more label residues. Generation of multi-label
compounds can be achieved by covalent or non-covalent, association of labelling
molecules with a major structural molecule. Examples of such structures are synthetic
or natural polymers (e.g. dextramers), proteins (e.g. streptavidin), or polymers. The
labelling molecules in a multi-labelling compound can all be of the same type or can be
a mixture of different labelling molecules.
Detection principles can be applied to flow cytometry, stationary cytometry, and batch-
based analysis. Most batch-based approaches can use any of the labelling substances
depending on the purpose of the assay. Flow cytometry primarily employs
fluorescence, whereas stationary cytometry primarily employs light absorption, e.g.
dyes or chromophore deposit from enzymatic activity.
In flow cytometry the typical label is detected by its fluorescence. Most often a positive
detection is based on the presence of light from a single fluorochrome, but in other
techniques the signal is detected by a shift in wavelength of emitted light; as in FRET
based techniques, where the exited fluorochrome transfer its energy to an adjacent
bound fluorochrome that emits light, or when using Ca2+ chelating fluorescent props,
which change the emission (and absorption) spectra upon binding to calcium.
Preferable labelling molecules employed in flowcytometry are illustrated in th etables
and described in the following.
Simple fluorescent labels:
• Fluor dyes, Pacific Blue™, Pacific Orange™, Cascade Yellow™,
• AlexaFluor®(AF);
o AF405, AF488,AF500, AF51 4 , AF532, AF546, AF555, AF568, AF594,
AF61 0 , AF633, AF635, AF647, AF680, AF700, AF71 0 , AF750, AF800
· Quantum Dot based dyes, QDot® Nanocrystals (Invitrogen, MolecularProbs)
o Qdot®525, Qdot®565, Qdot®585, Qdot®605, Qdot®655, Qdot®705,
Qdot®800
• DyLight™ Dyes (Pierce) (DL);
o DL549, DL649, DL680, DL800
· Fluorescein (Flu) or any derivate of that, ex. FITC
• Cy-Dyes
o Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7
• Fluorescent Proteins;
o RPE, PerCp, APC
o Green fluorescent proteins;
■ GFP and GFP-derived mutant proteins; BFP,CFP, YFP, DsRed,
T 1, Dimer2, mRFP1 ,MBanana, mOrange, dTomato, tdTomato,
mTangerine, mStrawberry, mCherry
• Tandem dyes:
o RPE-Cy5, RPE-Cy5.5, RPE-Cy7, RPE-AlexaFluor® tandem conjugates;
RPE-Alexa61 0 , RPE-TxRed
o APC-Aleca600, APC-Alexa61 0 , APC-Alexa750, APC-Cy5, APC-Cy5.5
• lonophors; ion chelating fluorescent props
o Props that change wavelength when binding a specific ion, such as
Calcium
Props that change intensity when binding to a specific ion, such as
Calcium
Combinations of fluorochromes on the same marker. Thus, the marker is not
identified by a single fluorochrome but by a code of identification being a
specific combination of fluorochromes, as well as inter related ratio of
intensities.
Example: Antibody Ab1 and Ab2, are conjugated to both. FITC and BP but Ab1
have 1 FITC to 1 BP whereas Ab2 have 2 FITC to 1 BP. Each antibodymay
then be identified individually by the relative intensity of each fluorochrome. Any
such combinations of n fluorochromes with m different ratios can be generated.
Examples of preferable fluorochromes:
Fluorofor / Fluorochrome Excitation nm Emission nm
2-(4'-maleimidylanilino)naphthalene-6- 322 4 17
sulfonic acid, sodium salt
5-((((2-iodoacetyl)amino)ethyl)amino) 336 490
naphthalene-1 -sulfonic acid
Pyrene-1-butanoic acid 340 376
AlexaFluor 350 (7-amino-6-sulfonic acid-4- 346 442
methyl coumarin-3-acetic acid)
AMCA (7-amino-4-methyl coumarin-3- 353 442
acetic acid)
7-hydroxy-4-methyl coumarin-3-acetic acid 360 455
Marina Blue (6,8-difluoro-7-hydroxy-4- 362 459
methyl coumarin-3-acetic acid)
7-dimethylamino-coumarin-4-acetic acid 370 459
Fluorescamin-N-butyl amine adduct 380 464
7-hydroxy-coumarine-3-carboxylic acid 386 448
CascadeBlue (pyrene-trisulphonic acid 396 4 10
acetyl azide)
Cascade Yellow 409 558
Pacific Blue (6,8 difluoro-7-hydroxy 4 16 451
coumarin-3-carboxylic acid)
7-diethylamino-coumarin-3-carboxylic acid 420 468
N-(((4-azidobenzoyl)amino)ethyl)- 4- 426 534
amino-3,6-disulfo-1 ,8-naphthalimide,
dipotassium salt
Alexa Fluor 430 434 539
3-perylenedodecanoic acid 440 448
8-hydroxypyrene-1 ,3,6-trisulfonic acid, 454 5 1 1
trisodium salt
12-(N-(7-nitrobenz-2-oxa-1 ,3- diazol-4- 467 536
yl)amino)dodecanoic acid
Ν ,Ν'-dimethyl-N- (iodoacetyl)-N'-(7- 478 541
nitrobenz-2- oxa-1 ,3-diazol-4-
yl)ethylenediamine
Oregon Green 488 (difluoro carboxy 488 5 18
fluorescein)
5-iodoacetamidofluorescein 492 5 15
Propidium iodide-DNA adduct 493 636
Carboxy fluorescein 495 5 19
Examples of preferable fluorochrome families:
Fluorochrome family Example fluorochrome
AlexaFluor®(AF) AF®350, AF405, AF430, AF488,AF500, AF514, AF532,
AF546, AF555, AF568, AF594, AF610, AF633, AF635,
AF647, AF680, AF700, AF710, AF750, AF800
Quantum Dot (Qdot®) Qdot®525, Qdot®565, Qdot®585, Qdot®605,
based dyes Qdot®655, Qdot®705, Qdot®800
DyLight™ Dyes (DL) DL549, DL649, DL680, DL800
Small fluorescing dyes FITC, Pacific Blue™, Pacific Orange™, Cascade
Yellow™, Marina blue™, DSred, DSred-2, 7-AAD, TO-
Pro-3,
Cy-Dyes Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7
Phycobili Proteins: R-Phycoerythrin (RPE), PerCP, Allophycocyanin (APC),
B-Phycoerythrin, C-Phycocyanin
Fluorescent Proteins (E)GFP and GFP ((enhanced) green fluorescent protein)
derived mutant proteins; BFP, CFP, YFP, DsRed, T 1,
Dimer2, mRFP1 ,MBanana, mOrange, dTomato,
tdTomato, mTangerine, mStrawberry, mCherry
Tandem dyes with RPE RPE-Cy5, RPE-Cy5.5, RPE-Cy7, RPE-AlexaFluor®
tandem conjugates; RPE-Alexa61 0 , RPE-TxRed
Tandem dyes with APC APC-Aleca600, APC-Alexa610, APC-Alexa750, APC-
Cy5, APC-Cy5.5
Calcium dyes lndo-1-Ca2+ lndo-2-Ca2+
Preferable labelling molecules employed in stationary cytometry and IHC:
• Enzymatic labelling, :
o Horse radish peroxidase; reduces peroxides (H20 2),and the signal is
generated by the Oxygen acceptor when being oxidized.
■ Precipitating dyes; Dyes that when they arereduced they are
soluble, and precipitate when oxidized, generating a coloured
deposit at the site of the reaction.
■ Precipitating agent, carrying a chemical residue, a hapten, for
second layer binding of binding molecules, for amplification of
the primary signal.
■ Luminol reaction, generating a light signal at the site of reaction.
o Other enzymes, such as Alkaline Phosphatase, capable of converting a
chemical compound from a non-detectable molecule to a precipitated
detectable molecule, which can be coloured, or carries a hapten as
described above.
· Fluorescent labels; as those described for Flow cytometry are likewise
important for used in stationary cytometry, such as in fluorescent microscopy.
Examples of preferable labels for stationary cytometry:
In one embodiment the label comprises a connector molecule, which connector
molecule is able to interact with a component on the linker and/or binding molecule of
the detection molecule. In one embodiment the connector molecule is biotin or avidin.
In one embodiment the linker comprises streptavidin to which the label binds via its
biotin or avidin connector molecule.
Nucleic acid label
In one embodiment the detection molecule comprises at least one nucleic acid label,
such as a nucleotide label, for example an oligonucleotide label.
In a preferred embodiment the label is an oligonucleotide. In a preferred embodiment,
the label of the detection molecule is a DNA oligonucleotide (DNA label).
The terms nucleic acid label, nucleic acid molecule, nucleotide label, oligonucleotide
label, DNA molecule, DNA label, DNA tag, DNA oligonucleotides and nucleic acid
component may be used interchangeably herein.
In one embodiment the nucleic acid label comprises one or more of the following
components:
- barcode region,
- 5' first primer region (forward)
- 3' second primer region (reverse),
- random nucleotide region,
- connector molecule
- stability-increasing components
short nucleotide linkers in between any of the above-mentioned components
- adaptors for sequencing
- annealing region
Preferably the nucleic acid label comprises at least a barcode region (i.e. barcode
sequence). A barcode region comprises a sequence of consecutive nucleic acids.
A nucleic acid label of the present invention comprises a number of consecutive nucleic
acids. The nucleic acid can be any type of nucleic acid or modifications thereof,
naturally occurring or synthetically made (artificial nucleic acids).
In one embodiment the nucleic acid label comprises or consists of DNA.
In another embodiment the nucleic acid label comprises or consists of RNA.
In yet another embodiment the nucleic acid label comprises or consists of artificial
nucleic acids or Xeno nucleic acid (XNA).
Artificial nucleic acid analogs have been designed and synthesized by chemists, and
include peptide nucleic acid (PNA), morpholino- and locked nucleic acid (LNA), as well
as glycol nucleic acid (GNA), threose nucleic acid (TNA), HNA and CeNA. Each of
these is distinguished from naturally occurring DNA or RNA by changes to the
backbone of the molecule.
In yet another embodiment the nucleic acid label comprises or consists of one or more
of XNA, PNA, LNA, TNA, GNA, HNA and CeNA,
In a further embodiment the at least one nucleic acid molecule comprises or consists of
DNA, RNA, and/or artificial nucleotides such as PLA or LNA. Preferably DNA, but other
nucleotides may be included to e.g. increase stability.
In a preferred embodiment the oligonucletide used in the invention is a natural
oligonucleotide such as DNA or RNA, or it may be PNA, LNA, or another type of
unnatural oligonucleotide. The oligonucletides may be modified on the base entity, the
sugar entity, or in the linker connecting the individual nucleotides.
The length of the nucleic acid molecule may also vary. Thus, in one embodiment the at
least one nucleic acid molecule has a length in the range 20-1 00 nucleotides, such as
30-1 00, such as 30-80, such as 30-50 nucleotides.
In one embodiment the label is an oligonucleotide of length 1, 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ,
11, 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20, 2 1, 22, 23, 24, 25, 26, 27, 28, 29, 30, 3 1-35, 36-
50, 5 1- 100, or more than 100 nucleotides.
In one embodiment the nucleic acid label comprises 1 to 1,000,000 nucleic acids, such
as 1, 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11, 12 , 13, 14, 15 , 16, 17, 18 , 19, 20, 2 1 , 22, 23, 24, 25,
26, 27, 28, 29, 30, 3 1, 32, 33, 34, 35, 36, 37, 38, 39, 40 nucleic acids; for example 1-3,
3-5, 5-1 0 , 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-50, 50-60, 60-70, 70-80, 80-90,
90-1 00, 100-1 10 , 110-1 20, 120-130, 130-140, 140-1 50, 150-1 75, 175-200, 200-250,
250-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, 900-1 000, 1000-
1500, 1500-2000, 2000-3000, 3000-4000, 4000-5000, 5000-7500, 7500-10,000,
10,000-1 00,000, 100,000-1 ,000,000 nucleic acids.
A nucleic acid label of the present invention as minimum comprises a number of
consecutive nucleic acids. The sequence of the nucleic acids serves as a code that can
be identified, such as amplified and/or sequenced.
The identifiable consecutive nucleic acids, or the identifiable sequence, of the nucleic
acid label are denoted a 'barcode', 'barcode region', 'nucleic acid barcode', 'unique
sequence', 'unique nucleotide sequence' and 'coding sequence' herein (used
interchangably). The barcode region comprises of a number of consecutive nucleic
acids making up a nucleic acid sequence.
In one embodiment the nucleic acid label comprises a central stretch of nucleic acids
(barcode region) designed to be amplified by e.g. PCR.
In one embodiment, a nucleic acid barcode is a unique oligo-nucleotide sequence
ranging for 10 to more than 50 nucleotides. In this embodiment, the barcode has
shared amplification sequences in the 3' and 5' ends, and a unique sequence in the
middle. This unique sequence can be revealed by sequencing and can serve as a
specific barcode for a given binding molecule.
The unique sequence, the barcode, is composed of a series of nucleotides that
together forms a sequence (series of nucleotides) that can be specifically identified
based on its composition. This sequence composition enables barcode#1 to be
distinguishable from barcode#2, #3, #4 etc, up to more than 100.000 barcodes, based
solely on the unique sequence of each barcode. The complete nucleotide barcode may
also be composed of a combination of series of unique nucleotide sequences linked to
each other. The series of unique sequences will together assign the barcode.
In one embodiment, each unique nucleotide sequence (barcode) holds 1, 2 , 3 , 4 , 5 , 6 ,
7 , 8 , 9 , 10, 11, 12, 13, 14, 15, 16 , 17, 18 , 19, 20, 2 1 , 22, 23, 24, 25, 26, 27, 28, 29, 30,
3 1-35, 36-50, 51-1 00, or more than 100 nucleotides (nucleic acids).
In a preferred embodiment the label is an oligonucleotide, where the unique sequence
has a length of 1, 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10, 11, 12 , 13, 14, 15 , 16, 17 , 18, 19, 20, 2 1 , 22,
23, 24, 25, 26, 27, 28, 29, 30, 31-35, 36-50, 5 1- 100, or more than 100 nucleotides. In
one embodiment the unique sequence is shorter than the total length of the label.
In one embodiment the barcode region comprises or consists of 2-5, 5-10, 10-1 5 , 15-
20, 20-25, 25-30, 30-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-1 10,
110-1 20, 120-1 30, 130-140, 140-1 50, 150-1 75, 175-200, 200-250, 250-300, 300-400,
400-500 nucleic acids.
The unique nucleotide sequence (barcode) is solely used as an identification tag for the
molecular interaction between the binding molecule and its target. The unique
nucleotide sequences preferably are not identical to any natural occurring DNA
sequence, although sequence similarities or identities may occur.
Each nucleic acid barcode should hold sufficient difference from the additional
barcodes in a given experiment to allow specific identification of a given barcode,
distinguishable from the others.
The nucleic acid component (preferably DNA) has a special structure. Thus, in an
embodiment the at least one nucleic acid molecule (label) is composed of at least a 5'
first primer region, a central region (barcode region), and a 3' second primer region. In
this way the central region (the barcode region) can be amplified by a primer set.
The coupling of the nucleic acid molecule to the backbone may also vary. Thus, in one
embodiment the at least one nucleic acid molecule is linked to said backbone via a
streptavidin-biotin binding and/or streptavidin-avidin binding. Other coupling moieties
may also be used.
In one embodiment the nucleic acid label comprises a connector molecule, which
connector molecule is able to interact with a component on the linker and/or binding
molecule of the detection molecule. In one embodiment the connector molecule is
biotin or avidin. In one embodiment the linker comprises streptavidin to which the label
binds via its biotin or avidin connector molecule.
In one embodiment the nucleic acid label comprises a random nucleotide region. This
random nt region is a potential tool for detecting label contaminants. A random nt
region of the invention in one embodiment comprises from 3-20 nucleotides, such as 3 ,
4 , 5 , 6 , 7 , 8 , 9 , 10, 11, 12 , 13,1 4,1 5 , 16 , 17, 18 , 19 or 20 nt.
In some embodiments, the different labels used in an experiment possess the same
amplification properties and share common primer regions: Common primer regions
together with shared amplification properties will ensure that all labels that are present
after cellular interaction and sorting are amplified equally whereby no sequences will be
biased due to the sequencing reaction.
With identical primer regions on differing labels there is an inherent risk of
contaminating one label with another - especially following amplification reactions. To
be able to trace potential contaminants a short 'random nucleotide region' can be
included in the nucleic acid label. Since the random nucleotide region is unique for
each label, it will be possible to inspect the sequencing data and see whether
numerous reads of a given label is present. I.e. the random nucleotide region is a
clonality control region. In one embodiment the random nucleotide region consist of 2-
20 nucleic acids; such as 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11, 12, 13 , 14, 15 , 16, 17, 18 , 19 or
20 nucleic acids. A random nucleotide region consisting of 6 nucleotides may be
denoted 'N6' herein, and so forth.
In one embodiment the nucleic acid label comprises one or more stability-increasing
components (such as HEG or TEG)
The label is preferably stable when mixing with cells: as this may expose the label to
nuclease digestion. A measure to minimize this may be to add modifications in the form
of hexaethylene glycol (HEG) or TEG at one or both ends of the oligonucleotide label.
Additionally stability can be accounted for in the buffers applied by adding constituents
that exert a protective effect towards the oligo-nucleotides, e.g herring DNA and EDTA
In one embodiment the nucleic acid label comprises a sample identifying sequence. To
be able to analyze more than a single sample in each sequencing reaction the nucleic
acid labels may be appointed an additional recognition feature, namely a sample
identifying sequence. The sample identifying sequence is not a part of the initial design
of the label, but will be appointed after cellular interaction and sorting via primers in a
PCR - thus all cells originating from the same sample, will have the same sample
identification sequence. In one embodiment the sample identifying sequence is a short
sequence, consisting of 2-20 nucleic acids; such as 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11, 12 , 13 ,
14, 15 , 16, 17 , 18, 19 or 20 nucleic acids. The sample identifying sequence may be
attached to a primer, such as the forward primer.
The nucleic acid label is in one embodiment a Ί oligo system' comprising a forward
primer, a barcode region and a reverse primer.
The nucleic acid label is in one embodiment a '2 oligo system' with two sequences, the
first comprising a forward primer, a barcode region and a annealing region; and the
second comprising an annealing region, a barcode region and a reverse primer.
Peptide label
In one embodiment the label, or the coding label, is a peptide label comprising a stretch
of consecutive amino acid residues. This is the 'coding region' the identity of which can
be determined.
In one embodiment the peptide label comprises or consists of a defined number of
consecutive amino acids. It follows that the nucleic acid label in one embodiment
comprises 2 or more consecutive amino acids, such as 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9,
9-10, 10-1 1, 11-12, 12-13, 13-14, 14-1 5 , 15-16, 16-17, 17-1 8 , 18-19, 19-20, 20-21 , 2 1-
22, 22-23, 23-24, 24-25, 25-26, 26-27, 27-28, 28-29, 29-30, 30-31 , 31-32, 32-33, 33-
34, 34-35, 35-36, 36-37, 37-38, 38-39, 39-40, 40-45, 45-50, 50-55, 55-60, 60-65, 65-
70,70-75, 75-80, 80-85, 85-90, 90-95, 95-1 00, 100-1 10, 110-120, 120-1 30, 130-140,
140-150, 150-1 60, 160-170,170-180, 180-1 90, 190-200, 200-225, 225-250, 250-275,
275-300, 300-350, 350-400, 400-450, 450-500, 500-600, 600-700, 700-800, 800-900,
900-1 000, 1000-1 500, 1500-2000, or more than 2000, consecutive amino acids.
In one embodiment the peptide label comprises a stretch of consecutive amino acid
residues (coding region) and a protease cleavage site. The protease cleavage site is
preferably located proximal to the linker that connects the label to the binding molecule.
When the detection molecule is brought into proximity of a protease, the peptide label
is cleaved and the coding region released from the detection molecule. The sample
cells may be precipitated and the supernatant can be analysed by mass spectrometry
to determine the identity and amount of the labels that was released.
Proteases capable of cleaving the peptide labels may be coated on the surface of
sample cells, for example by adding antibody-protease conjugates where the antibody
recognizes a particular cell surface structure.
In one embodiment the peptide label comprises natural (or standard) amino acids. In
another embodiment the peptide label comprises non-naturally occurring amino acids
(non-proteinogenic or non-standard ) . In one embodiment the peptide label comprises
standard and non-standard amino acids.
A natural amino acid is a naturally occurring amino acid existing in nature and being
naturally incorporated into polypeptides (proteinogenic). They consist of the 20
genetically encoded amino acids Ala, Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, lie, Leu,
Lys, Met, Phe, Pro, Ser, Tyr, Thr, Trp, Val, and 2 which are incorporated into proteins
by unique synthetic mechanisms: Sec (selenocysteine, or U) and Pyl (pyrrolysine, O).
These are all L-stereoisomers.
Aside from the 22 natural or standard amino acids, there are many other non-naturally
occurring amino acids (non-proteinogenic or non-standardj. They are either not found
in proteins, or are not produced directly and in isolation by standard cellular machinery.
Non-standard amino acids are usually formed through modifications to standard amino
acids, such as post-translational modifications.
Any amino acids according to the present invention may be in the L- or D-configuration.
The standard and/or non-standard amino acids may be linked by peptide bonds to form
a linear peptide chain.
The term peptide also embraces post-translational modifications introduced by
chemical or enzyme-catalyzed reactions, as are known in the art. Also, functional
equivalents may comprise chemical modifications such as ubiquitination, labeling (e.g.,
with radionuclides, various enzymes, etc.), pegylation (derivatization with polyethylene
glycol), or by insertion (or substitution by chemical synthesis) of amino acids (amino
acids) which do not normally occur in human proteins.
Protein post-translational modification (PTM) increases the functional diversity of the
proteome by the covalent addition of functional groups or proteins, proteolytic cleavage
of regulatory subunits or degradation of entire proteins. These modifications include
phosphorylation, glycosylation, ubiquitination, nitrosylation, methylation, acetylation,
lipidation (C-terminal glycosyl phosphatidylinositol (GPI) anchor, N-terminal
myristoylation, S-myristoylation, S-prenylation), amidation, and proteolysis and
influence almost all aspects of normal cell biology and pathogenesis.
Sterically similar compounds may be formulated to mimic the key portions of the
peptide structure and that such compounds may also be used in the same manner as
the peptides of the invention. This may be achieved by techniques of modelling and
chemical designing known to those of skill in the art. For example, esterification and
other alkylations may be employed to modify the amino terminus of e.g a di-arginine
peptide backbone, to mimic a tetra peptide structure. It will be understood that all such
sterically similar constructs fall within the scope of the present invention.
Peptides with N-terminal alkylations and C-terminal esterifications are also
encompassed within the present invention. Functional equivalents also comprise
glycosylated and covalent or aggregative conjugates formed with the same molecules,
including dimers or unrelated chemical moieties. Such functional equivalents are
prepared by linkage of functionalities to groups which are found in fragment including at
any one or both of the N- and C-termini, by means known in the art.
Binding molecules
A binding molecule is a molecule that specifically associates covalently or non-
covalently with a structure belonging to or associated with an entity in a sample. The
defined structure in sample bound by a binding molecule is also called the target
structure or target of the binding molecule. A typical target for a binding molecule is a
'marker molecule', which marker molecule is specific for a given cell or cell type.
Example binding molecule include but is not limited to proteins, antibodies (monoclonal
or polyclonal, derived from any species e.g. man, mouse, rat, rabbit, pig or camel,
monkey or may be recombinant antibodies), antibody fragments, MHC multimers
(including but not limited to MHC dextramers, MHC tetramers, MHC Pentamers, cells
expressing MHC molecules, MHC-peptide molecules covalently or non-covalently
attached to beads, streptactin or other molecule structures), scaffold molecules,
ligands, small organic molecules, nulceic acids (e.g. DNA, RNA, PNA),
polysaccharides, other polymers, Aptamers including nucleic acid aptamers and
peptide aptamers, affimers, beads, cells, living cells, dead cells, naturally occurring
cells, genetic modified cells, hybridoma cells, gene transfected cells, cell like structures
(e.g. liposomes, micelles), multicomponent complexes comprising 2 , 3 , 4 , 5 , 6 , 7 , 8 , or
more binding molecule subunits, and supramolecular structures, or other molecules,
cells or substances able to bind defined structure in sample.
A binding molecule is useful for detection of a given defined structure in sample if the
binding molecule binds the defined structure with a certain affinity. In order to be
specific the binding molecule has to have a binding affinity that is higher than the
binding molecules binding affinity for other structures in sample.
When the detection molecule comprises two or more binding molecules, the binding
molecule may be referred to as a binding molecule multimer. When the detection
molecule comprises two or more binding molecules, wherein the binding molecules are
MHC molecules or MHC complexes, the MHC complexes may be referred to as a MHC
multimer.
Typical defined structures or targets to which the binding molecule associate include
but is not limited to: surface receptors on cells (e.g. TCR, CD molecules, growth
receptors, MHC complexes, mannose binding receptor, transporter proteins), other
structures on the surface of cells (e.g. lipids, sugars, proteins), intracellular substances
in cells (e.g. DNA, RNA, ribosomes, organelles, cytokines, transcription factors,
cytoskeleton components, intracellular proteins, sugars), components in fluidics (e.g.
antibodies, blood plates, serum proteins, sugars), structures in interstitial space in
tissues ect.
A binding molecule may have a molecular weight of between 50 Da and several million
Da. In some instances a very low molecular weight is preferred, such as a molecular
weight of 50-250 Da, or 251 -500 Da. In other cases a low molecular weight, e.g. 501-
2000 Da, 2001-5000 Da, or 5001 - 10000 Da may be preferred. In yet other cases, a
high molecular weight of the binding molecule is practical, and the molecular weight of
the binding molecule may be 10001-50000 Da, 50001-200000 Da, or 200000-1 000000
Da. Finally, multi-molecule structures, such as in cases where a number of different
fluorescent proteins are ordered in an array by binding to specific regions in a template
DNA, where the total binding molecule thus is 50000-200000 Da, 200001-1 00000, or
1000001 - 10000000 Da.
Examples of binding molecules and corresponding target molecules are given below:
I. Antibodies binding to membrane components on, or within cells; e.g.
Polysaccharides, proteins, or lipid residues.
II. MHC multimers (e.g. MHC dextramers, MHC tetramers, MHC
pentamers), optionally complexed with a specific peptide, binds to the T-
cell receptor (TCR) on T-cells.
III. MHC multimers (e.g. MHC dextramers, MHC tetramers, MHC
pentamers), complexed with a so-called nonsense peptide (i.e. a
peptide that binds the MHC protein but expectably does not mediate
efficient MHC complex-TCR interaction with any T-cell), are used as
negative control for the specific binding of a specific MHC multimers to
the cell.
IV. Binding molecules such as Propidium Iodide (PI) that stain DNA in cells,
here the binding molecule and the label can optionally be the same
molecule.
V. Binding molecules that stain DNA, and that is used to characterize the
state of a cell (e.g. state of cell cycle), e.g. Draq 5 , PI, or other DNA
binding molecules.
VI. Binding molecules that bind specifically to incorporated molecules. An
example is BrdU, which may be added to a cell which will incorporate
BrdU into its DNA; by using anti-BrdU antibody, cells that have
incorporated BrdU will be detected.
VII. Binding molecules such as hormones, or growth factors, that specifically
interacts with a cellular component, such as the estrogen receptor with
estrogen or the EGF receptor with EGF.
VIII. Introduction of modified nucleotides, amino acids, or vitamins into cells
which incorporate these into cellular components that subsequently can
be detected, by themselves (e.g. if they are radioactive, or fluoresce) or
by their association with a detection molecule.
In one embodiment the binding molecule is an MHC or MHC like complex, such as
CD1 a , CD1 b, CD1 c, or CD1 d in complex with a peptide, lipid, glycolipid or any other
molecule that binds to CD1 a , CD1 b, CD1 c , or CD1 d , or such as MR1 in complex with
any epitope that binds to the MR1 complex, or such as an empty CD1a, CD1 b, CD1c,
CD1d or MR1 , i.e. without epitope bound.
In one embodiment the detection molecule is CD1 , such as CD1 selected from the
group consisting of CD1 CD1 a , CD1 b, CD1c, CD1d and CD1 e.
CD1 (cluster of differentiation 1) is a family of glycoproteins expressed on the surface
of various human antigen-presenting cells. They are related to the class I MHC
molecules, and are involved in the presentation of lipid antigens to T cells.
In one embodiment the detection molecule is a MHC Class l-like proteins; such as MIC
A, MIC B, CD1d, HLA E, HLA F, HLA G, HLA H, ULBP-1 , ULBP-2, and ULBP-3.
In one embodiment the binding molecule of the invention comprises one peptide-major
histocompatibility complex (pMHC) or MHC complex. In another embodiment the
binding molecule of the invention comprises 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11, 12 , 13 , 14 , 15 ,
16 , 17 , 18,1 9 , 20, such as 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-1 0 , 10-1 1, 11-1 2 , 12-
13 , 13-1 5 , 15-1 6 , 16-20, 20-21 , 2 1-50, 50-1 00, 5 1- 100, or more than 100 MHC
complexes, such as peptide-MHC complexes.
In a particular embodiment the binding molecule of the detection molecule is an
oligonucleotide, wherein said oligonucleotide preferably binds to DNA or RNA
molecules inside a cell. Optionally, the identity of the detection molecule within a cell is
determined by extending the oligonucleotide-binding molecule using a polymerase, in
this way identifying the detection molecule as well as the RNA or DNA template to
which it is attached.
The MHC multimer can be composed of MHC class I, class II, CD1 or other MHC-like
molecules. Thus, when the term MHC multimers is used herein this includes all MHC-
like molecules. The MHC multimer is formed through multimerization of peptide-MHC
molecules via different backbones.
An aspect of the invention relates to a multimeric major histocompatibility complex
(MHC) comprising
two or more MHC's linked by a backbone molecule; and
- at least one nucleic acid molecule linked to said backbone, wherein said nucleic
acid molecule comprises a central stretch of nucleic acids (barcode region)
designed to be amplified by e.g. PCR.
Different types of backbones may be used. Thus, in an embodiment the backbone
molecule is selected from the group consisting of polysaccharides, such as glucans
such as dextran, a streptavidin or a streptavidin multimer. The skilled artisan may find
other alternative backbones.
The MHC's may be coupled to the backbone by different means. Thus, in an
embodiment the MHC's are coupled to the backbone through a streptavidin-biotin
binding or a streptavidin-avidin binding. Again other binding moieties may be used. The
specific binding may use specific couplings points. In another embodiment the MHC's
are linked to the backbone via the MHC heavy chain.
The MHC consists of different elements, which may partly be expressed and purified
from cell systems (such as the MHC heavy chain and the Beta-2-microglobulin
element). Alternatively, the elements may be chemically synthesized. The specific
peptide is preferably chemically synthesized.
All three elements are required for the generation of a stable MHC (complex). Thus, in
an embodiment the MHC is artificially assembled.
The multimeric MHC may comprise different numbers of MHC's. Thus, in yet an
embodiment the multimeric major histocompatibility complex (MHC) is composed of at
least four MHC's, such as at least eight, such as at least ten, 2-30, 2-20, such as 2-1 0
or such as 4-10 MHC's.
In one embodiment there is provided a detection molecule comprising two or more
MHC complexes and a multimerization domain, such as comprising 2 MHC complexes,
such as 3 MHC complexes, for example 4 MHC complexes, such as 5 MHC
complexes, for example 6 MHC complexes, such as 7 MHC complexes, for example 8
MHC complexes, such as 9 MHC complexes, for example 10 MHC complexes, such as
11 MHC complexes, for example 12 MHC complexes, such as 13 MHC complexes, for
example 14 MHC complexes, such as 15 MHC complexes, for example 16 MHC
complexes, such as 17 MHC complexes, for example 18 MHC complexes, such as 19
MHC complexes, for example 20 MHC complexes, such as 2 1 MHC complexes, for
example 22 MHC complexes, such as 23 MHC complexes, for example 24 MHC
complexes, such as 25 MHC complexes, for example 26 MHC complexes, such as 27
MHC complexes, for example 28 MHC complexes, such as 29 MHC complexes, for
example 30 MHC complexes, such as more than 30 MHC complexes.
In one embodiment there is provided a detection molecule comprising two or more
MHC complexes and a multimerization domain, such as 2-3 MHC complexes, for
example 3-4 MHC complexes, such as 4-5 MHC complexes, for example 5-6 MHC
complexes, such as 6-7 MHC complexes, for example 7-8 MHC complexes, such as 8-
9 MHC complexes, for example 9-1 0 MHC complexes, such as 10-1 1 MHC complexes,
for example 11- 12 MHC complexes, such as 12-13 MHC complexes, for example 13-
14 MHC complexes, such as 14-15 MHC complexes, for example 15-16 MHC
complexes, such as 16-17 MHC complexes, for example 17-1 8 MHC complexes, such
as 18-1 9 MHC complexes, for example 19-20 MHC complexes, such as 20-25 MHC
complexes, for example 25-30 MHC complexes, such as 30-35 MHC complexes, for
example 35-40 MHC complexes, such as 40-45 MHC complexes, for example 45-50
MHC complexes, such as 50-55 MHC complexes, for example 55-60 MHC complexes,
such as 60-65 MHC complexes, for example 65-70 MHC complexes, such as 70-75
MHC complexes, for example 75-80 MHC complexes, such as 80-85 MHC complexes,
for example 85-90 MHC complexes, such as 90-95 MHC complexes, for example 95-
100 MHC complexes, such as 100-1 25 MHC complexes, for example 125-1 50 MHC
complexes, such as 150-1 75 MHC complexes, for example 175-200 MHC complexes,
such as more than 200 MHC complexes.
In one embodiment the detection molecule comprises 2-20 MHC complexes, for
example 2-1 0 MHC complexes, such as 4-20 MHC complexes, for example 4-10 MHC
complexes, such as 5-10 MHC complexes, for example 5-20 MHC complexes, such as
5-25 MHC complexes.
In one embodiment there is provided a detection molecule comprising two or more
MHC complexes and a multimerization domain, and comprising one or more labels,
such as DNA labels, as defined herein elsewhere.
Different types of MHC's may form part of the multimer. Thus, in an embodiment the
MHC is selected from the group consisting of class I MHC, a class I I MHC, a CD1 , or a
MHC-like molecule. For MHC class I the presenting peptide is a 9-1 1mer peptide; for
MHC class II, the presenting peptide is 12-18mer peptides. For alternative MHC-
molecules it may be fragments from lipids or gluco-molecules which are presented.
In one embodiment the binding molecule comprises a connector molecule, which
connector molecule is able to interact with a component on the linker and/or label of the
detection molecule. In one embodiment the connector molecule is biotin or avidin. In
one embodiment the linker comprises streptavidin to which the binding molecule binds
via its biotin or avidin connector molecule.
BM: MHC COMPLEXES
In a preferred embodiment the binding molecule of the detection molecule of the
present invention comprises one or more MHC complexes (or MHC molecules).
The present invention in one embodiment provides a detection molecule comprising a
binding molecule (BM), a linker (Li) and a label (La), wherein the binding molecule
comprises one or more MHC complexes.
The present invention in one embodiment provides a detection molecule comprising a
binding molecule (BM), a linker (Li) and a label (La), wherein the binding molecule
comprises one or more MHC complexes, and the label is a nucleic acid label, such as
a DNA label.
The present invention in one embodiment provides a detection molecule comprising a
binding molecule (BM), a linker (Li) and a label (La), wherein the binding molecule
comprises one or more MHC complexes, the label is a nucleic acid label, such as a
DNA label, and the linker is a multimerization domain (or carrier molecule, or
backbone).
The present invention in one embodiment provides a detection molecule comprising a
binding molecule (BM), a linker (Li) and a label (La), wherein the binding molecule
comprises two or more MHC complexes, the linker is a dextran multimerization domain
(also known as 'MHC dextramers'), and the label is a nucleic acid label, such as a DNA
label.
The MHC as a binding molecule (MHC-BM) according to the present invention is
described in more detail herein below. The MHC as a binding molecule according to
the present invention in combination with some linkers is also disclosed in detail herein
below.
Each embodiment wherein the binding molecule is a MHC complex can be combined
individually with any of the herein disclosed further components of the detection
molecules namely linker and label.
The present invention in one aspect refers to a detection molecule comprising a MHC
monomer comprising a-b-P, or a MHC multimer comprising (a-b-P)n, wherein n > 1,
wherein a and b together form a functional MHC protein capable of binding an
antigenic peptide P,
wherein (a-b-P) is a MHC-peptide complex formed when the antigenic peptide P binds
to the functional MHC protein.
The present invention in another aspect refers to a MHC monomer comprising a-b-P,
or a MHC multimer comprising (a-b-P)n, wherein n > 1,
wherein a and b together form a functional MHC protein capable of binding an
antigenic peptide P,
wherein (a-b-P) is a MHC-peptide complex formed when the antigenic peptide P binds
to the functional MHC protein, and
wherein each MHC complex or MHC peptide complex of a MHC multimer is associated
with one or more multimerization domains.
MHC monomers and MHC multimers comprising two or more MHC complexes and/or
MHC peptide complexes of class 1 or class 2 MHC are covered by the present
invention.
In another aspect the present invention is directed to a composition comprising a
plurality of MHC monomers and/or MHC multimers according to the present invention,
wherein the MHCs of the MHC multimers individually are identical or different, and a
linker such as a carrier.
The present invention further relates to a method for detection of antigen-specific T
cells, said method comprising the steps of 1) providing a detection molecule comprising
a MHC multimer, 2) providing a population of antigen-specific T cells, and 3) detecting
antigen-specific T cells specific for the peptide P of the MHC multimer.
In a further embodiment the present invention relates to a method for counting of
antigen-specific T cells, said method comprising the steps of 1) providing a detection
molecule comprising a MHC multimer, 2) providing a population of antigen-specific T
cells, and 3) counting antigen-specific T cells specific for the peptide P of the MHC
multimer.
The present invention also relates to a method for sorting of antigen-specific T cells,
said method comprising the steps of 1) providing a detection molecule comprising a
MHC multimer, 2) providing a population of antigen-specific T cells, and 3) sorting
antigen-specific T cells specific for the peptide P of the MHC multimer.
In yet another embodiment the present invention relates to a method for isolation of
antigen-specific T cells, said method comprising the steps of 1) providing a detection
molecule comprising a MHC multimer, 2) providing a population of antigen-specific T
cells, and 3) isolating antigen-specific T cells specific for the peptide P of the MHC
multimer.
In a still further aspect there is provided a method for immune monitoring of one or
more diseases comprising monitoring of antigen-specific T cells, said method
comprising the steps of
i) providing a detection molecule comprising a MHC monomer or MHC multimer or
individual components thereof according to the present invention,
ii) providing a population of antigen-specific T cells or individual antigen-specific T
cells, and
iii) measuring the number, activity or state and/or presence of antigen-specific of T
cells specific for the peptide P of the said MHC monomer or MHC multimer, thereby
immune monitoring said one or more diseases.
In one aspect, the present invention is directed to MHC complexes comprising a linker
which is a multimerization domain, preferably comprising a carrier molecule and/or a
scaffold.
There is also provided a MHC multimer comprising 2 or more MHC-peptide complexes
and a multimerization domain to which the 2 or more MHC-peptide complexes are
associated. The MHC multimer can generally be formed by association of the 2 or
more MHC complexes with the multimerization domain to which the 2 or more MHC
complexes are capable of associating.
The multimerization domain can be a scaffold associated with one or more MHC
complexes, or a carrier associated with one or more, preferably more than one, MHC
complex(es), or a carrier associated with a plurality of scaffolds each associated with
one or more MHC complexes, such as 2 MHC complexes, 3 MHC complexes, 4 MHC
complexes, 5 MHC complexes or more than 5 MHC complexes. Accordingly,
multimerization domain collectively refers to each and every of the above. It will be
clear from the detailed description of the invention provided herein below when the
multimerization domain refers to a scaffold or a carrier or a carrier comprising one or
more scaffolds. It is understood that MHC complexes of the invention may or may not
be loaded with antigenic peptides; when they are this may be referred to as a MHC-
peptide complex.
Generally, when a multimerization domain comprising a carrier and/or a scaffold is
present, the MHC complexes can be associated with this domain either directly or via
one or more binding entities. The association can be covalent or non-covalent.
Accordingly, there is provided in one embodiment a MHC complex comprising one or
more entities (a-b-P) n, wherein a and b together form a functional MHC protein capable
of binding a peptide P, and wherein (a-b-P) is the MHC-peptide complex formed when
the peptide P binds to the functional MHC protein, said MHC complex optionally further
comprising a multimerization domain comprising a carrier molecule and/or a scaffold.
"MHC complex" refers to any MHC complex, including MHC monomers in the form of a
single MHC complex and MHC multimers comprising a multimerization domain to
which more than one MHC complex is associated. MHC complexes can be with or
without peptide P included in the binding groove of the MHC.
When the invention is directed to complexes comprising a MHC multimer, i.e. a plurality
of MHC complexes of the general composition (a-b-P)n associated with a
multimerization domain, n is by definition more than 1, i.e. at least 2 or more.
Accordingly, the term "MHC multimer" is used herein specifically to indicate that more
than one MHC complex is associated with a multimerization domain, such as a scaffold
or carrier or carrier comprising one or more scaffolds. Accordingly, a single MHC
complex can be associated with a scaffold or a carrier or a carrier comprising a scaffold
and a MHC-multimer comprising 2 or more MHC complexes can be formed by
association of the individual MHC complexes with a scaffold or a carrier or a carrier
comprising one or more scaffolds each associated with one or more MHC complexes.
When the MHC complex comprises a multimerization domain to which the n MHC
complexes are associated, the association can be a covalent linkage so that each or at
least some of the n MHC complexes is covalently linked to the multimerization domain,
or the association can be a non-covalent association so that each or at least some of
the n MHC complexes are non-covalently associated with the multimerization domain.
The MHC complexes of the invention may be provided in non-soluble or soluble form,
depending on the intended application.
Effective methods to produce a variety of MHC complexes comprising highly
polymorphic human HLA encoded proteins makes it possible to perform advanced
analyses of complex immune responses, which may comprise a variety of peptide
epitope specific T-cell clones.
One of the benefits of the MHC complexes of the present invention is that the MHC
complexes overcome low intrinsic affinities of monomer ligands and counter receptors.
The MHC complexes have a large variety of applications that include targeting of high
affinity receptors (e.g. hormone peptide receptors for insulin) on target cells. Taken
together poly-ligand binding to target cells has numerous practical, clinical and
scientifically uses.
Thus, the present invention provides MHC complexes which present mono-valent or
multi-valent binding sites for MHC-peptide recognising cells, such as MHC complexes
optionally comprising a multimerization domain, such as a scaffold or a carrier
molecule, which multimerization domain have attached thereto, directly or indirectly via
one or more connectors, covalently or non-covalently, one or more MHC complexes.
"One or more" as used herein is intended to include one as well as a plurality, such as
at least 2 . This applies i.a. to the MHC complexes and to the binding entities of the
multimerization domain. The scaffold or carrier molecule may thus have attached
thereto a MHC complex or a plurality of such MHC complexes, and/or a connectoror a
plurality of connectors.
In one preferred embodiment the MHC multimer is between 50,000 Da and 1,000,000
Da, such as from 50,000 Da to 980,000; for example from 50,000 Da to 960,000; such
as from 50,000 Da to 940,000; for example from 50,000 Da to 920,000; such as from
50,000 Da to 900,000; for example from 50,000 Da to 880,000; such as from 50,000
Da to 860,000; for example from 50,000 Da to 840,000; such as from 50,000 Da to
820,000; for example from 50,000 Da to 800,000; such as from 50,000 Da to 780,000;
for example from 50,000 Da to 760,000; such as from 50,000 Da to 740,000; for
example from 50,000 Da to 720,000; such as from 50,000 Da to 700,000; for example
from 50,000 Da to 680,000; such as from 50,000 Da to 660,000; for example from
50,000 Da to 640,000; such as from 50,000 Da to 620,000; for example from 50,000
Da to 600,000; such as from 50,000 Da to 580,000; for example from 50,000 Da to
560,000; such as from 50,000 Da to 540,000; for example from 50,000 Da to 520,000;
such as from 50,000 Da to 500,000; for example from 50,000 Da to 480,000; such as
from 50,000 Da to 460,000; for example from 50,000 Da to 440,000; such as from
50,000 Da to 420,000; for example from 50,000 Da to 400,000; such as from 50,000
Da to 380,000; for example from 50,000 Da to 360,000; such as from 50,000 Da to
340,000; for example from 50,000 Da to 320,000; such as from 50,000 Da to 300,000;
for example from 50,000 Da to 280,000; such as from 50,000 Da to 260,000; for
example from 50,000 Da to 240,000; such as from 50,000 Da to 220,000; for example
from 50,000 Da to 200,000; such as from 50,000 Da to 180,000; for example from
50,000 Da to 160,000; such as from 50,000 Da to 140,000; for example from 50,000
Da to 120,000; such as from 50,000 Da to 100,000; for example from 50,000 Da to
80,000; such as from 50,000 Da to 60,000; such as from 100,000 Da to 980,000; for
examp e from 100,000 Da to 960,000; such as from 100,000 Da to 940,000; for
examp e from 100,000 Da to 920,000; such as from 100,000 Da to 900,000; for
examp e from 100,000 Da to 880,000; such as from 100,000 Da to 860,000; for
examp e from 100,000 Da to 840,000; such as from 100,000 Da to 820,000; for
examp e from 100,000 Da to 800,000; such as from 100,000 Da to 780,000; for
examp e from 100,000 Da to 760,000; such as from 100,000 Da to 740,000; for
examp e from 100,000 Da to 720,000; such as from 100,000 Da to 700,000; for
examp e from 100,000 Da to 680,000; such as from 100,000 Da to 660,000; for
examp e from 100,000 Da to 640,000; such as from 100,000 Da to 620,000; for
examp e from 100,000 Da to 600,000; such as from 100,000 Da to 580,000; for
examp e from 100,000 Da to 560,000; such as from 100,000 Da to 540,000; for
examp e from 100,000 Da to 520,000; such as from 100,000 Da to 500,000; for
examp e from 100,000 Da to 480,000; such as from 100,000 Da to 460,000; for
examp e from 100,000 Da to 440,000; such as from 100,000 Da to 420,000; for
examp e from 100,000 Da to 400,000; such as from 100,000 Da to 380,000; for
examp e from 100,000 Da to 360,000; such as from 100,000 Da to 340,000; for
examp e from 100,000 Da to 320,000; such as from 100,000 Da to 300,000; for
examp e from 100,000 Da to 280,000; such as from 100,000 Da to 260,000; for
examp e from 100,000 Da to 240,000; such as from 100,000 Da to 220,000; for
examp e from 100,000 Da to 200,000; such as from 100,000 Da to 180,000; for
examp e from 100,000 Da to 160,000; such as from 100,000 Da to 140,000; for
examp e from 100,000 Da to 120,000; such as from 150,000 Da to 980,000; for
examp e from 150,000 Da to 960,000; such as from 150,000 Da to 940,000; for
examp e from 150,000 Da to 920,000; such as from 150,000 Da to 900,000; for
examp e from 150,000 Da to 880,000; such as from 150,000 Da to 860,000; for
examp e from 150,000 Da to 840,000; such as from 150,000 Da to 820,000; for
examp e from 150,000 Da to 800,000; such as from 150,000 Da to 780,000; for
examp e from 150,000 Da to 760,000; such as from 150,000 Da to 740,000; for
examp e from 150,000 Da to 720,000; such as from 150,000 Da to 700,000; for
examp e from 150,000 Da to 680,000; such as from 150,000 Da to 660,000; for
examp e from 150,000 Da to 640,000; such as from 150,000 Da to 620,000; for
examp e from 150,000 Da to 600,000; such as from 150,000 Da to 580,000; for
examp e from 150,000 Da to 560,000; such as from 150,000 Da to 540,000; for
example from 150,000 Da to 520,000 such as from 150,000 Da to 500,000; for
example from 150,000 Da to 480,000 such as from 150,000 Da to 460,000; for
example from 150,000 Da to 440,000 such as from 150,000 Da to 420,000; for
example from 150,000 Da to 400,000 such as from 150,000 Da to 380,000; for
example from 150,000 Da to 360,000 such as from 150,000 Da to 340,000; for
example from 150,000 Da to 320,000 such as from 150,000 Da to 300,000; for
example from 150,000 Da to 280,000 such as from 150,000 Da to 260,000; for
example from 150,000 Da to 240,000 such as from 150,000 Da to 220,000; for
example from 150,000 Da to 200,000 such as from 150,000 Da to 180,000; for
example from 150,000 Da to 160,000
In another preferred embodiment the MHC multimer is between 1,000,000 Da and
3,000,000 Da, such as from 1,000,000 Da to 2,800,000; for example from 1,000,000
Da to 2,600,000; such as from 1,000,000 Da to 2,400,000; for example from 1,000,000
Da to 2,200,000; such as from 1,000,000 Da to 2,000,000; for example from 1,000,000
Da to 1,800,000; such as from 1,000,000 Da to 1,600,000; for example from 1,000,000
Da to 1,400,000.
Number of MHC complexes per multimer
A non-exhaustive list of possible MHC mono- and multimers illustrates the possibilities
'n' indicates the number of MHC complexes comprised in the multimer:
a) n=1 , Monomers
b) n=2, Dimers, multimerization can be based on IgG scaffold, streptavidin with
two MHC's, coiled-coil dimerization e.g. Fos.Jun dimerization
c) n=3, Trimers, multimerization can be based on streptavidin as scaffold with
three MHC's, TNFalpha-MHC hybrids, triplex DNA-MHC konjugates or
other trimer structures
d) n=4, Tetramers, multimerization can be based on streptavidin with all four
binding sites occupied by MHC molecules or based on dimeric IgA
e) n=5, Pentamers, multimerization can take place around a pentameric coil-coil
structure
f) n=6, Hexamers
g) n=7, Heptamers
h) n=8-1 2 , Octa- dodecamers, multimerization can take place using Streptactin
i) n=1 0 , Decamers, multimerization can take place using IgM
j) 1<n< 00, Dextramers, as multimerization domain polymers such as polypeptide,
polysaccharides and Dextrans can be used
k) 1<n<1 000, Multimerization can make use of dendritic cells (DC), antigen-presenting
cells (APC), micelles, liposomes, beads, surfaces e.g. microtiterplate,
tubes, microarray devices, micro-fluidic systems
I) 1<n, n in billions or trillions or higher, multimerization take place on beads, and
surfaces e.g. microtiterplate, tubes, microarray devices, micro-fluidic
systems
MHC multimers thus include MHC-dimers, MHC-trimers, MHC-tetramers, MHC-
pentamers, MHC-hexamers, as well as organic molecules, cells, membranes, polymers
and particles that comprise two or more MHC-peptide complexes. Example organic
molecule-based multimers include functionalized cyclic structures such as benzene
rings where e.g. a benzene ring is functionalized and covalently linked to e.g. three
MHC complexes; example cell-based MHC multimers include dendritic cells and
antigen presenting cells (APCs); example membrane-based MHC multimers include
liposomes and micelles carrying MHC-peptide complexes in their membranes; example
polymer-based MHC multimers include MHC-dextramers (dextran to which a number of
MHC-peptide complexes are covalently or non-covalently attached) and example
particles include beads or other solid supports with MHC complexes immobilized on the
surface. Obviously, any kind of multimerization domain can be used, including any kind
of cell, polymer, protein or other molecular structure, or particles and solid supports.
More than 600 MHC alleles (class 1 and 2) are known in humans; for many of these,
the peptide binding characteristics are known. The frequency of the different HLA
alleles varies considerably, also between different ethnic groups. Thus it is of outmost
importance to carefully select the MHC alleles that corresponds to the population that
one wish to study.
Any of the components of a MHC complex can be of any of the below mentioned
origins. The list is non-exhaustive. A complete list would encompass all Chordate
species. By origin is meant that the sequence is identical or highly homologous to a
naturally occurring sequence of the specific species.
List of origins: Human, Mouse , Primate (Chimpansee , Gorilla , Orang Utan), Monkey
(Macaques), Porcine (Swine/Pig) , Bovine (Cattle/Antilopes) , Equine (Horse) ,
Camelides (Camels) , Ruminants (Deears) , Canine (Dog) , Feline (Cat) , Bird
(Chicken, Turkey ) , Fish , Reptiles , Amphibians .
In one embodiment the binding molecule is a MHC class I complex of HLA-type A.
In one embodiment the binding molecule is a MHC class I complex of HLA-type B.
In one embodiment the binding molecule is a MHC class I complex of HLA-type C.
In one embodiment the binding molecules is a MHC class I complex, of supertype HLA-
A 1 (eg. HLA-A * 0101 , HLA-A * 2601 , HLA-A * 2602, HLA-A2603, HLA-A * 3002, HLA-
A* 3003, HLA-A * 3004, HLA-A * 3201).
In one embodiment the binding molecules is a MHC class I complex, of supertype HLA-
A01 A03 (eg. HLA-A * 3001).
In one embodiment the binding molecules is a MHC class I complex, of supertype HLA-
A01 A024 (eg. HLA-A * 2902).
In one embodiment the binding molecules is a MHC class I complex, of supertype HLA-
A2 (eg. HLA-A * 0201 , HLA-A * 0202, HLA-A * 0203, HLA-A * 0204, HLA-A * 0205, HLA-
A* 0206, HLA-A * 0207, HLA-A * 0214, HLA-A * 0217, HLA-A * 6802, HLA-A * 6901 ) .
In one embodiment the binding molecules is a MHC class I complex, of supertype HLA-
A3 (eg. HLA-A * 0301 , HLA-A * 1101 , HLA-A * 3 10 1 , HLA-A * 3301 , HLA-A * 3303, HLA-
A* 6601 , HLA-A * 6801 , HLA-A * 7401).
In one embodiment the binding molecules is a MHC class I complex, of supertype HLA-
A24 (eg. HLA-A * 2301 , HLA-A * 2402).
In one embodiment the binding molecules is a MHC class I complex, of supertype HLA-
B7 (eg. HLA-BW02, HLA-BW03, HLA-B * 0705, HLA B* 1508, HLA-B * 3501 , HLA-
B* 3503, HLA-B *4201 , HLA-B * 5101 , HLA-B * 5 102, HLA-B * 5 103, HLA-B * 5301 , HLA-
B* 5401 , HLA-B * 5501 , HLA-B * 5502, HLA-B * 5601 , HLA-B * 6701 , HLA-B * 7801 ) .
In one embodiment the binding molecules is a MHC class I complex, of supertype HLA-
B8 (eg. HLA-B * 0801 , HLA-B * 0802).
In one embodiment the binding molecules is a MHC class I complex, of supertype HLA-
B27 (eg. HLA-B * 1402, HLA-B * 1503, HLA-B * 1509, HLA-B * 1510, HLA-B * 151 8 , HLA-
B* 2702, HLA-B * 2703, HLA-B * 2704, HLA-B * 2705, HLA-B * 2706, HLA-B * 2707, HLA-
B* 2708, HLA-B * 2709, HLA-B * 3801 , HLA-B * 3901 , HLA-B * 3902, HLA-B * 3909, HLA-
B*4801 , HLA-B * 7301).
In one embodiment the binding molecules is a MHC class I complex, of supertype HLA-
B44 (eg. HLA-B * 1801 , HLA-B * 3701 , HLA-B *4001 , HLA-B *4002, HLA-B *4006, HLA-
B*4402, HLA-B *4403, HLA-B *4501).
In one embodiment the binding molecules is a MHC class I complex, of supertype HLA-
B58 (eg. HLA-B * 1516, HLA-B * 1517, HLA-B * 5701 , HLA-B * 5702, HLA-B * 5801 , HLA-
B* 5802).
In one embodiment the binding molecules is a MHC class I complex, of supertype HLA-
B62 (eg. HLA-B * 1501 , HLA-B * 1502, HLA-B * 15 12 , HLA-B * 1513, HLA-B *4601 , HLA-
B* 5201 ) .
In one embodiment the binding molecules is a MHC class I complex, of supertype HLA
Cw 1-8 (eg. HLA-C * 0 1 , HLA-C * 02, HLA-C * 03, HLA-C * 04, HLA-C * 05, HLA-C * 06, HLA-
C* 07, HLA-C * 08).
In one embodiment the binding molecule is a MHC class I complex, which binds
peptides with an acidic amino acid on 3rd position (eg. HLA-A * 0101 , HLA-A * 2601 , HLA-
A* 2602, HLA-A * 2603, HLA-A * 3002, HLA-A * 3003, HLA-A * 3004, HLA-A * 3201 ) .
In one embodiment the binding molecule is a MHC class I complex, which binds
peptides with a hydrophobic amino acid on 9th position (eg. HLA-A * 0201 ...0207,
A* 0214, A* 0217, A * 6802, A * 6901 , HLA-B * 1516, B* 15 17 , B* 5701 , B* 5702, B* 5801 ,
B* 5802).
In one embodiment the binding molecule is a MHC class I complex, which binds
peptides with a Basic amino acid on 9th position (eg. HLA-A * 0301 , HLA-A * 110 1 , HLA-
A* 3 10 1 , HLA-A * 3301 , HLA-A * 3303, HLA-A * 6601 , HLA-A * 6801 , HLA-A * 7401 ) .
In one embodiment the binding molecule is a MHC class I complex, which binds
peptides with a Tyrosine amino acid on 2nd position (eg. HLA-A * 2301 , HLA-A * 2402).
In one embodiment the binding molecule is a MHC class I complex, which binds
peptides with a Proline amino acid on 2nd position (eg. HLA-BW02, HLA-B * 0703, HLA-
B* 0705, HLA-B * 1508, HLA-B * 3501 , HLA-B * 3503, HLA-B *4201 , HLA-B * 5101 , HLA-
B* 5 102, HLA-B * 5103, HLA-B * 5301 , HLA-B * 5401 , HLA-B * 5501 , HLA-B * 5502, HLA-
B* 5601 , HLA-B * 6701 , HLA-B * 7801 ) .
In one embodiment the binding molecule is a MHC class I complex, which binds
peptides with a Lysine amino acid on 3rd and 5th position (eg. HLA-B * 0801 , B* 0802).
In one embodiment the binding molecule is a MHC class I complex, which binds
peptides with a Arginine amino acid on 2nd position (eg. HLA-B * 1402, HLA-B * 1503,
HLA-B * 1509, HLA-B * 1510, HLA-B * 15 18 , HLA-B * 2702, HLA-B * 2703, HLA-B * 2704,
HLA-B * 2705, HLA-B * 2706, HLA-B * 2707, HLA-B * 2708, HLA-B * 2709, HLA-B * 3801 ,
HLA-B * 3901 , HLA-B * 3902, HLA-B * 3909, HLA-B *4801 , HLA-B * 7301).
In one embodiment the binding molecule is a MHC class I complex, which binds
peptides with a Glutamic acid amino acid on 2nd position (eg. HLA-B * 1801 , HLA-
B* 3701 , HLA-B *4001 , HLA-B *4002, HLA-B *4006, HLA-B *4402, HLA-B *4403, HLA-
B*4501 ) .
In one embodiment the binding molecule is a MHC class I complex, which binds
peptides with a Tyrosine amino acid on 9th position (eg. HLA-B * 1501 , HLA-B * 1502,
HLA-B * 15 12 , HLA-B * 1513, HLA-B *4601 , HLA-B * 5201 ) .
In one embodiment the binding molecule is a MHC class I complex, which in the B
pocket selectively binds small or aliphatic peptides (eg. HLA-A * 0 10 1 , HLA-A * 2601 ,
HLA-A * 2602, HLA-A * 2603, HLA-A * 3002, HLA-A * 3003, HLA-A * 3004, HLA-A * 3201 ,
HLA-A * 0201 , HLA-A * 0202, HLA-A * 0203, HLA-A * 0204, HLA-A * 0205, HLA-A * 0206,
HLA-A * 0207, HLA-A * 0214, HLA-A * 021 7 , HLA-A * 6802, HLA-A * 6901 , HLA-A * 0301 ,
HLA-A * 1101 , HLA-A * 3 10 1 , HLA-A * 3301 , HLA-A * 3303, HLA-A * 6601 , HLA-A * 6801 ,
HLA-A * 7401).
In one embodiment the binding molecule is a MHC class I complex, which in the F
pocket selectively binds aliphatic peptides (eg. HLA-A * 0 10 1 , HLA-A * 2601 . ..2603, HLA-
A* 3002, HLA-A * 3003, HLA-A * 3004, HLA-A * 3201 , HLA-A * 0201 , HLA-A * 0202, HLA-
A* 0203, HLA-A * 0204, HLA-A * 0205, HLA-A * 0206, HLA-A * 0207, HLA-A * 0214, HLA-
A* 0217, HLA-A * 6802, HLA-A * 6901 , HLA-A * 0301 , HLA-A * 110 1 , HLA-A * 3101 , HLA-
A* 3301 , HLA-A * 3303, HLA-A * 6601 , HLA-A * 6801 , HLA-A * 7401 , HLA-B * 1501 , HLA-
B* 1502, HLA-B * 15 12 , HLA-B * 15 13 , HLA-B *4601 , HLA-B * 5201 ) .
In one embodiment the binding molecule is a MHC class I I complex, of HLA-type DP.
In one embodiment the binding molecule is a MHC class I I complex, of HLA-type DQ.
In one embodiment the binding molecule is a MHC class I I complex, of HLA-type DR.
In one embodiment the binding molecule is a MHC class I I complex of HLA supertype
DR1 (eg. HLA-DR1 * 0 10 1 , HLA-DR * 0 102).
In one embodiment the binding molecule is a MHC class I I complex of HLA supertype
DR3 (eg. HLA-DR1 * 1107, HLA-DR * 0301 , HLA-DR * 0305, HLA-DR * 0306, HLA-
DR* 0309).
In one embodiment the binding molecule is a MHC class I I complex of HLA supertype
DR4 (eg. HLA-DR1 * 0401 , HLA-DR * 0402, HLA-DR * 0404, HLA-DR * 0405, HLA-
DR* 0408, HLA-DR * 0410, HLA-DR * 0426).
In one embodiment the binding molecule is a MHC class I I complex of HLA supertype
DR7 (eg. HLA-DR1 * 0701).
In one embodiment the binding molecule is a MHC class I I complex of HLA supertype
DR8 (eg. HLA-DR1 * 0801 , HLA-DR * 0802, HLA-DR * 0804, HLA-DR * 0806, HLA-
DR* 081 3 , HLA-DR * 0817).
In one embodiment the binding molecule is a MHC class I I complex of HLA supertype
DR1 1 (eg. HLA-DR1 * 1101 , HLA-DR * 1104, HLA-DR * 1128, HLA-DR * 1307, HLA-
DR* 1321).
In one embodiment the binding molecule is a MHC class I I complex of HLA supertype
DR13 (eg. HLA-DR1 * 1102, HLA-DR * 1114, HLA-DR * 1120, HLA-DR * 1301 , HLA-
DR* 1304, HLA-DR * 1322).
In one embodiment the binding molecule is a MHC class I I complex of HLA supertype
DR15 (eg. HLA-DR1 * 1501 , HLA-DR * 1502).
In one embodiment the binding molecule is a MHC class I I complex of HLA supertype
DR51 (eg. HLA-DR5 * 0101 ) .
Generation of MHC multimers
Different approaches to the generation of various types of MHC multimers are
described in US patent 5,635,363 (Altmann et al.), patent application WO 02/072631
A2 (Winther et al.), patent application WO 99/42597, US patent 2004209295, US
patent 5,635,363. In brief, MHC multimers can be generated by first expressing and
purifying the individual protein components of the MHC protein, and then combining the
MHC protein components and the peptide, to form the MHC-peptide complex. Then an
appropriate number of MHC-peptide complexes are linked together by covalent or non-
covalent bonds to a multimerization domain. This can be done by chemical reactions
between reactive groups of the multimerization domain (e.g. vinyl sulfone functionalities
on a dextran polymer) and reactive groups on the MHC protein (e.g. amino groups on
the protein surface), or by non-covalent interaction between a part of the MHC protein
(e.g. a biotinylated peptide component) and the multimerization domain (e.g. four
binding sites for biotin on the strepavidin tetrameric protein). As an alternative, the
MHC multimer can be formed by the non-covalent association of amino acid helices
fused to one component of the MHC protein, to form a pentameric MHC multimer, held
together by five helices in a coiled-coil structure making up the multimerization domain.
Appropriate chemical reactions for the covalent coupling of MHC and the
multimerization domain include nucleophilic substitution by activation of electrophiles
(e.g. acylation such as amide formation, pyrazolone formation, isoxazolone formation;
alkylation; vinylation; disulfide formation), addition to carbon-hetero multiple bonds (e.g.
alkene formation by reaction of phosphonates with aldehydes or ketones; arylation;
alkylation of arenes/hetarenes by reaction with alkyl boronates or enolethers),
nucleophilic substitution using activation of nucleophiles (e.g. condensations; alkylation
of aliphatic halides or tosylates with enolethers or enamines), and cycloadditions.
Appropriate molecules, capable of providing non-covalent interactions between the
multimerization domain and the MHC-peptide complex, involve the following molecule
pairs and molecules: streptavidin/biotin, avidin/biotin, antibody/antigen, DNA/DNA,
DNA/PNA, DNA/RNA, PNA/PNA, LNA/DNA, leucine zipper e.g. Fos/Jun, IgG dimeric
protein, IgM multivalent protein, acid/base coiled-coil helices, chelate/metal ion-bound
chelate, streptavidin (SA) and avidin and derivatives thereof, biotin, immunoglobulins,
antibodies (monoclonal, polyclonal, and recombinant), antibody fragments and
derivatives thereof, leucine zipper domain of AP-1 (jun and fos), hexa-his (metal
chelate moiety), hexa-hat GST (glutathione S-transferase) glutathione affinity,
Calmodulin-binding peptide (CBP), Strep-tag, Cellulose Binding Domain, Maltose
Binding Protein, S-Peptide Tag, Chitin Binding Tag, Immuno-reactive Epitopes, Epitope
Tags, E2Tag, HA Epitope Tag, Myc Epitope, FLAG Epitope, AU1 and AU5 Epitopes,
Glu-Glu Epitope, KT3 Epitope, IRS Epitope, Btag Epitope, Protein Kinase-C Epitope,
VSV Epitope, lectins that mediate binding to a diversity of compounds, including
carbohydrates, lipids and proteins, e.g. Con A (Canavalia ensiformis) or WGA (wheat
germ agglutinin) and tetranectin or Protein A or G (antibody affinity). Combinations of
such binding entities are also comprised. In particular, when the MHC complex is
tagged, the binding entity can be an "anti-tag". By "anti-tag" is meant an antibody
binding to the tag and any other molecule capable of binding to such tag.
Generation of components of MHC
When employing MHC multimers for diagnostic purposes, it is preferable to use a MHC
allele that corresponds to the tissue type of the person or animal to be diagnosed.
Once the MHC allele has been chosen, a peptide derived from the antigenic protein
may be chosen. The choice will depend on factors such as known or expected binding
affinity of the MHC protein and the various possible peptide fragments that may be
derived from the full sequence of the antigenic peptide, and will depend on the
expected or known binding affinity and specificity of the MHC-peptide complex for the
TCR. Preferably, the affinity of the peptide for the MHC molecule, and the affinity and
specificity of the MHC-peptide complex for the TCR, should be high.
Similar considerations apply to the choice of MHC allele and peptide for therapeutic
and vaccine purposes. In addition, for some of these applications the effect of binding
the MHC multimer to the TCR is also important. Thus, in these cases the effect on the
T-cell's general state must be considered, e.g. it must be decided whether the desired
end result is apoptosis or proliferation of the T-cell.
Likewise, it must be decided whether stability is important. For some applications low
stability may be an advantage, e.g. when a short-term effect is desired; in other
instances, a long-term effect is desired and MHC multimers of high stability is desired.
Stabilities of the MHC protein and of the MHC-peptide complex may be modified as
described elsewhere herein.
Finally, modifications to the protein structure may be advantageous for some
diagnostics purposes, because of e.g. increased stability, while in for vaccine purposes
modifications to the MHC protein structure may induce undesired allergenic responses.
The generation of protein chains of MHC as well as the Stabilization of MHC
complexes is thoroughly explained in WO 2009/106073, which is incorporated herein
by reference in its entirety.
OTHER TCR BINDING MOLECULES
MHC I and MHC I I complexes bind to TCRs. However, other molecules also bind TCR.
Some TCR-binding molecules are described in the following.
In one embodiment the binding molecule is an anti-target-molecule capable of binding
TCR.
In one embodiment the anti-target-molecule capable of binding TCR is a molecule that
has homology to the classical MHC molecules and therefore potentially could be TCR
binding molecules. These other TCR binding or MHC like molecules include:
Non-classical MHC complexes and other MHC-like molecules
Non-classical MHC complexes include protein products of MHC lb and MHC lib genes.
MHC lb genes encode 2m-associated cell-surface molecules but show little
polymorphism in contrast to classical MHC class I genes. Protein products of MHC
class lb genes include HLA-E, HLA-G, HLA-F, HLA-H, MIC A , MIC B, ULBP-1 , ULBP-
2 , ULBP-3 in humans and H2-M, H2-Q, H2-T and Rae1 in mice.
Non-classical MHC I I molecules (protein products of MHC lib genes) include HLA-DM,
HLA-DO in humans and H2-DM and H2-DO in mice that are involved in regulation of
peptide loading into MHC I I molecules.
Another MHC-like molecule of special interest is the MHC l-like molecule CD1 . CD1 is
similar to MHC I molecules in its organization of subunits and association with β2ηι but
presents glycolipids and lipids instead of peptides.
Artificial molecules capable of binding specific TCRs
Of special interest are antibodies that bind TCRs. Antibodies herein include full length
antibodies of isotype IgG, IgM, IgE, IgA and truncated versions of these, antibody
fragments like Fab fragments and scFv. Antibodies also include antibodies of antibody
fragments displayed on various supramolecular structures or solid supports, including
filamentous phages, yeast, mammalian cells, fungi, artificial cells or micelles, and
beads with various surface chemistries.
Peptide binding TCR
Another embodiment of special interest is peptides that bind TCRs. Peptides herein
include peptides composed of natural, non-natural and/or chemically modified amino
acids with a length of 8-20 amino acid. The peptides could also be longer than 20
amino acids or shorter than 8 amino acids. The peptides can or cannot have a defined
tertiary structure.
Aptamers
Aptamers are another preferred group of TCR ligands. Aptamers are herein understood
as natural nucleic acids (e.g. RNA and DNA) or unnatural nucleic acids (e.g. PNA,
LNA, morpholinos) capable of binding TCR. The aptamer molecules consist of natural
or modified nucleotides in various lengths.
Other TCR-binding molecules can be ankyrin repeat proteins or other repeat proteins,
Avimers, or small chemical molecules, as long as they are capable of binding TCR with
a dissociation constant smaller than 10 3 M.
BM: ANTI-TARGET MOLECULES
In one embodiment the binding molecule is an anti-target-molecule capable of
associating with, recognizing and/or binding to a predetermined target structure
belonging to or associated with an entity / cell, e.g. in a sample. A typical target for a
binding molecule is a 'marker molecule', which marker molecule is specific for a given
cell or cell type.
Any binding molecule that is capable of specifically associating with, recognizing and/or
binding to a predetermined target structure is encompassed within the present
invention.
In one embodiment the binding molecule is an anti-target-molecule capable of binding
a specific cell type.
In one embodiment the binding molecule is an anti-target-molecule capable of binding
a specific cell type selected from the group consisting of immune cells, lymphocytes,
monocytes, dendritic cells, T-cells, B-cells and NK cells.
In one embodiment the binding molecule is an anti-target-molecule capable of binding
a specific cell type selected from the group consisting CD4+ T cells, CD8+ T cells, αβ T
cells, invariant γ δ T cells and antigen-specific T-cells.
In one embodiment the binding molecule is an anti-target-molecule capable of binding
a cell comprising TCRs. In one embodiment the binding molecule is an anti-target-
molecule capable of binding a cell comprising BCRs.
In one embodiment the binding molecule is an anti-target-molecule capable of binding
a specific cancer cell.
In one embodiment the binding molecule is an anti-target-molecule capable of binding
a target specifically associated with an organ selected from the group consisting of
lymph nodes, kidney, liver, skin, brain, heart, muscles, bone marrow, skin, skeleton,
lungs, the respiratory tract, spleen, thymus, pancreas, exocrine glands, bladder,
endocrine glands, reproduction organs including the phallopian tubes, eye, ear,
vascular system, the gastroinstestinal tract including small intestines, colon, rectum,
canalis analis and prostate gland.
Anti-target-molecule is in one embodiment selected from antibodies, antibody
mimetics, natural ligands, variants or fragments of natural ligands, synthetic ligands,
agonists, antagonists, aptamers (including DNA aptamers, RNA aptamers and peptide
aptamers), peptides, and artificial molecules capable of binding a specific target.
Peptide aptamer
In one embodiment the binding molecule is an anti-target-molecule. In one embodiment
the anti-target-molecule is a peptide aptamer, such as a peptide that bind a target.
Peptides herein include peptides composed of natural, non-natural and/or chemically
modified amino acids, in one embodiment with a length of 8-20 amino acid, such as 5-
25 amino acids, for example 5-40 amino acids. The peptides can or cannot have a
defined tertiary structure.
In one embodiment the binding molecule is a peptide of 1-100 amino acid residues
without tertiary structure.
Nucleic acid aptamer
In one embodiment the binding molecule is an anti-target-molecule. In one embodiment
the anti-target-molecule is a nucleic acid aptamer (or oligonucleotide aptamer, or
simply Oligonucleotide'). Nucleic acid aptamers are herein understood as natural
nucleic acids (e.g. RNA and DNA) or artificial nucleic acids (e.g. PNA, LNA,
morpholinos) capable of binding a target. The aptamer molecules consist of natural or
modified nucleotides in various lengths.
Other target-binding molecules include ankyrin repeat proteins or other repeat proteins,
Avimers, or small chemical molecules, as long as they are capable of binding the target
with an acceptable dissociation constant such as smaller than 10 3 M.
Ligand
In one embodiment the binding molecule is an anti-target-molecule. In one embodiment
the anti-target-molecule is a ligand capable of binding a target.
Antibodies
In one embodiment the binding molecule is an anti-target-molecule. In one embodiment
anti-target-molecule is an antibody. In a preferred embodiment the anti-target-molecule
is an antibody that selectively associates with, recognizes and/or binds to a
predetermined target structure belonging to or associated with an entity / cell in a
sample.
Immunoglobulins are a class of structurally related glycoproteins consisting of two pairs
of polypeptide chains, one pair of light (L) low molecular weight chains and one pair of
heavy (H) chains, all four inter-connected by disulfide bonds. The structure of
immunoglobulins has been well characterized. Briefly, each heavy chain typically is
comprised of a heavy chain variable region (VH) and a heavy chain constant region
(CH) typically comprised of three domains, CH1 , CH2, and CH3. Each light chain
typically is comprised of a light chain variable region (VL) and a light chain constant
region, typically comprised of one domain (CL). The VH and VL regions may be further
subdivided into regions of hypervariability also termed complementarity determining
regions (CDRs), interspersed with regions that are more conserved, termed framework
regions (FRs).
The term "antibody" or "Ab" in the context of the present invention refers to an
immunoglobulin molecule, a fragment of an immunoglobulin molecule, or a derivative of
either thereof, which has the ability to specifically bind to an antigen under typical
physiological conditions. The variable regions of the heavy and light chains of the
immunoglobulin molecule contain a binding domain that interacts with an antigen. An
antibody may also be multispecific, having specificities for two or more different
epitopes, typically non-overlapping. Examples of multispecific antibodies include
bispecific antibodies, diabodies, and similar antibody molecules. As indicated above,
the term antibody herein, unless otherwise stated, includes fragments of an antibody
that retain the ability to specifically bind to the antigen. The antigen-binding function of
an antibody may be performed by fragments of a full-length antibody, e.g., Fab and
F(ab')2 fragments. In the context of the present invention the term antibody, unless
specified otherwise, includes polyclonal antibodies, monoclonal antibodies (mAbs),
antibody-like polypeptides such as chimeric antibodies and humanized antibodies. An
antibody as generated can possess any isotype. The term "epitope" means a protein
determinant capable of specific binding to an antibody.
The terms "human antibody" include antibodies having variable and constant regions
derived from human germline immunoglobulin sequences. The human antibodies of the
invention may include amino acid residues not encoded by human germline
immunoglobulin sequences (e.g., mutations introduced by random or site-specific
mutagenesis in vitro or by somatic mutation in vivo). However, the term "human
antibody", as used herein, is not intended to include antibodies in which CDR
sequences derived from the germline of another mammalian species, such as a
mouse, have been grafted onto human framework sequences.
The terms "monoclonal antibody" (mAb), refer to a preparation of antibody molecules of
single molecular composition. A monoclonal antibody composition displays a single
binding specificity and affinity for a particular epitope. Accordingly, the term "human
monoclonal antibody" refers to antibodies displaying a single binding specificity which
have variable and constant regions derived from human germline immunoglobulin
sequences. The human monoclonal antibodies may be produced by a hybridoma which
includes a B cell obtained from a transgenic or transchromosomal non-human animal,
such as a transgenic mouse, having a genome comprising a human heavy chain
transgene and a light chain transgene, fused to an immortalized cell.
As used herein, "isotype" refers to the immunoglobulin class (for instance IgGI, lgG2,
lgG3, lgG4, IgD, IgA, IgE, or IgM) that is encoded by heavy chain constant region
genes. The term "full-length antibody" when used herein, refers to an antibody which
contains all heavy and light chain constant and variable domains that are normally
found in an antibody of that isotype.
Antibody mimetics
In one embodiment the binding molecule is an anti-target-molecule. In one embodiment
anti-target-molecule is an antibody mimetic. Antibody mimetics are organic compounds
that, like antibodies, can specifically bind antigens, but that are not structurally related
to antibodies.
Antibody mimetics include, but is not limited to, affibody molecules, affilinns, affimers,
affitins, alphabodies, anticalins, avimers, DARPins, fynomers, Kunitz domain peptides
and monobodies.
Avimers (short for avidity multimers) are artificial proteins that are able to specifically
bind to certain antigens via multiple binding sites. Avimers consist of two or more
peptide sequences of 30 to 35 amino acids each, connected by linker peptides.
TARGETS OF BINDING MOLECULES
In one embodiment the binding molecule is an anti-target-molecule capable of
associating with, recognizing and/or binding to a predetermined target structure
belonging to or associated with an entity / cell in a sample.
In one embodiment the target for a binding molecule is a 'marker molecule', which
marker molecule is specific for a given cell or cell type.
In one embodiment the target is an intracellular target.
In one embodiment the target is a cell-surface target.
In one embodiment the target is a membrane-associated target.
In one embodiment the target is a receptor.
In one embodiment the receptor is an intracellular receptor.
In one embodiment the receptor is a cell-surface receptor or membrane-associated
receptor.
In one embodiment the target is a soluble receptor.
In one embodiment the target is a extracellular receptor.
In one embodiment the binding molecule is an anti-target-molecule capable of binding
a target selected from the group consisting of CD1 , CD1 a , CD1 b, CD1 c , CD1 d , and
MR1 .
In one embodiment the target is a T cell receptor.
In one embodiment the target is a B cell receptor.
In one embodiment the target is CD4.
In one embodiment the target is CD8.
In one embodiment the target is CD20.
In one embodiment the target of the binding molecule (anti-target molecule) binds a
target selected from the group consisting of cancer cell markers, developmental
markers, stem cell markers, cell cycle markers, proliferation markers, activation
markers, hormones, hormone receptors, cluster of differentiation (CD), cytokines and
cytokine receptors.
In one embodiment the cluster of differentiation is selected from a group consisting of
CD1 - 10 , CD1 0-20, CD20-30, CD30-40, CD40-50, CD50-1 00, CD1 00-200, CD200-300
and CD300-364.
In one embodiment the cancer cell marker is selected from a group consisting of
HER2, CA125, Tyrosinase, Melanoma-associated antigen (MAGE), abnormal products
of Ras or p53, Carcinoembryonic antigen, Muc-1 , Epithelial tumor antigen, Carbonic
Anhydrase, VEGFR, EGFR, TRAI and RANKL.
In one embodiment the stem cell marker is selected from a group consisting of Stro-1 ,
CD146, CD105, CD44, c-kit, Oct4, Sox-2, Klf4, EphB, Nestin and TWIST-1 .
In one embodiment the developmental cell marker is selected from a group consisting
of Nanog, Oct4, Sox2, TEKT-1 , NANOS, c-kit, Sox9, Notch, Msx1 , Msx2 and Coll .
In one embodiment the cytokine is selected from a group consisting of TNFa, ΤΝ ,
TNF, IFNa, IFNy, IL-1 , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-10-20,
IL-20-30, IL-30, IL-31 , IL-32, IL-33, IL-34, IL-35, IL-36, IL-37, IL-38, IL-39, IL-40, NFKB,
chemokines including CC chemokines (CCL1-CCL-28), CXC chemokines (CXCL1-
CXCL17) C chemokines (XCL-1 and -2) and CX3X chemokines (CX3CL1 ) .
In one embodiment the proliferation marker is selected from a group consisting of
CyclinA, CyclinB, PCNA, PC10, p53, Mdm2, Cyclin D, Cyclin E, Rb, ARF and HDM2.
In one embodiment the activation marker is selected from a group consisting of CD28,
Tbet, Eomes, Blimp, Bcl-6, CD27, MHC-II, TNF, IFN, Fizzl , ARG1 and CCL22R.
In one embodiment the hormone is selected from a group consisting of estrogen, PTH,
ADH, T3, ANP, Epinephrine, Norepinephrine, Cortisol, Corticosterone, Aldosterone,
Progestin, EPO, Leptin, Insulin, Glucagon, T4, ACTH, FSH, oxytocin and Calcitriol.
In one embodiment the hormone receptor is selected from a group consisting of
EstrogenR (ER), GLP-1 R, Thyroid receptor, Leptin receptor, Epinephrine receptor,
Insulin receptor and Glucagon receptor.
In one embodiment the intracellular marker is selected from a group consisting of
Cyclins, Cytokines and organelle markers (for example Apg12, Syntaxin, PAF-46,
Histones, Early endosome antigen, clathrin, tubulins, PAF49, FTCD).
In one embodiment the target of the binding molecule is selected from the group
consisting of CD2, CD3, CD4, CD5, CD8, CD9, CD27, CD28, CD30, CD69, CD1 34
(OX40), CD137 (4-1 BB), CD147, CDw150 (SLAM), CD1 52 (CTLA-4), CD153 (CD30L),
CD40L (CD1 54), NKG2D, ICOS, HVEM, HLA Class II, PD-1 , Fas (CD95), FasL, CD40,
CD48, CD58, CD70, CD72, B7.1 (CD80), B7.2 (CD86), B7RP-1 , B7-H3, PD-L1 , PD-L2,
CD134L, CD1 37L, ICOSL, LIGHT CD16, NKp30, NKp44, NKp46, NKp80, 2B4, KIR,
LIR, CD94/NKG2A, CD94/NKG2C, LFA-1 , CD1 1a/1 8 , CD54 (ICAM-1 ) , CD1 06
(VCAM), CD49a,b,c,d,e,f/CD29 (VLA-4), CD1 1a , CD14, CD15, CD1 9 , CD25, CD30,
CD37, CD49a, CD49e, CD56, CD27, CD28, CD45, CD45RA, CD45RO, CD45RB,
CCR7, CCR5, CD62L, CD75, CD94, CD99, CD107b, CD1 09, CD152, CD1 53, CD154,
CD160, CD161 , CD1 78, CDw197, CDw21 7 , Cd229, CD245, CD247 and Foxp3.
Additional components of detection molecule
Additional components or substituents may be coupled to the detection molecule,
either coupled to carrier or added as individual components not coupled to carrier.
In one embodiment the detection molecule further comprises an enzyme capable of
catalysing the transfer of a cell surface moiety from a cell surface entity to the binding
molecule of the detection molecule, wherein said cell surface moiety binds to (or
associates with) the binding molecule.
In one embodiment the cell surface entity is a cell surface protein.
In one embodiment the cell surface moiety is a peptide fragment or 'peptide tag'.
The peptide tag added to the binding molecule can be used as a means of isolating the
detection molecules that have been in contact with said cell surface entity.
Attachment of biologically active molecules to binding molecules
Engagement of MHC complex to the specific T cell receptor leads to a signaling
cascade in the T cell. However, T-cells normally respond to a single signal stimulus by
going into apoptosis. T cells needs a second signal in order to become activated and
start development into a specific activation state e.g. become an active cytotoxic T cell,
helper T cell or regulatory T cell.
It is to be understood that the binding molecule such as MHC complex or MHC
multimer of the invention may further comprise one or more additional substituents,
such as biologically active molecules. The definition of the terms "one or more", "a
plurality", "a", "an", and "the" also apply here. Such biologically active molecules may
be attached to the construct in order to affect the characteristics of the constructs, e.g.
with respect to binding properties, effects, MHC molecule specificities, solubility,
stability, or detectability. For instance, spacing could be provided between the two or
more binding molecules such as two or more MHC complexes, one or both
chromophores of a Fluorescence Resonance Energy Transfer (FRET) donor/acceptor
pair could be inserted, functional groups could be attached, or groups having a
biological activity could be attached.
Binding molecules such as MHC multimers can be covalently or non-covalently
associated with various molecules: having adjuvant effects; being immune targets e.g.
antigens; having biological activity e.g. enzymes, regulators of receptor activity,
receptor ligands, immune potentiators, drugs, toxins, co-receptors, proteins and
peptides in general; sugar moieties; lipid groups; nucleic acids including siRNA; nano
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particles; small molecules. In the following these molecules are collectively called
biologically active molecules. Such molecules can be attached to the binding molecule
such as MHC multimer using the same principles as those described for attachment of
binding molecule such as MHC complexes to multimerisation domains as described
elsewhere herein. In brief, attachment can be done by chemical reactions between
reactive groups on the biologically active molecule and reactive groups of the
multimerisation domain and/or between reactive groups on the biologically active
molecule and reactive groups of the binding molecule such as MHC-peptide complex.
Alternatively, attachment is done by non-covalent interaction between part of the
multimerisation domain and part of the biological active molecule or between part of the
binding molecule such as MHC-peptide complex and part of the biological active
molecule. In both covalent and non-covalent attachment of the biologically molecule to
the multimerisation domain a connector molecule can connect the two. The connecotr
molecule can be covalent or non-covalent attached to both molecules. Examples of
connector molecules are described elsewhere herein. Some of the binding molecules
such as MHCmer structures better allow these kinds of modifications than others.
Biological active molecules can be attached repetitively aiding to recognition by and
stimulation of the innate immune system via Toll or other receptors.
Binding molecules such as MHC multimers carrying one or more additional groups can
be used as therapeutic or vaccine reagents.
In particular, the biologically active molecule may be selected from:
• proteins such as MHC Class l-like proteins like MIC A , MIC B, CD1d, HLA E,
HLA F, HLA G, HLA H, ULBP-1 , ULBP-2, and ULBP-3,
· co-stimulatory molecules such as CD2, CD3, CD4, CD5, CD8, CD9, CD27,
CD28, CD30, CD69, CD1 34 (OX40), CD1 37 (4-1 BB), CD147, CDw150 (SLAM),
CD152 (CTLA-4), CD1 53 (CD30L), CD40L (CD154), NKG2D, ICOS, HVEM,
HLA Class II, PD-1 , Fas (CD95), FasL expressed on T and/or NK cells, CD40,
CD48, CD58, CD70, CD72, B7.1 (CD80), B7.2 (CD86), B7RP-1 , B7-H3, PD-L1 ,
PD-L2, CD1 34L, CD1 37L, ICOSL, LIGHT expressed on APC and/or tumour
cells,
• cell modulating molecules such as CD1 6 , NKp30, NKp44, NKp46, NKp80, 2B4,
KIR, LIR, CD94/NKG2A, CD94/NKG2C expressed on NK cells, IFN-alpha, IFN-
beta, IFN-gamma, IL-1 , IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10, IL-1 1, IL-12, IL-1 5 ,
CSFs (colony-stimulating factors), vitamin D3, IL-2 toxins, cyclosporin, FK-506,
rapamycin, TGF-beta, clotrimazole, nitrendipine, and charybdotoxin,
• accessory molecules such as LFA-1 , CD1 1a/1 8 , CD54 (ICAM-1 ) , CD1 06
(VCAM), and CD49a,b,c,d,e,f/CD29 (VLA-4),
· adhesion molecules such as ICAM-1 , ICAM-2, GlyCAM-1 , CD34, anti-LFA-1 ,
anti-CD44, anti-beta7, chemokines, CXCR4, CCR5, anti-selectin L, anti-selectin
E, and anti-selectin P,
• toxic molecules selected from toxins, enzymes, antibodies, radioisotopes,
chemiluminescent substances, bioluminescent substances, polymers, metal
particles, and haptens, such as cyclophosphamide, methrotrexate,
Azathioprine, mizoribine, 15-deoxuspergualin, neomycin, staurosporine,
genestein, herbimycin A , Pseudomonas exotoxin A , saporin, Rituxan, Ricin,
gemtuzumab ozogamicin, Shiga toxin, heavy metals like inorganic and organic
mercurials, and FN18-CRM9, radioisotopes such as incorporated isotopes of
iodide, cobalt, selenium, tritium, and phosphor, and haptens such as DNP, and
digoxiginin,
and combinations of any of the foregoing, as well as antibodies (monoclonal,
polyclonal, and recombinant) to the foregoing, where relevant. Antibody derivatives or
fragments thereof may also be used.
Biological active molecules as described above may also be attached to antigenic
peptide products or antigenic polypeptide products using same principles for
attachment.
Linker
The linker comprised in the detection molecule of the present invention is a molecular
entity and/or bond that connect the binding molecule and the label of the detection
molecule. The connection may be direct or indirect, and may comprise a covalent or
non-covalent binding. A linker according to the present invention comprises, or is
identical to, a carrier molecule (or carrier), a multimerization domain and/or a
backbone, and may equally be referred to as such herein.
In a preferred embodiment the linker consist of or comprises one or more molecules
chosen from the group of dextran, streptavidin, peptide, or antibody.
In a preferred embodiment the linker connecting the binding molecule and the label has
a length of 1-2 A, 3-4 A, 5-8 A, 9-1 5 A , 16-30 A , 31-50 A , 5 1- 100 A, 10 1-200 A, 201 -
500 A, 501-2000 A , or longer than 2000 A.
In one embodiment the linker of the invention, connecting the binding molecule and the
label, consists or comprises one or more of the following entities: a short peptide, a
modified or non-modified alkane, alkene or alkyne, a polyamide, ethylenglycol or
polyethylenglycol, a small chemical entity such as an amide bond or other chemical
bond, an oligonucleotide, biotin, the bond formed after reaction of a thiol with an NHS-
ester or a maleimide.
Multimerisation domain
In a preferred aspect of the invention one or multiple binding molecules (BM), as well
as one or more labels, associate with a multimerization domain to form a detection
molecule,
Wherein at least two binding molecules are associated via a multimerization domain
this constitutes a binding molecule multimer (BM multimer).
The term 'multimerization domain' is used to refer to a type of linker in the below;
namely any molecular entity and/or bond that connect the binding molecule and the
label of the detection molecule; alone or via a connector.
A number of binding molecules associate with one or more multimerization domains to
form a detection molecule comprising one or more binding molecules and one or more
labels. In one embodiment a number of MHC complexes (binding molecules) associate
with a multimerization domain to form a MHC multimer.
The size of the multimerization domain spans a wide range, from multimerisation
domains based on small organic molecule scaffolds to large multimers based on a
cellular structure or solid support. The multimerization domain may thus be based on
different types of carriers or scaffolds, and likewise, the attachment of binding
molecules, such as MHC complexes, to the multimerization domain may involve
covalent or non-covalent connectorss. Characteristics of different kinds of
multimerization domains are described below.
Molecular weight of multimerization domain.
• In one embodiment the multimerization domain(s) in the present invention is
preferably less than 1,000 Da (small molecule scaffold). Examples include short
peptides (e.g. comprising 10 amino acids), and various small molecule scaffolds
(e.g. aromatic ring structures).
· In another embodiment the multimerization domain(s) is preferably between
1,000 Da and 10,000 Da (small molecule scaffold, small peptides, small
polymers). Examples include polycyclic structures of both aliphatic and aromatic
compounds, peptides comprising e.g. 10-1 00 amino acids, and other polymers
such as dextran, polyethylenglycol, and polyureas.
· In another embodiment the multimerization domain(s) is between 10,000 Da
and 100,000 Da (Small molecule scaffold, polymers e.g. dextran, streptavidin,
IgG, pentamer structure). Examples include proteins and large polypeptides,
small molecule scaffolds such as steroids, dextran, dimeric streptavidin, and
multi-subunit proteins such as used in Pentamers.
· In another embodiment the multimerization domain(s) is preferably between
100,000 Da and 1,000,000 Da (Small molecule scaffold, polymers e.g. dextran,
streptavidin, IgG, pentamer structure). Typical examples include larger
polymers such as dextran (used in e.g. Dextramers), and streptavidin tetramers.
• In another embodiment the multimerization domain(s) is preferably larger than
1,000,000 Da (Small molecule scaffold, polymers e.g. dextran, streptavidin,
IgG, pentamer structure, cells, liposomes, artificial lipid bilayers, polystyrene
beads and other beads. Most examples of this size involve cells or cell-based
structures such as micelles and liposomes, as well as beads and other solid
supports.
As mentioned elsewhere herein multimerisation domains can comprise carrier
molecules (connectors), scaffolds or combinations of the two.
Type of multimerization domain.
In principle any kind of carrier or scaffold can be used as multimerization domain,
including any kind of cell, polymer, protein or other molecular structure, or particles and
solid supports. Below different types and specific examples of multimerization domains
are listed.
· Cell . Cells can be used as carriers. Cells can be either alive and mitotic active,
alive and mitotic inactive as a result of irradiation or chemically treatment, or the
cells may be dead. The MHC expression may be natural (i.e. not stimulated) or
may be induced/stimulated by e.g. Inf-γ . Of special interest are natural antigen
presenting cells (APCs) such as dendritic cells, macrophages, Kupfer cells,
Langerhans cells, B-cells and any MHC expressing cell either naturally
expressing, being transfected or being a hybridoma.
• Cell-like structures . Cell-like carriers include membrane-based structures
carrying MHC-peptide complexes in their membranes such as micelles,
liposomes, and other structures of membranes, and phages such as
filamentous phages.
• Solid support . Solid support includes beads, particulate matters and other
surfaces. A preferred embodiment include beads (magnetic or non-magnetic
beads) that carry electrophilic groups e.g. divinyl sulfone activated
polysaccharide, polystyrene beads that have been functionalized with tosyl-
activated esters, magnetic polystyrene beads functionalized with tosyl-activated
esters), and where binding molecules such as MHC complexes may be
covalently immobilized to these by reaction of nucleophiles comprised within the
BM such as the MHC complex with the electrophiles of the beads. Beads may
be made of sepharose, sephacryl, polystyrene, agarose, polysaccharide,
polycarbamate or any other kind of beads that can be suspended in aqueous
buffer.
Another embodiment includes surfaces, i.e. solid supports and particles
carrying immobilized binding molecules such as MHC complexes on the
surface. Of special interest are wells of a microtiter plate or other plate formats,
reagent tubes, glass slides or other supports for use in microarray analysis,
tubings or channels of micro fluidic chambers or devices, Biacore chips and
beads
• Molecule . Multimerization domains may also be molecules or complexes of
molecules held together by non-covalent bonds. The molecules constituting the
multimerization domain can be small organic molecules or large polymers, and
may be flexible linear molecules or rigid, globular structures such as e.g.
proteins. Different kinds of molecules used in multimerization domains are
described below.
o Small organic molecules. Small organic molecules here includes
steroids, peptides, linear or cyclic structures, and aromatic or aliphatic
structures, and many others. The prototypical small organic scaffold is a
functionalized benzene ring, i.e. a benzene ring functionalized with a
number of reactive groups such as amines, to which a number of
binding molecules such as MHC molecules may be covalently linked.
However, the types of reactive groups constituting the connector
connecting the binding molecules such as MHC complex and the
multimerization domain, as well as the type of scaffold structure, can be
chosen from a long list of chemical structures. A non-comprehensive list
of scaffold structures are listed below.
Typical scaffolds include aromatic structures, benzodiazepines,
hydantoins, piperazines, indoles, furans, thiazoles, steroids,
diketopiperazines, morpholines, tropanes, coumarines, qinolines,
pyrroles, oxazoles, amino acid precursors, cyclic or aromatic ring
structures, and many others.
Typical carriers include linear and branched polymers such as peptides,
polysaccharides, nucleic acids, and many others. Multimerization
domains based on small organic or polymer molecules thus include a
wealth of different structures, including small compact molecules, linear
structures, polymers, polypeptides, polyureas, polycarbamates, cyclic
structures, natural compound derivatives, alpha-, beta-, gamma-, and
omega-peptides, mono-, di- and tri-substituted peptides, L- and D-form
peptides, cyclohexane- and cyclopentane-backbone modified beta-
peptides, vinylogous polypeptides, glycopolypeptides, polyamides,
vinylogous sulfonamide peptide, Polysulfonamide-conjugated peptide (i.e.,
having prosthetic groups), Polyesters, Polysaccharides such as dextran
and aminodextran, polycarbamates, polycarbonates, polyureas, poly-
peptidylphosphonates, Azatides, peptoids (oligo N-substituted glycines),
Polyethers, ethoxyformacetal oligomers, poly-thioethers, polyethylene,
glycols (PEG), polyethylenes, polydisulfides, polyarylene sulfides,
Polynucleotides, PNAs, LNAs, Morpholinos, oligo pyrrolinone, polyoximes,
Polyimines, Polyethyleneimine, Polyacetates, Polystyrenes,
Polyacetylene, Polyvinyl, Lipids, Phospholipids, Glycolipids, polycycles,
(aliphatic), polycycles (aromatic), polyheterocycles, Proteoglycan,
Polysiloxanes, Polyisocyanides, Polyisocyanates, polymethacrylates,
Monofunctional, Difunctional, Trifunctional and Oligofunctional open-chain
hydrocarbons, Monofunctional, Difunctional, Trifunctional and
Oligofunctional Nonaromat Carbocycles, Monocyclic, Bicyclic, Tricyclic
and Polycyclic Hydrocarbons, Bridged Polycyclic Hydrocarbones,
Monofunctional, Difunctional, Trifunctional and Oligofunctional
Nonaromatic, Heterocycles, Monocyclic, Bicyclic, Tricyclic and Polycyclic
Heterocycles, bridged Polycyclic Heterocycles, Monofunctional,
Difunctional, Trifunctional and Oligofunctional Aromatic Carbocycles,
Monocyclic, Bicyclic, Tricyclic and Polycyclic Aromatic Carbocycles,
Monofunctional, Difunctional, Trifunctional and Oligofunctional Aromatic
Hetero-cycles. Monocyclic, Bicyclic, Tricyclic and Polycyclic Heterocycles.
Chelates, fullerenes, and any combination of the above and many others.
Biological polymers. Biological molecules here include peptides,
proteins (including antibodies, coiled-coil helices, streptavidin and many
others), nucleic acids such as DNA and RNA, and polysaccharides such
as dextran. The biological polymers may be reacted with MHC
complexes (e.g. a number of MHC complexes chemically coupled to e.g.
the amino groups of a protein), or may be linked through e.g. DNA
duplex formation between a carrier DNA molecule and a number of DNA
oligonucleotides each coupled to a MHC complex. Another type of
multimerization domain based on a biological polymer is the
streptavidin-based tetramer, where a streptavidin binds up to four
biotinylated MHC complexes, as described above (see Background of
the invention).
Self-assembling multimeric structures. Several examples of commercial
MHC multimers exist where the multimer is formed through self-
assembling. Thus, the Pentamers are formed through formation of a
coiled-coil structure that holds together 5 MHC complexes in an
apparently planar structure. In a similar way, the Streptamers are based
on the Streptactin protein which oligomerizes to form a MHC multimer
comprising several MHC complexes.
In the following, alternative ways to make binding molecules such as MHC multimers
based on a molecule multimerization domain are described. They involve one or more
of the above-mentioned types of multimerization domains.
MHC dextramers can be made by coupling MHC complexes to dextran via a
streptavidin-biotin interaction. In principle, biotin-streptavdin can be replaced by any
dimerization domain, where one half of the dimerization domain is coupled to the MHC
complex and the other half is coupled to dextran. For example, an acidic helix (one half
of a coiled-coil dimer) is coupled or fused to MHC, and a basic helix (other half of a
coiled-coil dimmer) is coupled to dextran. Mixing the two results in MHC binding to
dextran by forming the acid/base coiled-coil structure.
Binding molecule dextramers can be made by coupling binding molecules to dextran
via a streptavidin-biotin interaction. In principle, biotin-streptavdin can be replaced by
any dimerization domain, where one half of the dimerization domain is coupled to the
binding molecule and the other half is coupled to dextran. For example, an acidic helix
(one half of a coiled-coil dimer) is coupled or fused to the BM, and a basic helix (other
half of a coiled-coil dimmer) is coupled to dextran. Mixing the two results in the BM
binding to dextran by forming the acid/base coiled-coil structure.
Antibodies can be used as scaffolds by using their capacity to bind to a carefully
selected antigen found naturally or added as a tag to a part of the binding molecule
such as the MHC molecule not involved in peptide binding. For example, IgG and IgE
will be able to bind two binding molecules such as two MHC molecules, and IgM having
a pentameric structure will be able to bind 10 binding molecules such as 10 MHC
molecules. The antibodies can be full-length or truncated; a standard antibody-
fragment includes the Fab2 fragment.
Peptides involved in coiled-coil structures can act as scaffold by making stable dimeric,
trimeric, tetrameric and pentameric interactions. Examples hereof are the Fos-Jun
heterodimeric coiled coil, the E. coli homo-trimeric coiled-coil domain Lpp-56, the
engineered Trp-zipper protein forming a discrete, stable, a-helical pentamer in water at
physiological pH.
Further examples of suitable scaffolds, carriers and connectors are streptavidin (SA)
and avidin and derivatives thereof, biotin, immunoglobulins, antibodies (monoclonal,
polyclonal, and recombinant), antibody fragments and derivatives thereof, leucine
zipper domain of AP-1 (jun and fos), hexa-his (metal chelate moiety), hexa-hat GST
(glutathione S-tranferase), glutathione, Calmodulin-binding peptide (CBP), Strep-tag,
Cellulose Binding Domain, Maltose Binding Protein, S-Peptide Tag, Chitin Binding Tag,
Immuno-reactive Epitopes, Epitope Tags, E2Tag, HA Epitope Tag, Myc Epitope, FLAG
Epitope, AU1 and AU5 Epitopes, Glu-Glu Epitope, KT3 Epitope, IRS Epitope, Btag
Epitope, Protein Kinase-C Epitope, VSV Epitope, lectins that mediate binding to a
diversity of compounds, including carbohydrates, lipids and proteins, e.g. Con A
{Canavalia ensiformis) or WGA (wheat germ agglutinin) and tetranectin or Protein A or
G (antibody affinity). Combinations of such binding entities are also comprised. Non-
limiting examples are streptavidin-biotin and jun-fos. In particular, when the MHC
molecule is tagged, the binding entity may be an "anti-tag". By "anti-tag" is meant an
antibody binding to the tag, or any other molecule capable of binding to such tag.
Wherein the binding molecule comprise MHC complexes, these can be multimerized
by other means than coupling or binding to a multimerization domain. Thus, the
multimerization domain may be formed during the multimerization of MHCs. One such
method is to extend the bound antigenic peptide with dimerization domains. One end of
the antigenic peptide is extended with dimerization domain A (e.g. acidic helix, half of a
coiled-coil dimer) and the other end is extended with dimerization domain B (e.g. basic
helix, other half of a coiled-coil dimer). When MHC complexes are loaded/mixed with
these extended peptides the following multimer structure will be formed: A-MHC-BA-
MHC-BA-MHC-B etc. The antigenic peptides in the mixture can either be identical or a
mixture of peptides with comparable extended dimerization domains. Alternatively both
ends of a peptide are extended with the same dimerization domain A and another
peptide (same amino acid sequence or a different amino acid sequence) is extended
with dimerization domain B. When MHC and peptides are mixed the following
structures are formed: A-MHC-AB-MHC-BA-MHC-AB-MHC-B etc. Multimerization of
MHC complexes by extension of peptides are restricted to MHC I I molecules since the
peptide binding groove of MHC I molecules is typically closed in both ends thereby
limiting the size of peptide that can be embedded in the groove, and therefore
preventing the peptide from extending out of the groove.
Another multimerization approach applicable to both MHC I and MHC I I complexes is
based on extension of N- and C-terminal of the MHC complex. For example the N-
terminal of the MHC complex is extended with dimerization domain A and the C-
terminal is extended with dimerization domain B. When MHC complexes are incubated
together they pair with each other and form multimers like: A-MHC-BA-MHC-BA-MHC-
BA-MHC-B etc. Alternatively the N-terminal and the C-terminal of a MHC complex are
both extended with dimerization domain A and the N-terminal and C-terminal of
another preparation of MHC complex (either the same or a different MHC) are
extended with dimerization domain B. When these two types of MHC complexes are
incubated together multimers will be formed: A-MHC-AB-MHC-BA-MHC-AB-MHC-B
etc.
In all the above-described examples the extension can be either chemically coupled to
the peptide/MHC complex or introduced as extension by gene fusion. Dimerization
domain AB can be any molecule pair able to bind to each other, such as acid/base
coiled-coil helices, antibody-antigen, DNA-DNA, PNA-PNA, DNA-PNA, DNA-RNA,
LNA-DNA, leucine zipper e.g. Fos/Jun, streptavidin-biotin and other molecule pairs as
described elsewhere herein.
In one embodiment the one or more multimerization domains each have a molecular
weight of from 50,000 Da to preferably less than 1,000,000 Da, such as from 50,000
Da to 980,000; for example from 50,000 Da to 960,000; such as from 50,000 Da to
940,000; for example from 50,000 Da to 920,000; such as from 50,000 Da to 900,000;
for example from 50,000 Da to 880,000; such as from 50,000 Da to 860,000; for
example from 50,000 Da to 840,000; such as from 50,000 Da to 820,000; for example
from 50,000 Da to 800,000; such as from 50,000 Da to 780,000; for example from
50,000 Da to 760,000; such as from 50,000 Da to 740,000; for example from 50,000
Da to 720,000; such as from 50,000 Da to 700,000; for example from 50,000 Da to
680,000; such as from 50,000 Da to 660,000; for example from 50,000 Da to 640,000;
such as from 50,000 Da to 620,000; for example from 50,000 Da to 600,000; such as
from 50,000 Da to 580,000; for example from 50,000 Da to 560,000; such as from
50,000 Da to 540,000; for example from 50,000 Da to 520,000; such as from 50,000
Da to 500,000; for example from 50,000 Da to 480,000; such as from 50,000 Da to
460,000; for example from 50,000 Da to 440,000; such as from 50,000 Da to 420,000;
for example from 50,000 Da to 400,000; such as from 50,000 Da to 380,000; for
example from 50,000 Da to 360,000; such as from 50,000 Da to 340,000; for example
from 50,000 Da to 320,000; such as from 50,000 Da to 300,000; for example from
50,000 Da to 280,000; such as from 50,000 Da to 260,000; for example from 50,000
Da to 240,000; such as from 50,000 Da to 220,000; for example from 50,000 Da to
200,000; such as from 50,000 Da to 180,000; for example from 50,000 Da to 160,000;
such as from 50,000 Da to 140,000; for example from 50,000 Da to 120,000; such as
from 50,000 Da to 100,000; for example from 50,000 Da to 80,000; such as from
50,000 Da to 60,000; for example from 100,000 Da to 1,000,000; such as from 100,000
Da to 980,000; for example from 100,000 Da to 960,000; such as from 100,000 Da to
940,000; for examp e from 100,000 Da to 920,000; such as from 100,000 Da to
900,000; for examp e from 100,000 Da to 880,000; such as from 100,000 Da to
860,000; for examp e from 100,000 Da to 840,000; such as from 100,000 Da to
820,000; for examp e from 100,000 Da to 800,000; such as from 100,000 Da to
780,000; for examp e from 100,000 Da to 760,000; such as from 100,000 Da to
740,000; for examp e from 100,000 Da to 720,000; such as from 100,000 Da to
700,000; for examp e from 100,000 Da to 680,000; such as from 100,000 Da to
660,000; for examp e from 100,000 Da to 640,000; such as from 100,000 Da to
620,000; for examp e from 100,000 Da to 600,000; such as from 100,000 Da to
580,000; for examp e from 100,000 Da to 560,000; such as from 100,000 Da to
540,000; for examp e from 100,000 Da to 520,000; such as from 100,000 Da to
500,000; for examp e from 100,000 Da to 480,000; such as from 100,000 Da to
460,000; for examp e from 100,000 Da to 440,000; such as from 100,000 Da to
420,000; for examp e from 100,000 Da to 400,000; such as from 100,000 Da to
380,000; for examp e from 100,000 Da to 360,000; such as from 100,000 Da to
340,000; for examp e from 100,000 Da to 320,000; such as from 100,000 Da to
300,000; for examp e from 100,000 Da to 280,000; such as from 100,000 Da to
260,000; for examp e from 100,000 Da to 240,000; such as from 100,000 Da to
220,000; for examp e from 100,000 Da to 200,000; such as from 100,000 Da to
180,000; for examp e from 100,000 Da to 160,000; such as from 100,000 Da to
140,000; for examp e from 100,000 Da to 120,000; such as from 150,000 Da to
1,000,000; for example from 150,000 Da to 960,000; such as from 150,000 Da to
940,000 for examp rom 50,000 Da to 920,000; such as rom 150,000 Da to
900,000 for examp rom 50,000 Da to 880,000; such as rom 150,000 Da to
860,000 for examp rom 50,000 Da to 840,000; such as rom 150,000 Da to
820,000 for examp rom 50,000 Da to 800,000; such as rom 150,000 Da to
780,000; for example from 150,000 Da to 760,000; such as from 150,000 Da to
740,000; for example from 150,000 Da to 720,000; such as from 150,000 Da to
700,000; for example from 150,000 Da to 680,000; such as from 150,000 Da to
660,000; for example from 150,000 Da to 640,000; such as from 150,000 Da to
620,000; for example from 150,000 Da to 600,000; such as from 150,000 Da to
580,000; for example from 150,000 Da to 560,000; such as from 150,000 Da to
540,000; for example from 150,000 Da to 520,000; such as from 150,000 Da to
500,000; for example from 150,000 Da to 480,000; such as from 150,000 Da to
460,000; for example from 150,000 Da to 440,000; such as from 150,000 Da to
420,000; for example from 150,000 Da to 400,000; such as from 150,000 Da to
380,000; for example from 150,000 Da to 360,000; such as from 150,000 Da to
340,000; for example from 150,000 Da to 320,000; such as from 150,000 Da to
300,000; for example from 150,000 Da to 280,000; such as from 150,000 Da to
260,000; for example from 150,000 Da to 240,000; such as from 150,000 Da to
220,000; for example from 150,000 Da to 200,000; such as from 150,000 Da to
180,000; for example from 150,000 Da to 160,000.
Connector
In one embodiment a number of binding molecules (BM) associate with a
multimerization domain to form a binding molecule multimer (BM multimer). The
association may be direct - between the binding molecule and the multimerization
domain, or may be via an association with a connector, such as a connector molecule,
which interconnects the binding molecule and the multimerization domain. A
multimerization domain with a connector is an example of linkers according to the
present invention,
In another embodiment the linker of the detection molecule comprises or consists of
one or more connectors and/or connector molecules. Connectors may be formed of
chemical bonds and/or molecules.
The attachment of binding molecules to the multimerization domain may involve
covalent or non-covalent connectors, and may involve small reactive groups as well as
large protein-protein interactions. The coupling of multimerization domains and binding
molecules involve the association of an entity X (attached to or part of the
multimerization domain) and an entity Y (attached to or part of the binding molecule
and/or label). Thus, the connector that connects the multimerization domain and the
binding molecule comprises an XY portion.
A connector according to the invention in on one embodiment comprises one or more
chemical bond formed between the linker / multimerization domain, and each of the
binding molecules and labels.
A connector according to the invention in on one embodiment comprises one or more
connector molecules associated with the linker / multimerization domain, and each of
the binding molecules and labels.
In one embodiment, a number of MHC complexes associate with a multimerization
domain to form a MHC multimer. The attachment of MHC complexes to the
multimerization domain may involve covalent or non-covalent connectors, and may
involve small reactive groups as well as large protein-protein interactions.
The coupling of multimerization domains and MHC complexes involve the association
of an entity X (attached to or part of the multimerization domain) and an entity Y
(attached to or part of the MHC complex and/or label). Thus, the connector that
connects the multimerization domain and the MHC complex comprises an XY portion.
• Covalent connector. The XY linkage can be covalent, in which case X and Y
are reactive groups. In this case, X can be a nucleophilic group (such as -NH 2,
-OH, -SH, -NH-NH2) , and Y an electrophilic group (such as CHO, COOH, CO)
that react to form a covalent bond XY; or Y can be a nucleophilic group and X
an electrophilic group that react to form a covalent bond XY. Other possibilities
exist, e.g either of the reactive groups can be a radical, capable of reacting with
the other reactive group.
X and Y can be reactive groups naturally comprised within the multimerization
domain and/or the binding molecule such as MHC complex, or they can be
artificially added reactive groups. Thus, connectors containing reactive groups
can be linked to either of the multimerization domain and binding molecule such
as MHC complex; subsequently the introduced reactive group(s) can be used to
covalently link the multimerization domain and binding molecule such as MHC
complex.
Example natural reactive groups of binding molecule such as MHC complexes
include amino acid side chains comprising -NH2, -OH, -SH, and -NH-. Example
natural reactive groups of multimerization domains include hydroxyls of
polysaccharides such as dextrans, but also include amino acid side chains
comprising -NH2, -OH, -SH, and -NH- of polypeptides, when the polypeptide is
used as a multimerization domain.
In some MHC multimers, one of the polypeptides of the MHC complex (i.e. the
β2Μ, heavy chain or the antigenic peptide) is linked by a protein fusion to the
multimerization domain. Thus, during the translation of the fusion protein, an
acyl group (reactive group X or Y) and an amino group (reactive group Y or X)
react to form an amide bond. Example MHC multimers where the bond between
the multimerization domain and the MHC complex is covalent and results from
reaction between natural reactive groups, include MHC-pentamers (described
in US patent 2004209295) and MHC-dimers, where the linkage between
multimerization domain and MHC complex is in both cases generated during
the translation of the fusion protein.
Example artificial reactive groups include reactive groups that are attached to
the multimerization domain or the binding molecule such as MHC complex,
through association of a connector molecule comprising the reactive group. The
activation of dextran by reaction of the dextran hydroxyls with divinyl sulfone,
introduces a reactive vinyl group that can react with e.g. amines of the binding
molecule such as MHC complex, to form an amine that now links the
multimerization domain (the dextran polymer) and the binding molecule such as
MHC complex. An alternative activation of the dextran multimerization domain
involves a multistep reaction that results in the decoration of the dextran with
maleimide groups, as described in the patent Siiman et al. US 6,387,622. In this
approach, the amino groups of MHC complexes are converted to -SH groups,
capable of reacting with the maleimide groups of the activated dextran. Thus, in
the latter example, both the reactive group of the multimerization domain (the
maleimide) and the reactive group of the MHC complex (the thiol) are artificially
introduced.
Sometimes activating reagents are used in order to make the reactive groups
more reactive. For example, acids such as glutamate or aspartate can be
converted to activated esters by addition of e.g. carbodiimid and NHS or
nitrophenol, or by converting the acid moiety to a tosyl-activated ester. The
activated ester reacts efficiently with a nucleophile such as -NH 2, -SH, -OH, etc.
For the purpose of this invention, the multimerization domains (including small
organic scaffold molecules, proteins, protein complexes, polymers, beads,
liposomes, micelles, cells) that form a covalent bond with the binding molecules
such as MHC complexes can be divided into separate groups, depending on
the nature of the reactive group that the multimerization domain contains. One
group comprise multimerization domains that carry nucleophilic groups (e.g. -
NH2, -OH, -SH, -CN, -NH-NH2) , exemplified by polysaccharides, polypeptides
containing e.g. lysine, serine, and cysteine; another group of multimerization
domains carry electrophilic groups (e.g. -COOH, -CHO, -CO, NHS-ester, tosyl-
activated ester, and other activated esters, acid-anhydrides), exemplified by
polypeptides containing e.g. glutamate and aspartate, or vinyl sulfone activated
dextran; yet another group of multimerization domains carry radicals or
conjugated double bonds.
Likewise, binding molecules such as MHC complexes can be divided into
separate groups, depending on the nature of the reactive group comprised
within the binding molecule. One group comprise binding molecules such as
MHCs that carry nucleophilic groups (e.g. -NH 2, -OH, -SH, -CN, -NH-NH2) , e.g.
lysine, serine, and cysteine; another group of binding molecules such as MHCs
carry electrophilic groups (e.g. -COOH, -CHO, -CO, NHS-ester, tosyl-activated
ester, and other activated esters, acid-anhydrides), exemplified by e.g.
glutamate and aspartate; yet another group of binding molecules such as MHCs
carry radicals or conjugated double bonds.
The reactive groups of the binding molecule such as MHC complex are either
carried by the amino acids of the binding molecule such as MHC-peptide
complex (and may be comprised by any of the peptides of the MHC-peptide
complex, including the antigenic peptide), or alternatively, the reactive group of
the binding molecule such as MHC complex has been introduced by covalent or
non-covalent attachment of a molecule containing the appropriate reactive
group.
Preferred reactive groups in this regard include -CS0 2OH, phenylchloride, -SH,
-SS, aldehydes, hydroxyls, isocyanate, thiols, amines, esters, thioesters,
carboxylic acids, triple bonds, double bonds, ethers, acid chlorides, phosphates,
imidazoles, halogenated aromatic rings, any precursors thereof, or any
protected reactive groups, and many others.
Reactions that may be employed include acylation (formation of amide,
pyrazolone, isoxazolone, pyrimidine, comarine, quinolinon, phthalhydrazide,
diketopiperazine, benzodiazepinone, and hydantoin), alkylation, vinylation,
disulfide formation, Wittig reaction, Horner-Wittig-Emmans reaction, arylation
(formation of biaryl or vinylarene), condensation reactions, cycloadditions
((2+4), (3+2)), addition to carbon-carbon multiplebonds, cycloaddition to
multiple bonds, addition to carbon-hetero multiple bonds, nucleophilic aromatic
substitution, transition metal catalyzed reactions, and may involve formation of
ethers, thioethers, secondary amines, tertiary amines, beta-hydroxy ethers,
beta-hydroxy thioethers, beta-hydroxy amines, beta-amino ethers, amides,
thioamides, oximes, sulfonamides, di- and tri-functional compounds, substituted
aromatic compounds, vinyl substituted aromatic compounds, alkyn substituted
aromatic compounds, biaryl compounds, hydrazines, hydroxylamine ethers,
substituted cycloalkenes, substituted cyclodienes, substituted 1, 2 , 3 triazoles,
substituted cycloalkenes, beta-hydroxy ketones, beta-hydroxy aldehydes, vinyl
ketones, vinyl aldehydes, substituted alkenes, substituted alkenes, substituted
amines, and many others.
Binding molecule dextramers, preferably MHC dextramers, can be made by
covalent coupling of binding molecules such as MHC complexes to the dextran
backbone, e.g. by chemical coupling of binding molecules such as MHC
complexes to dextran backbones.
The MHC complexes can be coupled through either heavy chain or β2-
microglobulin if the MHC complexes are MHC I or through -chain or β-chain if
the MHC complexes are MHC II. MHC complexes can be coupled as folded
complexes comprising heavy chain/beta2microglobulin or -chain^-chain or
either combination together with peptide in the peptide-binding cleft.
Alternatively either of the protein chains can be coupled to dextran and then
folded in vitro together with the other chain of the MHC complex not coupled to
dextran and together with peptide.
Direct coupling of binding molecules such as MHC complexes to dextran
multimerization domain can be via an amino group or via a sulphide group.
Either group can be a natural component of the binding molecule such as MHC
complex or attached to the binding molecules such as MHC complex
chemically. Alternatively, a cysteine may be introduced into the genes of the
binding molecules such as either chain of the MHC complex.
Another way to covalently link binding molecules such as MHC complexes to
dextran multimerization domains is to use the antigenic peptide as a connector
between MHC and dextran. Connectors containing antigenic peptide at one end
is coupled to dextran. Antigenic peptide here means a peptide able to bind
MHC complexes in the peptide-binding cleft. As an example, 10 or more
antigenic peptides may be coupled to one dextran molecule. When MHC
complexes are added to such peptide-dextran construct the MHC complexes
will bind the antigenic peptides and thereby MHC-peptide complexes are
displayed around the dextran multimerization domain. The antigenic peptides
can be identical or different from each other. Similarly MHC complexes can be
either identical or different from each other as long as they are capable of
binding one or more of the peptides on the dextran multimerization domain.
Non-covalent connector. The linkage moleculethat connects the
multimerization domain and the binding molecule such as MHC complex
comprises an XY portion. Above different kinds of covalent linkages XY were
described. However, the XY linkage can also be non-covalent.
Non-covalent XY linkages can comprise natural dimerization pairs such as
antigen-antibody pairs, DNA-DNA interactions, or can include natural
interactions between small molecules and proteins, e.g. between biotin and
streptavidin. Artificial XY examples include XY pairs such as His6 tag (X)
interacting with Ni-NTA (Y) and PNA-PNA interactions.
Protein-protein interactions. The non-covalent connector may comprise a
complex of two or more polypeptides or proteins, held together by non-covalent
interactions. Example polypeptides and proteins belonging to this group include
Fos/Jun, Acid/Base coiled coil structure, antibody/antigen (where the antigen is
a peptide), and many others.
A preferred embodiment involving non-covalent interactions between
polypeptides and/or proteins are represented by the Pentamer structure
described in US patent 2004209295.
Another preferred embodiment involves the use of antibodies, with affinity for
the surface of the binding molecule (BM). Thus, an anti-BM antibody, with its
two binding sites, will bind two binding molecules and in this way generate a
bivalent BM multimer. In addition, the antibody can stabilize the BM through the
binding interactions.
Another preferred embodiment involves the use of antibodies, with affinity for
the surface of MHC opposite to the peptide-binding groove. Thus, an anti-MHC
antibody, with its two binding sites, will bind two MHC complexes and in this
way generate a bivalent MHC multimer. In addition, the antibody can stabilize
the MHC complex through the binding interactions. This is particularly relevant
for MHC class I I complexes, as these are less stable than class I MHC
complexes.
Polynucleotide-polynucleotide interactions. The non-covalent connector may
comprise nucleotides that interact non-covalently. Example interactions include
PNA/PNA, DNA/DNA, RNA/RNA, LNA/DNA, and any other nucleic acid duplex
structure, and any combination of such natural and unnatural polynucleotides
such as DNA/PNA, RNA/DNA, and PNA/LNA.
Protein-small molecule interactions . The non-covalent connector may comprise
a macromolecule (e.g. protein, polynucleotide) and a small molecule ligand of
the macromolecule. The interaction may be natural (i.e., found in Nature, such
as the Streptavidin/biotin interaction) or non-natural (e.g. His-tag peptide/Ni-
NTA interaction). Example interactions include Streptavidin/biotin and anti-biotin
antibody/biotin.
Combinations - non-covalent connector molecules. Other combinations of
proteins, polynucleotides, small organic molecules, and other molecules, may
be used to link the MHC to the multimerization domain. These other
combinations include protein-DNA interactions (e.g. DNA binding protein such
as the gene regulatory protein CRP interacting with its DNA recognition
sequence), RNA aptamer-protein interactions (e.g. RNA aptamer specific for
growth hormone interacting with growth hormone)
Synthetic molecule-synthetic molecule interaction. The non-covalent connector
may comprise a complex of two or more organic molecules, held together by
non-covalent interactions. Example interactions are two chelate molecules
binding to the same metal ion (e.g. EDTA-Ni++-NTA), or a short polyhistidine
peptide (e.g. His6) bound to NTA-Ni++ .
In another preferred embodiment the multimerization domain is a bead. The bead is
covalently or non-covalently coated with binding molecules, such as BM multimers or
BM monomers, for example MHC multimers or single MHC complexes, through non-
cleavable or cleavable connectors. As an example, the bead can be coated with
streptavidin monomers, which in turn are associated with biotinylated binding
molecules such as MHC complexes; or the bead can be coated with streptavidin
tetramers, each of which are associated with 0 , 1, 2 , 3 , or 4 biotinylated binding
molecules such as MHC complexes; or the bead can be coated with BM-dextramers
such as MHC-dextramers where e.g. the reactive groups of the BM- or MHC-dextramer
(e.g. the divinyl sulfone-activated dextran backbone) has reacted with nucleophilic
groups on the bead, to form a covalent linkage between the dextran of the dextramer
and the beads.
In another preferred embodiment, the binding molecule multimers such as MHC
multimers described above (e.g. where the multimerization domain is a bead) further
contains a flexible or rigid, and water soluble, connector that allows for the immobilized
binding molecules such as MHC complexes to interact efficiently with cells; such as T-
cells with affinity for the MHC complexes. In yet another embodiment, the connector is
cleavable, allowing for release of the binding molecules such as MHC complexes from
the bead. If T-cells have been immobilized, by binding to the BMs such as MHC
complexes, the T-cells can very gently be released by cleavage of this cleavable
connector. Most preferably, the connector is cleaved at physiological conditions,
allowing for the integrity of the isolated cells.
Further examples of connector molecules that may be employed in the present
invention include Calmodulin-binding peptide (CBP), 6xHIS, Protein A , Protein G,
biotin, Avidine, Streptavidine, Strep-tag, Cellulose Binding Domain, Maltose Binding
Protein, S-Peptide Tag, Chitin Binding Tag, Immuno-reactive Epitopes, Epitope Tags,
GST tagged proteins, E2Tag, HA Epitope Tag, Myc Epitope, FLAG Epitope, AU1 and
AU5 Epitopes, Glu-Glu Epitope, KT3 Epitope, IRS Epitope, Btag Epitope, Protein
Kinase-C Epitope, VSV Epitope.
The list of dimerization- and multimerization domains, described elsewhere in this
document, define alternative non-covalent connectors between the multimerization
domain and the binding molecule such as the MHC complex.
The abovementioned dimerization- and multimerization domains represent specific
binding interactions. Another type of non-covalent interactions involves the non-specific
adsorption of e.g. proteins onto surfaces. As an example, the non-covalent adsorption
of proteins onto glass beads represents this class of XY interactions. Likewise, the
interaction of binding molecules such as MHC complexes (comprising full-length
polypeptide chains, including the transmembrane portion) with the cell membrane of for
example dendritic cells is an example of a non-covalent, primarily non-specific XY
interaction.
In some of the abovementioned embodiments, several multimerization domains (e.g.
streptavidin tetramers bound to biotinylated MHC complexes) are linked to another
multimerization domain (e.g. the bead). For the purpose of this invention we shall call
both the smaller and the bigger multimerization domain, as well as the combined
multimerization domain, for multimerization domain.
Kit of parts
The composition of the invention may form part of a kit. Thus, yet an aspect of the
invention relates to a kit of parts comprising
a . one or more detection molecules,wherein each detection molecule or set
of detection molecules are as disclosed herein throughout, and
b. one or more additional components.
In one embodiment the kit of parts comprises
- a composition comprising a detection molecule, wherein said detection
molecule comprises a DNA molecule label, according to the invention; and
one or more sets of primers for amplifying the nucleic acid molecule label, such
as DNA molecule label.
In one embodiment said additional components comprise reagents for detecting and/or
amplifying the label of the detection molecule.
In one embodiment said additional components comprise reagents for detecting and/or
amplifying the nucleic acid label of the detection molecule.
In one embodiment said additional components comprise one or more primer sets
capable of amplifying the label of the nucleic acid label, such as amplifying the barcode
region of the nucleic acid label via hybridization to the primer regions of the nucleic acid
label.
DETECTION METHOD
It is an aspect of the invention to provide a detection method comprising one or more
steps of:
a . Combining a sample with at least one detection molecule; wherein the
detection molecule comprises a binding molecule (BM), a linker (Li), and
a label (La), each as defined according to the present invention; and
wherein said sample comprises at least one cell and/or entity,
b. Incubating the at least one detection molecule and the sample;
c . Isolating and/or detecting the at least one detection molecule of step b),
and
d . Optionally determining the identity of the at least one detection molecule
of step c).
It is understood that each step of the detection method, namely the sample, the
isolation and/or detection and the determination of label, individually can be selected
from any of the samples, isolation and/or detection steps and determination of label
steps disclosed herein throughout. Thus, any combination of sample, isolation and/or
detection and determination of label are encompassed within the present disclosure
and invention.
In one embodiment there is provided a method comprising the following steps:
a . Combining at least one cell with at least one detection molecule, wherein the
detection molecule comprises a binding molecule (BM), a linker (Li), and a label
(La);
b. Allowing the detection molecules to recognize and bind cells through their
binding molecule (BM);
c . Detecting and/or isolating cell-detection molecule complexes formed in step (b);
and
d . Identifying detection molecules capable of binding to a cell in step (b)
Also provided is a method for detecting antigen-responsive cells in a sample
comprising:
a . providing one or more multimeric major histocompatibility complexes (MHC's)
according to the invention or a composition according to the invention;
b. contacting said multimeric MHC's with said sample; and
c . detecting binding of the multimeric MHC's to said antigen responsive cells,
thereby detecting cells responsive to an antigen present in a set of MHC's;
wherein said binding is detected by amplifying the barcode region of said
nucleic acid molecule linked to the one or more MHC's.
It is understood that the detection molecule and each of the components of the
detection molecule (BM, Li and La) referred to in the detection methods of the invention
can individual be as outlined herein elsewhere.
The detection molecules and methods (e.g. detection methods) of the present invention
can be used for or applied in a number of methods and assays. The assays for which
the detection molecules and the methods of using same can be employed include
assays for recognizing or detecting well-known targets or epitopes (such as diagnosis,
detection of antigen-specific T-cells), and assays for investigating novel or unknown
targets or epitopes (such as epitope discovery, whereby the binding properties of the
detection molecule are unknown).
Methods include, but are not limited to one or more of: epitope discovery, analytical
studies, diagnosis, therapy/treatment, detection of antigen-responsive cells, detection
of antigen-specific T-cells, characterization of cells of their detection molecule-binding
properties, T-cell epitope mapping, immune-related therapies, immune-recognition
discovery and measuring immune reactivity after vaccination.
In one embodiment the present invention allows for detection of multiple antigen-
responsive cells present in the same sample, wherein said antigen-responsive cells
have different specificities and detect different antigens and/or epitopes. This can be
achieved since each detection molecule has a unique and detectable label (La)
associated with a specific binding molecule (BM) for the antigen-responsive cell.
In one embodiment the detection method further comprises one or more steps of
providing a sample, preferably a sample comprising at least one entity and/or at least
one cell.
In one embodiment the detection method further comprises one or more steps of pre-
treatment of the sample, and/or pre-treatment of cells of the sample.
The method thus in one embodiment involves first the mixing of one or more detection
molecules capable of binding certain cells with a sample comprising cells, followed by
complex formation between some or all of the detection molecules and some or all of
the cells, and finally detection and/or isolation of the cell-detection molecule complexes
formed.
It follows that in step b) the one or more detection molecules are allowed to associate
with, recognize, and/or bind to said at least one cell and/or entity through their binding
molecule.
The detection method in some embodiment further comprises one or more steps of
separating unbound detection molecules from cell- or entity-detection molecule
complexes.
The detection method in some embodiment further comprises one or more steps of
removing unbound detection molecules by washing and/or centrifuging.
In one embodiment in step c) and d) said detection molecule is comprised in a cell-
detection molecule complex or an entity-detection molecule complex.
In another embodiment in step c) and d) said detection molecule is not comprised in a
cell-detection molecule complex or an entity-detection molecule complex.
In one embodiment in step c) and d) said detection molecule is no longer comprised in
a cell-detection molecule complex or an entity-detection molecule complex, wherein
said detection molecule has previously interacted with a cell-detection molecule
complex or an entity-detection molecule complex.
In steps c) and/or d) of the detection method the sorting and/or detecting thus ensues
on the detection molecule per se, or the cell-detection molecule complex (or entity-
detection molecule complex).
In one embodiment step c) comprises isolating and detecting the at least one detection
molecule.
In one embodiment step c) comprises first isolating and then detecting the at least one
detection molecule.
In one embodiment step c) comprises detecting the at least one detection molecule.
In one embodiment step c) comprises isolating the at least one detection molecule.
In one embodiment step c) comprises first detecting and then isolating the at least one
detection molecule.
The isolation in step c) may be performed by any method known to the skilled person.
Isolation is used interchangeably with enrichment and cell sorting herein.
In a particular embodiment the detection molecule further comprises one or more
fluorescent labels, which are useful in the sorting of specific cell populations. Examples
of specific cell populations include T-cells (CD8 or CD4 restricted), other immune cells
or specifically MHC multimer binding T-cells
In one embodiment, specific cell populations are sorted by methods comprising one or
more of flow cytometry, FACS sorting, centrifugation, washing, precipitation, filtration
and affinity column sorting, or any other means of cell sorting/selection.
In one embodiment in step c) isolating comprises sorting of cell populations based on
the functional response to a stimuli (responsive or non-responsive population), such as
cytokine secretion, phosphorylation, calcium release.
In one embodiment in step c) isolating comprises sorting of cell populations based on
phenotype, such as by linking a certain set of phenotypic characteristics to the antigen-
responsiveness.
In one embodiment in step c) isolating comprises immobilization of the detection
molecule and/or cell-detection molecule complexes, such as by by precipitating cells,
such as by centrifugation, by immunoprecipitation, or any other means that precipitates
the cells.or by binding the cell-detection molecule complexes to a bead, a particle,
another surface, an antibody or an MHC complex.
In one embodiment said immobilization of the detection molecule and/or cell-detection
molecule complexes comprises hybridization onto an array.
In one embodiment said immobilization of the detection molecule and/or cell-detection
molecule complexes by hybridization onto an array comprises a nucleic acid/nucleic
acid-interaction between the nucleic acid label of the detection molecule and an
antisense nucleic acid sequence in the array.
In one embodiment said immobilization of the detection molecule and/or cell-detection
molecule complexes by hybridization onto an array comprises a DNA/DNA-interaction
between the DNA label of the detection molecule and an antisense DNA in the array.
In one embodiment said detecting in step c) and/or determining the identity in step d)
comprises one or more steps of adding primary antibodies that bind to the immobilized
detection molecule and/or cell-detection molecule complexes and detecting said
primary antibodies directly wherein the primary antibody is labelled, or indirectly by
adding labelled secondary antibodies.
In one embodiment said detecting in step c) and/or determining the identity in step d)
comprises one or more steps of detecting the immobilized detection molecule and/or
cell-detection molecule complexes by monitoring read-out from a second label such as
a fluorophore.
In one embodiment detecting in step c) and/or determining the identity in step d)
comprises interaction between 'coating DNA' on the cell surface and the DNA label of
the detection molecule.
In one embodiment detecting in step c) and/or determining the identity in step d)
comprises protease cleavage of the peptide label of the detection molecule.
In one embodiment detecting in step c) and/or determining the identity in step d)
comprises transfer of a cell surface moiety to the detection molecule (e.g. a 'peptide
tag').
In one embodiment detecting in step c) and/or determining the identity in step d)
comprises detection of the label based on the physical characteristics of the label,
including mass, sequence, charge, volume, size, dimensions, fluorescence, absorption,
emission, NMR spectra and others.
In one embodiment detecting in step c) and/or determining the identity in step d)
comprises amplification of the label.
In one embodiment detecting in step c) and/or determining the identity in step d)
comprises sequencing of the label (e.g. DNA sequencing, peptide sequencing).
In one embodiment detecting in step c) and/or determining the identity in step d)
comprises amplification of the barcode sequence of a nucleic acid label by PCR and/or
sequencing of the barcode sequence.
In one embodiment sequencing comprises deep sequencing or next generation
sequencing.
In one embodiment detecting in step c) and/or determining the identity in step d)
comprises mass spectrometry.
In one embodiment detecting in step c) and/or determining the identity in step d)
comprises one or more of gel electrophoresis, gel filtration, PAGE, column
fractionation, PCR and QPCR.
The detection method in some embodiments further comprises one or more steps of
single-cell sorting and sequencing, such as single-cell T cell sorting of and single-cell
TCR sequencing.
In an aspect of the present invention a nucleic acid label comprising a barcode will
serve as a specific label for a given binding molecule, such as a peptide-MHC molecule
that is multimerized to form a MHC multimer. The multimer can be composed of MHC
class I, class II, CD1 or other MHC-like molecules. Thus, when the term MHC
multimers is used this includes all MHC-like molecules. The MHC multimer is formed
through multimerization of peptide-MHC molecules via different backbones. The
barcode will be co-attached to the multimer and serve as a specific label for a particular
peptide-MHC complex. In this way up to 1000 to 10.000 (or potentially even more)
different peptide-MHC multimers can be mixed, allow specific interaction with T-cells
from blood or other biological specimens, wash-out unbound MHC-multimers and
determine the sequence of the DNA-barcodes. When selecting a cell population of
interest, the sequence of barcodes present above background level, will provide a
fingerprint for identification of the antigen responsive cells present in the given cell-
population. The number of sequence-reads for each specific barcode will correlate with
the frequency of specific T-cells, and the frequency can be estimated by comparing the
frequency of reads to the input-frequency of T-cells. This strategy may expand our
understanding of T-cell recognition.
In one embodiment a nucleic acid-label, DNA-label or DNA-barcode serves as a
specific label for certain antigen specific T-cells and can be used to determine the
specificity of a T-cell after e.g. single-cell sorting, functional analyses or phenotypical
assessments. In this way antigen specificity can be linked to both the T-cell receptor
sequence (that can be revealed by single-cell sequencing methods) and functional and
phenotypical characteristics of the antigen specific cells.
Furthermore, this strategy may allow for attachment of several different (sequence
related) peptide-MHC multimers to a given T-cell - with the binding avidity of the given
peptide-MHC multimer determining the relative contribution of each peptide-MHC
multimer to the binding of cell-surface TCRs. By applying this feature it is possible to
allow the determination of the fine-specificity/consensus recognition sequence of a
given TCR by use of overlapping peptide libraries or alanine substitution peptide
libraries. Such determination is not possible with current MHC multimer-based
technologies.
As previously described a pool (library) of different sets of multimeric major
histocompatibility complexes (MHC's) may be used to analyze an overall cell
population for its specificity for peptides. Thus, another aspect of the invention relates
to a composition comprising a subset of multimeric major histocompatibility complexes
(MHC's) according to the invention, wherein each set of MHC's has a different peptide,
decisive for T cell recognition and a unique "barcode" region in the DNA molecule. In
the present context, it is to be understood that each specific multimeric major
histocompatibility complex is present in the composition with a certain number and that
there is subset of different multimeric major histocompatibility complexes present in the
composition.
Preferably all specific region for each multimeric MHC can be determined with only a
few primer sets, preferably only one primer set. Thus, in an embodiment the primer
regions in the DNA molecule are identical for each set of MHC's. In this way only one
primer set is required. In an alternative embodiment, the mulitmeric MHC's are grouped
by different primer sets, thereby allowing multiplication of different sets of the
multimeric MHCs. In this way background noise may be limited, while also retrieving
information of specific bindings. Thus, different primer set for different sets of MHC's
may be used.
The number of individual sets of multimeric MHC's may vary. Thus, in an embodiment
the composition comprises at least 10 different sets of multimeric MHC's such as at
least 100, such as at least 500, at least 1000, at least 5000, such as in the range 10-
50000, such as 10-1000 or such as 50-500 sets of MHC's.
Through analyses of barcode-sequence data, the antigen specificity of cells in the
specimen can be determined. When DNA-barcode#1 is detected above background
level of reads it means that peptide-MHC multimer#1 was preferentially bound to the
selected cell type. Same goes for barcode no. 2 , 3 , 4 , 5 , ....etc. up to the potential
combination of more than 1000 (but not restricted to this particular number). When the
number of input cells are known, e.g. when cell populations of interest is captured via a
fluorescence signal also attached to the multimer by flow cytometry-based sorting or
other means of capturing/sorting, the specific T-cell frequency can be calculated
comparing the frequency of barcode-reads to the number of sorted T-cells.
In a particular embodiment the cells have not been permeabilized or lysed and
therefore the detection molecules bind predominantly to the outer surface of the cells.
In one embodiment the cells are intact, the cell membrane of the cells are intact.
In a particular embodiment the cells are permeable to the detection molecules
wherefore the detection molecules bind to the outer surface of the cell as well as one or
more components of the interior of the cell.
In a preferred embodiment, the combining of one or more cells (step a.), followed by
incubation to allow binding (step b.), is performed in a buffer, such as a buffer selected
from the group consisting of a PBS buffer, a Tris buffer, a phosphate buffer and any
other buffer with appropriate ionic strength and pH, suitable for formation of the cell-
detection molecule complexes.
In a preferred embodiment the detecting of the cell-detection molecule complexes is
done by first spinning down the cells (and the detection molecules attached to the
cells), removing the supernatant, optionally washing one or more times, and optionally
amplifying the DNA oligonucleotide labels e.g. by PCR, then identifying the DNA label
of the detection molecules still bound to the cells by e.g. sequencing of the DNA or by
running polyacrylamide gel electrophoresis to identify different DNA oligonucleotides
based on their differential migration in the gel , thereby identifying the detection
molecules capable of binding cells.
As known to the skilled person, unbound molecules should preferably be removed.
Thus, in an embodiment unbound (multimeric) MHC's are removed before
amplification, e.g. by washing and/or spinning e.g. followed by removing of the
supernatant.
The detection of the barcode in one embodiment includes sequencing of the amplified
barcode regions. Thus, in an embodiment the detection of barcode regions includes
sequencing of said barcode region, such as by deep sequencing or next generation
sequencing.
In a preferred embodiment the isolation of cell-detection molecule complexes of step c .
is done by immobilization of a population of cells by binding to a marker molecule
attached to a surface such as the bottom of a well of a microtiter plate, a bead such as
a magnetic polystyrene bead, or a glass plate, where the marker molecule binds to all
or a subset of the cells.
In a preferred embodiment the marker molecule is an antibody against the CD8 or CD4
receptor of T cells, and the binding molecule of the detection molecule is a pMHC
complex or a number of pMHC complexes, where the pMHC are of class I or class II,
respectively.
In a preferred embodiment the cell-detection moleculecomplexes are first isolated, and
then diluted and aliquoted into separate wells, under conditions where the majority of
wells as a result will contain zero or one cell, and wherefore the detection molecules
bound to each individual cell may be determined.
It may also be advantageously to be able to sort the cells. Thus, in an embodiment the
method further comprises cell sorting by e.g. flow cytometry such as FACS. This may
e.g. be done if the backbone is equipped with a fluorescent marker. Thus, unbound
cells may also be removed/sorted.
In a preferred embodiment, the method is performed on known negative control cell
samples (i.e. cell samples that are known to not contain cells that can bind to the
detection molecules used in the method) to ensure that non-specific ("faulty") binding
events occur. The method will typically be performed in parallel using two cell samples:
one that contain cells that may comprise cells with binding affinity for one or more of
the detection molecules; and one cell sample that does not contain cells with significant
affinity for one or more detection molecules.
In a preferred embodiment, the method is performed including a negative control
detection molecule (i.e. a detection molecule that is expected to not bind any of the
cells).
In a preferred embodiment, the method is performed including a positive control
detection molecule (i.e. a detection molecule that is expected to bind one or some of
the cells).
As also known to the skilled person, the measured values are preferably compared to a
reference level. Thus, in an embodiment said binding detection includes comparing
measured values to a reference level, e.g. a negative control and/or total level of
response in the sample. In a further embodiment, said amplification is PCR such as
QPCR.
Isolating and/or detecting detection molecules
Isolating detection molecules that are complexes with a certain cell, or that have been
in contact with a certain cell, can be done in many ways.
In one embodiment, the detection molecules that are in contact with the cells are
enriched by removing detection molecules that are not in contact with cells. This can
for example be done by centrifugation of the mixture of detection molecules and cell,
whereby cells are precipitated along with the detection molecules that bind them. When
the supernatant is then removed, the detection molecules that do not bind the cells are
removed. As a result, the detection molecules that bind the cells are enriched for.
In one embodiment the incubation mixture of detection molecules and cells is
centrifuged, in order to precipitate the cells, and thereby the detection molecules bound
to the cells. When the supernatant is the removed, the detection molecules that did not
bind to cells are removed as well. Optionally, one may repeat centrifugation and
resuspension one or more times, and then finally the enriched pool of detection
molecules can be examined, e.g. the identity and quantity of the recovered detection
molecules may be determined.
In one embodiment the incubation mixture of detection molecules and cells is
centrifuged, in order to precipitate the cells, and thereby the detection molecules bound
to the cells. When the supernatant is then removed, the detection molecules that did
not bind to cells are removed as well. Optionally, one may repeat centrifugation and
resuspension one or more times, and then finally the enriched pool of detection
molecules can be examined, e.g. the identity and quantity of the recovered detection
molecules may be determined. In one embodiment the resulting detection molecules,
still bound to cells, may be released from the cells, by e.g. mild acid or mild base
treatment or protease treatment if the binding molecule or linker is a peptide. Once
released, the detection molecules may be examined by hybridization to an array of
anti-sense molecules. For example, if the labels of e.g. 100 detection molecules are
oligonucloetide labels of different sequence, the array can comprise the corresponding
100 complementary sequences, positioned in a way so that a given position or area of
the array comprises only oligonucleotides of a given sequence. The identity of the
oligonucleotide label and hence the detection molecule to which it is bound, can then
be determined when examining to which position in the array that it anneals.
In another embodiment of the above embodiment, the cells and detection molecules
are not separated before applying the cell-detection molecule complexes to the array.
As a result, the cells will become immobilized on the array at those positions where the
sequence of the oligonucleotide label of the detection molecule bound to said cell is
complementary to the oligonucleotide of the array. This way, both the identity of the
recovered detection molecules, as well as the number of cells capable of binding said
detection molecules, can be deduced from the array.
In the two embodiments immediately above, the binding of detection molecules to the
array is detected for example by adding antibodies that bind the binding molecule, and
then staining these antibodies using secondary antibodies and e.g. chromophores or
fluorophores as a readout, using standard procedures. Alternatively, the detection
molecule can simply carry a signal molecule, such as a fluorophore.
In one embodiment the incubation mixture of detection molecules and cells is
centrifuged, under conditions and buffer choice where a gradient develops in the
centrifugation vial. As a result of the gradient being established in the centrifugation
vial, the cells and detetion molecules and cell-detection molecule complexes will be
distributed along the gradient according to their weight and volume. Different cell types
with different characteristics will locate to different positions in the gradient. Therefore,
cells of different kinds, along with the detection molecules that bind to them, can be
recovered from specific positions along the gradient. Unbound detection molecules will
locate far from the cells. After collecting the cells and detection molecules bound to
these cells, from a given position in the gradient, the identity and quantity of the
recovered detection molecules may be determined.
In one embodiment the incubation mixture of detection molecules and cells is applied
to a filter that retains structures of same or larger size than cells, and let smaller
structures and molecules pass through. The retained cells may be resuspended and
applied to the filter one or more times. Finally, the identity and quantity of the recovered
detection molecules, i.e. the detection molecules that bound to the cells, may be
determined.
In one embodiment the detection molecules are incubated with a solid sample
comprising cells, such as a tissue section or biopsy. After incubation, the solid tissue or
biopsy is washed one or more times, to remove unbound detection molecules. Finally,
the remaining detection molecules, bound to cells of the solid tissue, can be identified
and quantified by determining the identity and amount of label remaining on the solid
tissue.
In one embodiment, the detection molecules that are capable of binding certain cells
are isolated by immobilizing said cells on e.g. beads, for example coated with an
antibody specific for said cells (e.g. beads coated with anti-CD4 antibodies to
specifically examine binding of detection molecules to CD4 T cells). When the cells
have been immobilized on the beads, the beads are washed a couple of times to
remove unbound or weakly bound detection molecules. The enriched pool of detection
molecules, each of which are capable of binding the immobilized cells, can then be
identified and quantified by identification and quantification of their respective labels.
In one embodiment, both the ability to secrete certain molecules, as well as the ability
to bind specific detection molecules, is used as a means of enrichment of certain
detection molecules. For example, if certain T cells of a cell sample are stimulated to
secrete INF-γ (e.g by addition of free peptides to the cell suspension, or by binding of
MHC multimers such as Dextramers or tetramers), and if bi-specific antibodies,
recognizing both a T cell-specific protein on the cell surface, and INF-y, are added, the
secreted INF-y will be captured by the bi-specific antibody and become immobilized on
the cell surface. If then beads, coated with anti-INF-y antibody recognizing another face
of INF-y are added, the cells that secrete INF-y will become immobilized on the beads.
If then detection molecules comprising pMHC binding molecules are added to the
cell/bead suspension, detection molecules capable of binding T cells will become
immobilized on the beads as well. After washing to remove unbound detection
molecules, the detection molecules binding to T cells that were secreting INF-y, can be
recovered. Finally, the identity and amount of the recovered detection molecules can
be determined by identifying the label of the recovered detection molecules. Thus, in
this approach, the detection molecules are identified that bind to T cells, where said T
cells are known to secrete INF-y.
In one embodiment, the detection molecules carry both binding molecules (e.g. pMHC
complexes) and anti-INF-y antibody. INF-y will be secreted from certain cells as a
result of the stimulation brought about by the binding of the detection molecule (i.e.
brought about by the binding of the pMHC binding molecule), and the secreted INF-y
will be captured on detection molecules bound to the same cell. These cells may be
immobilized on beads carrying anti-INF-y antibodies. After washing to remove unbound
detection molecules, the detection molecules binding to T cells that were secreting INF-
y, can be recovered. Finally, the identity and amount of the recovered detection
molecules can be determined by identifying the label of the recovered detection
molecules. Thus, in this approach, the detection molecules are identified that bind to T
cells, where said T cells are known to secrete INF-y.
In one embodiment, the detection molecules that are capable of binding certain cells
are isolated by applying the incubation mixture of cells and detection molecules to an
affinity column, e.g. carrying antibodies or other proteins that bind to a certain cell
membrane protein of said cells (where the cell membrane protein is indicative of the
cell being e.g. in a certain development stage, a certain stage in the mitotic cycle, or
indicative of the cell being of a certain kind). It is of course important that the column
material allows the cells to migrate relatively unhindered through the column unless
they bind to the affinity target (e.g. antibody) on the column. The cells that bind to the
affinity column will migrate slower through the column and can be recovered from the
later column fractions. The detection molecules that do not bind cells will flow through
much faster than the cells, and can be recovered in early fractions. The enriched pool
of detection molecules, each of which are capable of binding the immobilized cells, can
then be identified and quantified from the later fractions, by identification and
quantification of their respective labels.
In one embodiment, the detection molecules that are capable of binding certain cells
are isolated by immobilizing all the detection molecules recovered after washing cells.
Thus, in this embodiment, the detection molecules that are not bound to a cell are
removed, by recovering the cell (e.g. by centrifugation, filtration through a filter that
allows molecules but not cells to pass through, or any other means that recovers the
cells (and the detection molecules bound to them) but does not recover the unbound
detection molecules. The recovered cells may be re-suspended and the
centrifugation/filtration process repeated, and then the recovered cells with detection
molecules bound are immobilized on a surface (e.g. a microtiter-plate well coated with
antibodies that recognize and bind detection molecules) or a bead (e.g. a bead coated
with antibodies that recognize and bind detection molecules), or are precipitated by
adding primary antibodies that bind detection molecules, and secondary antibodies that
bind the primary antibodies, thus resulting in the formation of large aggregates of cells,
detection molecules, and primary and secondary antibodies, which can easily be
precipitated. Finally, the identity and quantity of each kind of recovered detection
molecule is determined.
In one embodiment involving the isolation of detection molecules that are capable of
binding to certain cells, flow-activated cell sorting (FACS) is used. For example, the
detection molecule may, in addition to a linker, binding molecule and label, comprise a
fluorescent moiety (i.e. a fluorophore). Detection molecules and cells are incubated,
and those cells that are bound by a (fluorescent) detection molecule can be identified
and collected by a flow activated cell sorter (FACS). Thus, after sorting, the detection
molecules that were capable of binding to cells, are collected together with the cells
they bind to. The identity and amount of the recovered binding molecules can then be
identified by identification and quantification of the corresponding labels.
In one embodiment, the invention is used to perform single-cell phenotyping and/or
analysis. Thus, most of the abovementioned isolation procedures, in which (a subset
of) cells are isolated, e.g. by centrifugation, FACS sorting, or bead immobilization, the
cells may (following their enrichment) be diluted and placed in separate containers (e.g.
separate wells of a microtiter-plate well), at a dilution where there is on average
significantly less than one cell per well. Consequently, those wells comprising one cell
can be used to do single-cell phenotyping, by identifying the labels (and hence the
detection molecules) associated with the one cell present in the well.
In one embodiment, the binding molecule binds to an intracellular target, e.g. a protein
or a mRNA. For such cases, the detection molecule needs to become intracellularized,
either as a means of active or passive transport across the fully functional membrane,
or as a result of the cells having been mildly permeabilized. The cells may be
permeabilized using standard methods such as those used routinely in intracellular
staining (ICS) procedures.
Detecting detection molecules that are complexed with a certain cell, or that have
been in contact with a certain cell, can be done in many ways.
In one embodiment, the detection molecules that are or have been in contact with the
cells are marked specifically. In one embodiment the detection molecules carry DNA
oligonucleotide labels ("label DNA") of different lengths, i.e. the length of the DNA label
identifies the detection molecule. The surface of the sample cells is coated with DNA
oligonucletides ("coating DNA"), for example by adding antibody-DNA conjugates
where the antibody recognizes a particular cell surface structure.
The "label DNA" and "coating DNA" have complementary regions in their 3'-ends but
the 3'-end of "label DNA" is blocked and cannot serve as primer for an extension
reaction. When a detection molecule binds the DNA coated cells, the "label DNA" is
brought into proximity of the "coating DNA", allowing the complementary 3'ends to
anneal. When a polymerase and radioactive nucleosides are added, the strand
complementary to the "label DNA" is generated by extension from the 3'end of "coating
DNA". DNA is then purified from the mixture and applied to an appropriate gel, allowing
separation of the radioactive DNA fragments. The identity and amount of the labels
(and hence the corresponding detection molecules) can be determined from the
position and intensity of the band on the gel.
In one embodiment, the detection molecules that have been in contact with cells are
marked specifically. In one embodiment the detection molecules carry peptide labels.
The peptide label consists of a coding region and a protease cleavage site proximal to
the linker that connects the label to the binding molecule. The surface of the sample
cells is coated with proteases capable of cleaving the peptide labels, for example by
adding antibody-protease conjugates where the antibody recognizes a particular cell
surface structure. Thus, when the detection molecules bind to the sample cells, they
are brought into proximity of the protease, which results in cleavage of the label and
release of the coding region from the detection molecule and hence, release from the
cells. After centrifugation to precipitate the cells, the supernatant can be analysed by
mass spectrometry to determine the identity and amount of the labels that were
released from the cells, and hence, the identity and amount of detection molecules that
bound to the cells in question.
In one embodiment, the detection molecules that have been in contact with cells are
marked, allowing their enrichment and analysis. For example, if the detection molecule
carries - in addition to the binding molecule, linker and label - an enzyme catalyzing the
transfer of a cell surface moiety (e.g. a peptide fragment) from a cell surface protein to
the binding molecule of the detection molecule, when said surface protein binds to the
binding molecule. This peptide tag that has been added to the binding molecule, can
then be used as a means of isolating all the detection molecules that have been in
contact with said cell surface protein (e.g. by purifying the tagged detection molecules
by applying the incubation mixture to beads coated with anti-peptide tag antibodies).
Finally, the isolated detection molecules can be identified by identification and
quantification of their labels.
Determining the identity of the label
The identity of the label and thereby the identity of the binding molecule, may be
determined from the label's physical characteristics, such as its mass, composition or
sequence, charge, volume, size and dimensions, fluorescence, absorption, emission,
NMR spectrum, and many other physical characteristics.
The mass of a label can be determined by e.g. mass spectrometry.
The composition of a label can be determined by degradation to its components (e.g a
peptide being degraded to its amino acid residues), and the amounts of each of its
components be determined by e.g. chemical methods (e.g. specific reactions), whereby
the composition can be determined.
The sequence of a polymer can be determined by appropriate sequencing methods.
Thus, for peptides the sequence can be deduced by standard peptide sequencing
methods (e.g. Edman degradation). Likewise, for natural oligonucleotides the sequence
can be determined using standard sequencing reactions, involving chemical or
enzymatic procedures. Oligonucleotides comprising certain unnatural nucleotides may
also be sequenced by some of these methodologies.
The sequence and amount of an oligonucleotide can also be determined by measuring
its ability to anneal to complementary oligonucleotide sequences. This principle is
applied in Q-PCR, where a polymerase chain reaction is performed. Here, forward and
reverse primers are added to the composition of labels, whereafter the amount
corresponding (complementary) oligonucleotide template (label) can be determined by
determining the amount of double-stranded PCR product generated at different stages
(number of cycles) of the PCR reaction.
Where a composition of detection molecules carry labels of similar size and/or mass,
but different charge, these may be separated and identified and their relative amounts
determined by e.g. running them on a gel. If the labels are of similar size and
dimension, and if the labels migrate from the negative to positive electrode, the labels
with the highest negative charge will migrate the fastest through the gel. The relative
amounts of the different labels are reflected in the density, optionally staining density if
the gel is stained after electrophoresis, of the different bands on the gel.
The volume, size and dimensions of a label molecule determines how fast it will flow
through a column. For some column types, the largest molecules flow through the
column the fastest (e.g. gel filtration columns). For other column types, the largest
molecules flow through the slowest. Both column types can be used to separate and
identify and determine the relative amounts of different labels, by applying the
composition of labels to the top of the column, and measuring the flow-through time for
each of the labels, as well as the amount of label detected in a given fraction.
Labels emitting any kind of radiation can be identified and quantified from its spectrum
of emission and intensity of radiation. Detection of radiation is used in e.g. flow
cytometers and spectrophotometers.
Labels can also be identified and quantified from their NMR signal.
Binding of detection molecules can be detected using various principles:
o Fluidic samples are one embodiment of the present invention where binding and
detection of binding molecules can be used to make a diagnostic analysis. One or
more defined structures may be measured.
Often entities like cells or other particles in a sample are detected by binding
molecules associated to surface receptors or intracellular structures of the cell or
binding structures exposed on the bead
One way to analyse fluidic samples is using flow cytometry. In flow cytometry, the
sample is a suspension of entities, which are moved to and centered in the flow cell
(interrogation point) by co-flow with sheath fluid, or is directly injected into the
instrument.
Liquid cell samples can be analyzed using a flow cytometer, able to detect and count
individual cells passing in a stream through a laser beam. For identification of specific
cells in a sample, cells are tagged with fluorescent labeled detection molecules by
incubating cells with labelled detection molecule and then force the cells with a large
volume of liquid through a nozzle creating a stream of individually spaced cells. Each
cell passes through a laser beam and during the passage the laser light is scattered
and any fluorochrome bound to the cell is excited and thereby fluoresce. Sensitive
photomultipliers detect emitted fluorescence and thereby gives information of binding
detection molecules to the surface of a given cell. By this method labelled ddetection
molecules can be used to identify specific cell populations in cell samples of any
individual. In here the term "labeling" of cells with labelled detection molecules is used
interchangeably with the term "staining".
Flow cytometry allows detection of a single entity with a specified set of characteristics,
within a population of entities with other sets of characteristics. A major advantage of
flowcytometry is that it allows rapid analysis of multiple parameters for each individual
entity, simultaneously.
Another example of a method measuring binding of labeled binding molecules
(detection molecules) to structures in fluidic samples is detection of cells or particles in
the sample by binding labeled binding molecule followed by identification of labeled
structures using microscopy include light microscopy, immunofluorescence
microscopy, confocal microscopy or other forms of microscopy. Basically the fluidic
sample is stained with labeled binding molecule and non-binding binding molecule
removed by washing. Then the sample is spread out on a slide or similar in a thin layer
and labelled cells identified using a microscope.
o Measurement of detection molecule can also be used on solid samples. Example
solid sample include but is not limited to solid tissue, blocks of solid tissue, slices
of solid tissue, cells or particles embedded in a solid matrix or any other solid or
semisolid sample.
Solid samples are typically analysed by placing them in instruments as blocks or in
the form of thin slide of material on e.g. a glass plate. Solid material can then be
labeled by binding deteciton molecule and the amount of bound detection
molecule measured.
An example of a method measuring binding of detection molecule to solid sample is
immunohistochemistry. This assay technique involves immobilization of the tissue slice
on a glass slice, carrying the sample through the assay steps to the final analysis.
The means of detection typically involve photometric methods, microcopy and/or digital
scanning of the sample. It may be simple light or fluorescence microscopy, for
determination of chemiluminescence, morphology, shape, and fluorescence. Also,
laser scanning techniques may be employed, where confocal microscopy or standard
light microscopy is employed to give a 3- and 2-dimensional picture, respectively, of the
sample. A digital image may be acquired, whereby the individual features e.g. light
intensity at a given area of the sample can be determined.
Another example of a method measuring binding of detection molecule to solid sample
is immunoelectron microscopy. In this technique deetction molecules labeled with gold
particle are applied to thin section of sample which are then examined in a
transmission electron microscope. This method is used to detect intracellular location
of structures or particular matter in a sample at high resolution.
Samples can also be attached to solid support and then incubated with detection
molecule and bound detection molecule measured. Alternatively detection molecule of
interest is bound to structure in sample before immobilization of sample to solid
support. This principle is especially useful for binding detection molecules in solution to
its binding partner in fluidic samples but can also be used on solid samples.
Below different principles for measurement of binding detection molecule to sample
immobilized to solid support is listed.
• Molecule of interest is immobilized on solid support and detected using labeled
marker. Alternatively the sample is first labeled and then immobilized on solid
support. An example is ELISA based and Radioimmuno based assays. In both
assays the immobilized sample is incubated with detection molecule (or the sample
is incubated with detection molecule and then immobilized on solid support), then
non-binding detection molecule is removed by washing. Bound detection molecule
is measured. The detection molecule may be labeled directly orindirectly. In ELISA
the label is most often an enzyme while in radioimmuno assays the label is a
radioactive molecule. Other labeling molecules may also be used like
fluorochromes, chromophores or other molecules that can be measured. Useful
labeling molecules are described elsewhere herein.
• Structure of interest in sample is catched by its partner; the specific detection
molecule that is immobilized on solid support. Bound sample or part of sample is
then detected using a labeled marker specific for the same or a different structure
in the bound sample.
Different detection molecules to two or more structures of interest in same sample
are immobilized on solid support in a defined pattern. Structures of interest in
sample are bound to the defined areas of the support and are detected by a labeled
marker. Each individual structure binds to different partners immobilized in different
positions on the solid support. Thereby the sample may be phenotyped.
Two or more solid supports (e.g. beads) with different characteristics (e.g. size,
fluorescence, fluorescence intensities, labels), where each kind of bead has a
specific detection molecule immobilized. Structures of interest in sample are bound
to specific populations of beads, where each bead population is defined by the
detection molecule they have immobilized. The different populations of beads are
detected through their special characteristics.
The sample analysed by the above described methods may first be subjected to
another analysis e.g. separation according to size. An example is Blotting techniques
were molecular structures of a sample are first separated according to size and then
transferred to a solid support followed by detection with labeled detection molecule.
Depending on the structure to be analysed different forms of blotting exist, e.g.
Western blotting for analysis of proteins, Northern blotting for analysis of RNA and
Southern blotting for analysis of DNA.
o Binding may also be measured without using labeled detection molecules for
detection. A sample may be captured by immobilized binding molecule, then eluted
and quantified. Usually the starting point is a sample in solution, such as a cell
lysate, growth medium or blood. The molecule or structure of interest will have a
well known and defined property which can be exploited during the binding
process. The process itself can be thought of as an entrapment, with the target
molecule becoming trapped on a solid or stationary phase or medium. The other
molecules in solution will not become trapped as they do not possess this property.
The solid medium can then be removed from the mixture, washed and the target
molecule released from the entrapment in a process known as elution.
Binding to the solid phase may be achieved by column chromatography, whereby
the solid medium is packed onto a chromatography column, the initial mixture run
through the column to allow binding, a wash buffer run through the column and the
elution buffer subsequently applied to the column and collected. These steps are
usually done at ambient pressure (as opposed to HPLC or FPLC).
Alternatively binding may be achieved using a batch treatment, by adding the initial
mixture to the solid phase in a vessel, mixing, separating the solid phase (by
centrifugation for example), removing the liquid phase, washing, re-centrifuging,
adding the elution buffer, re-centrifuging and removing the eluate.
Sometimes a hybrid method is employed, the binding is done by the batch method,
then the solid phase with the target molecule bound is packed onto a column and
washing and elution are done on the column.
A third method, expanded bed adsorption, which combines the advantages of the
two methods mentioned above, has also been developed. The solid phase particles
are placed in a column where liquid phase is pumped in from the bottom and exits
at the top. The gravity of the particles ensures that the solid phase does not exit the
column with the liquid phase.
Following elution the purified or enriched molecule or structure can be quantitated,
enriched further or used in new analytical processes or treatment processes.
o Measurement of alteration of physical state of sample or structure in sample upon
binding molecule. For example addition of binding molecule to a fluidic sample may
induce cross-linking of structures, clumping and/or aggregation of sample. E.g.
antibodies or other binding molecules can bind large particles and make the particle
to clump or agglutinate. The antibody or other molecule binds multiple particles and
joins them, creating a large complex.
Similar addition of binding molecule to solid sample may make the solid sample
becoming semi solid, fluidic or in another way change texture.
Other physical characteristics may be changed as a consequence of addition of
binding molecule to sample and if measureable they can be used for analysis of
sample.
An example of a specific assay measuring alteration in the physical state of a
sample upon addition of binding molecule is turbidimetry. This is a method for
determining the concentration of a substance in a solution by the degree of
cloudiness or turbidity it causes or by the degree of clarification it induces in a
turbid solution.
• Indirect measurement of binding is measurement of the result of the interaction
between binding molecule and structure in sample in contrast to direct measurement
of the binding molecule bound in sample. The result of interaction between binding
molecule and structure in sample can be measured in several ways indirect ways.
o Measurement of produced substance. Upon binding of binding molecule to
structure in sample the sample may release and/or produce a substance that can
be measured. Depending on the nature of the sample different principles exists
The produced substance may be measured in solution either directly or by
detection with a labeled detection molecule. The produced substance may
be easily accessible for detection or alternatively need to be extracted from
sample before measurement is possible.
One example of measurement of produced substance in solution is Polymerase Chain
reaction (PCR). In this method fragments of DNA in solution are amplified by binding
DNA primers (binding molecules) to defined areas of the DNA in sample. The amount
of amplified DNA is then measured.
Another example is measurement of produced soluble substance inside cells using
intracellular flow cytometry. This can be done using block of secretion of soluble
substance (e.g. by monensin), permeabilization of cell (by e.g. saponine) followed by
immunofluorescent staining. The method involves the following steps: 1) An reagent
able to block extracellular secretion of cytokine is added, e.g. monensin that interrupt
intracellular transport processes leading to accumulation of produced soluble factor,
e.g. cytokine in the Golgi complex. 2) Fixation of cell membrane using mild fixator
followed by permeabilization of cell membrane by. e.g. saponine. 3) Addition of labelled
detection molecule specific for the produced soluble substance to be determined. 5)
Measurement of labelled cells using a flow cytometer. Optionally this analysis can be
combined with labeling with detection molecules specific for surface exposed
structures. If so these detection molecules are added before step 2 .
An alternative to this procedure is to trap secreted soluble factors on the surface of the
secreting cells followed by detection with specific detection molecules as described by
Manz, R. et al., Proc. Natl. Acad. Sci. USA 92:1 921 ( 1995).
■ The produced substance may be immobilized to solid support followed by
detection using labeled marker. Principles for immobilization and detection
are as described elsewhere herein for immobilization of samples and direct
detection
An example of indirect detection of produced substance immobilized on
solid support is measurement of substances secreted from stimulated cells
by capture of the secreted substance on solid support followed by
detection with labeled detection molecule. Secreted soluble substance in
the supernatant is immobilized on solid support either directly or through a
linker molecule. The cells may be stimulated by addition of other cells to
the sample, addition of antigens (peptides/proteins) to the sample, addition
of stimulatory proteins or other molecules or stimulated by other means.
The amount of secreted substance can be measured in different ways:
Soluble substances secreted from individual cells can be detected by
capturing of the secreted soluble substances locally by detection
molecules, e.g. antibody specific for the soluble substance. Soluble
substance recognizing detection molecules are then immobilised on a
solid support together with cells and soluble substances secreted by
individual cells are thereby captured in the proximity of each cell.
Bound soluble substance can be measured using labelled detection
molecule specific for the captured soluble substance. The number of
cells that has given rise to labelled spots on solid support can then be
enumerated and these spots indicate the presence of specific cells that
have beene stimulated with particular stimulator.
Soluble substances secreted from a population of cells are detected by
capture and detection of soluble substance secreted from the entire
population of specific cells. In this case soluble substance do not have
to be captured locally close to each cell but the secreted soluble
substances may be captured and detected in the same well as where
the cells are or transferred to another solid support with detection
molecules for capture and detection e.g. beads or wells of ELISA plate.
■ The produced substance is measured directly in solid sample using
principles as described for solid samples elsewhere herein.
o Measurement of effector function in sample. Binding of binding molecule may also
result in changes in effector function of sample. Effector function is inhere any
function of sample or produced in sample. This type of measurement is only
relevant for samples comprising living cells, living organisms or other living
material. Examples of effector function of/in a sample include but are not limited to
cytolytic activity, catalytic activity, ability to stimulate other cells or samples or ability
to induce apoptosis in sample itself or in other samples.
An example is measurement of activation of T cells in a sample by measurement of
cytolytic activity of the T cell in a cytolytic assay, e.g. a chromium release assay.
o Measurement of growth. Binding of binding molecule may induce or inhibit growth
in a sample. This type of measurement is only relevant for samples comprising
living cells, living organisms or other living material. In cell samples growth can be
measured as proliferation of cells in the sample.
Examples of methods useful for measuring proliferation include but are not limited
to:
■ Detection of mRNA. Proliferation of T cells can be detected by
measurement of mRNA inside cell. Cell division and proliferation requires
production of new protein in each cell which as an initial step requires
production of mRNA encoding the proteins to be synthesized.
■ Detection of incorporation of thymidine. The proliferative capacity of T cells
in response to stimulation by MHC multimer can be determined by a
radioactive assay based on incorporation of [3H]thymidine ([3H]TdR) into
newly generated DNA followed by measurement of radioactive signal.
■ Detection of incorporation of BrdU. Cell proliferation can also be detected
by of incorporation of bromo-2'-deoxyuridine (BrdU) followed by
measurement of incorporated BrdU using a labeled anti-BrdU antibody in
an ELISA based analysis.
■ Viability of cells may be measured by measurement ATP in a cell culture.
Separation according to size, structure or other physical characteristics
Properties of a sample can also be determined by measuring size and/or structure of
sample. Below different methods based on different principles are listed.
Gel electrophoresis
Gel electrophoresis is a technique used for the separation of deoxyribonucleic acid,
ribonucleic acid, or protein molecules using an electric current applied to a gel matrix.
The term "gel" in this instance refers to the matrix used to contain andseparate the
target molecules. In most cases the gel is a crosslinked polymer whose composition
and porosity is chosen based on the specific weight and composition of the target to be
analyzed. When separating proteins or small nucleic acids (DNA, RNA, or
oligonucleotides) the gel is usually composed of different concentrations of acrylamide
and a cross-linker, producing different sized mesh networks of polyacrylamide. When
separating larger nucleic acids (greater than a few hundred bases), the preferred
matrix is purified agarose. In both cases, the gel forms a solid, yet porous matrix.
Acrylamide, in contrast to polyacrylamide, is a neurotoxin and must be handled using
appropriate safety precautions to avoid poisoning.
"Electrophoresis" refers to the electromotive force (EMF) that is used to move the
molecules through the gel matrix. By placing the molecules in wells in the gel and
applying an electric current, the molecules will move through the matrix at different
rates, usually determined by mass, toward the positive anode if negatively charged or
toward the negative cathode if positively charged.
After the electrophoresis is complete, the molecules in the gel can be stained to make
them visible. Ethidium bromide, silver, or coomassie blue dye may be used for this
process. Other methods may also be used to visualize the separation of the mixture's
components on the gel. If the analyte molecules fluoresce under ultraviolet light, a
photograph can be taken of the gel under ultraviolet lighting conditions. If the molecules
to be separated contain radioactivity added for visibility, an autoradiogram can be
recorded of the gel.
If several mixtures have initially been injected next to each other, they will run parallel
in individual lanes. Depending on the number of different molecules, each lane shows
separation of the components from the original mixture as one or more distinct bands,
one band per component. Incomplete separation of the components can lead to
overlapping bands, or to indistinguishable smears representing multiple unresolved
components.
Bands in different lanes that end up at the same distance from the top contain
molecules that passed through the gel with the same speed, which usually means they
are approximately the same size. There are molecular weight size markers available
that contain a mixture of molecules of known sizes. If such a marker was run on one
lane in the gel parallel to the unknown samples, the bands observed can be compared
to those of the unknown in order to determine their size. The distance a band travels is
approximately inversely proportional to the logarithm of the size of the molecule.
Gel electrophoresis is usually performed for analytical purposes, but may be used as a
preparative technique prior to use of other methods such as mass spectrometry, RFLP,
PCR, cloning, DNA sequencing, or Southern blotting for further characterization.
Depending on the type of material to be separated different techniques may be used
some of these are listed below:
■ Polypeptide length can be determined by SDS PAGE. The solution of proteins to be
analyzed is first mixed with SDS, an anionic detergent which denatures secondary
and non-disulfide-linked tertiary structures, and applies a negative charge to each
protein in proportion to its mass. Without SDS, different proteins with similar
molecular weights would migrate differently due to differences in mass charge ratio,
as each protein has an isoelectric point and molecular weight particular to its
primary structure. This is known as Native PAGE. Adding SDS solves this problem,
as it binds to and unfolds the protein, giving a near uniform negative charge along
the length of the polypeptide.
SDS binds in a ratio of approximately 1.4 g SDS per 1.0 g protein (although binding
ratios can vary from 1.1-2.2 g SDS/g protein), giving an approximately uniform
mass:charge ratio for most proteins, so that the distance of migration through the
gel can be assumed to be directly related to only the size of the protein. A tracking
dye may be added to the protein solution to allow the experimenter to track the
progress of the protein solution through the gel during the electrophoretic run.
Native Gel Electrophoresis is a technique used mainly in protein
electrophoresis where the proteins are not denatured and therefore separated
based on their charge-to-mass ratio. The two main types of native gels used in
protein electrophoresis are polyacrylamide gels and agarose gels.
Polyacrylamide gel electrophoresis (PAGE) is used for separating proteins ranging
in size from 5 to 2,000 kDa due to the uniform pore size provided by the
polyacrylamide gel. Pore size is controlled by controlling the concentrations of
acrylamide and bis-acrylamide powder used in creating a gel. Care must be used
when creating this type of gel, as acrylamide is a potent neurotoxin in its liquid and
powdered form. The other type of gel used is agarose gel. Agarose gels can also
be used to separate native protein. They do not have a uniform pore size, but are
optimal for electrophoresis of proteins that are larger than 200 kDa.
Unlike SDS-PAGE type electrophoreses, Native gel electrophoresis does not use a
charged denaturing agent. The molecules being separated (usually proteins)
therefore differ in Molecular mass and intrinsic charge and experience different
electrophoretic forces dependent on the ration of the two. Since the proteins remain
in the native state they may be visualised not only by general protein staining
reagents but also by specific enzyme-linked staining.
QPNC-PAGE, or quantitative preparative native continuous polyacrylamide
gel electrophoresis, is a high-resolution technique applied in biochemistry and
bioinorganic chemistry to separate proteins by isoelectric point. This variant of gel
electrophoresis is used by biologists to isolate active or native metalloproteins in
biological samples and to resolve properly and improperly folded metal cofactor-
containing proteins in complex protein mixtures
Determination of size of DNA or RNA fragments, e.g. agarose gel
electrophoresis
Separation of proteins according to mass and isoelectric point, e.g. 2D gel
electrophoresis. Two-dimensional gel electrophoresis, abbreviated as 2-DE or 2-D
electrophoresis, is a form of gel electrophoresis where mixtures of proteins are
separated by two properties in two dimensions on 2D gels.
2-D electrophoresis begins with 1-D electrophoresis but then separates the
molecules by a second property in a direction 90 degree from the first. In 1-D
electrophoresis, proteins (or other molecules) are separated in one dimension, so
that all the proteins/molecules will lie along a lane but be separated from each other
by a property {e.g. isoelectric point). The result is that the molecules are spread out
across a 2-D gel. Because it is unlikely that two molecules will be similar in two
distinct properties, molecules are more effectively separated in 2-D electrophoresis
than in 1-D electrophoresis.
The two dimensions that proteins are separated into using this technique can be
isoelectric point, protein complex mass in the native state, and protein mass.
Chromatography
Chromatography is another method to separate structures according to size, structure
or other physical characteristics. In principle a sample dissolved in a "mobile phase" is
passed through a stationary phase, which separates the analyte to be measured from
other molecules in the mixture and allows it to be isolated.
Below different types of chromatography is listed
o Column chromatography
■ Ion exchange chromatography
■ Size exclusion chromatography
■ Liquid chromatography (LC, HPLC)
■ Gas chromatography
o Planar chromatography
■ Paper chromatography
■ Thin layer chromatography
Separation based on chemical properties
Samples can also be analysed be analyzing their chemical composition. The chemical
composition of the whole sample med be determined, alternatively the chemical
composition of fragments or individual structures of the sample is identified. Often this
type of analysis are preceded by one or more other diagnostic or analytical methods
e.g. separation according to size.
An example of this type of analysis is mass spectrometry. Mass spectrometry is an
analytical technique that identifies the chemical composition of a compound or sample
on the basis of the mass-to-charge ratio of charged particles. The method employs
chemical fragmentation of a sample into charged particles (ions) and measurements of
two properties, charge and mass, of the resulting particles, the ratio of which is
deduced by passing the particles through electric and magnetic fields in a mass
spectrometer. The design of a mass spectrometer has three essential modules: an ion
source, which transforms the molecules in a sample into ionized fragments; a mass
analyzer, which sorts the ions by their masses by applying electric and magnetic fields;
and a detector, which measures the value of some indicator quantity and thus provides
data for calculating the abundances each ion fragment present. The technique has
both qualitative and quantitative uses, such as identifying unknown compounds,
determining the isotopic composition of elements in a compound, determining the
structure of a compound by observing its fragmentation, quantifying the amount of a
compound in a sample using carefully designed methods (e.g., by comparison with
known quantities of heavy isotopes), studying the fundamentals of gas phase ion
chemistry (the chemistry of ions and neutrals in vacuum), and determining other
physical, chemical, or biological properties of compounds.
Measurement of catalysis
Catalysis is the process in which the rate of a chemical reaction is increased by means
of a chemical substance known as a catalyst. Unlike other reagents that participate in
the chemical reaction, a catalyst is not consumed. Thus, the catalyst may participate in
multiple chemical transformations, although in practice catalysts are sometimes
consumed in secondary processes. Examples of catalysis include but are not limited to:
• Measurement of enzymatic activity
o Measurement of induction of enzymatic activity
o Measurement of inhibition of enzymatic activity
• Measurement of substrate for enzyme in a sample
Measurement of growth
Growth is another parameter that can be measured in a sample. It can be natural
growth in sample, the samples impact of growth on another sample or analysis system
and/or the growth in sample after the sample has been added stimulus, inhibitor or
other substance influencing growth.
Examples of measurement of growth in sample include but are not limited to:
• Measurement of proliferation
• Measurement of viability
· Measurement of volume
• Measurement of density
The above described chemical assays may be combined with one or more other
chemical assays in order to make the final diagnosis of the unit. The chemical assays
may be applied to the sample of the unit or to different samples from the same unit.
Further aspects relates to different uses
Overall, the multimeric MHC's or compositions comprising such sets of MHC's may find
different uses. Thus, an aspect relates to the use of a multimeric major
histocompatibility complex (MHC) or a composition according to the invention for the
detection of antigen-responsive cells in a sample.
Another aspect relates to the use of a multimeric major histocompatibility complex
(MHC) or a composition according to the invention in the diagnosis of diseases or
conditions, preferably cancer and/or infectious diseases.
A further aspect relates to the use of a multimeric major histocompatibility complex
(MHC) or a composition according to the invention in the development of immune-
therapeutics.
Yet a further aspect relates to the use of a multimeric major histocompatibility complex
(MHC) or a composition according to the invention in the development of vaccines.
Another aspect relates to the use of a multimeric major histocompatibility complex
(MHC) or a composition according to the invention for the identification of epitopes.
In sum, the advantages of the present invention include, without limitation, the
possibility for detection of multiple (potentially, but exclusively, > 1000) different antigen-
responsive cells in a single sample. The technology can be used, but is not restricted,
for T-cell epitope mapping, immune-recognition discovery, diagnostics tests and
measuring immune reactivity after vaccination or immune-related therapies.
This level of complexity allow us to move from model antigens to determination of
epitope-specific immune reactivity covering full organisms, viral genomes, cancer
genomes, all vaccine components etc. It can be modified in a personalized fashion
dependent of the individuals MHC expression and it can be used to follow immune
related diseases, such as diabetes, rheumatoid arthritis or similar.
Biological materials are for instance analyzed to monitor naturally occurring immune
responses, such as those that can occur upon infection or cancer. In addition,
biological materials are analyzed for the effect of immunotherapeutics including
vaccines on immune responses. Immunotherapeutics as used here is defined as active
components in medical interventions that aim to enhance, suppress or modify immune
responses, including vaccines, non-specific immune stimulants, immunosuppressives,
cell-based immunotherapeutics and combinations thereof.
The invention can be used for, but is not restricted to, the development of diagnostic
kits, where a fingerprint of immune response associated to the given disease can be
determined in any biological specimen. Such diagnostic kits can be used to
determining exposure to bacterial or viral infections or autoimmune diseases, e.g., but
not exclusively related to tuberculosis, influenza and diabetes. Similar approach can be
used for immune-therapeutics where immune-responsiveness may serve as a
biomarker for therapeutic response. Analyses with a barcode labelled MHC multimer
library allow for high-throughput assessment of large numbers of antigen responsive
cells in a single sample.
Furthermore, barcode labelled MHC-multimers can be used in combination with single-
cell sorting and TCR sequencing, where the specificity of the TCR can be determined
by the co-attached barcode. This will enable us to identify TCR specificity for potentially
1000+ different antigen-responsive T-cells in parallel from the same sample, and match
the TCR sequence to the antigen specificity. The future potential of this technology
relates to the ability to predict antigen responsiveness based on the TCR sequence.
This would be highly interesting as changes in TCR usage has been associated to
immune therapy ( 1 1, 1 ).
Further, there is a growing need for the identification of TCRs responsible for target-cell
recognition (e.g., but not exclusive, in relation of cancer recognition). TCRs have been
successfully used in the treatment of cancer ( 13), and this line of clinical initiatives will
be further expanded in the future. The complexity of the barcode labeled MHC multimer
libraries will allow for personalized selection of relevant TCRs in a given individual.
Due to the barcode-sequence readout, the barcode labeled MHC multimer technology
allow for the interaction of several different peptide-MHC complexes on a single cell
surface, while still maintaining a useful readout. When one T-cell binds multiple
different peptide-MHC complexes in the library, their relative contribution to T-cell
binding can be determined by the number of reads of the given sequences. Based on
this feature it is possible to determine the fine-specificity/consensus sequences of a
TCR. Each TCR can potential recognize large numbers of different peptide-MHC
complexes, each with different affinity (14). The importance of such quantitative
assessment has increased with clinical used of TCRs and lack of knowledge may have
fatal consequences as recently exemplified in a clinical study where cross recognition
of a sequence related peptide resulted in fatal heart failure in two cases (15,1 6). Thus,
this particular feature for quantitative assessment of TCR binding of peptide-MHC
molecules related to the present invention can provide an efficient solution for pre-
clinical testing of TCRs aimed for clinical use.
Also related to the above, this allows for determination of antigen responsiveness to
libraries of overlapping or to very similar peptides. Something that is not possible with
present multiplexing technologies, like the combinatorial encoding principle. This allows
for mapping of immune reactivity e.g. to mutation variant of viruses, such as, but not
exclusive, HIV.
In broad embodiment, the present invention is the use of barcode labelled MHC
multimers for high-throughput assessment of large numbers of antigen responsive cells
in a single sample, the coupling of antigen responsiveness to functional and
phenotypical characteristic, to TCR specificity and to determine the quantitative binding
of large peptide-MHC libraries to a given TCR.
While the foregoing written description of the invention enables one of ordinary skill to
make and use what is considered presently to be the best mode thereof, those of
ordinary skill will understand and appreciate the existence of variations, combinations,
and equivalents of the specific embodiment, method, and examples herein. The
invention should therefore not be limited by the above described embodiment, method,
and examples, but by all embodiments and methods within the scope and spirit of the
invention.
It is as aspect of the invention to provide the use of barcode labelled MHC multimers
for multiplex detection of different T-cell specificities in a single sample, enabling
simultaneous detection of potentially more than 1000 different T-cell specificities where
the specificity is revealed through sequencing of the barcode label.
It is as aspect of the invention to provide the use of barcode labelled MHC multimers in
combination with single-cell sorting and TCR sequencing, where the specificity of the
TCR can be determined by the co-attached barcode. This will enable identification of
TCRs specific for a mixture of numerous (potentially, but not restricted to >1000)
different peptide-MHC multimers, and match the TCR sequence to the antigen
specificity.
It is as aspect of the invention to provide the use of barcode labelled MHC multimers
for determining the affinity and binding motif of a given TCR. The barcode labelling
strategy will allow for attachment of several different (sequence related) peptide-MHC
multimers to a given T-cell - with the binding affinity determining the relative
contribution by each peptide-MHC multimer. Thereby it is possible to map the fine-
specificity/consensus recognition sequence of a given TCR by use of overlapping
peptide libraries or e.g. alanine substitution libraries.
It is as aspect of the invention to provide the use of barcode labelled MHC multimers to
map antigen responsiveness against sequence related/similar peptides in the same
libraries, e.g. mutational changes in HIV infection. This has not been possible with
previous MHC multimer based techniques.
It is as aspect of the invention to provide the use of barcode-labelled MHC multimers to
couple any functional feature of a specific T-cell or pool of specific T-cells to the
antigen (peptide-MHC) recognition. E.g. determine which T-cell specificities in a large
pool secrete cytokines, releases Calcium or other functional measurement after a
certain stimuli.
Sample
A binding molecule is a molecule that specifically associates covalently or non-
covalently with a structure belonging to or associated with an entity in a sample. In one
embodiment said entity is selected from the group consisting of a cell, a cell population,
a sample comprising one or more cells, a molecule, a marker molecule, a surface of a
biological cell, a cellular entity, and a cellular component (e.g. micelle),
In an embodiment the methods of the present invention includes providing a sample
such as a biological sample.
The type of sample may vary. In an embodiment the sample is a biological sample. In
an embodiment the sample is a blood sample, such as an peripheral blood sample, a
blood derived sample, a tissue biopsy or another body fluid, such as spinal fluid, or
saliva.
The source of the sample may also vary. Thus, in a further embodiment said sample
has been obtained from a mammal, such as a human, mouse, pigs, and/or horses.
In a preferred embodiment one cell may bind 1, 2-5, 6-20, 21-1 00, 10 1- 1000, 1001 -
50000, 50000-200000, or more than 200000 detection molecules.
Each individual cell to be combined with at least one detection molecule has the
capacity to bind a single or a number of detection molecules. It follows that one cell in
one embodiment binds 1 detection molecule according to the invention, such as 2 , 3 , 4 ,
5 , 6 , 7 , 8 , 9 , 10 detection molecules, such as binds 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9,
9-1 0 , 10-1 5 , 15-20, 20-25, 25-30, 30-40, 40-50, 50-75, 75-1 00, 100-1 50, 150-200, 200-
250, 250-500, 500-750, 750-1000, 1000-2000, 2000-5000, 5000-1 0.000, 10.000-
25.000, 25.000-50.000, 50.000-1 00.000, 100.000-250.000, 250.000-500.000, 500.000-
1.000.000, or more than 1.000.000 detection molecules.
In a preferred embodiment the binding molecule specifically associates covalently or
non-covalently with a structure belonging to or associated with a cell in a sample.
The sample in one embodiment is selected from the group consisting of a solid sample,
a fluid sample, a semifluid sample, a liquid sample, a solubilised sample and a sample
comprising dissociated cells of a solid sample.
The sample in one embodiment is selected from the group consisting of a biofilm, a
biopsy, a surgical sample, a tissue sample, a microarray-fixed sample, solid tissue
section such as a fresh section, a frozen section and a FFPE section.
Cell samples capable of being analyzed by detection molecules and then analysed
using flow cytometry include but is not limited to blood, CSF, lymph, cell lines (e.g.
hybridomas, transfected cells), semen, suspension of bacteria, suspension of viral
particles, suspension of beads or other particles or supra molecular structures,
homogenized tissues or any other fluidic sample from a given sample.
In one embodiment the sample is selected from the group consisting of blood, whole
blood, plasma, serum, Peripheral blood mononuclear cells (PBMC), human PBMN
(HPBMC), buffy coat, synovial fluid, bone marrow, cerebrospinal fluid, saliva, lymph
fluid, seminal fluid, urine, stool, exudate, transdermal exudates, pharyngeal exudates,
nasal secretions, sputum, sweat, bronchoalveolar lavage, tracheal aspirations, fluid
from joints, vitreous fluid, vaginal or urethral secretions or semen.
Herein, disaggregated cellular tissues such as, for example, hair, skin, synovial tissue,
tissue biopsies and nail scrapings are also considered as biological samples.
IN one embodiment the sample comprises one or more cells is selected from the group
consisting of immune cells, lymphocytes, monocytes, dendritic cells, T-cells, B-cells
and NK cells.
In one embodiment said sample comprises one or more cells selected from the group
consisting of CD4+ T cells, CD8+ T cells, αβ T cells, invariant γ δ T cells, an antigen-
specific T-cell, antigen-responsive T cell and cells comprises T-cell receptors.
Many of the assays and methods described in the present invention are particularly
useful for assaying T-cells in blood samples. Blood samples includes but is not limited
to whole blood samples or blood processed to remove erythrocytes and platelets (e.g.,
by Ficoll density centrifugation or other such methods known to one of skill in the art)
and the remaining PBMC sample, which includes the T-cells of interest, as well as B-
cells, macrophages and dendritic cells, is used directly. Also included are blood
samples processed in other ways e.g. isolating various subsets of blood cells by
selecting or deselecting cells or entities in blood.
In one embodiment said cell is a cancer cell.
In one embodiment said sample is derived from an organ selected from the group
consisting of lymph nodes, kidney, liver, skin, brain, heart, muscles, bone marrow, skin,
skeleton, lungs, the respiratory tract, spleen, thymus, pancreas, exocrine glands,
bladder, endocrine glands, reproduction organs including the phallopian tubes, eye,
ear, vascular system, the gastroinstestinal tract including small intestines, colon,
rectum, canalis analis and prostate gland; normal, diseased and/or cancerous.
In one embodiment the surface of sample cells is coated with proteases capable of
cleaving a peptide label, for example by adding antibody-protease conjugates where
the antibody recognizes a particular cell surface structure.
In one embodiment the surface of sample cells is coated with DNA oligonucletides
("coating DNA"), for example by adding antibody-DNA conjugates where the antibody
recognizes a particular cell surface structure.
Diseases
Detection molecules of the present invention can be used in immune monitoring,
diagnostics, prognostics, therapy and vaccines for many different diseases, including
but not limited to the diseases listed in the following.
a) Infectious diseases caused by virus such as,
Adenovirus (subgropus A-F), BK-virus, CMV (Cytomegalo virus, HHV-5), EBV (Epstein
Barr Virus, HHV-4), HBV (Hepatitis B Virus), HCV (Hepatitis C virus), HHV-6a and b
(Human Herpes Virus-6a and b), HHV-7, HHV-8, HSV-1 (Herpes simplex virus-1 , HHV-
1) , HSV-2 (HHV-2), JC-virus, SV-40 (Simian virus 40), VZV (Varizella-Zoster- Virus,
HHV-3), Parvovirus B 19 , Haemophilus influenza, HIV-1 (Human immunodeficiency
Virus-1 ) , HTLV-1 (Human T-lymphotrophic virus-1), HPV (Human Papillomavirus giving
rise to clinical manifestions such as Hepatitis, AIDS, Measles, Pox, Chicken pox,
Rubella, Herpes and others.
b) Infectious diseases caused by bacteria such as,
Gram positive bacteria, gram negative bacteria, intracellular bacterium, extracellular
bacterium, Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium avium
subsp. Paratuberculosis, Borrelia burgdorferi, Borrelia Garinii, Borrelia Afzelii, other
spirochetes, Helicobacter pylori, Streptococcus pneumoniae, Listeria monocytogenes,
Histoplasma capsulatum, Bartonella henselae, Bartonella quintana giving rise to clinical
manifestations such as Tuberculosis, Pneumonia, Stomach ulcers, Paratuberculosis
and others.
c) Infectious diseases caused by fungus such as,
Aspergillus fumigatus, Candida albicans, Cryptococcus neoformans, Pneumocystis
carinii giving rise to clinical manifestations such as skin-, nail-, and mucosal infections,
Meningitis, Sepsis and others.
d) Parasitic diseases caused by parasites such as,
Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Schistosoma
mansoni, Schistosoma japonicum, Schistosoma haematobium, Trypanosoma cruzi,
Trypanosoma rhodesiense, Trypanosoma gambiense, Leishmania donovani, and
Leishmania tropica.
e) Allergic diseases caused by allergens such as,
Birch, Hazel, Elm, Ragweed, Wormwood, Grass, Mould, Dust Mite giving rise to clinical
manifestations such as Asthma.
f) Transplantation-related diseases caused by
reactions to minor histocompatibility antigens such as HA-1 , HA-8, USP9Y, SMCY,
TPR-protein, HB-1 Y and other antigens in relation to, Graft-versus-host-related
disease, alio- or xenogene reactions i.e. graft-versus-host and host-versus-graft
disease.
g) Cancerous diseases associated with antigens such as
Survivin, Survivin-2B, Livin/ML-IAP, Bcl-2, Mcl-1 , Bcl-X(L), Mucin-1 , NY-ESO-1 ,
Telomerase, CEA, MART-1 , HER-2/neu, bcr-abl, PSA, PSCA, Tyrosinase, p53, hTRT,
Leukocyte Proteinase-3, hTRT, gp100, MAGE antigens, GASC, JMJD2C, JARD2
(JMJ), JHDM3a, WT-1 ,CA 9 , Protein kinases, where the cancerous diseases include
malignant melanoma, renal carcinoma, breast cancer, lung cancer, cancer of the
uterus, cervical cancer, prostatic cancer, pancreatic cancer, brain cancer, head and
neck cancer, leukemia, cutaneous lymphoma, hepatic carcinoma, colorectal cancer,
bladder cancer.
h) Autoimmune and inflammatory diseases, associated with antigens such as
GAD64, Collagen, human cartilage glycoprotein 39, β-amyloid, Αβ42, APP, Presenilin
1, where the autoimmune and inflammatory diseases include Diabetes type 1,
Rheumatoid arthritis, Alzheimer, chronic inflammatory bowel disease, Crohn's disease,
ulcerative colitis uterosa, Multiple Sclerosis, Psoriasis
EXAMPLES
Example A
This example relates to
i) the stability of DNA oligonucleotides (DNA tag/label), used in one embodiment of the
invention, in blood preparations, and
ii) an embodiment of the invention, in which certain tagged Dextramers (detection
molecules in which the binding molecule is a number of peptide-MHC complexes, and
the label is a DNA oligonucleotide) are enriched for. Allowing identification of the
Dextramers with binding specificity for certain (subpopulations of) cells in the cell
sample tested.
In i) it is shown that DNA oligos are stable during handling in PBMC's and in blood for a
time that will allow staining, washing and isolation of T cells and subsequent
amplification of DNA tags.
In ii) Show that a model system consisting of DNA-tagged Dextramers with MHC
specificities for CMV, Flu and negative control peptide will locate to and can be
captured/sorted with relevant T cell specificities and can be identified by PCR
amplification and/or sequencing.
Stability of single-stranded and double-stranded oligonucleotides in blood preparations
DNA tag oliqo design. 69-nucleotide long, biotinylated TestOligo was prepared,
consisting of
5'primer region (22nt italic type, left) -
random region (6xN-nt) - barcode region (21 nt underlined) -
3'primer region (20nt italic type, right):
'b' = Biotin-TEG 5' modification
'h' = HEG (terminal modifications)
Forward-01 primer GAGATACGTTGACCTCGTTG
Reverse-01 primer ATGCAACCAAGAGCTTAAGT
TestOligo-01
bGAGATACGUGACCTCGUGAA NNNNNNTCTATCCATTCCATCCAGCTC4CTTAAGCTCTTGGTTGCA T
TestOligo-02
bhGAGATACGUGACCTCGUGAA NNNNNUTCTATCCATTCCAJCCAGCTCACTTAAGCTCTTGGTTGCAT
TestOligo-03
bhGAGATACGUGACCTCGUGAA NNNNNUTCTATCCATTCCAJCCAGCTCACTTAAGCTCTTGGUGCATh
TestOligo-04
bhGAGATACGUGACCTCGUGAA NNNNNNTCTTGAACTATGAATCGTCTCACTTAAGCTCTTGGTTGCATh
TestOligo-05
bhGAGATACG UGA CCTCGUGAA NNNNNNTCTATAGGTGTCTACTACCTC4C7TA4GCTCTTGGU GCA Th
TestOligo-06
bhGAGATACG UGA CCTCGUGAA NNNNNNTCTTTATTGGAGAGCACGCTC C AAGC T GG G 7
Q-PCR probes for quantifying the amount of TestOligos 1-6:
+ = locked nucleic acid (LNA) modified RNA nucleotide
LNA-3
8 = FAM; 7 = BHQ-1-plus
TCT[+A][+T][+C]A[+T][+T]CC[+A][+T][+C]CAGC
LNA-4
8 = FAM; 7 = BHQ-1-plus
TCT[+T][+G][+A]AC[+T][+A]TG[+A][+A][+T]CGTC
LNA-5
9 = HEX; 7 = BHQ-1-plus
TCT[+A][+T][+A]GG[+T][+G]TC[+T][+A][+C]TACC
LNA-6
2 = Cy5; 1 = BHQ-2-plus
TCT[+T][+T][+A]TT[+G][+G]AG[+A][+G][+C]ACGC
The stability of oligo-tags by Q-PCR was analyzed under conditions relevant for T cell
isolation:
The testOligos 1-6 were incubated in anticoagulated EDTA blood, and following
incubation the amount of each of the testOligos was determined using Q-PCR using
the abovementioned primers and probes. The oligo tags were quantified by QPCR with
SYBR® Green JumpStart™ Taq ReadyMix™ according to manufacturer's protocol in
combination with any capillary QPCR instruments (e.g. Roche LightCycler or Agilent
Mx3005P).
Because of the different termini of the testOligos 1-6, this also was a test of the
stability of non-modified DNA oligo tag vs HEG modified 5' and HEG modified 5' and 3'
(TestOligo-01 , -02 and -03 respectively).
The results are shown in figure 8 . It is concluded that the stability of the testOligos is
appropriately high for all variants tested, to perform the invention.
Generation and screening of a 3 member DNA tagged MHC Dextramer library for
screening of antigen specific T cells in a lymphoid cell sample
This experiment involves the generation of 3 DNA-tagged Dextramers, each with a
unique specificity, as follows:
Dextramer 1: Flu (HLA-A *0201/GILGFVFTL/MP/lnfluenza)
Dextramer 2 : CMV (HLA-A *0201/NLVPMVATV/pp65/CMV)
Dextramer 3 : Negative (HLA-A *0201/ALIAPVHAV/Neg.Control).
Each of these Dextramers thus have a unique pMHC specificity (i.e. the three
Dextramers have different binding molecules), and each Dextramer carries a unique
label (DNA oligonucleotide) specific for that one pMHC specificity.
The library of DNA-tagged Dextramers are screened in a preparation of lymphoid cells
such as anticoagulated EDTA blood or preparations of peripheral blood mononucleated
cells (PBMC's). Those Dextramers that bind to cells of the cell sample will be relatively
more enriched than those that do not bind.
Finally, the MHC/antigen specificity of the enriched Dextramers is revealed by
identification of their DNA tags by Q-PCR with DNA tag-specific probes or by
sequencing of the DNA tags.
1. Production of 3 different DNA tagged Dextramers with HLA-A* 0201 -peptide (pMHC)
complexes.
pMHC complexes are generated and attached to dextran, along with unique DNA tags
identifying each of the individual pMHC complexes, as follows.
Generation of DNA tagged Dextramers with Flu (HLA-
A*0201/GILGFVFTMv1P/lnfluenza), CMV (HLA-A *0201/NLVPMVATV/pp65/CMV) and
Negative (HLA-A * rj201/ALIAPVHAV/Neg.Control).
Dextramer stock is 160 nanomolar (nM), TestOligo stock is diluted to 500 nM. Mix 10
micro liter (uL) 160 nM dextramer stock with 10 uL 500 nM TestOligo stock. Incubate
10 min at r.t. Mix with 1,5 ug pMHC complex of desired specificity. Adjust volume to 50
uL with a neutral pH buffer such as PBS or Tris pH 7,4, and store at 4 degrees Celsius.
This will produce a DNA tagged Dextramer with approximately 3 oligo tags and 12
pMHC complexes, respectively, per Dextramer.
a . Dex-Oligo-03 = Dextramer with TestOligo-03 and HLA-
A*0201/NLVPMVATV/pp65/CMV.
b. Dex-Oligo-04 = Dextramer with TestOligo-04 and HLA-
A*0201/GILGFVFTMv1P/lnfluenza.
c . Dex-Oligo-05 = Dextramer with TestOligo-05 and HLA-
A*0201/ALIAPVHAV/Neg.Control.
2 . Preparation of cell sample for screening for antigen-specific T cells.
a . Appropriate cell samples for identification of antigen specific T cells are
preparations of lymphoid cells such as preparations of peripheral blood
mononucleated cells (PBMC's) or anticoagulated blood. Such preparations of cell
samples are prepared by standard techniques known by a person having ordinary
skill in the art.
b. Transfer in the range of 1E7 lymphoid cells (from PBMC or EDTA anticoagulated
blood) to a 12 x 75 mm polystyrene test tube.
c . Add 2 ml PBS containing 5% fetal calf serum, pH 7.4. Centrifuge at 300 x g for 5
min. Remove supernatant and resuspend cells in a total volume of 2,5 ml PBS
containing 5% fetal calf serum, pH 7.4.
3 . Preparation and modification of library of DNA tagged Dextramers with three
MHC/peptide specificities (from 1).
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a . Mix 5 ul 10 uM biotin with 10 ul each of Dex-Oligo-03, Dex-Oligo-04 and Dex-Oligo
05.
4 . Mixing of preparations of lymphoid cells with a library of DNA tagged MHC
Dextramers.
a . Mix 1E7 lymphoid cells in 2,5 mL (from 2b) with 30 uL library of DNA tagged
Dextramers (from 3a).
b. Incubate 30 min at r.t.
c . Centrifuge at 300 x g for 5 min. and remove the supernatant.
d . Resuspend pellet in 2,5 ml PBS containing 5% fetal calf serum, pH 7.4. Centrifuge
at 300 x g for 5 min. and remove the supernatant.
e. Resuspend pellet in 2,5 ml PBS containing 5% fetal calf serum, pH 7.4
5 . Capture of all CD8+ antigen specific T cells by magnet assisted cell sorting,
performed according to Miltenyi Biotec catalog nr 130-090.878, Whole Blood CD8
MicroBead protocol.
a . Add 100 uL Whole Blood CD8 MicroBeads (Miltenyi Biotec catalog nr 130-090.878)
to resuspended lymphoid cells from 4e. Mix and allow capture of CD8+ T cells for
15 min at r.t.
b. Place Whole Blood Column in the magnetic field of a suitable MACS Separator. For
details see the Whole Blood Column Kit data sheet.
c . Prepare column by rinsing with 3 mL separation buffer (autoMACS Running Buffer
or PBS containing 5% fetal calf serum, pH 7.4).
d . Apply magnetically labeled cell suspension (4e) onto the prepared Whole Blood
Column. Collect flow-through containing unlabeled cells.
e. Wash Whole Blood Column with 3x3 mL separation buffer (autoMACS Running
Buffer or PBS containing 5% fetal calf serum, pH 7.4).
f . Remove Whole Blood Column from the separator and place it on a new collection
tube.
g . Capture CD8+ T cells by pipetting 5 mL Whole Blood Column Elution Buffer or PBS
containing 5% fetal calf serum, pH 7.4 onto the Whole Blood Column. Immediately
flush out the magnetically labeled cells by firmly pushing the plunger into the
column.
h. Centrifuge at 300 x g for 5 min. and remove the supernatant. Resuspend the
collected CD8+ cells in 50 uL and store at minus 20 degrees Celsius for
subsequent analysis.
6 . Identification of Dextramers that bound significantly to antigen specific T cells of the
lymphoid cell sample.
a . Quantifying ratios of DNA oligo tags in input (3a) vs captured fraction (5h) by
sequencing or alternatively quantifying by QPCR using the DNA tag specific probes
LNA-3, LNA-4 and LNA-5 will reveal the relative abundance of antigen specific T
cells in the lymphoid cell sample.
i . Quantifying ratios of DNA oligo tags in input (3a) vs captured fraction (5h) by
QPCR using the DNA tag specific probes LNA-3, LNA-4 and LNA-5.
1. Make 25 uL QPCR reactions of
a . input of library of DNA tagged Dextramers (3a)
b. output of library of DNA tagged Dextramers (5h)
c . Standard curves of 10 to 1E8 TestOligo-03, TestOligo-04 and
TestOligo-05 respectively.
2 . Mix 12,5 uL JumpStart Taq ReadyMix (Sigma-Aldrich # D7440) with 0,1 25
uL 100 uM primer each of Forward-01 and Reverse-01 , 0,625 ul 10 uM of
either probe LNA-3, LNA-4 or LNA-5, 0,025 ul Reference dye (Sigma-
Aldrich # R4526) and 12,5 uL of either input of library of DNA tagged
Dextramers (3a), output of library of DNA tagged Dextramers (5h) or
Standard curves of 10 to 1E8 TestOligo-03, TestOligo-04 and TestOligo-
05 respectively.
3 . Run two step QPCR thermal profile Cycle 1 = 5 min at 95 degrees
Celsius, Cycle 2-40 = 30 sec at 95 degrees Celsius and 1 min at 60
degrees Celsius.
4 . Estimate the relative abundance of T cells with antigen specificity against
one of the three MHC Dextramers by plotting the QPC cycle time (Ct)
values of the input of library of DNA tagged Dextramers (3a), the output of
library of DNA tagged Dextramers (5h) in a plot of Ct values of the QPCR
standard curve of TestOligo-03, TestOligo-04 and TestOligo-05
respectively.
ii. Quantifying ratios of DNA oligo tags in input (3a) vs captured fraction (5h) by
ultra-deep sequencing.
1. Make 25 uL PCR reactions of
a . input of library of DNA tagged Dextramers (3a)
b. output of library of DNA tagged Dextramers (5h)
2 . Mix PCR reaction using any standard PCR master mix with 1,25 uL 10 uM
primer each of Forward-01 and Reverse-01 , and 12,5 uL of either input of
library of DNA tagged Dextramers (3a) or output of library of DNA tagged
Dextramers (5h). Top up to 25 uL with pure water. For example use 2x
PCR Master Mix from Promega containing Taq DNA polymerase, dNTPs,
MgCI2 and reaction buffers.
3 . Ultra Deep Sequencing of the above PCR product can be provided by a
number of commercial suppliers such as for example Eurofins Genomics,
GATC Biotech or Beckman Coulter Genomics using well established Next
Generation Sequensing technologies such as Roche 454, Ion Torrent, the
lllumina technology or any other high throughput sequencing technique for
PCR amplicon sequencing.
4 . PCR amplicon analysis of the relative abundances of the input of library of
DNA tagged Dextramers (3a), the output of library of DNA tagged
Dextramers (5h) will reveal the relative abundance of T cells with antigen
specificity against one of the three MHC Dextramers.
7 . Predicted results and comments
a . It is expected that the relative abundance and ratios of DNA oligo tags in input of a
library of DNA tagged Dextramers (3a) as estimated by QPCR or sequencing is
primarily affected by three parameters namely i) the ratio in which the DNA oligo
tags were supplied during the generation of the DNA tagged Dextramers ( 1 .a.i.1),
ii) how the library input was mixed (3a) and iii) how efficiently the individual DNA
oligo tags are amplified in the PCR reactions.
i . In an example, the relative ratios of DNA oligo tags in input of a library of
DNA tagged Dextramers as generated in 3a and as measured by QPCR or
sequencing would be between 1 to 10 fold of each other.
b. It is expected that the relative abundance and ratios of DNA oligo tags in the
output of library of DNA tagged Dextramers (5h) as estimated by QPCR or
sequencing, in addition to the three parameters mentioned in 7a, is primarily
affected by three additional parameters namely i) the number of antigen specific T
cells with specificity for one of the three MHC-peptide combinations ii) the affinity of
the T cell receptor of the given T cell for the given MHC-peptide complex and finally
iii) the efficiency of separating antigen-specific T cells and their associated DNA
tagged MHC Dextramers from unbound DNA tagged MHC Dextramers by washing
and cell capture.
i . In an example, the relative ratios of DNA oligo tags in output of a library of
DNA tagged Dextramers as generated in 5h and as measured by QPCR or
sequencing would be more than 10 fold in favor of those DNA oligo tags
coupled to an MHC Dextramer with an MHC-peptide complex for which
antigen-specific T cells are present in the lymphoid cell sample.
1. In a lymphoid cell sample from an influenza positive and CMV
positive HLA-A0201 donor with antigen-specific T cells against HLA-
A * 0201/NLVPMVATV/pp65/CMV and HLA-
A * 0201/GILGFVFTL/MP/lnfluenza and no antigen-specific T cells
against HLA-A * 0201/ALIAPVHAV/Neg.Control it is expected that the
relative ratios of TestOligo-03 (Dex-Oligo-03 = Dextramer with
TestOligo-03 and HLA-A * 0201/NLVPMVATV/pp65/CMV), TestOligo-
04 (Dex-Oligo-04 = Dextramer with TestOligo-04 and HLA-
A * 0201/GILGFVFTMv1P/lnfluenza) and TestOligo-05 (Dex-Oligo-05
= Dextramer with TestOligo-05 and HLA-
A * 0201/ALIAPVHAV/Neg.Control) will be more than 10 fold in the
favor of TestOligo-03 and TestOligo-04 over TestOligo-05. That is
TestOligo-03 and TestOligo-04 is expected to be more than 10 fold
more abundant or frequent than TestOligo-05 as measured by
sequencing or QPCR of the output of library of DNA tagged
Dextramers (5h) if they were supplied in equal amounts in the input
of library of DNA tagged Dextramers (3a).
Example B
Figure 7 shows results that act as proof-of-principle for the claimed invention. Fig 7A,
Flow cytometry data of peripheral blood mononuclear cells (PBMCs) from healthy
donors.
Materials and methods
PBMCs were stained with CMV specific peptide-MHC multimers coupled to a specific
nucleotide-barcode. In addition to CMV peptide-MHC reagents the cells were stained in
the presence of negative control reagents i.e. HIV-peptide MHC multimers coupled to
another specific barcode label and the additional negative control peptide-MHC
reagents (p* ) not holding a barcode - all multimers were additionally labeled with a PE-
fluorescence label. The amounts of MHC multimers used for staining of PBMCs were
equivalent to the required amount for staining of 1000 different peptide-MHC
specificities i.e. 1x oligo-labeled CMV specific MHC multimers, 1x oligo-labeled HIV
specific MHC multimers and 998x non-labeled p*MHC multimers, so as to give an
impression whether background staining will interfere with the true positive signal.
Prolonged washing steps were included (either 0 min (A), 30 min (B) or 60 min (C))
after removing the MHC multimers, and data from all experiments are shown. The PE-
MHC-multimer positive cells were sorted by fluorescence activated cell sorting (FACS)
Fig 7B, Cross threshold (Ct) values from multiplex qPCR of the sorted PE-MHC-
multimer positive cells. QPCR was used to assess the feasibility of detecting certain
cell specificity through barcode-labeled peptide-MHC-multimers. Reagents associated
with a positive control (CMV) barcode and a negative control (HIV) barcode were
present during staining, but negative control (HIV) barcode-peptide-MHC multimers
should be washed out.
Examples of nucleic acid sequences are:
DNA-barcode oligo for CMV MHC multimer attachment:
5GAGATACGTTG ACCTCGTTG AANNNNNNTCTATCCATTCCATCCAGCTCACTTAA
GCTCTTGGTTGCAT
DNA-barcode oligo for HIV MHC multimer attachment:
5GAGATACGTTG ACCTCGTTG AANNNNNNTCTATAGGTGTCTACTACCTCACTTAA
GCTCTTGGTTGCAT
5= Biotin-TEG
Results
Results shows Ct value only detectable to the CMV peptide-MHC multimer associated
barcode, whereas the HIV-peptide MHC multimer associated barcode was not detected
Conclusion
This experiment is a representative example of several similar experiment performed
with other antigen specificities. Overall these data show that it is feasible to
1) stain with at least 1000 different MHC-multimers in a single sample while still
maintain a specific signal,
2) attach a DNA-barcode to an MHC multimer ,
3) amplify the DNA-barcode after cellular selection steps,
4) read the barcode with QPCR, using barcode specific probes,
5) obtain a specific signal corresponding to the antigen specific T cell population
present in the sample, while non-specific MHC multimer barcodes are non-
detectable.
Together these (and similar data available) provide proof of feasibility for the steps
described in Figure 3 , 4 and 5 .
EXAMPLES 1-12, 20-21, 60-61 , 79-82 and 120-124
In the following examples, the experimental methods comprise one or more of the
following steps
1. Sample preparation.
a . Acquiring sample
b. Modifying sample
2 . Linker preparation.
3 . Binding molecules preparation
a . Synthesis
b. Modification
c . Purification
4 . Label preparation
a . Synthesis
b. Modification
c . Purification
5 . Detection molecules preparation
a . Synthesis
b. Modification
c . Purification
6 . Incubation of sample and detection molecules
a . Amount of sample
b.Amount of detection molecule
c . Conditions
7 . Enrichment of detection molecules with desired characteristics
a .Apply
b. Wash
c . Separate
8 . Identification of enriched detection molecule
a .Apply
b.Analysis
Example 1
In this example the binding molecules are pMHC complexes, the linker is a dextran-
streptavidin-fluorochrome conjugate, and the label is a DNA oligonucleotide.
The sample is a HPBMC from humans, the isolating and/or detecting is done by flow
cytometry (FACS), and the determining of the identity of the label is done by
quantitative PCR (QPCR).
Example 1 explained
This is an example where the Sample (1) was blood from one CMV positive and HIV
negative donor which was modified ( 1b) to generate Peripheral blood mononuclear
cells (PBMCs).
The Linker (2) was a dextran conjugate with streptavidin and fluorochrome (Dextramer
backbone from Immudex).
The binding molecules (3) were peptide-MHC (pMHC) complexes displaying either
CMV (positive antigen) or HIV (negative antigen) derived peptide-antigens. The binding
molecules were modified (3b) by biotinylation to provide a biotin capture-tag for the
Linker. The binding molecules were purified (2c) by HPLC and quality controlled in
terms of the formation of functional pMHC multimers for staining of a control T-cell
population.
The Labels (4) were oligonucleotides applied as DNA-barcodes. The oligonucleotides
were synthetized (4a) by DNA Technology A/S (Denmark) and were synthetically
modified (4b) with a terminal biotin capture-tag. The labels were combined
oligonucleotide labels arising by annealing an A oligonucleotide (modified with biotin) to
a partially complimentary B oligonucleotide label followed by enzymatic DNA
polymerase extension of Oligo A and Oligo B to create a fully double stranded label.
The detection molecule (5) was synthetized (5a) by attaching binding molecules in the
form of biotinylated pMHC and labels in the form of biotin-modified double stranded
oligonucleotides onto a streptavidin-modified dextran linker. The detection molecule
further contained a modification (5b) in the form of a fluorochrome. Two different
detection molecules were generated wherein the two individual detection molecules
containing different pMHC were encoded by corresponding individual oligonucleotide
labels.
An amount of sample, PBMC's ( 1b) was incubated with an amount of mixed detection
molecules (5) under conditions (6c) that allowed binding of detection molecules to T
cells in the sample.
The cell-bound detection molecules were separated from the non-cell bound detection
molecules (7) by first a few rounds of washing the PBMC's through centrifugation
sedimentation of cells and resuspension in wash buffer followed by Fluorescence
Activated Cell Sorting (FACS) of fluorochrome labeled cells. T cells that can efficiently
bind detection molecules will fluoresce because of the fluorochrome comprised within
the detection molecules; T cells that cannot bind detection molecules will not fluoresce.
FACS-sorting leads to enrichment of fluorescent cells, and hence, enrichment of the
detection molecules along with the associated labels that bind T cells of the PBMC
sample.
FACS isolated cells were subjected to quantitative PCR analysis of the oligonucleotide
label associated with the detection molecules bound to the isolated cells to reveal the
identity of the detection molecules that bound to the T cells present in the sample.
This example thus revealed the presence of T cells in the blood expressing a T cell
receptor that binds to peptide-MHC molecules represented within the library of
Detection Molecules. It also revealed the feasibility of enriching for Detection Molecules
based on the presence of T cells specific for the positive peptide-antigen (CMV) over
the negative peptide-antigen (HIV) antigens.
Example 1 in detail
1. Sample preparation. The cell sample used in this example was obtained by
preparing PBMC's from blood drawn from a donor that was CMV positive as
well as HIV negative as determined by conventional MHC-multimer staining.
a . Acquiring sample: Blood was obtained from the Danish Blood Bank, in the
form of buffy coats (BC). A peripheral blood mononuclear cell
preparation obtained following standard donor blood preparations.
b. Modifying sample: Peripheral blood mononuclear cells (PBMCs) were
isolated from whole blood by density gradient centrifugation. The density
gradient medium, Lymphoprep (Axis-Shield), which consists of
carbohydrate polymers and a dense iodine compound, facilitate
separation of the individual constituents of blood. Blood samples were
diluted 1: 1 in RPMI (RPMI 1640, GlutaMAX, 25mM Hepes; gibco-Life
technologies) and carefully layered onto the Lymphoprep. After
centrifugation, 30 min, 490g, PBMCs together with platelets were
harvested from the middle layer of cells. The isolated cells, the buffy
coat (BC), was washed twice in RPMI and cryopreserved at - 150^ in
fetal calf serum (FCS; gibco-Life technologies) containing 10% dimethyl
sulfoxide (DMSO; Sigma-Aldrich). BC's used in this example are listed
in table 1 along with peptide-antigen specific T cells identified within
these samples by conventional MHC multimer staining.
Linker preparation: The linker used in this example was a dextran molecule, to
which was attached streptavidin and fluorochromes. The streptavidin served as
attachment sites for biotinylated oligonucleotides (Label) and biotinylated
peptide-MHC complexes (Binding Molecules). The fluorochrome allowed
separation of cells bound to detection molecules from cells not bound to
detection molecules.
i . In this example linkers were linear and branched dextran
molecules with covalently attached streptavidin (5-10 per linker)
and fluorochromes (2-20 per linker) in the form of PE. Linkers
were essentially Dextramer backbone as described by Immudex.
Binding molecules preparation: The binding molecules used in this example
were two different class I MHC-peptide complexes. MHC heavy chains (HLA-
A0201 and HLA-B0702) and B2M were expressed in E.coli as previously
described (Hadrup et al. 2009) and each MHC-I complex generated with two
peptide antigens. The individual specificities (allele and peptide combination)
were generated in the following way:
a . Synthesis: Binding molecules in this example were specific pMHC
monomers that were produced from UV-exchange of selected HLA-I
monomers carrying a photolabile 9-residue peptide-ligand (p* ) . When
exposed to UV-light (366 nm) the photolabile ligand will be cleaved and
leave the binding groove empty. Due to the instability of empty MHC-I
molecules, the complexes will quickly degrade if they are not rescued by
replacement with another peptide that match that HLA-type. In this way
specific pMHC monomers were produced by mixing excess of desired
HLA ligands with p* MHC monomers. p* MHC monomers were refolded,
biotinylated and purified as previously described (Hadrup et al. 2009).
i . HIV derived peptide ILKEPVHGV from antigen HIV polymerase
and CMV derived peptide TPRVTGGGAM from antigen pp65
TPR (Pepscan Presto, NL) were diluted in phosphate buffered
saline (DPBS; Lonza) and mixed to final concentrations
100µ /η Ι:200µΜ (HLA-A0201 : ILKEPVHGV and HLA-
B0702 :TPRVTGGGAM) . The mixtures were exposed to 366 nm
UV light (UV cabinet; CAMAG) for one hour and optionally stored
for up to 24 h at 4°C.
b. Modification: No further modifications
c . Purification: Before applying the peptide exchanged HLA monomer
Binding Molecules for preparation of detection molecules these were
centrifuged 5 min, 3300g, to sediment any aggregated MHC molecules.
Label preparation: In this example, two different double stranded
oligonucleotides, DNA barcodes, of the same length but partially different
sequence, were generated. Each of the DNA barcodes would become attached
to a specific pMHC, and thus functioned as a Label for this specific Binding
Molecule. The oligonucleotides were biotinylated, allowing easy attachment to
the dextran-streptavidin conjugate linker.
a . Synthesis: The Labels were generated from partially complementary
oligonucleotides which were purchased from DNA Technology
(Denmark) and delivered as lyophilized powder. Stock dilutions of 100
µΜ oligonucleotides were made in nuclease free water and stored at -20
°C.
i . The Label system used in this example was named 20S and
was developed to increase the complexity of a limited number of
oligonucleotide sequences. This was enabled by applying a
combinatorial strategy where two partially complementary
oligonucleotides (an A oligonucleotide with a 5' biotin tag and a B
oligonucleotide) where annealed and then elongated to produce
new unique oligonucleotide-sequences (AxBy) which were
applied as a DNA-barcodes (Labels) (see figure 9 for design of
the DNA-barcodes). By combining 2 unique oligonucleotide-
sequences (A label precursor) that were partly complementary to
2 other unique oligonucleotide sequences (B label precursor) a
combinatorial library of 4 different (AxBy) Labels were produced.
Only 2 of these Labels were used in this example (A1 B 1 and
A2B2). Refer to table 2 for an overview of the different 20S A
and B nucleotide sequences. Briefly:
Partly complementary A and B oligonucleotides were annealed
to produce two combined A+B DNA barcodes (A1 +B1 to produce
A 1B 1 and A2+B2 to produce A2B2). The respective A and B
oligonucleotides were mixed as stated in table 3 , heated to 65 °C
for 2 min and cooled slowly to <35 C in 15-30 min. The annealed
A and B oligonucleotides were then elongated as stated in table
3 . Elongation reagents were mixed <15 min before use. After
mixing, the reactions were incubated 5 min, RT, to allow
elongation of the annealed oligonucleotides. The reagents used
for annealing (left) and elongation (right) of partly complementary
oligonucleotides is described in table 3 . Reagents marked in
italic were from the the Sequenase Version 2.0 DNA Sequencing
Kit (Affymetrix #70770).
b. Modification: All labels were diluted to working concentrations (2.17 uM)
in nuclease free water with 0.1% Tween and stored at -20 °C.
c . Purification: Labels were not purified further.
Detection Molecules preparation: The Binding Molecules (pMHCs) and Labels
(DNA-barcodes) were attached to the Linker (dextran-streptavidin-PE
conjugate), to form Detection Molecules, in such a way that a given pMHC was
always attached to a given DNA-barcode.
a . Synthesis: For preparation of Detection Molecules the 20S DNA-
barcodes were attached to the dextramer prior to addition of pMHC. 1 ul
dextramer was used for every 3 ul of prepared Detection Molecule.
Briefly, for generation of Detection Molecules:
i . The Labeklinker conjugate were generated by addition of label in
two fold excess over linker (labeklinker, 2:1 ) i.e. 1X 0.16 uM
linker (dex), were mixed with 0.1 5X 2.1 7 uM label (20S DNA-
barcode) and incubated at least 30 min, 4°C.
ii. Binding molecules, in the form of biotinylated UV-exchanged
peptide-MHC monomer, were added to the labehlinker conjugate
to reach a concentration of 44 ug/ml of the given pMHC in 3 ul,
and incubated 30 min, RT.
The final volume was reached by addition of 0.02% NaN2 in PBS
together with D-biotin (Avidity Bio200) in a final concentration of
12.6x1 0 6M. The detection molecule preparation was incubated
30 min, 4°C, and optionally stored for up to 4 weeks at 4°C
(overview of the amounts used can be found in table 4).
Two sets of two detection molecules were generated. Each set
with the two specificities individually labeled. The label was
inverted between the two sets as described below.
1. 1xCMV specific pMHCs (HLA-A0201 : ILKEPVHGV)
coupled to 20S-A1 B 1 , 1xHIV specific pMHCs (HLA-
B0702:TPRVTGGGAM) coupled to 20S-A2B2 .
2 . 1xCMV specific pMHCs (HLA-A0201 : ILKEPVHGV)
coupled to 20S-A2B2, 1xHIV specific pMHCs (HLA-
B0702:TPRVTGGGAM) coupled to 20S-A1 B 1 .
b. Modification: No further modifications were performed
c . Purification: The Detection Molecules were centrifuged 5 min, 3300g, to
sediment any aggregates before being added to the cell sample,
Incubation of sample and Detection Molecules: The cell sample and the
Detection Molecules were mixed in one container to allow Detection Molecules
to bind to T cells.
a . Amount of sample: 1x 10E6-2x1 0E6 cells in the form of BC's, were used.
b.Amount of detection molecule: According to table 4 . for staining in 100 ul
1.32 ug/ml calculated in relation to each binding molecule (specific
peptide-MHC) on the Detection Molecule was required per incubation,
i.e. 3 ul of each Detection Molecule.
c . Conditions: BCs were thawed in 10 ml, 37 C , RPMI with 10% fetal bovine
serum (FBS), centrifuged 5 min, 490g, and washed twice in 10 ml RPMI
with 10% FBS. All washing of cells refer to centrifugation 5 min, 490g,
with subsequent removal of supernatant. 1x1 0E6-2x1 0E6 cells were
washed in 200 ul barcode-buffer (PBS/0.5% BSA/2 mM EDTA/100
µg/ml herring DNA) and resuspended in this buffer to approximately 20
µ Ι per sample. The barcode buffer is optimized to increase the stability
of the oligonucleotides associated with the Detection molecules. The
cells were incubated with 50 nM dasatinib, 30 min, 37°C, prior to
incubation of cells with Detection Molecules.
i . The Detection molecules were added in the required amount. If
necessary barcode-buffer was added to reach a total volume of
100 ul and cells were incubated 15 min, 37 °C. 20 ul antibody
mixture containing PerCP-conjugated anti-CD8 antibody and
dump channel FITC-conjugated antibodies (table 5) along with
0.1 µ Ι near- IR-viability dye (Invitrogen L 10 119) was added for
every 100 ul of PBMC:detection molecule sample. The samples
were incubated 30 min, 4°C, and cells were washed twice in 200
ul barcode-buffer. Optionally cells were fixed in 1%
paraformaldehyde in DPBS overnight, 4°C, and washed twice in
barcode-buffer. Fixed cells were stored for up to a week at 4°C.
Enrichment of detection molecules with desired characteristics: The Detection
Molecules were enriched by using flow cytometry, more specifically,
Fluorescence-Activated-Cell-Sorting (FACS). Since all Detection Molecules
carried a PE-fluorescent label, the cells that bound to Detection Molecules
would fluoresce according to this fluorochromes emission peak. By applying a
FACS sorter this feature could be used to separate cells that bound to detection
molecules from cells that did not bind Detection Molecules i.e. to separate those
cells that did fluoresce from those cells that did not fluoresce. As a result the
Detection Molecules that bound to cells, and hence the associated Labels, were
enriched for.
a .Apply: Cells were sorted on a BD FACSAria, equipped with three lasers
(488 nm blue, 633 nm red and 405 nm violet). The flow cytometry data
analyses were performed using the BD FACSDiva software version
6.1 .2. The following gating strategy was applied: Lymphocytes were
identified in a FSC/SSC plot. Additional gating on single cells (FSC-
A/FSC-H), live cells (near-IR-viability dye negative), and CD4, CD14,
CD1 6 , CD1 9 , CD40 negative (FITC)/CD8 positive cells (PerCP) were
used to define the CD8 T cell population (table 5). The PE positive
population, i.e. the cells that bound to detection molecules, were defined
within the PerCP positive population
b. Wash: not applied
c . Separate: The PE positive cells were sorted by FACS, as described in 7a,
into tubes that contained 200 µ Ι barcode-buffer and that had been pre-
saturated for 2h-O.N. in 2% BSA. The sorted cells were centrifuged 5
min, 5000 g , to allow removal of excess buffer (<10ul should reside in
the container). Cells were stored at -80 °C.
8 . Identification of enriched Detection Molecules: Since the Detection Molecules
were enriched based on specific binding of the Binding Molecule (the pMHC) to
cells, the identification of the associated Labels (oligonucleotide barcodes)
amongst the sorted cells would also reveal the pMHCs that had bound to cells
in the PBMC sample. In this example the enriched Detection Molecules were
identified by quantitative PCR (QPCR) using Label-specific fluorescent reporter
probes.
a . Apply: Labels derived from sorted cells were analyzed by QPCR with the
Brilliant I I QRT-PCR Low ROX Master Mix Kit (Agilent technologies,
#600837) according to table 6 . PCR was run on the thermal cycler:
Mx3000P qPCR system (Agilent Technologies). The thermal profile is
listed in table 7 and the label-specific fluorescent reporter probes were:
Probel 23: 5'6-FAM/GCCTGTAGTCCCACGCGATCTAACA/3'BHQ_1
for detection of label 20S-A1 B 1 and Probel 24:
5'HEX/CAACCATTGATTGGGGACAACTG GG/3'BHQ_1 for detection of
label 20S-A2B2. The label specific reporter probes were purchased
from DNA Technology (Denmark) and delivered as lyophilized powder.
Stock dilutions of 100 µΜ oligonucleotides were made in nuclease free
water and stored at -20 °C. Primers used for amplification in this
experiment forward: GAAGTTCCAGCCAGCGTC, and reverse:
CTGTGACTATGTGAGGCTTTC.
b.Analysis: combined with the above.
Example 1 - Results and conclusions
After sorting of PE labeled cells and QPCR the resultant Ct values confirmed that
Detection Molecules were enriched, i.e. 20S DNA-barcode Labels were successfully
recovered, only when associated with the CMV epitope, while they were not detected
when associated with the HIV epitope (figure 10). This was observed even when labels
were inverted between the two Binding Molecules, implying that the recovery was not
Label specific, but truly specific for the Binding molecule.
It was verified that the 20S labels were recovered after cellular interaction, sorting and
QPCR only if they were associated with positive control Detection molecules, and not if
they were associated with negative control Detection molecules.
Example 2
In this example the binding molecules are pMHC complexes, the linker is a dextran-
streptavidin-fluorochrome conjugate, and the label is a DNA oligonucleotide.
The sample is a HPBMC, the isolating and/or detecting is by FACS, and the
determining of the identity of the label is by QPCR.
Example 2 explained
This is an example where the Sample (1) was blood from one CMV positive and HIV
negative donor which was modified ( 1b) to generate Peripheral blood mononuclear
cells (PBMCs).
The Linker (2) was a dextran conjugate with streptavidin and fluorochrome (Dextramer
backbone from Immudex).
The example is similar to example 1 except that a 1000 fold excess of Detection
Molecules with irrelevant Binding Molecules but without label were included. The
Binding Molecules used (3) are peptide-MHC (pMHC) complexes displaying either
CMV (positive antigen) or HIV (negative antigen) derived peptide-antigens or pMHC
complexes displaying irrelevant peptide antigen. The Binding Molecules were modified
(3b) by biotinylation to provide a biotin capture-tag for the Linker. The binding
Molecules were purified (2c) by HPLC.
The Labels (4) were single stranded oligonucleotides applied as DNA-barcodes. The
oligonucleotides were synthetized (4a) by DNA Technology A/S (Denmark) and were
synthetically modified (4b) with a terminal biotin capture-tag.
The Detection Molecule (5) was synthetized (5a) by attaching binding molecules in the
form of biotinylated pMHC and Labels in the form of biotin-modified oligonucleotides,
DNA-barcodes, onto a streptavidin-modified dextran linker. The detection molecule
further contained a modification (5b) in the form of a fluorochrome. Three different
detection molecules were generated wherein the two of these individual detection
molecules containing CMV- and HIV-directed pMHC were encoded for by
corresponding individual DNA-barcodes. Detection Molecules with irrelevant Binding
Molecules (p* MHC) were not encoded for with a DNA-barcode.
An amount of sample, PBMC's ( 1b) was incubated with an amount of mixed detection
molecules (5) in a ratio of 1: 1 :998 (Labeled-CMV:Labeled-HIV:unlabeled-irrelevant
directed Binding Molecules) under conditions (6c) that allowed binding of detection
molecules to T cells in the sample.
The cell-bound detection molecules were separated from the non-cell bound detection
molecules (7) by first a few rounds of washing the PBMC's through centrifugation
sedimentation of cells and resuspension in wash buffer followed by Fluorescence
Activated Cell Sorting (FACS) of fluorochrome labeled cells. T cells that can efficiently
bind detection molecules will fluoresce because of the fluorochrome comprised within
the detection molecules; T cells that cannot bind detection molecules will not fluoresce.
FACS-sorting leads to enrichment of fluorescent cells, and hence, enrichment of the
detection molecules along with the associated labels that bind T cells of the PBMC
sample.
FACS isolated cells were subjected to quantitative PCR analysis of the oligonucleotide
label associated with the detection molecules bound to the isolated cells to reveal the
identity of the detection molecules that bound to the T cells present in the sample.
This example thus revealed the presence of T cells in the blood expressing a T cell
receptor that binds to peptide-MHC molecules represented within the library of
Detection Molecules. It also revealed the feasibility of enriching for Detection Molecules
based on the presence of T cells specific for the positive peptide-antigen (CMV) over
the negative peptide-antigen (HIV) antigens. In this setting, it was proved that it was
possible to specifically enrich Detection Molecules associated with positive peptide-
antigen when excess of irrelevant Detection Molecule was included in the sample
incubation.
Example 2 in detail
Sample preparation. The cell sample used in this example was obtained in the
same way as described in example 1
Linker preparation: The linker used in this example was prepared as in example
1
Binding Molecules preparation: The binding molecules used in this example
were two different class I MHC-peptide complexes. MHC heavy chains (HLA-
A02 and HLA-B07) and B2M were expressed in E.coli as previously described
(Hadrup et al. 2009) and each MHC-I complex generated with two peptide
antigens or left with an irrelevant photolabile 9-mer peptide. The individual
specificities (allele and peptide combination) were generated in the following
way:
a . Synthesis: As in example 1.
i . HIV derived peptide ILKEPVHGV from antigen HIV polymerase
and CMV derived peptide TPRVTGGGAM from antigen pp65
TPR (Pepscan Presto, NL) were diluted in phosphate buffered
saline (DPBS; Lonza) and mixed to final concentrations
100µ /η Ι:200µΜ (HLA-A0201 : ILKEPVHGV and HLA-
B0702 :TP RVTGGGAM) . The mixtures were exposed to 366 nm
UV light (UV cabinet; CAMAG) for one hour and optionally stored
for up to 24 h at 4°C. The irrelevant Binding Molecules, p* HLA-
A0201 and p* HLA-B0702 were mixed in equal amounts ( g/ml)
and diluted to 100 µ /ιηΙ in DPBS.
b. Modification: No further modifications
c . Purification: Before applying the peptide exchanged HLA monomer
Binding Molecules for preparation of detection molecules these were
centrifuged 5 min, 3300g, to sediment any aggregated MHC molecules.
The p* MHC monomers were not purified further.
Label preparation: In this example Labels were synthetic oligonucleotides
modified with biotin for coupling to the Linker.
a . Synthesis: The Labels were oligonucleotides, DNA barcodes, which were
purchased from DNA Technology (Denmark) and delivered as
lyophilized powder. Stock dilutions of 100 µΜ oligonucleotide were
made in nuclease free water and stored at -20 °C.
i . The Label system used in this example was named 10S and
comprised of single stranded oligonucleotides which were
applied as a DNA barcodes (Oligo 4 :
5GAGATACGTTG ACCTCGTTG AANNNNNNTCTTGAACTATG A
ATCGTCTCACTTAAGCTCTTGGTTGCAT and Oligo 5 :
5GAGATACGTTG ACCTCGTTG AANNNNNNTCTATAGGTGTC
TACTACCTCACTTAAGCTCTTGGTTGCAT were used in this
experiment, 5 indicates a 5' biotin modification).
b. Modification: All Labels were diluted to working concentrations (2.17 uM)
in nuclease free water with 0.1% Tween and stored at -20 °C.
c . Purification: Labels were not purified further.
Detection Molecules preparation: The Binding Molecules (pMHCs) and Labels
(oligonucleotides) were attached to the Linker (dextran-streptavidin-PE
conjugate), to form Detection Molecules, in such a way that a given pMHC was
always attached to a given DNA-barcode.
a . Synthesis: In this example the Detection Molecules were prepared by
attaching 10S DNA-barcodes prior to addition of pMHC. Detection
Molecules were essentially generated in the same way as described in
example 1, with the difference that two different sets of two detection
molecules were generated.
Each set had two specificities individually labeled. The Labels were
inverted between the two sets as described below. Moreover a third
Detection Molecule was generated without any Label, but comprised of
the Linker and a Binding Molecule (p* MHC), this detection molecule was
included in both sets of Detection Molecules as described below in the
indicated stoichiometry:
1. 1xCMV specific pMHCs (HLA-A0201 : ILKEPVHGV)
coupled to Oligo4, 1xHIV specific pMHCs (HLA-
B0702:TPRVTGGGAM) coupled to Oligo5 and 998x non-
labeled p* MHC (HLA-A0201 :p* and HLA-B0702:p * ) .
2 . 1xCMV specific pMHCs (HLA-A0201 : ILKEPVHGV)
coupled to Oligo5, 1xHIV specific pMHCs (HLA-
B0702:TPRVTGGGAM) coupled to Oligo4 and 998x non-
labeled p* MHC (HLA-A0201 :p* and HLA-B0702:p * ) .
b. Modification: Since the total volume of each set of Detection Molecules
exceeded 100 µ Ι this volume was reduced to reach a desired
concentration of specific Binding Molecules in the pooled solution of
Detection Molecules.
i . Size exclusion spin columns (Nanosep 300K Omega, Pall
Corporation) with a cut-off at 300 kDa were saturated by adding
500 µ Ι 2% BSA/DPBS and centrifuging 5000g, until the volume
had passed through. Subsequently, the columns were washed
twice by adding 500 µ Ι DPBS and centrifuging 5000g until no
volume was left in the columns. Each pooled set of detection
molecules were added to a spin column and centrifuged 5000g,
4°C, until the desired volume resided in the column (80 µ Ι per
incubation with sample). The reduced volume of each set of
Detection Molecules was moved to new containers
c . Purification: The Detection Molecules were centrifuged 5 min, 3300g, to
sediment any aggregates before being added to the sample.
6 . Incubation of sample and Detection Molecules: The cell sample and the
Detection Molecules were incubated in the same way as described in example
1.
7 . Enrichment of Detection Molecules with desired characteristics: The Detection
Molecules were enriched for in the same way as described in example 1.
8 . Identification of enriched Detection Molecules: Enriched Detection Molecules
were essentially identified in the same way as described in example 1, with the
difference that two different label-specific fluorescent reporter probes were
applied: LNA-4: 5'6-
FAM/TCT[+T][+G][+A]AC[+T][+A]TG[+A][+A][+T]CGTC/3'BHQ-1-plus for
detection of Oligo4 and LNA-5:
5'HEX/TCT[+A][+T][+A]GG[+T][+G]TC[+T][+A][+C]TACC/3'BHQ-1-plus for
detection of Oligo5 ([+X] indicating locked nucleic acids (LNAs)).
Primers used for amplification of Oligo 4 and Oligo 5 , forward:
GAGATACGTTGACCTCGTTG and reverse: ATGCAACCAAGAGCTTAAGT .
Example 2 - Results and conclusions
After sorting of PE labeled cells and QPCR the resultant Ct values confirmed that
Detection Molecules were enriched, i.e. 10S DNA-barcode Labels were successfully
recovered, only when associated with the CMV epitope, while they were not detected
when associated with the HIV epitope (figure 11). This was observed even when labels
were inverted between the two Binding Molecules, implying that the recovery was not
Label specific, but truly specific for the Binding molecule. Moreover the example
demonstrated that a great amount of irrelevant Detection molecule equipped with the
same fluorescent label as all Detection molecules in the incubation would not be
detrimental for enrichment of cells that would fluoresce due to specific binding with a
Detection molecule.
It was verified that the 10S Labels were recovered after cellular interaction, sorting and
QPCR only if they were associated with positive control Detection molecules, and not if
they were associated with negative control Detection molecules, even in the presence
of a high amount of irrelevant Detection molecule.
Example 3
In this example the binding molecules are pMHC representing 6 different HLA- alleles,
the linker is dextran-streptavidin-PE conjugate and the label is a DNA oligonucleotide.
The sample is HPBMC, the isolating and/or detecting is by FACS, and the determining
of the identity of the label is by sequencing.
Example 3 explained
This is an example where the Samples (1) were blood from one donor that were HLA-
B0702:CMV pp65 TPR positive and another donor that were HLA-B0702 negative
which were modified (1b) to generate Peripheral blood mononuclear cells (PBMCs).
These samples were mixed in different ratios to generate new samples with different
but known frequencies of T cells specific toward the HLA-B0702:CMV epitope.
The Linker (2) was a dextran conjugate with streptavidin and fluorochrome (Dextramer
backbone from Immudex).
The Binding Molecules (3) were peptide-MHC (pMHC) complexes displaying one out of
110 different peptide-antigens comprised within 6 different HLA-types. The MHC
molecules were modified (3b) by biotinylation to provide a biotin capture-tag for the
Linker. The binding molecules were purified (2c) by HPLC and quality controlled in
terms of the formation of functional pMHC multimers for staining of control T-cell
populations.
The Labels (4) were single stranded oligonucleotide applied as DNA-barcodes. The
oligonucleotides were synthetized (4a) by DNA Technology A/S (Denmark) and were
synthetically modified (4b) with a terminal biotin capture-tag.
The Detection Molecule (5) was synthetized (5a) by attaching Binding Molecules in the
form of biotinylated pMHC and Labels in the form of biotin-modified oligonucleotides
(DNA-barcodes) onto a streptavidin-modified dextran linker. The detection molecule
further contained a modification (5b) in the form of a fluorochrome. A library of 110
different Detection Molecules were generated wherein individual Binding Molecules,
comprised of different pMHC, were encoded for by corresponding individual Labels,
comprised of different DNA-barcodes.
An amount of sample, PBMC's ( 1b) was incubated with an amount of mixed Detection
Molecules (5) under conditions (6c) allowing binding of Detection Molecules to T cells
in the sample.
The cell-bound Detection Molecules were separated from the non-cell bound Detection
Molecules (7) by first a few rounds of washing the PBMC's through centrifugation
sedimentation of cells and resuspension in wash buffer followed by Fluorescence
Activated Cell Sorting (FACS) of fluorochrome labeled cells. T cells that can efficiently
bind Detection Molecules will fluoresce because of the fluorochrome comprised within
the detection molecules; T cells that cannot bind detection molecules will not fluoresce.
FACS-sorting leads to enrichment of fluorescent cells, and hence, enrichment of the
detection molecules along with the associated labels that bind T cells of the PBMC
sample.
FACS isolated cells were subjected to PCR for specific amplification of the DNA-
barcode Label associated with the Detection Molecules bound to the isolated cells.
High throughput sequencing of the resultant PCR product revealed the identity of
Detection Molecules that bound to T cells present in the sample.
This example thus revealed the presence of T cells in the blood expressing a T cell
receptor that binds to pMHC molecules represented within the library of Detection
Molecules. The number of sequencing reads mapped to a given DNA-barcode and its
corresponding Binding Molecule would mirror the frequency of the T cells found by
conventional MHC multimer stainings using the same Binding Molecule.
Example 3 in detail
1. Sample preparation. The cell samples used in this example was obtained by
preparing PBMC's from blood drawn from one donor that were HLA-
B0702:CMV pp65 TPR positive and from another donor that were HLA-B0702
negative, as determined by conventional pMHC-multimer and antibody
stainings.
a . Acquiring sample: As in example 1
b. Modifying sample: PBMCs were isolated from whole blood as described
in example 1.
i . Mixing of PBMCs from the two donors provided a titration of the
HLA-B0702 CMV pp65 TPR responses in a B0702 negative
donor sample. 5 fold dilutions of BC260 into BC262 were applied
to generate seven samples with: 100, 20, 4 , 0.8, 0.1 6 , 0.032 and
0.0064% of cells derived from BC260. This corresponded to
theoretical frequencies of HLA-B0702 CMV pp65 TPR specific T
cells of 5%, 1%, 0.2%, 0.04%, 0.008%, 0.001 6% and 0.00032%.
The samples were in turn applied to evaluate the sensitivity of
the Detection Molecules for detecting antigen-specific T cells in a
sample. The relevance of the results obtained after applying the
Detection Molecules could be evaluated by comparison of results
obtained by conventional pMHC-multimer staining when applying
a corresponding sample.
Linker preparation: The linker used in this example was prepared as in
example 1-2.
Binding Molecules preparation: The Binding Molecules used in this example
were class I MHC-peptide complexes. The individual specificities (allele and
peptide combination) were generated as described in example 1. A library of
110 different pMHCs, comprised of 6 different HLA-types, were generated,
these are listed in table 9 .
a . Synthesis: As described in example 1-2
b. Modification: No further modifications
c . Purification: As described in example 1-2
Label preparation: In this example Labels were synthetic oligonucleotides
modified with biotin for coupling to the Linker. 110 different Labels from the 10S
system were applied (table 8).
a . Synthesis: As described in example 2
i . The Label system used in this example were named 10S and
comprised of single stranded oligonucleotides which were
applied as a DNA barcodes.
b. Modification: As described in example 1-2.
c . Purification: As described in example 1-2.
Detection Molecules preparation: 110 different Detection Molecules were
generated, each with a different Binding Molecule encoded by a unique Label.
The Binding Molecules (pMHCs) and Labels (10S DNA-barcodes) were
attached to the Linker (dextran-streptavidin-PE conjugate), to form Detection
Molecules, in such a way that a given pMHC was always attached to a given
DNA-barcode.
a . Detection Molecules were essentially generated in the same way as
described in example 2 , with the difference that 110 different Detection
Molecules were generated. The given combination of Label (DNA-
barcode) and Binding Molecule (pMHC) of each Detection Molecule are
presented in table 9 .
b. Modification: Since the total volume of 110 pooled Detection Molecules
exceeded 100 µ Ι this volume was reduced to reach a desired
concentration of specific Binding Molecules. This was done as described
in example 2
c . Purification: As described in example 1-2.
Incubation of sample and Detection Molecules: The cell sample and the
Detection Molecules were mixed in one container to allow Detection Molecules
to bind to T cells.
a . Amount of sample: Duplicates of seven samples each comprised of
2x1 0E6 cells in the form of BC's, i.e. 2x(1x 100% BC260 and 6x five-fold
dilutions of BC260 into BC262) (as described in 1.b)
b.Amount of Detection Molecule: As described in example 1
c . Conditions: BC260 and BC262 were thawed individually in 10 ml, 37 °C,
RPMI with 10% fetal bovine serum (FBS), centrifuged 5 min, 490g, and
washed twice in 10 ml RPMI with 10% FBS. All washing of cells refer to
centrifugation 5 min, 490g, with subsequent removal of supernatant.
BC's were incubated individually in 50 nM dasatinib, 30 min, 37 °C and
resuspended in 10 ml per 2x1 0E6 cells of the respective BC. Five-fold
dilutions of BC260 were produced by adding 2.5ml (0.5x1 0E6) of the
former cell sample into 10 ml (2x1 0E6 cells) of the BC262 sample. The
mixed cellular samples were washed in 200 ul barcode-buffer
(PBS/0.5% BSA 2 mM EDTA/100 µ /ιηΙ herring DNA) and resuspended
in this buffer to approximately 20 µ Ι per sample prior to incubation of
cells with Detection Molecules.
i . The Detection molecules were added in the required amount and
samples were incubated as described in example 1-2.
Enrichment of Detection Molecules with desired characteristics: The Detection
Molecules were enriched for in the same way as described in example 1-2.
Identification of enriched Detection Molecules: Because the Detection
Molecules were enriched based on specific binding of the Binding Molecule (the
pMHC) to cells, the identification of the associated Labels (DNA-barcodes)
amongst the sorted cells would also reveal the pMHCs that had bound to cells
in the PBMC sample. In this example the DNA-barcodes associated with the
enriched Detection Molecules, were amplified by PCR and identified by high-
throughput sequencing.
a . Apply. The sorted cell sample which contained DNA-barcodes derived
from the enriched Detection Molecules were amplified by PCR. See
table table 10 for composition of the PCR and table 11 for the thermal
profile. The Taq PCR Master Mix Kit (Qiagen, #201443) was applied
and PCR was run on the thermal cycler: GeneAmp, PCR System 9700
(Applied Biosystem). PCR products were visualized after gel
electrophoresis on a Bio-Rad Gel Doc EZ Imager. DNA was sequenced
using the Ion Torrent PGM platform (Life Technologies)
i . Primers were purchased from DNA Technology (Denmark) and
delivered as lyophilized powder. Stock dilutions of 100 µΜ
were made in nuclease free water and stored at -20 °C. The
primers included adaptors for Ion Torrent sequencing, i.e. an
A-key and a P1-key on the forward and reverse primer
respectively. Additionally the forward primers had unique DNA
sequences besides the primer region and the A-key (the primer
sequences are listed in table 12). These primers were used to
assign DNA-barcodes derived from the same sample with a
sample-identification sequence (Sample-ID barcode) (see
figure 9 for a schematic presentation of this design). This
enabled distribution of DNA-barcode sequence reads
according to their originating sample, when DNA-barcodes
from multiple samples were sequenced in the same
sequencing reaction. The non-enriched library of the 110
different Detection Molecules (diluted 100.000x after being
reduced in volume) were also assigned with a sample-ID
barcode through PCR (referred to as the Detection Molecule
input). Information about the distribution of Labels within the
library of Detection Molecules before enrichment would allow
normalization of the sequence output. Pooled PCR products
derived from the sample input and from multiple incubations of
Detection Molecule and sample were purified with the MinElute
PCR purification Kit (Qiagen, #28006) according to standard
procedure.
ii. Purified DNA was sequenced by GeneDx (U.S.A) on an Ion
Torrent PGM 314 chip
b.Analysis. Positive sequence reads were aligned to sequences that read
from the sample-barcode-identity at the 5'-end all the way through the
DNA-barcode-identity. The number of reads was normalized according
to the total number of reads that mapped to the same sample-ID
barcode and according to the Detection Molecule input reads
i . Mapping sequencing reads to 10 S DNA-barcodes: A
sequence database was created consisting of the possible
combinations of 15 sample-identification barcodes and 110
10S DNA-barcodes together with the primer sequences from
the 10S system. This accumulated to 1650 sequences that
could be expected from a sequencing run. Each sequencing
read was then used to search the database for alignments,
using the nucleotide BLAST algorithm, with a match reward of
1, mismatch reward of -2 and a gap cost of 2 for both opening
and extending a gap. In this way sequencing errors were
penalized equally, whether a base was miscalled or
inserted/deleted in the sequencing read compared to the actual
sequence. Alignments were discarded by the following criteria:
E-value > 1e-12; insufficient length of alignment (should
be greater than 60 for the 10S barcodes) .
Start position in subject sequence larger than 2 , i.e. fewer
than 5 out of 6 bases in the unique part of the sample-
identification barcode was included in the alignment.
If multiple alignments could still be found for any sequencing
read, only the alignment with the best percent identity was
kept. Finally, the number of reads mapping to each DNA
barcode in the database was counted.
Identifying overrepresented DNA barcodes: Relative read
counts were calculated by normalizing each read to the total
read count mapping to the same sample-ID barcode. The
relative read counts were then used to calculate the fold
change per DNA-barcode compared to the control DNA-
barcode Detection Molecule input (the non-enriched Detection
Molecule library). Significantly overrepresented DNA-barcodes
were identified using a 2-sample test for equality of proportions
on the raw read counts in a sample versus the DNA-barcode
input-sample, and p-values were corrected for multiple testing
using the Benjamini-Hochberg FDR method.
Example 3 - Results and conclusions
FACS sorting of fluorescent labeled cells, specific amplification of DNA-barcode Labels
and high-throughput sequencing verified that it was possible to enrich and detect 10S
barcodes from a library of multiple different Detection molecules composed of 110
different 20S DNA-barcode Labels encoding for 110 different antigen specificities
distributed on 6 different HLA-types (figure 12). Moreover the number of sequence
reads recovered from a given 10 S barcode was sensitive to the frequency of antigen
specific T cells in the sample.
This example demonstrates that it is possible to detect antigen specific T cell
responses of different frequencies in a panel of 110 different 10S labeled Detection
Molecules.
Example 4
In this example the binding molecules are class I pMHC complexes comprising 6
different HLA alleles, the linker is dextran-streptavidin-PE conjugate and the label is a
DNA oligonucleotide.
The sample is HPBMC, the isolating and/or detecting is by FACS, and the determining
of the identity of the label is by sequencing.
Example 4 explained
This example was essentially the same as example 3 only another Label system was
applied.
This is an example where the Samples (1) were blood from one donor that were HLA-
B0702:CMV pp65 TPR positive and another donor that were HLA-B0702 negative
which were modified (1b) to generate Peripheral blood mononuclear cells (PBMCs).
These samples were mixed in different ratios to generate new samples with different
but known frequencies of T cells specific toward the HLA-B0702:CMV epitope.
The Linker (2) was a dextran conjugate with streptavidin and fluorochrome (Dextramer
backbone from Immudex).
The Binding Molecules (3) were peptide-MHC (pMHC) complexes displaying one out of
110 different peptide-antigens comprised within 6 different HLA-types. The MHC
molecules were modified (3b) by biotinylation to provide a biotin capture-tag for the
Linker. The binding molecules were purified (2c) by HPLC and quality controlled in
terms of the formation of functional pMHC multimers for staining of control T-cell
populations.
The Labels (4) were oligonucleotides applied as DNA-barcodes. The oligonucleotides
were synthetized (4a) by DNA Technology A/S (Denmark) and were synthetically
modified (4b) with a terminal biotin capture-tag. The labels were combined
oligonucleotide labels arising by annealing an A oligonucleotide (modified with biotin) to
a partially complimentary B oligonucleotide label followed by enzymatic DNA
polymerase extension of Oligo A and Oligo B to create a fully double stranded label.
The Detection Molecule (5) was synthetized (5a) by attaching Binding Molecules in the
form of biotinylated pMHC and Labels in the form of biotin-modified oligonucleotides
(DNA-barcodes) onto a streptavidin-modified dextran linker. The detection molecule
further contained a modification (5b) in the form of a fluorochrome. A library of 110
different Detection Molecules were generated wherein individual Binding Molecules,
comprised of different pMHC, were encoded for by corresponding individual Labels,
comprised of different DNA-barcodes.
An amount of sample, PBMC's ( 1b) was incubated with an amount of mixed Detection
Molecules (5) under conditions (6c) allowing binding of Detection Molecules to T cells
in the sample.
The cell-bound Detection Molecules were separated from the non-cell bound Detection
Molecules (7) by first a few rounds of washing the PBMC's through centrifugation
sedimentation of cells and resuspension in wash buffer followed by Fluorescence
Activated Cell Sorting (FACS) of fluorochrome labeled cells. T cells that can efficiently
bind Detection Molecules will fluoresce because of the fluorochrome comprised within
the detection molecules; T cells that cannot bind detection molecules will not fluoresce.
FACS-sorting leads to enrichment of fluorescent cells, and hence, enrichment of the
detection molecules along with the associated labels that bind T cells of the PBMC
sample.
FACS isolated cells were subjected to PCR for specific amplification of the DNA-
barcode associated with the Detection Molecules bound to the isolated cells. High
throughput sequencing of the resultant PCR product revealed the identity of Detection
Molecules that bound to T cells present in the sample.
This example thus revealed the presence of T cells in the blood expressing a T cell
receptor that binds to pMHC molecules represented within the library of Detection
Molecules. The number of sequencing reads mapped to a given DNA-barcode and its
corresponding Binding Molecule would mirror the frequency of the T cells found by
conventional MHC multimer stainings using the same Binding Molecule. Moreover it
revealed that Labels, i.e. Detection Molecules, associated with T cells in a sample
would be sufficiently enriched to reveal the presence of low frequent T cells binding
such Detection Molecules.
Example 4 in detail
1. Sample preparation. The cell samples used in this example were obtained by
preparing PBMC's from blood drawn from one donor that were HLA-
B0702:CMV pp65 TPR positive and from another donor that were HLA-B0702
negative, as determined by conventional pMHC-multimer and antibody staining.
They were acquired (a.) and modified (b.) in the same way as described in
example 3 .
Linker preparation: The linker used in this example was prepared as in
example 1-3.
Binding Molecules preparation: The Binding Molecules used in this example
were class I MHC-peptide complexes. The individual specificities (allele and
peptide combination) were generated as described in example 1-3. A library of
110 different pMHCs were generated, comprised of 6 different HLA-types, these
are listed in table 9 .
a . Synthesis: As described in example 1-3
b. Modification: No further modifications
c . Purification: As described in example 1-3
Label preparation: In this example Labels were synthetic oligonucleotides
modified with biotin for coupling to the Linker. 110 different Labels from the 20S
system were applied (table 2 ) .
a . Synthesis: As described in example 1.
i . The Label system used in this example was named 20S and
was developed to increase the complexity of a limited number of
oligonucleotide sequences. This was enabled by applying a
combinatorial strategy where two partially complementary
oligonucleotides (an A oligonucleotide with a 5' biotin tag and a B
oligonucleotide) where annealed and then elongated to produce
new unique oligonucleotide-sequences (AxBy) which were
applied as a DNA-barcodes (Labels) (figure 9). By combining 6
unique oligonucleotide-sequences (A label precursor) that were
all partly complementary to 20 other unique oligonucleotide
sequences (B label precursor) a combinatorial library of 120
different (AxBy) Labels were produced. Only 110 of these Labels
were used in this example (table 9).
b. Modification: As described in example 1-3.
c . Purification: As described in example 1-3.
Detection Molecules preparation: 110 different Detection Molecules were
generated, each with a different Binding Molecule encoded by a unique Label.
The Binding Molecules (pMHCs) and Labels (20S DNA-barcodes) were
attached to the Linker (dextran-streptavidin-PE conjugate), to form Detection
Molecules, in such a way that a given pMHC was always attached to a given
DNA-barcode.
a . Detection Molecules were essentially generated in the same way as
described in example 3 . The given combination of Label (20S DNA-
barcode) and Binding Molecule (pMHC) of each Detection Molecule are
presented in table 9 .
b. Modification: Since the total volume of 110 pooled Detection Molecules
exceeded 100 µ Ι this volume was reduced to reach a desired
concentration of specific Binding Molecules. This was done as described
in example 2-3.
c . Purification: As described in example 1-3.
Incubation of sample and Detection Molecules: The cell sample and the
Detection Molecules were mixed in one container to allow Detection Molecules
to bind to T cells.
a .Amount of sample: Samples were equivalent to those used in example 3 .
b.Amount of Detection Molecule: As described in example 1-3
c . Conditions: Samples and Detection Molecules were treated under the
same conditions as described in example 3 .
Enrichment of MHC molecules with desired characteristics: The Detection
Molecules were enriched for in the same way as described in example 1-3.
Identification of enriched Detection Molecules: Because the Detection
Molecules were enriched based on specific interaction of the Binding Molecule
(the pMHC) with cells, the identification of the associated Labels (DNA-
barcodes) amongst the sorted cells would also reveal the pMHCs that had
bound to cells in the PBMC sample. In this example the DNA-barcodes
associated with the enriched Detection Molecules, were amplified by PCR and
identified by high-throughput sequencing.
a .Apply. The sorted cell sample which contained DNA-barcodes derived
from the enriched Detection Molecules were amplified by PCR. See
table table 10 for composition of the PCR and table 11 for the thermal
profile. The Taq PCR Master Mix Kit (Qiagen, #201443) was applied
and PCR was run on the thermal cycler: GeneAmp, PCR System 9700
(Applied Biosystem). PCR products were visualized after gel
electrophoresis on a Bio-Rad Gel Doc EZ Imager. DNA was sequenced
using the Ion Torrent PGM platform (Life Technologies)
i . Primers were purchased from DNA Technology (Denmark) and
delivered as lyophilized powder. Stock dilutions of 100 µΜ
were made in nuclease free water and stored at -20 °C. The
primers included adaptors for Ion Torrent sequencing, i.e. an
A-key and a P1-key on the forward and reverse primer
respectively. Additionally the forward primers had unique DNA
sequences besides the primer region and the A-key . These
primers were used to assign DNA-barcodes derived from the
same sample with a sample-identification sequence (Sample-
ID barcode) (the primer sequences are listed in table 13). This
enabled distribution of DNA-barcode sequence reads
according to their originating sample, when DNA-barcodes
from multiple samples were sequenced in the same
sequencing reaction. The non-enriched library of the 110
different Detection Molecules (diluted 100.000x after being
reduced in volume) were also assigned with a sample-ID
barcode through PCR (referred to as the Detection Molecule
input)(see figure 9 for a schematic overview of the primer
design). Information about the distribution of Labels within the
library of Detection Molecules before enrichment would allow
normalization of the sequence output. Pooled PCR products
derived from the sample input and from multiple incubations of
Detection Molecule and sample were purified with the MinElute
PCR purification Kit (Qiagen, #28006) according to standard
procedure.
ii. The purified DNA was sequenced by GeneDx (U.S.A) on an
Ion Torrent PGM 314 chip
b.Analysis. Positive sequence reads were aligned to sequences that read
from the sample-barcode-identity at the 5'-end all the way through the
DNA-barcode-identity. The number of reads was normalized according
to the total number of reads that mapped to the same sample-ID
barcode and according to the Detection Molecule input reads. The
Analysis was essentially as in example 3 except that another database
of 20S sequences was generated and sequences were mapped
according to corresponding 20S DNA-barcodes.
i . Mapping sequencing reads to 20S DNA-barcodes: A
sequence database was created consisting of the possible
combinations of 15 sample-identification barcodes and 120
20S DNA barcodes (together with the primer and annealing
sequences from the 20S system). This accumulated to1 800
sequences that could be expected from a sequencing run.
Each sequencing read was then used to search the database
for alignments, using the nucleotide BLAST algorithm, with a
match reward of 1, mismatch reward of -2 and a gap cost of 2
for both opening and extending a gap. In this way sequencing
errors were penalized equally, whether a base was miscalled
or inserted/deleted in the sequencing read compared to the
actual sequence. Alignments were discarded by the following
criteria:
1. E-value > 1e-1 2 ; insufficient length of alignment (should
be greater than 102 for the 20S barcodes).
2 . Start position in subject sequence larger than 2 , i.e. fewer
than 5 out of 6 bases in the unique part of the sample-
identification barcode was included in the alignment.
If multiple alignments could still be found for any sequencing
read, only the alignment with the best percent identity was
kept. Finally, the number of reads mapping to each DNA
barcode in the database was counted.
Identifying overrepresented DNA barcodes: Relative read
counts were calculated by normalizing each read to the total
read count mapping to the same sample-ID barcode. The
relative read counts were then used to calculate the fold
change per DNA-barcode compared to the control DNA-
barcode Detection Molecule input (the non-enriched Detection
Molecule library). Significantly overrepresented DNA-barcodes
were identified using a 2-sample test for equality of proportions
on the raw read counts in a sample versus the DNA-barcode
input-sample, and p-values were corrected for multiple testing
using the Benjamini-Hochberg FDR method.
Example 4 - Results and conclusions
FACS sorting of fluorescent labeled cells, specific amplification of DNA-barcode Labels
and high-throughput sequencing verified that it was possible to enrich and detect 20S
barcodes from a library of multiple different Detection molecules composed of 110
different 20S DNA-barcode Labels encoding for 110 different antigen specificities
distributed on 6 different HLA-types (figure 13). Moreover the number of sequence
reads recovered from a given 20S barcode was sensitive to the frequency of antigen
specific T cells in the sample, also indicating that it will be possible to detect Labels
associated with responses of very low frequency (<0.002).
This example demonstrates that it is possible to detect antigen specific T cell
responses of different and of low frequencies in a panel of 110 different 20S labeled
Detection Molecules.
Example 5
In this example the binding molecules are class I pMHCs, the linker is streptavidin
conjugate and the label is DNA.
The isolating and/or detecting is by FACS, and the determining of the identity of the
label is by sequencing.
Example 5 explained
This is an example where the Samples (1) were blood from six different donors with
different HLA-types which were modified ( 1b) to generate Peripheral blood
mononuclear cells (PBMCs).
The Linker (2) was a dextran conjugate with streptavidin and fluorochrome (Dextramer
backbone from Immudex).
The Binding Molecules (3) were peptide-MHC (pMHC) complexes displaying one out of
110 different peptide-antigens comprised within 6 different HLA-types. The MHC
molecules were modified (3b) by biotinylation to provide a biotin capture-tag for the
Linker. The binding molecules were purified (2c) by HPLC and quality controlled in
terms of the formation of functional pMHC multimers for staining of control T-cell
populations.
The Labels (4) were single stranded oligonucleotide applied as DNA-barcodes. The
oligonucleotides were synthetized (4a) by DNA Technology A/S (Denmark) and were
synthetically modified (4b) with a terminal biotin capture-tag.
The Detection Molecule (5) was synthetized (5a) by attaching Binding Molecules in the
form of biotinylated pMHC and Labels in the form of biotin-modified oligonucleotides
(DNA-barcodes) onto a streptavidin-modified dextran linker. The detection molecule
further contained a modification (5b) in the form of a fluorochrome. A library of 110
different Detection Molecules were generated wherein individual Binding Molecules,
comprised of different pMHC, were encoded for by corresponding individual Labels,
comprised of different DNA-barcodes.
An amount of sample, PBMC's ( 1b) was incubated with an amount of mixed Detection
Molecules (5) under conditions (6c) allowing binding of Detection Molecules to T cells
in the sample.
The cell-bound Detection Molecules were separated from the non-cell bound Detection
Molecules (7) by first a few rounds of washing the PBMC's through centrifugation
sedimentation of cells and resuspension in wash buffer followed by Fluorescence
Activated Cell Sorting (FACS) of fluorochrome labeled cells. T cells that can efficiently
bind Detection Molecules will fluoresce because of the fluorochrome comprised within
the detection molecules; T cells that cannot bind detection molecules will not fluoresce.
FACS-sorting leads to enrichment of fluorescent cells, and hence, enrichment of the
detection molecules along with the associated labels that bind T cells of the PBMC
sample.
FACS isolated cells were subjected to PCR for specific amplification of the DNA-
barcode associated with the Detection Molecules bound to the isolated cells. High
throughput sequencing of the resultant PCR product revealed the identity of Detection
Molecules that bound to T cells present in the sample.
This example thus revealed the presence of T cells in the blood expressing a T cell
receptor that binds to pMHC molecules represented within the library of Detection
Molecules. The application of multiple ( 1 10) Detection Molecules in one sample
enabled detection of T cells with different T cell receptor specificities in parallel.
Example 5 in detail
1. Sample preparation. The cell samples used in this example were obtained by
preparing PBMC's from blood drawn from six different donors with a number of
different peptide-antigen responsive T cells, as determined by conventional
pMHC-multimer staining.
a . Acquiring sample: Blood was obtained from the Danish Blood Bank, as
example 1-4
b. Modifying sample: PBMCs were isolated from whole blood as described
in example 1-4.
Linker preparation: The linker used in this example was prepared as in
example 1-4.
Binding Molecules preparation: The Binding Molecules used in this example
were class I MHC-peptide complexes. The individual specificities (allele and
peptide combination) were generated as described in example 1. A library of
110 different pMHCs, comprised of 6 different HLA-types, were generated,
these are listed in table 9 .
a . Synthesis: As described in example 1-4
b. Modification: No further modifications
c . Purification: As described in example 1-4
Label preparation: In this example Labels were synthetic oligonucleotides
modified with biotin for coupling to the Linker. 110 different Labels from the 10S
system were applied (table 8).
a . Synthesis: As described in example 2-3.
i . The Label system used in this example were named 10 S and
comprised of single stranded oligonucleotides which were
applied as a DNA barcodes.
b. Modification: As described in example 1-4.
c . Purification: As described in example 1-4.
Detection Molecules preparation: 110 different Detection Molecules were
generated, each with a different Binding Molecule encoded by a unique Label.
The Binding Molecules (pMHCs) and Labels (10S DNA-barcodes) were
attached to the Linker (dextran-streptavidin-PE conjugate) to form Detection
Molecules, in such a way that a given pMHC was always attached to a given
DNA-barcode.
a . Detection Molecules were generated in the same way as
described in example 3 . The given combination of Label (DNA-
barcode) and Binding Molecule (pMHC) of each Detection
Molecule are presented in table 9 .
b. Modification: Since the total volume of 110 pooled Detection
Molecules exceeded 100 µ Ι this volume was reduced to reach a
desired concentration of specific Binding Molecules. This was
done as described in example 2-4.
c . Purification: As described in example 1-4.
6 . Incubation of sample and Detection Molecules: The cell sample and the
Detection Molecules were incubated in the same way as described in example
1-2.
7 . Enrichment of MHC molecules with desired characteristics: The Detection
Molecules were enriched for in the same way as described in example 1-6.
8 . Identification of enriched Detection Molecules: Because the Detection
Molecules were enriched based on specific interaction of the Binding Molecule
(the pMHC) with cells, the identification of the associated Labels (DNA-
barcodes) amongst the sorted cells would also reveal the pMHCs that had
bound to cells in the PBMC sample. In this example the DNA-barcodes
associated with the enriched Detection Molecules, were amplified by PCR and
identified by high-throughput sequencing. The enriched Labels, of the 10S
DNA-barcode system, were identified as in example 3 .
Example 5 - Results and conclusions
FACS sorting of fluorescent labeled cells, specific amplification of DNA-barcode Labels
and high-throughput sequencing verified that it was possible to enrich and detect 10S
barcodes from a library of multiple different Detection molecules composed of 110
different 10S DNA-barcode Labels encoding for 110 different antigen specificities
distributed on 6 different HLA-types (figure 14). It was verified that several DNA-
barcodes, encoding different antigen specificities on different HLA-types, could be
enriched for and detected in parallel, indicative for the presence of multiple antigen-
specific T cell responses in that sample.
This example demonstrates that it is possible to detect several antigen-specific T cell
responses in parallel when applying a library of Detection molecules of increasing
complexity.
Example 6
In this example 110 different binding molecules are used, the linker is dextran for all of
the detection molecules and 110 different labels are used.
Example 6 explained
This example was essentially the same as example 5 only another Label system was
applied.
This is an example where the Samples (1) were blood from six different donors with
different HLA-types which were modified ( 1b) to generate Peripheral blood
mononuclear cells (PBMCs).
The Linker (2) was a dextran conjugate with streptavidin and fluorochrome (Dextramer
backbone from Immudex).
The Binding Molecules (3) were peptide-MHC (pMHC) complexes displaying one out of
110 different peptide-antigens comprised within 6 different HLA-types. The MHC
molecules were modified (3b) by biotinylation to provide a biotin capture-tag for the
Linker. The binding molecules were purified (2c) by HPLC and quality controlled in
terms of the formation of functional pMHC multimers for staining of control T cell
populations.
The Labels (4) were oligonucleotides applied as DNA-barcodes. The oligonucleotides
were synthetized (4a) by DNA Technology A/S (Denmark) and were synthetically
modified (4b) with a terminal biotin capture-tag. The labels were combined
oligonucleotide labels arising by annealing an A oligonucleotide (modified with biotin) to
a partially complimentary B oligonucleotide label followed by enzymatic DNA
polymerase extension of Oligo A and Oligo B to create a fully double stranded label.
The Detection Molecule (5) was synthetized (5a) by attaching Binding Molecules in the
form of biotinylated pMHC and Labels in the form of biotin-modified oligonucleotides
(DNA-barcodes) onto a streptavidin-modified dextran linker. The detection molecule
further contained a modification (5b) in the form of a fluorochrome. A library of 110
different Detection Molecules were generated wherein individual Binding Molecules,
comprised of different pMHC, were encoded for by corresponding individual Labels,
comprised of different DNA-barcodes.
An amount of sample, PBMC's ( 1b) was incubated with an amount of mixed Detection
Molecules (5) under conditions (6c) allowing binding of Detection Molecules to T cells
in the sample.
The cell-bound Detection Molecules were separated from the non-cell bound Detection
Molecules (7) by first a few rounds of washing the PBMC's through centrifugation
sedimentation of cells and resuspension in wash buffer followed by Fluorescence
Activated Cell Sorting (FACS) of fluorochrome labeled cells. T cells that can efficiently
bind Detection Molecules will fluoresce because of the fluorochrome comprised within
the detection molecules; T cells that cannot bind detection molecules will not fluoresce.
FACS-sorting leads to enrichment of fluorescent cells, and hence, enrichment of the
detection molecules along with the associated labels that bind T cells of the PBMC
sample.
FACS isolated cells were subjected to PCR for specific amplification of the DNA-
barcode associated with the Detection Molecules bound to the isolated cells. High
throughput sequencing of the resultant PCR product revealed the identity of Detection
Molecules that bound to T cells present in the sample.
This example thus revealed the presence of T cells in the blood expressing a T cell
receptor that binds to pMHC molecules represented within the library of Detection
Molecules. The application of multiple ( 1 10) Detection Molecules in one sample
enabled detection of T cells with different T cell receptor specificities in parallel.
Example 6 in detail
1. Sample preparation. The cell samples used in this example were obtained by
preparing PBMC's from blood drawn from six different donors with a number of
different peptide-antigen responsive T cells, as determined by conventional
pMHC-multimer.
a . Acquiring sample: Blood was obtained from the Danish Blood Bank.
b. Modifying sample: PBMCs were isolated from whole blood as described
in example 1-2, 5 .
2 . Linker preparation: The linker used in this example was prepared as in
example 1-5.
3 . Binding Molecules preparation: The Binding Molecules used in this example
were class I MHC-peptide complexes. The individual specificities (allele and
peptide combination) were generated as described in example 1-5. A library of
110 different pMHCs, comprised of 6 different HLA-types, were generated,
these are listed in table 9 .
a . Synthesis: As described in example 1-5.
b. Modification: No further modifications
c . Purification: As described in example 1-5
Label preparation: In this example Labels were synthetic oligonucleotides
modified with biotin for coupling to the Linker. 110 different Labels from the 20S
system were applied (table 2).
a . Synthesis: As described in example 1, 4 .
i . The Label system used in this example was named 20S and
was developed to increase the complexity of a limited number
of oligonucleotide sequences. This was enabled by applying a
combinatorial strategy where two partially complementary
oligonucleotides (an A oligonucleotide with a 5' biotin tag and a
B oligonucleotide) where annealed and then elongated to
produce new unique oligonucleotide-sequences (AxBy) which
were applied as a molecular barcodes (Labels) (figure 9). By
combining 6 unique oligonucleotide-sequences (A label
precursor) that were all partly complementary to 20 other
unique oligonucleotide sequences (B label precursor) a
combinatorial library of 120 different (AxBy) Labels were
produced. Only 110 of these Labels were used in this example
(table 9).
b. Modification: As described in example 1-5.
c . Purification: As described in example 1-5.
Detection Molecules preparation: 110 different Detection Molecules were
generated, each with a different Binding Molecule encoded by a unique Label.
The Binding Molecules (pMHCs) and Labels (20S DNA-barcodes) were
attached to the Linker (dextran-streptavidin-PE conjugate) to form Detection
Molecules, in such a way that a given pMHC was always attached to a given
DNA-barcode.
a . Detection Molecules were generated in the same way as
described in example 3 , 4 , 5 . The given combination of Label
(20S DNA-barcode) and Binding Molecule (pMHC) of each
Detection Molecule are presented in table 9 .
b. Modification: Since the total volume of 110 pooled Detection
Molecules exceeded 100 µ Ι this volume was reduced to reach a
desired concentration of specific Binding Molecules (done as
described in example 2-5).
c . Purification: As described in example 1-5.
6 . Incubation of sample and Detection Molecules: The cell sample and the
Detection Molecules were incubated in the same way as described in example
1-2, 5 .
7 . Enrichment of MHC molecules with desired characteristics: The Detection
Molecules were enriched for in the same way as described in example 1-5.
8 . Identification of enriched Detection Molecules: Because the Detection
Molecules were enriched based on specific binding of the Binding Molecule (the
pMHC) to cells, the identification of the associated Labels (DNA-barcodes)
amongst the sorted cells would also reveal the pMHCs that had bound to cells
in the PBMC sample. In this example the DNA-barcodes associated with the
enriched Detection Molecules, were amplified by PCR and identified by high-
throughput sequencing. The enriched Labels, of the 20S DNA-barcode system,
were identified as in example 4 .
Example 6 - Results and conclusions
FACS sorting of fluorescent labeled cells, specific amplification of DNA-barcode Labels
and high-throughput sequencing verified that it was possible to enrich and detect 20S
barcodes from a library of multiple different Detection molecules composed of 110
different 20S DNA-barcode Labels encoding for 110 different antigen specificities
distributed on 6 different HLA-types (figure 15). It was verified that several DNA-
barcodes, encoding different antigen specificities of different HLA-types, could be
enriched for and detected in parallel, indicative for the presence of multiple antigen-
specific T cell responses in that sample.
This example demonstrates that it is possible to detect several antigen-specific T cell
responses in parallel when applying a library of Detection molecules of increasing
complexity.
Example 7
In this example 175 different pMHC complexes are used as binding molecules. The
sample is tumor infiltrating Lymphocytes from a resected tumor lesion of a human
being.
Example 7 explained
This is an example where the Samples (1) were resected tumor lesions from 11 HLA-
A0201 positive patients with malignant melanoma. The samples were modified (1b) to
generate Tumor Infiltrating Lymphocytes (TILs).
The Linker (2) was a dextran conjugate with streptavidin and fluorochrome (Dextramer
backbone from Immudex).
The Binding Molecules (3) were peptide-MHC (pMHC) complexes displaying one out of
175 different peptide-antigens. The MHC molecules were modified (3b) by biotinylation
to provide a biotin capture-tag for the Linker. The binding molecules were purified (2c)
by HPLC and quality controlled in terms of the formation of functional pMHC multimers
for staining of control T-cell populations.
The Labels (4) were oligonucleotides applied as DNA-barcodes. The oligonucleotides
were synthetized (4a) by DNA Technology A/S (Denmark) and were synthetically
modified (4b) with a terminal biotin capture-tag. The labels were combined
oligonucleotide labels arising by annealing an A oligonucleotide (modified with biotin) to
a partially complimentary B oligonucleotide label followed by enzymatic DNA
polymerase extension of Oligo A and Oligo B to create a fully double stranded label.
The Detection Molecule (5) was synthetized (5a) by attaching Binding Molecules in the
form of biotinylated pMHC and Labels in the form of biotin-modified oligonucleotides
(DNA-barcodes) onto a streptavidin-modified dextran linker. The detection molecule
further contained a modification (5b) in the form of a fluorochrome. A library of 175
different Detection Molecules were generated wherein individual Binding Molecules,
comprised of different pMHC, were encoded for by corresponding individual Labels,
comprised of different DNA-barcodes.
An amount of sample, TILs (1b), was incubated with an amount of mixed Detection
Molecules (5) under conditions (6c) allowing binding of Detection Molecules to T cells
in the sample.
The cell-bound Detection Molecules were separated from the non-cell bound Detection
Molecules (7) by first a few rounds of washing the TIL's through centrifugation
sedimentation of cells and resuspension in wash buffer followed by Fluorescence
Activated Cell Sorting (FACS) of fluorochrome labeled cells. T cells that can efficiently
bind Detection Molecules will fluoresce because of the fluorochrome comprised within
the detection molecules; T cells that cannot bind detection molecules will not fluoresce.
FACS-sorting leads to enrichment of fluorescent cells, and hence, enrichment of the
detection molecules along with the associated labels that bind T cells of the TIL
sample.
FACS isolated cells were subjected to PCR for specific amplification of the DNA-
barcode Label associated with the Detection Molecules bound to the isolated cells.
High throughput sequencing of the resultant PCR product revealed the identity of
Detection Molecules that bound to T cells present in the sample.
This example thus revealed the presence of T cells among the TIL's expressing a T cell
receptor that binds to pMHC molecules represented within the library of Detection
Molecules. The number of sequencing reads mapped to a given DNA-barcode and its
corresponding Binding Molecule would mirror the frequency of the T cells found by
conventional MHC multimer stainings using the same Binding Molecules. The
application of multiple (175) Detection Molecules in one sample enabled detection of T
cells with different T cell receptor specificities in parallel. This is feasible also when the
sample, as in present example is TILs that on average basis has a lower avidity of their
TCR to their pMHC antigen. Consequently they are more challenging to detect than
virus-responsive T cells using traditional fluorescence labelled MHC mulitimers.
Example 7 in detail
1. Sample preparation. The 11 cell samples used in this example were obtained
from resected tumor lesions obtained from patients with malignant melanoma.
a .Acquiring sample. TILs were derived from tumor fragments from
melanoma patients. Tumor lesion were resected following surgical
removal of the given tumor lesion.
b. Modifying sample. Tumor fragments (1-3 mm3 ) were cultured
individually in complete medium (RPMI with 10% human serum, 100
U/ml penicillin, 100 µg/ml streptomycin, 1.25 µg/ml fungizone [Bristol-
Myers Squibb] and 6000 U/ml IL-2) at 37 C and 5% C02, allowing TILs
to migrate to the medium. TILs were expanded to reach >50x106 total
cells originated from approximately 24 fragments, which had expanded
to confluent growth in 2-ml wells and eliminated adherent tumor cells
(average of approximately 2x106 cells per well from each tumor
fragment). TIL cultures were expanded on a clinical scale using a
standard rapid expansion protocol (REP). Briefly, TILs were stimulated
with 30 ng/ml anti-CD3 antibody (OKT-3; Ortho Biotech) and 6000 U/ml
IL-2 in the presence of irradiated (40 Gy) allogenic feeder cells (PBMCs
from a healthy donor) at a feeder:TIL ratio of 200:1 . Initially, TILs were
rapidly expanded in a 1: 1 mix of complete medium and REP medium
(AIM-V [Invitrogen] with 10% human serum, 1.25 µg/ml fungizone and
6000 U/ml IL-2), but after seven days complete medium and serum were
removed stepwise from the culture by adding REP medium without
serum to maintain cell densities around 1-2x1 06 cells/ml. TIL cultures
were cryopreserved at -150°C in human serum containing 10% DMSO.
All patients were HLA-A0201 positive.
Linker preparation: The linker used in this example was prepared as in
example 1-6.
Binding Molecules preparation: The Binding Molecules used in this example
were class I MHC-peptide complexes (peptide-HLA-A0201). The individual
specificities (allele and peptide combination) were generated as described in
example 1-6. A library of 175 different pMHCs were generated, these are listed
in table 2 .
a . Synthesis: As described in example 1-6
b. Modification: No further modifications
c . Purification: As described in example 1-6
Label preparation: In this example Labels were synthetic oligonucleotides
modified with biotin for coupling to the Linker. 175 different Labels from the 20S
system were applied (table 14).
a . Synthesis: As described in example 1.
i . The Label system used in this example was named 20S and
was developed to increase the complexity of a limited number
of oligonucleotide sequences. This was enabled by applying a
combinatorial strategy where two partially complementary
oligonucleotides (an A oligonucleotide with a 5' biotin tag and a
B oligonucleotide) where annealed and then elongated to
produce new unique oligonucleotide-sequences (AxBy) which
were applied as a DNA-barcodes (Labels) (figure 9). By
combining 22 unique oligonucleotide-sequences (A label
precursor) that are all partly complementary to 55 other unique
oligonucleotide sequences (B label precursor) a combinatorial
library of 1,21 0 different (AxBy) Labels were produced. Only
175 of these Labels were used in this example (table 14).
Refer to table 2 for an overview of the different 20S A and B
nucleotide sequences.
b. Modification: As described in example 1-6.
c . Purification: As described in example 1-6.
Detection Molecules preparation: 175 different Detection Molecules were
generated, each with a different Binding Molecule encoded by a unique Label.
The Binding Molecules (pMHCs) and Labels (20S DNA-barcodes) were
attached to the Linker (dextran-streptavidin-PE conjugate), to form Detection
Molecules, in such a way that a given pMHC was always attached to a given
DNA-barcode.
a . Detection Molecules were essentially generated in the same way as
described in example 1-6. The given combination of Label (20S DNA-
barcode) and Binding Molecule (pMHC) of each Detection Molecule are
presented in table 14.
b. Modification: Since the total volume of 175 pooled Detection Molecules
exceeded 100 µ Ι this volume was reduced to reach a desired
concentration of specific Binding Molecules. This was done as described
in example 2-6.
c . Purification: As described in example 1-6.
Incubation of sample and Detection Molecules: The cell sample and the
Detection Molecules were mixed in one container to allow Detection Molecules
to bind to T cells.
a .Amount of sample: Between 0.2x1 0E6-2.3x1 0E6 cells in the form of TILs,
were used.
b.Amount of Detection Molecule: As described in example 1-6
c . Conditions: Samples and Detection Molecules were treated as described
in example 1-2 and 5-6.
Enrichment of MHC molecules with desired characteristics: The Detection
Molecules were enriched for in the same way as described in example 1-6.
Identification of enriched Detection Molecules: Because the Detection
Molecules were enriched based on specific interaction of the Binding Molecule
(the pMHC) with cells, the identification of the associated Labels (DNA-
barcodes) amongst the sorted cells would also reveal the pMHCs that had
bound to cells in the TIL sample. In this example the DNA-barcodes associated
with the enriched Detection Molecules, were amplified by PCR and identified by
high-throughput sequencing.
Apply. The sorted cell samples which contained DNA-barcodes derived
from the enriched Detection Molecules were amplified by PCR. See
table table 10 for composition of the PCR and table 11 for the thermal
profile. The Taq PCR Master Mix Kit (Qiagen, #201443) was applied
and PCR was run on the thermal cycler: GeneAmp, PCR System 9700
(Applied Biosystem). PCR products were visualized after gel
electrophoresis on a Bio-Rad Gel Doc EZ Imager. DNA was sequenced
using the Ion Torrent PGM platform (Life Technologies)
i . Primers were purchased from DNA Technology (Denmark) and
delivered as lyophilized powder. Stock dilutions of 100 µΜ
were made in nuclease free water and stored at -20 °C. The
primers included adaptors for Ion Torrent sequencing, i.e. an
A-key and a P1-key on the forward and reverse primer
respectively. Additionally the forward primers had unique DNA
sequences besides the primer region and the A-key. These
primers were used to assign DNA-barcodes derived from the
same sample with a sample-identification sequence (Sample-
ID barcode) (refer to table 13 for primer sequences). This
enabled distribution of DNA-barcode sequence reads
according to their originating sample, when DNA-barcodes
from multiple samples were sequenced in the same
sequencing reaction (see figure 9 for a schematic presentation
of the primer design). If > 10.000 cells were sorted in the
enrichment step, only a volume corresponding to 10.000 cells
were applied as template in the PCR. To further examine the
potential impact on the number of cells selected with
associated Detection moleclues, we included Enriched
Detection Molecules derived from one sample (sample 8)
multiple times, so that triplicate PCRs were run with equivalent
to 10.000 sorted cells and 100 sorted cells respectively.
Moreover a single PCR was run with 1000 cells from the same
sample. The non-enriched library of the 175 different Detection
Molecules (diluted 10.000x after being reduced in volume)
were also assigned with a sample-ID barcode through PCR
(referred to as the Detection Molecule-input). Triplicate PCRs
were run with the Detection Molecule-input. Information about
the distribution of Labels within the library of Detection
Molecules before enrichment would allow normalization of the
sequence output. Pooled PCR products derived from the
Detection Molecule-input and from multiple incubations of
Detection Molecule and sample were separated according to
size, by gel-electrophoresis, and the excised gel-fragment
containing DNA-fragments of -200 bp were purified with the
QIAquick PCR Purification Kit (Qiagen, #281 04) according to
standard procedure.
ii. The purified DNA was sequenced by Amplexa (Denmark) on
an Ion Torrent PGM 314 chip
b.Analysis. Positive sequence reads were aligned to sequences that read
from the sample-barcode-identity at the 5'-end all the way through the
DNA-barcode-identity. The number of reads was normalized according
to the total number of reads that mapped to the same sample-ID
barcode and according to the Detection Molecule input reads. The
Analysis was essentially as in example 4 and 6 except that the database
of 20S sequences was expanded to include the new 175 Labels and
sequences were mapped according to corresponding 20S DNA-
barcodes.
i . Mapping sequencing reads to 20S DNA-barcodes: A
sequence database was created consisting of the possible
combinations of 20 sample-identification barcodes and 192
20S DNA barcodes (together with the primer and annealing
sequences from the 20S system). This accumulated to 3840
sequences that could be expected from a sequencing run.
Each sequencing read was then used to search the database
for alignments, using the nucleotide BLAST algorithm, with a
match reward of 1, mismatch reward of -2 and a gap cost of 2
for both opening and extending a gap. In this way sequencing
errors were penalized equally, whether a base was miscalled
or inserted/deleted in the sequencing read compared to the
actual sequence. Alignments were discarded by the following
criteria:
1. E-value > 1e-1 2 ; insufficient length of alignment (should
be greater than 102 for the 20S barcodes).
2 . Start position in subject sequence larger than 2 , i.e. fewer
than 5 out of 6 bases in the unique part of the sample-
identification barcode was included in the alignment.
If multiple alignments could still be found for any sequencing
read, only the alignment with the best percent identity was
kept. Finally, the number of reads mapping to each DNA
barcode in the database was counted.
Identifying overrepresented DNA barcodes: Two amendments
of the analysis performed in example 4 and 6 (as well as 3 and
5 in respect to the 10S label system) were introduced:
a . The N6 sequence (figure 9) were applied to reduce the
clonality of the amplification product to avoid potential
biases derived from amplification of enriched 20S
sequence Labels.
i . Any repetitive reads that would share a N6 and
map to a given sample-ID all through the 20S
barcode region were virtually removed ensuring
that this sequence was only accounted for once.
b. The sequencing data was reanalyzed after virtual
removal of the most high-frequent sequences. This
ensured that potential biases derived from high-
percentage enrichment of a given Detection Molecule,
resulting in large read counts from the associated 20S
sequence Label, would not mask the presence of lower
percentages yet enriched Detection Molecules.
Collectively this strategy is termed clonality reduction.
Relative read counts were calculated by normalizing each read
to the total read count mapping to the same sample- ID
barcode. The relative read counts were then used to calculate
the fold change per DNA-barcode compared to the control
DNA-barcode Detection Molecule input (the non-enriched
Detection Molecule library). Significantly overrepresented DNA-
barcodes were identified using a 2-sample test for equality of
proportions on the raw read counts in a sample versus the
DNA-barcode input-sample, and p-values were corrected for
multiple testing using the Benjamini-Hochberg FDR method.
The algorithm applied for this analysis is available at:
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Example 7 - Results and conclusions
FACS sorting of fluorescent labeled cells, specific amplification of DNA-barcode Labels
and high-throughput sequencing verified that it was possible to enrich and detect 20S
barcodes from a library of multiple different Detection molecules composed of 175
different 20S DNA-barcode Labels encoding for 175 different cancer-specificities
(figure 16). It implied that several DNA-barcodes, encoding different antigen
specificities, could be enriched for and detected in parallel, also when the samples, as
in the present example, were TILs that on average has a lower avidity of their TCR to
their pMHC antigen. The results indicated that the presence of multiple cancer-specific
T cell responses could be detected in parallel in a sample.
This example implies that it is possible to detect several cancer-specific T cell
responses in parallel when applying a library of Detection molecules of increasing
complexity.
Example 8
In this example 1025 different binding molecules are used in the form of pMHC
complexes (each with DNA labels).
The sample is a mixture of two different blood samples, the isolating and/or detecting is
done by flow cytometry and the determining of the identity of the label is done by
sequencing the DNA label.
Example 8 explained
This example is essentially the same as example 4 but will apply a larger Detection
Molecule library ( 1025) and will include a greater number of different HLA-types ( 1 1) to
analyze the same samples.
This is an example where the Samples (1) are blood from one donor that is HLA-
B0702:CMV pp65 TPR positive and another donor that is HLA-B0702 negative which
are modified (1b) to generate Peripheral blood mononuclear cells (PBMCs). These
samples are mixed in different ratios to generate new samples with different but known
frequencies of T cells specific toward the HLA-B0702:CMV epitope.
The Linker (2) is a dextran conjugate with streptavidin and fluorochrome (Dextramer
backbone from Immudex).
The Binding Molecules (3) are peptide-MHC (pMHC) complexes displaying one out of
1025 different peptide-antigens. The MHC molecules are modified (3b) by biotinylation
to provide a biotin capture-tag for the Linker. The binding molecules are purified (2c) by
HPLC and quality controlled in terms of the formation of functional pMHC multimers for
staining of control T-cell populations.
The Labels (4) are oligonucleotides applied as DNA-barcodes. The oligonucleotides
are synthetized (4a) by DNA Technology A/S (Denmark) and are synthetically modified
(4b) with a terminal biotin capture-tag. The labels are combined oligonucleotide labels
arising by annealing an A oligonucleotide (modified with biotin) to a partially
complimentary B oligonucleotide label followed by enzymatic DNA polymerase
extension of Oligo A and Oligo B to create a fully double stranded label.
The Detection Molecule (5) is synthetized (5a) by attaching Binding Molecules in the
form of biotinylated pMHC and Labels in the form of biotin-modified oligonucleotides
(DNA-barcodes) onto a streptavidin-modified dextran linker. The detection molecule
further contains a modification (5b) in the form of a fluorochrome. A library of 1025
different Detection Molecules are generated wherein individual Binding Molecules,
comprised of different pMHC, are encoded for by corresponding individual Labels,
comprised of different DNA-barcodes.
An amount of sample, PBMC's ( 1b) is incubated with an amount of mixed Detection
Molecules (5) under conditions (6c) allowing binding of Detection Molecules to T cells
in the sample.
The cell-bound Detection Molecules are separated from the non-cell bound Detection
Molecules (7) by first a few rounds of washing the PBMC's through centrifugation
sedimentation of cells and resuspension in wash buffer followed by Fluorescence
Activated Cell Sorting (FACS) of fluorochrome labeled cells. T cells that can efficiently
bind Detection Molecules will fluoresce because of the fluorochrome comprised within
the detection molecules; T cells that cannot bind detection molecules will not fluoresce.
FACS-sorting leads to enrichment of fluorescent cells, and hence, enrichment of the
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detection molecules along with the associated labels that bind T cells of the PBMC
sample.
FACS isolated cells are subjected to PCR for specific amplification of the DNA-barcode
associated with the Detection Molecules bound to the isolated cells. High throughput
sequencing of the resultant PCR product will reveal the identity of Detection Molecules
that binds to T cells present in the sample.
This example will reveal the presence of T cells in the blood expressing a T cell
receptor that binds to pMHC molecules represented within the library of 1025 Detection
Molecules. The number of sequencing reads that will map to a given DNA-barcode and
its corresponding Binding Molecule will mirror the frequency of the T cells found by
conventional MHC multimer stainings using the same Binding Molecules. The
increased complexity of the Detection Molecule library, in terms of the number of
different Binding Molecules and Labels, will reflect positively upon the sensitivity for
detecting a given Label, i.e. a Detection Molecule, associated with low frequencies of T
cells binding such Detection Molecules.
ample 8 in detail
Sample preparation. The cell samples used in this example are obtained by
preparing PBMC's from blood drawn from one donor that is HLA-B0702:CMV
pp65 TPR positive and from another donor that is HLA-B0702 negative, as
determined by conventional pMHC-multimer and antibody staining. They are
acquired (a.) and modified (b.) in the same way as described in example 3-4.
Linker preparation: The linker used in this example is prepared as in example
1-7.
Binding Molecules preparation: The Binding Molecules used in this example are
class I MHC-peptide complexes. The individual specificities (allele and peptide
combination) are generated as described in example 1-7. A library of 1025
different pMHCs are generated including 11 different HLA-types.
a . Synthesis: As described in example 1-7
b. Modification: No further modifications
c . Purification: As described in example 1-7
Label preparation: In this example Labels are synthetic oligonucleotides
modified with biotin for coupling to the Linker. 1025 different Labels from the
20S system were applied (table 2).
a . Synthesis: As described in example 1.
i . The Label system used in this example is named 20S and was
developed to increase the complexity of a limited number of
oligonucleotide sequences. This is enabled by applying a
combinatorial strategy where two partially complementary
oligonucleotides (an A oligonucleotide with a 5' biotin tag and a
B oligonucleotide) are annealed and then elongated to produce
new unique oligonucleotide-sequences (AxBy) which are
applied as a DNA-barcodes (Labels) (figure 2). By combining
22 unique oligonucleotide-sequences (A label precursor) that
are all partly complementary to 55 other unique oligonucleotide
sequences (B label precursor) a combinatorial library of 1210
different (AxBy) Labels are produced. Only 1025 of these
Labels are used in this example.
b. Modification: As described in example 1-7.
c . Purification: As described in example 1-7.
Detection Molecules preparation: 1025 different Detection Molecules are
generated, each with a different Binding Molecule encoded by a unique Label.
The Binding Molecules (pMHCs) and Labels (20S DNA-barcodes) are attached
to the Linker (dextran-streptavidin-PE conjugate), to form Detection Molecules,
in such a way that a given pMHC is always attached to a given DNA-barcode.
a . Detection Molecules are essentially generated in the same way as
described in example 1-7. The given combination of Label (20S DNA-
barcode) and Binding Molecule (pMHC) of each Detection Molecule are
registered.
b. Modification: Since the total volume of 1025 pooled Detection Molecules
exceeds 100 µ Ι this volume is reduced to reach a desired concentration
of specific Binding Molecules. This is done as described in example 2-7.
c . Purification: As described in example 1-7.
Incubation of sample and Detection Molecules: The cell sample and the
Detection Molecules are mixed in one container to allow Detection Molecules to
bind to T cells.
a . Amount of sample: Samples are equivalent to those used in example 3 -
4 .
b.Amount of Detection Molecule: As described in example 1-7
c . Conditions: Samples and Detection Molecules are treated under the
same conditions as described in example 3-4.
Enrichment of MHC molecules with desired characteristics: The Detection
Molecules are enriched for in the same way as described in example 1-7.
Identification of enriched Detection Molecules: Because the Detection
Molecules are enriched based on specific interaction of the Binding Molecule
(the pMHC) with cells, the identification of the associated Labels (DNA-
barcodes) amongst the sorted cells will also reveal the pMHCs that bind to cells
in the PBMC sample. In this example the DNA-barcodes associated with the
enriched Detection Molecules, are amplified by PCR and identified by high-
throughput sequencing.
a . Apply. The sorted cell samples which contain DNA-barcodes derived from
the enriched Detection Molecules are amplified by PCR. See table table
10 for composition of the PCR and table 11 for the thermal profile. The
Taq PCR Master Mix Kit (Qiagen, #201443) is applied and PCR is run
on the thermal cycler: GeneAmp, PCR System 9700 (Applied
Biosystem). PCR products are visualized after gel electrophoresis on a
Bio-Rad Gel Doc EZ Imager. DNA is sequenced using the Ion Torrent
PGM platform (Life Technologies)
i . Primers are purchased from DNA Technology (Denmark) and
delivered as lyophilized powder. Stock dilutions of 100 µΜ are
made in nuclease free water and stored at -20 °C. The primers
include adaptors for Ion Torrent sequencing, i.e. an A-key and
a P1-key on the forward and reverse primer respectively.
Additionally the forward primers have unique DNA sequences
besides the primer region and the A-key. These primers are
used to assign DNA-barcodes derived from the same sample
with a sample-identification sequence (Sample-ID barcode)
(refer to table 13 for primer sequences). This enables
distribution of DNA-barcode sequence reads according to their
originating sample, when DNA-barcodes from multiple samples
are sequenced in the same sequencing reaction (see figure 9
for a schematic presentation of the primer design). The non-
enriched library of the 1025 different Detection Molecules
(diluted 100.000x after being reduced in volume) are also
assigned with a sample-ID barcode through PCR (referred to
as the Detection Molecule input). Triplicate PCRs are run with
the Detection Molecule-input. Information about the distribution
of Labels within the library of Detection Molecules before
enrichment will allow normalization of the sequence output.
Pooled PCR products derived from the sample input and from
multiple incubations of Detection Molecule and sample are
separated according to size, by gel-electrophoresis, and the
excised gel-fragment containing DNA-fragments of -200 bp
are purified with the QIAquick PCR Purification Kit (Qiagen,
#281 04) according to standard procedure
ii. The purified DNA was sequenced on an Ion Torrent PGM 314
chip.
b.Analysis. Positive sequence reads are aligned to sequences that read
from the sample-barcode-identity at the 5'-end all the way through the
DNA-barcode-identity. The number of reads is normalized according to
the total number of reads that maps to the same sample-ID barcode and
according to the Detection Molecule input reads. The Analysis is
essentially as in example 7 except that the database of 20S sequences
now includes 1025 Labels and sequences are mapped according to
corresponding 20S DNA-barcodes.
i . Mapping sequencing reads to 20S DNA-barcodes: A
sequence database is created consisting of the possible
combinations of 10 sample-identification barcodes and 1025
20S DNA barcodes (together with the primer and annealing
sequences from the 20S system). This accumulates to 10250
sequences that can be expected from a sequencing run. Each
sequencing read is then used to search the database for
alignments, using the nucleotide BLAST algorithm, with a
match reward of 1, mismatch reward of -2 and a gap cost of 2
for both opening and extending a gap. In this way sequencing
errors are penalized equally, whether a base was miscalled or
inserted/deleted in the sequencing read compared to the actual
sequence. Alignments are discarded by the following criteria:
1. E-value > 1e-1 2 ; insufficient length of alignment (should
be greater than 102 for the 20S barcodes).
2 . Start position in subject sequence larger than 2 , i.e. fewer
than 5 out of 6 bases in the unique part of the sample-
identification barcode was included in the alignment.
If multiple alignments can still be found for any sequencing
read, only the alignment with the best percent identity is kept.
Finally, the number of reads mapping to each DNA barcode in
the database is counted.
ii. Identifying overrepresented DNA barcodes: Is essentially
performed as described in example 7 with the strategy of
applying clonality reduction.
Relative read counts are calculated by normalizing each read
to the total read count mapping to the same sample- ID
barcode. The relative read counts are then used to calculate
the fold change per DNA-barcode compared to the control
DNA-barcode Detection Molecule input (the non-enriched
Detection Molecule library). Significantly overrepresented DNA-
barcodes are identified using a 2-sample test for equality of
proportions on the raw read counts in a sample versus the
DNA-barcode input-sample, and p-values are corrected for
multiple testing using the Benjamini-Hochberg FDR method.
The algorithm applied for this analysis is available at:
hi :/ A bs /services/Eiarracoda/
Example 8 - Results and conclusions
The expected outcome of this example is knowledge on the sensitivity for detecting
antigen-specific T cell responses of decreasing frequency (<0.002% of CD8 T cells) in
a number of similar samples. The sensitivity will expectantly increase with increasing
numbers of Detection molecules incubated with a given sample, because any
sequencing reads that are caused by background will be distributed on a greater
number of Labels, in this example 1025.
Example 9
In this example 1025 different pMHC complexes, comprising 11 different HLA-alleles,
are used as binding molecules. The sample is a mixture of blood from 10 different
donors.
Example 9 explained
This example is essentially the same as example 6 but a greater number of samples
(10) will be analyzed with a larger Detection Molecule library (1025), which will include
a greater number of different HLA-types ( 1 1).
This is an example where the Samples ( 1) are blood from 10 different donors with
different HLA-types which are modified ( 1b) to generate Peripheral blood mononuclear
cells (PBMCs).
The Linker (2) is a dextran conjugate with streptavidin and fluorochrome (Dextramer
backbone from Immudex).
The Binding Molecules (3) are peptide-MHC (pMHC) complexes displaying one out of
1025 different peptide-antigens. The MHC molecules are modified (3b) by biotinylation
to provide a biotin capture-tag for the Linker. The binding molecules are purified (2c) by
HPLC and quality controlled in terms of the formation of functional pMHC multimers for
staining of control T-cell populations.
The Labels (4) are oligonucleotides applied as DNA-barcodes. The oligonucleotides
are synthetized (4a) by DNA Technology A/S (Denmark) and are synthetically modified
(4b) with a terminal biotin capture-tag. The labels are combined oligonucleotide labels
arising by annealing an A oligonucleotide (modified with biotin) to a partially
complimentary B oligonucleotide label followed by enzymatic DNA polymerase
extension of Oligo A and Oligo B to create a fully double stranded label.
The Detection Molecule (5) is synthetized (5a) by attaching Binding Molecules in the
form of biotinylated pMHC and Labels in the form of biotin-modified oligonucleotides
(DNA-barcodes) onto a streptavidin-modified dextran linker. The detection molecule
further contains a modification (5b) in the form of a fluorochrome. A library of 1025
different Detection Molecules are generated wherein individual Binding Molecules,
comprised of different pMHC, are encoded for by corresponding individual Labels,
comprised of different DNA-barcodes.
An amount of sample, PBMC's ( 1b) is incubated with an amount of mixed Detection
Molecules (5) under conditions (6c) allowing binding of Detection Molecules to T cells
in the sample.
The cell-bound Detection Molecules are separated from the non-cell bound Detection
Molecules (7) by first a few rounds of washing the PBMC's through centrifugation
sedimentation of cells and resuspension in wash buffer followed by Fluorescence
Activated Cell Sorting (FACS) of fluorochrome labeled cells. T cells that can efficiently
bind Detection Molecules will fluoresce because of the fluorochrome comprised within
the detection molecules; T cells that cannot bind detection molecules will not fluoresce.
FACS-sorting leads to enrichment of fluorescent cells, and hence, enrichment of the
detection molecules along with the associated labels that bind T cells of the PBMC
sample.
FACS isolated cells are subjected to PCR for specific amplification of the DNA-barcode
associated with the Detection Molecules bound to the isolated cells. High throughput
sequencing of the resultant PCR product will reveal the identity of Detection Molecules
that binds to T cells present in the sample.
This example will reveal the presence of T cells in the blood expressing a T cell
receptor that binds to pMHC molecules represented within the library of 1025 Detection
Molecules. The number of sequencing reads that will map to a given DNA-barcode and
its corresponding Binding Molecule will mirror the frequency of the T cells found by
conventional MHC multimer stainings using the same Binding Molecules. The
increased complexity of the Detection Molecule library, in terms of the number of
different Binding Molecules and Labels, will enable detection of T cells of 1025 different
T cell receptor specificities in parallel and will reflect positively upon the sensitivity for
detecting a given Label, i.e. a Detection Molecule, associated with low frequencies of T
cells binding such Detection Molecules.
Example 9 in detail
1. Sample preparation. The cell samples used in this example are obtained by
preparing PBMC's from blood drawn from 10 different donors with a number of
different peptide-antigen responsive T cells, as determined by conventional
pMHC-multimer.
a . Acquiring sample: Blood is obtained from the Danish Blood Bank.
b. Modifying sample: PBMCs are isolated from whole blood as described in
example 1-2, 5-6.
2 . Linker preparation: The linker used in this example is prepared as in example
1-7 and example 8 .
Binding Molecules preparation: The Binding Molecules used in this example are
class I MHC-peptide complexes. The individual specificities (allele and peptide
combination) are generated as described in example 1-7 and example 8 . A
library of 1025 different pMHCs are generated including 10 different HLA-types.
a . Synthesis: As described in example 1-7 and example 8 .
b. Modification: No further modifications
c . Purification: As described in example 1-7 and example 8 .
Label preparation: In this example Labels are synthetic oligonucleotides
modified with biotin for coupling to the Linker. 1025 different Labels from the
20S system were applied (table 2).
a . Synthesis: As described in example 1.
i . The Label system used in this example is named 20S and was
developed to increase the complexity of a limited number of
oligonucleotide sequences. This is enabled by applying a
combinatorial strategy where two partially complementary
oligonucleotides (an A oligonucleotide with a 5' biotin tag and a
B oligonucleotide) are annealed and then elongated to produce
new unique oligonucleotide-sequences (AxBy) which are
applied as a DNA-barcodes (Labels) (figure 9). By combining
22 unique oligonucleotide-sequences (A label precursor) that
are all partly complementary to 55 other unique oligonucleotide
sequences (B label precursor) a combinatorial library of 1210
different (AxBy) Labels are produced. Only 1025 of these
Labels are used in this example.
b. Modification: As described in example 1-7 and example 8 .
c . Purification: As described in example 1-7 and example 8 .
Detection Molecules preparation: 1025 different Detection Molecules are
generated, each with a different Binding Molecule encoded by a unique Label.
The Binding Molecules (pMHCs) and Labels (20S DNA-barcodes) are attached
to the Linker (dextran-streptavidin-PE conjugate), to form Detection Molecules,
in such a way that a given pMHC is always attached to a given DNA-barcode.
a . Detection Molecules are essentially generated in the same way as
described in example 1-7 and example 8 . The given combination of
Label (20S DNA-barcode) and Binding Molecule (pMHC) of each
Detection Molecule are registered.
b. Modification: Since the total volume of 1025 pooled Detection Molecules
exceeds 100 µ Ι this volume is reduced to reach a desired concentration
of specific Binding Molecules. This is done as described in example 2-7
and example 8 .
c . Purification: As described in example 1-7 and example 8 .
Incubation of sample and Detection Molecules: The cell sample and the
Detection Molecules are incubated in the same way as described in example 1-
2 , 5-7.The cell sample and the Detection Molecules are mixed in one container
to allow Detection Molecules to bind to T cells.
Enrichment of MHC molecules with desired characteristics: The Detection
Molecules are enriched for in the same way as described in example 1-7 and
example 8 .
Identification of enriched Detection Molecules: Because the Detection
Molecules are enriched based on specific interaction of the Binding Molecule
(the pMHC) with cells, the identification of the associated Labels (DNA-
barcodes) amongst the sorted cells will also reveal the pMHCs that bind to cells
in the PBMC sample. In this example the DNA-barcodes associated with the
enriched Detection Molecules, are amplified by PCR and identified by high-
throughput sequencing. The enriched Labels, of the 20S DNA-barcode system,
are identified as in example 8 .
Example 9 - Results and conclusions
The expected outcome of this example is knowledge of the potential complexity for
detecting multiple antigen-specific T cell responses in parallel in a single sample. Since
the sensitivity is expected to increase with increasing numbers of Detection molecules
incubated with a given sample (as described in example 8) it is expected that multiple
more T cell responses will also be detected in parallel when using a Detection molecule
library of the said complexity. The example will thus prove that it is possible to detect
multiple antigen-specific T cell responses in parallel when applying a Detection
molecule library comprised of 1025 different 20S Labels encoding 1025 different
Binding molecules distributed on 11 HLA-types.
Example 0
In this example it is shown how multiple, single-cell analyses can be rapidly performed
using the present invention. The isolating and/or detecting is done by FACS, leading to
the identification of a T cell and its TCR, as well as the pMHC complex that recognizes
the T cell by binding to the TCR.
Example 10 explained
This example will describe how the detection of Binding Molecules can be linked to the
T cell receptor (TCR) sequence following single cell sorting of T-cells associated with
Detection Molecules.
This is an example where the Sample (1) will be a mixture of T cells comprising TCRs
of interest. This could e.g. be tumor infiltrating lymphocytes from a cancer patient.
The Linker (2) is a dextran conjugate with streptavidin and fluorochrome (Dextramer
backbone from Immudex).
The Binding Molecules (3) is peptide-MHC (pMHC) complexes displaying a of library
peptides that are potentially recognized by the T cells in the Sample. This could be a
library of melanoma-associated peptides, as used in example 7 , or it could be a library
of personally-defined potential epitope sequences based on the characteristics of the
given patient ' s tumor. This could e.g. be mutation-derived T cell epitopes and/or
epitopes selected based on the expression pattern in the individual tumor. The Binding
Molecules will be modified (3b) by biotinylation and quality controlled as described in
example 1-6.
The Labels (4) are oligonucleotides as in example 7-9.
The detection molecule (5) will be synthetized (5a) and modified (5b) as in example 7-
9 .
An amount of Sample, Tumor infiltrating lymphocytes ( 1b) will be mixed with detection
molecules (5) under conditions (6c) that allow binding of detection molecules to T cells
in the sample.
Cells will be FACS sorted based on the attachment of Detection Molecules, transferred
to a FLUIDIGM C 1 unit (or similar devicde) for single-cell amplification of nucleotide
labels and T cell receptor genes.
This example thus reveals the possibility to identify, on a single-cell level, both the
antigen-specificity and the T cell receptor sequence. This being done in a mixture of
multiple different Binding Molecules (potentially, but not exclusively, > 1000). This
technology provides a mean for high-throughput identification of TCRs combined with a
description of the antigen specificity of the TCR.
Example 10 in detail
1. Sample preparation. The cell sample to be used in this example is a collection
of T cells with a recognition profile of interest for determining the sequences of
the TCRs associated with this recognition. The sample could e.g. be tumor
infiltration lymphocytes from a cancer patient. As described in example 7 .
c . Acquiring sample: As in example 7 .
d . Modifying sample: As in example 7 .
2 . Linker preparation: The linker used in this example is prepared as in example 1-
10.The fluorochrome co-attachment is important for the selection process in the
example.
3 . Binding molecule preparation: The binding molecules used in this example will
be a collection of peptide-MHC molecules, designed to match the T cell
reactivity in the sample. This could be a library of melanoma-associated
peptides, as used in example 7 , or it could be a library of personally-defined
potential epitope sequences based on the characteristics of the given patient ' s
tumor. This could e.g. be mutation-derived T cell epitopes and/or epitopes
selected based on the expression pattern if the individual tumor
a . Synthesis: as in example 7-9.
b. Modification: No further modifications
c . Purification: as in example 7-9.
4 . Label preparation: as in example 7-9.
5 . Detection Molecules preparation: multiple (<1 000) different Detection Molecules
are generated, each with a different Binding Molecule encoded by a unique
Label. The Binding Molecules (pMHCs) and Labels (20S DNA-barcodes) are
attached to the Linker (dextran-streptavidin-PE conjugate), to form Detection
Molecules, in such a way that a given pMHC is always attached to a given
DNA-barcode.
a . Detection Molecules are essentially generated in the same way as
described in example 1-8.
b. Modification: Since the total volume of >1000 pooled Detection Molecules
exceeds 100 µ Ι this volume is reduced to reach a desired concentration
of specific Binding Molecules. This is done as described in example 2-8.
c . Purification: As described in example 1-8.
6 . Incubation of sample and Detection Molecules: The cell sample and the
Detection Molecules are incubated in the same way as described in example 1-
2 , 5-7.The cell sample and the Detection Molecules are mixed in one container
to allow Detection Molecules to bind to T cells
7 . Enrichment of MHC molecules with desired characteristics: The Detection
Molecules are enriched for in the same way as described in example 1-7. Cells
associated with Detection Molecules are sorted by FACS, through means of the
PE-fluorescence signal. The population of cells holding Detection Molecules are
following injected to the FLUIDIGM C 1 unit allowing for single cell distribution in
a micro-well system. Other similar devices or platforms for single cell
amplification can also be used.
8 . Identification of enriched Detection Molecules: For each cell in the FLUIDIGM
C 1 unit we will amplify a) the label (= DNA oiligonucleotide barcode) and b) the
TCR V-alpha and -beta chains. In each well specific primers holding cell
identification keys, will be used to amplify DNA oligonucleotide Label. Likewise
specific primers holding cell identification keys will be used to amplify the TCR-
associate genes, the TCR V-alpha and Beta chains. The complete sequence of
the TCR chains will allow the assembly of a fully functional TCR sequence. In
parallel knowledge about the Binding Molecules associated with the given T
cell, will provide insight o the antigen recognition of the given TCR. Thus we
can obtain paired samples of TCR sequences and antigen specificities, using
the strategy explained in this example.
Example 10 - Results and conclusions
The expected outcome of this example is knowledge of the TCR receptor coupled to
the knowledge of the recognition of Binding Molecules of this given TCR. Single-cell
sorting will enable the generation of a correctly paired and fully functional TCR. The
association of the labels will explain the recognition motif of this T cell receptor and
provide valuable information in this regard. The technique described here will allow the
parallel assessment of multiple different T cells while enabling the capture of specific T
cells receptor sequences and have paired knowledge about the Binding molecules
associated to this. The overall principle of example 10 is schematized in figure 6C.
Example 11
In this example all cells carry the same TCR (T cell receptor). A large number of
different pMHC complexes (binding molecules) are employed, in order to examine the
recognition breadth and affinity of a given T cell receptor (TCR).
Example 11 explained
This example describes how the detection of Binding Molecules can be used to
determine the recognition breadth and affinity of a given T cell receptor (TCR).
This is an example where the Sample (1) is a T cell clone or a culture of T cell receptor
transduced T cells. Importantly for this example all cells will hold the same T cell
receptor.
The Linker (2) was a dextran conjugate with streptavidin and fluorochrome (Dextramer
backbone from Immudex).
The Binding Molecules (3) will be peptide-MHC (pMHC) complexes displaying a library
of peptides that are potentially recognized by the T cell receptor in question. This could
ideally be a set of alanine-scanning substituted peptides modified based on the known
recognition sequence of the T cell receptor in question. The Binding Molecules will be
modified (3b) by biotinylation and quality controlled as described in example 1-6.
The Labels (4) are oligonucleotides as in example 7-9.
The detection molecule (5) will be synthetized (5a) and modified (5b) as in example 7-
9 . Multiple different detection molecules will be generated wherein the individual
detection molecules containing different pMHC were encoded by corresponding
individual oligonucleotide labels, as in example 7-9.
An amount of Sample, T cell clone (1b) will be mixed with detection molecules (5)
under conditions (6c) that allow binding of detection molecules to the T cells in the
sample.
Cells will be washed to remove excess Detection Molecules, and following the identity
of the Binding Molecules will be revealed through sequencing of the Label.
This example thus reveals the possibility to identify the specificity and breadth of
specificity of a given T cell receptor. This knowledge is essential for the development of
T cell receptor gene therapy strategies, and adoptive transfer of T cell population
carrying specific T cell receptors.
Example 11 in detail
Sample preparation. The cell sample to be used in this example is a T cell clone
(carrying a single, defined T cell receptor) or a culture of T cells transduced with
a given T cell receptor.
e.Acquiring sample: Any PBMC sample can be used as a source to
transduce the T cells with a characterized T cell receptor (TCR),
expressed in a retroviral vector.
f . Modifying sample: PBMCs modified to express a given TCR following
retroviral transduction using a vector expressing the selected TCR.
Linker preparation: The linker used in this example is prepared as in example 1-
10-The fluorochrome has no particular use in this example. Consequently, the
fluorochrome attachment is not needed.
Binding molecule preparation: The binding molecules used in this example will
be a collection of peptide-MHC molecules, designed to assess the breadth to
recognition of the given TCR. The peptide library could be alanine substitution
libraries of the known peptide-epitope recognized by the given TCR. Alanine
substitution is used to assess the essential amino acids in given positions
important for TCR recognition.
a . Synthesis: as in example 7-9.
b. Modification: No further modifications
c . Purification: as in example 7-9.
Label preparation: as in example 7-9.
Detection molecules preparation: as in example 7-9.
Incubation of sample and detection molecules: The cell sample and the
Detection Molecules were mixed in one container, to allow the Detection
Molecules to bind the T cells that they recognize.
a . Amount of sample: 100.000 cells expressing a given TCR
b.Amount of detection molecule: as in example 7-9.
c . Conditions: The 100.000 cells will be mixed with different quantities of
Detection Molecules. This being the standard amount of detection
molecules as given in example 7-9, but with parallel detection analysis
using e.g. 5x excess for Detection molecules, as well as 5x, 25x, 125x
fold less Detection Molecules. Such titration is done to assess the
avidity of the selected TCR towards the Binding Molecule library used.
Enrichment of detection molecules with desired characteristics: In this example,
excess Detection molecules are separated from Sample through centrifugation.
All cells are expected to bind Detection molecules to some extent, and
consequently all cells are used for characterization of Binding Molecules.
8 . Identification of enriched Detection Molecules: The identification of Detection
Molecules and analyses of sequencing results is conducted as described in
example 7 .
Example 11 - Results and conclusions
The expected outcome of this example is knowledge related to the Detection molecules
associated with a given T cell receptor. Through this technology we can gain
knowledge on the breadth and the avidity of a given TCR towards a large library of
similar, overlapping and/ or alanine substituted peptide-epitope sequences. The
technique can be used to understand both avidity and 'fine-specificity' of a given TCR.
This will be of crucial importance for development of TCR receptor-associated
therapies, such as TCR gene therapy in cancer treatment. The overall principle of
example 11 is schematized in figure 6D.
Example 2
In this example it is described how the present invention can be used to identify the
specificity of the stimuli that lead to a functional response of certain cells. In the
example, the external stimulus is the addition of tumor cells, and the functional
response measured is the release of INF-y.
Example 12 explained
This example will describe how the detection of Binding Molecules can be associated
to a functional response to a given stimuli provided to the Sample in vitro.
This is an example where the Sample (1) will be tumor infiltrating lymphocytes (TIL)
from cancer patients which are modified to determine the reactivity toward tumor cells
(1b). The Sample is mixed with tumor cells to allow cytokine release from responding T
cells in the Sample. The cytokines are trapped intracellular following Golgi-transport
blockade and cellular fixation.
The Linker (2) was a dextran conjugate with streptavidin and fluorochrome (Dextramer
backbone from Immudex).
The Binding Molecules (3) will be peptide-MHC (pMHC) complexes displaying a library
of melanoma-associated peptides (as described in Andersen et al. Dissection of T cell
antigen specificity in human melanoma. Cancer Research 20 2 Apr 1;72(7) : 642-50) , and
used in example 7 . The Binding Molecules will be modified (3b) by biotinylation and
quality controlled as described in example 1-6.
The Labels (4) were oligonucleotides as in example 7-9.
The detection molecule (5) will be synthetized (5a) and modified (5b) as in example 7-
9 . 175 different detection molecules were generated wherein the individual detection
molecules containing different pMHC were encoded by corresponding individual
oligonucleotide labels, as in example 7 .
An amount of Sample, TILs ( 1b) will mixed with detection molecules (5) under
conditions (6c) that allow binding of detection molecules to T cells in the sample.
Cells will be selected by FACS based on their cytokine release upon stimulation with
the tumor cells. After cellular selection, cells encompassing different cytokine profiles
will be analyzed for their binding to the Detection Molecules, consequently describing
the T cell receptor specificity of the responding T cells, i.e. T cells recognizing tumor
cells.
This example thus reveal the possibility to identify potential differences in T cell
specificity among cells responding differently to a given stimuli, here provided be the
mixture of T-cells with tumor cells.
Example 12 in detail
1. Sample preparation. The cell sample to be used in this example is tumor
infiltrating lymphocytes (TILs) obtained from melanoma patients (as example 7).
a .Acquiring sample: as in example 7 .
b Modifying sample: TILs will be purified and expanded as in example 7 .
Following, TILs will be mixed with tumor cell to assess cytokine release
upon T-cell mediated tumor cell recognition, using the following protocol
for intracellular cytokine staining: Tumor cells will be thawed, washed
twice in culture media (RPMI), and cultured in RPMI + 10% FCS (R10)
until they had expanded to a sufficient amount of cells. TILs will be
thawed in 10 ml RPMI + 2.5ul DNase and 50ul MgCI2, washed twice in
RPMI and rested overnight or at least 4 hr in X-vivo + 5% HS + 10OU/ml
IL-2. Following rest, the cells will be washed, counted and resuspended
in X-vivo + 5% HS obtaining a concentration of 3* 106 cells/ml. 10Oul of
the cell suspension will then be added to at least two wells in a 96 well
plate - more replicates will be made if enough cells are available. Thus
3* 105 cells will added to each well. Tumor cells will be trypsinated,
washed in R 10 , counted and resuspended in RPMI + 10% HS to a
concentration of 2* 106 cells/ml. 50ul of cell suspension containing 1* 105
cells will be added to the TILs. To every well, 50ul of Golgi medium,
containing 45ul RPMI + 10% HS, 5ul BV421 conjugated CD107a
antibody (BD pharmingen) and 0.2ul Golgi Plug (BD Bioscience 555029)
was added. The cells were then incubated 4-5 hours in 37 °C. All
samples were cultured in a ratio of 3:1 TILtumor cells, with a total of
4* 105 cells per well. After end incubation, the cells were spun and all
replicates were collected into one well. Cell will be washed in
PBS+2%FCS (FACS buffer) and resuspended in 50uL barcode-buffer
(PBS/0.5% BSA 2 mM EDTA/100 µ /η Ι herring DNA).
Linker preparation: The linker used in this example is prepared as in example 1-
8 . The fluorochrome has no particular use in this example. Consequently, the
fluorochrome attachment is not needed.
Binding molecule preparation: The binding molecules used in this example will
be 175 different class I MHC-peptide complexes, as in example 7 .
a . Synthesis: as in example 7 .
b. Modification: No further modifications
c . Purification: as in example 7 .
Label preparation: as in example 7 .
Detection molecules preparation: as in example 7 .
Incubation of sample and detection molecules: The cell sample and the
Detection Molecules were mixed in one container, to allow the Detection
Molecules to bind the T cells that they recognize.
a . Amount of sample: 50uL cell suspension as described in 1b.
b.Amount of detection molecule: as in example 7 .
c . Conditions: The Detection molecules were added in the required amount.
If necessary barcode-buffer was added to reach a total volume of 100 ul
and cells were incubated 15 min, 37^. Following incubation, cells were
and stained with the following surface antibodies: anti-CD3 antibody,
anti-CD8 antibody, anti-CD4 antibody and near-IR-viability dye
(Invitrogen L101 19). The cells were then incubated for 30 min at 4°C,
after which they were washed twice in barcode-buffer and incubated in
200ul fixation buffer ( 1 :4 concentrate, eBioscience 00-5123-43, to
diluent eBioscience 00-5223-56) overnight at 4°C. The following day,
cells were washed twice in permeabilization buffer ( 1 :10 buffer to water,
eBioscience 00-8333-56), resuspended in 50ul permeabilization buffer
and stained with intracellular antibodies: FITC-conjugated anti-TNF
antibody (BD pharmingen 562082), APC-conjugated anti-IFN antibody
(BD 341 117). After incubating for 30 min at 4°C with the antibodies, the
cells were washed twice in permeabilization buffer, resuspended in 50ul
barcode-buffer.
Enrichment of detection molecules with desired characteristics: In this Example,
the Sample is selected based on the cytokine secretion mediated following
incubation with tumor cells. Cytokines are visualized through intracellular
cytokine staining (ICS). The Sample is following stained with the Detection
Molecules. Cytokine producing cells will be selected by Fluorescence-Activated-
Cell-Sorting (FACS), and the Detection Molecules carried along with a given
cytokine profile of a given cell population will be assessed through sequencing
of the co-attached oligonucleotide barcodes
a .Apply: Cells were sorted on a BD FACSAria, equipped with three lasers
(488 nm blue, 633nm red and 405 violet). The flow cytometry data
analyses will be performed using the BD FACSDiva software version
6.1 .2. The following gating strategy will be applied. Lymphocytes were
identified in a FSC/SSC plot. Additional gating on single cells (FSC-
A/FSC-H), live cells (near-IR-viability dye negative), and CD8, CD3
positive cells, and CD4 negative.
From this defined cell population two separate subsets will be sorted
based ion the cytokine secretion in relation to tumor-cell stimulation. T
cells positive for any of the detected cytokines 'ICS positive' is sorted in
one tube, and T cells negative for any of the detected cytokines 'ICS
negative' is sorted in another tube .
b. Wash: not applicable.
c . Separate: Optionally cells were acquired up to one week after fixation in
1% paraformaldehyde. The 'ICS positive' and 'ICS negative' cells were
sorted by FACS, as described in 7a, into tubes that had been pre-
saturated for 2h-O.N. in 2% BSA and contained 200 µ Ι barcode-buffer to
increase the stability of the oligonucleotides that followed with the sorted
cells. The sorted cells were centrifuged 5 min, 5000 g , to allow removal
of all excess buffer. Cells were stored at -80 °C.
8 . Identification of enriched Detection Molecules: The identification of Detection
Molecules and analyses of sequencing results is conducted as described in
example 7 . The 'ICS positive' and 'ICS negative' cells are treated as two
independents samples. Following these two samples are compared for the
association with Binding Molecules.
Example 12 - Results and conclusions
The expected outcome of this examples is knowledge related to the Detection
molecules associated with tumor cell recognition (= 'ICS positive') as oppose to no
recognition (='ICS negative'). In other terms, we will gain knowledge on the T cell
recognition elements associated with tumor cell recognition, among a large pool of
different Detection Molecules, here peptide-MHC molecules. Knowledge of T cell
mediated recognition of tumor cells has major impact on the design and development
of immunotherapeutic strategies for cancer. The overall principle of example 12 is
schematized in figure 6A.
Cell could likewise be selected based on e.g. phenotypic characteristics, to assess
what T specificities are associated with selected phenotypic characteristics as
schematized in figure 6B.
Tables for Examples 1-12:
Table 1. BCs used in Examples 1-7 with indicated frequencies of peptide-antigen
specific T cells as identified by conventional MHC multimer staining:
Epitope Freq. (%)
BC171 A 11 EBV-EBNA4 0.32
A3 CMV pp1 50 TVY 0.015
BC254 A2 FLU MP 58-66 GIL 0.0522
A2 EBV LMP2 FLY 0.014
A2 CMV pp65 NLV 1. 1 28
BC261 A2 FLU MP 58-66 GIL 0.1 25
A3 EBV EBNA 3a RLR 0.0258
A2 EBV LMP2 FLY 0.0075
BC266 A 1 CMV pp65 YSE 0.0859
A 1 FLU BP-VSD 0.0628
BC268 A2 FLU MP 58-66 GIL 0.2523
A2 CMV pp65 NLV 0.5445
BC260 A2 FLU MP 58-66 GIL 0.0456
A2 CMV pp65 NLV 0.1 34
B7 CMV pp65 TPR 4.5395
BC262 A 11 EBV-EBNA4 0.0872
Table 2. Structure and sequences of 20S A oligonucleotides and 20S B
oligonucleotides, used to produce 20S DNA-barcodes:

Ar t ng
G TS S T ft AT rA C S S AATGATG GAC
CAA ATTGATTG S GA A SG S A GA TS GA
. G T G ATC T T CTC C GAT GS A i¾TS S TG.¾X
S T SA½ CA 6 G 6 GS AAft TS A S S A
Gra TTTTG ¾ T A G SGA¾ T AT TGA
A¾T G CAGT TG CGA ft TC GGA¾ATGATGCTGACC
G TS S T S GT AT TGTA :: SGAAATGATGCTGACC
TGAC T GG SS S T A I GA T S S A S A S - S AC
T GS TGAA¾ CS . G T T. GS AA G TG -&
A PS AS A CT T S GS AA TS B C S AiX
A ft S A SGA ATS TS T A
GC ft A GCA ft S A G A T S GA ATGATG GA
C AT G A¾ :TTSG iTAT CTS C 3 S A¾A GA GCT GAC
A S T TAI C T GAi¾ A C S S S A ATSATG TGA
ATGGCGC¾GACATTCiaTASTCSCA GGA¾ATGATGCTGACC
GACTS GS -S GA A T C S GAA A GA G GAC
TGT TT TTA S Aft T TTGG TC S G AA SA G GAC
A T A ¾ TC & " G S A ¾ S A G TG.i
SAAT TS GG CA GAGT GGA I S CTS
C S G S TA Aft CT ATTC GGAA TS TS ACC
2 S-I - ! ig -E4 i i A :& A t ! ! ·: i t
AS A .TTS T T S 3 G S TT AT A S A.¾ft AT £T¾
A T G S ATS CTTAA TA GT GQAAAISATSCTSACC
A A G- C A ¾A TS; TT . T S GAA T AT T A
ATT A : A A T5 S:S T ¾S S ¾A¾TGATG T AS
G . TT GTSSa T Ta S S-S.AA¾TGATGCTG
G A TAT S S STC A A GT T S S A S .ATS SA
f¾=;AAA! i - : A - ! ! - A TSATS S ¾
3 CT " GGATSTS 3 CT I S 3 AT GS A7 SA C
S STT .A¾ S 3 A ¾ T G GA AAT AT CTSA
.¾ S S& AA ¾TS A T CT A
¾ .¾ i¾ i¾ i ¾ S . .T AT& CT
AS T 3 A C ¾SA G A SC TT A SAA ATa AT T A
AT TSAGTTTS A T A A S A .ATS AT5 T A
¾G T i . TC T TTTST GS 5 ATS 7 A
A¾A TTTG T G S ST TA . I ATSAT CT SA C
AA ¾ AT S A AAT AT CTSA
S GS T I C a i TC TC G TA S AA TGA TG TGA
G TATS TA Afi CTS S G TS A S 3 * GATG TS
GG AS T A C GT &3 GAG T T G 3 A GAT5 GA €
A GA A GATT G G T. A GS A .AT5 AT5 € A
CA i¾T T ST A ¾T T T
CAC6TSTASCTGTSS6 :A CTA
CA TTS TCA ¾ T T S A G 3 ¾ S
ft iI . G T ATG CATTS 3 CTAJ¾ATG
GT T TG TCSTA GA T TCC T G A TG TS C S A
AG 3 SACSS :Gi 3T : A S S GAA T A A
CSG AATTT GG-STG €:A GT GA A A GA C
CCTTTA CT C AC A AA ST S GAAAT A CT SA
SATA TATA SAC S T T.AA TCS GGAA ¾T AT A
G GA S A T AT T
C T fi TT T 3 GGT 3 GTC GC GGAAATSATSCTSACC
A G; TT A S CA TS ATT G T
r r TTA CS S AGA A A A A TGAC
G TAT i iI S CSSG 6 AT TTGG. S GAA TGATG A
AT C TA ASTA T T C S S AA A G GA
Table 3 : The reagents used for annealing (left) and elongation (right) of partly
complementary oligonucleotides. Reagents marked in italic are from the
Sequenase Version 2.0 DNA
Annealing reaction (Ml) Elongation reaction (Ml)
Oligo A ( 100 µΜ) 2.6 Annealing reaction 10 µ Ι
Oligo B ( 100 µΜ) 5.4 0.1 M DTT 1 µ Ι
Sequenase reaction 2 H20 0.5 µ Ιbuffer
8x diluted
Total 10 Sequenase 2 µ Ι
polymerase
5x diluted Sequence 2 µ Ι
extension mixture
Total 15.5
Table 4 : Overview of reagents required for production of Binding Molecules
produced from 100 µg/ml pMHC exchange reaction. The amounts of Detection
Molecule used for staining 1x 106-2x1 06 cells in 100 µ Ι are also specified.
AmountExchanged pMHC/ul D-biotin End: pMHC perSA conjugate
staining
PE dex 1.32 µ Ι 12.6 µΜ 44 ug/ml 3 ul
Table 5 : The components of the antibody mixture added while Detection
Molecules are incubated with sample. The amount listed is for incubation of
1x1 06-2x1 06 cells in 100 ul.
Target Conjugate Amount (µ Ι) Source
CD8 PerCP 2 Invitrogen MHCD0831
CD4 FITC 1.25 BD bioscience 345768
CD14 FITC 3.1 3 BD bioscience 345784
CD16 FITC 6.25 BD bioscience 335035
CD19 FITC 2.50 BD bioscience 345776
CD40 FITC 1.56 Serotec MCA1590F 0
Table 6 : The Master mix applied for recovery of DNA-barcodes by QPCR. The
template was drawn from the residual fluid (5-9.25 ul) containing the sorted
cells. Nuclease free H2O was added to a final volume of 25 ul per PCR
Component Volume per sample (µ Ι)
Master mix 12.5
Probe/SYBR (10uM/100x) 0.25 (0.1 uM/1x)
Forward primer (5 uM) 1,5 (300 nM)
Reverse primer (5 uM) 1.5 (300 nM)
Template 5-9.25
Nuclease free H20 0-4.25
Total 25
Table 7 : The thermal profile applied for qPCR amplification of barcodes
associated with sorted cells.
Time No. of cycles
Temperature ( °C)
- 95 10 min 1
95 30 s
60 60 s 40
Table 8 : Structure and sequences of 1OS oligonucleotides applied as DNA
barcodes ( 1 OS-1 -Oligo-1 to 10S-1 -Oligo-1 10)
Coding region Reverse primer region
TATGAGGACGAATCTCCCGCTTATA GGTACGGCGCTATCATGTACTCATG
GGTCTTGACAAACGTGTGCTTGTAC GGTACGGCGCTATCATGTACTCATG
GTTTATCGGGCGTGGTGCTCGCATA GGTACGGCGCTATCATGTACTCATG
CCGATGTTGACGGACTAATCCTGAC GGTACGGCGCTATCATGTACTCATG
TAGTAGTTCAGACGCCGTTAAGCGC GGTACGGCGCTATCATGTACTCATG
CCGTACCTAGATACACTCAATTTGT GGTACGGCGCTATCATGTACTCATG
GGGG I I G I 11IA A I 1 AGGAA GGTACGGCGCTATCATGTACTCATG
TATCCCGTGAAGCTTGAGTGGAATC GGTACGGCGCTATCATGTACTCATG
CTGACGTGTGAGGCGCTAGAGCATA GGTACGGCGCTATCATGTACTCATG
GGTATGGCACGCCTAATCTGGACAC GGTACGGCGCTATCATGTACTCATG
GGATGCATGATCTAGGGCCTCGTCT GGTACGGCGCTATCATGTACTCATG
GAGGTCTTTCATGCGTATAGTCACA GGTACGGCGCTATCATGTACTCATG
GATTCAATATGTGTCGTCTATCCTC GGTACGGCGCTATCATGTACTCATG
GGTAACTGCGCATAGTTG GCTCTAT GGTACGGCGCTATCATGTACTCATG
GCGTTTAAGGTCACATCGCATGAAT GGTACGGCGCTATCATGTACTCATG
GCCCGGGAAGTGTGAGGATATACCC GGTACGGCGCTATCATGTACTCATG
GCTCTTAAAACTGGTATCACCTGAC GGTACGGCGCTATCATGTACTCATG
GGGTGGTTAGTGATTTGCCCGTCAC GGTACGGCGCTATCATGTACTCATG
10S-l-Oligo-19 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-20 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-21 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-22 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-23 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-24 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-25 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-26 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-27 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-28 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-29 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-30 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-31 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-32 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-33 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-34 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-35 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-36 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-37 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-38 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
TAGTTGGTGGGTTTCCCTACCGTGT GGTACGGCGCTATCATGTACTCATG
GGTACAGTAAGTGAGAATCCTCTCT GGTACGGCGCTATCATGTACTCATG
GGTTCTAAGTTTAGCGTAGCCGGTT GGTACGGCGCTATCATGTACTCATG
CTTTAGGTGGGTGCGATTGCCAGTT GGTACGGCGCTATCATGTACTCATG
GCCACCTTAACACGCGATGATATTG GGTACGGCGCTATCATGTACTCATG
GCTATTACGAGCGCTTGGATCCCGT GGTACGGCGCTATCATGTACTCATG
TATGTTGTGCCTTACGCCTCGATTA GGTACGGCGCTATCATGTACTCATG
TTAACCGAACTGACGGCCATCAAGG GGTACGGCGCTATCATGTACTCATG
GGGTACATGCGCCTTACTCCTTGTG GGTACGGCGCTATCATGTACTCATG
TTCTATTCTAAGCCGGCGGTCATAT GGTACGGCGCTATCATGTACTCATG
GCTTGATGCTTTACAAGATCGCGTT GGTACGGCGCTATCATGTACTCATG
TCCAAGTTAGCTTACTCCATGCCCC GGTACGGCGCTATCATGTACTCATG
AGAACTATTTCCTGGCTGTTACGCG GGTACGGCGCTATCATGTACTCATG
TCGGTTTCAAGGATGATCCGCGCTT GGTACGGCGCTATCATGTACTCATG
AGAGACTGCCCGACACATCTTAGTG GGTACGGCGCTATCATGTACTCATG
CTGTTAATTAGGCTCGGTCGGCCTA GGTACGGCGCTATCATGTACTCATG
AGGTAGTCCTATGCGGGCTTTCTCT GGTACGGCGCTATCATGTACTCATG
GGCTTGGACTATAGTCATCGCGTTT GGTACGGCGCTATCATGTACTCATG
CACTGTTTAACAAGCCCGTCAGTAG GGTACGGCGCTATCATGTACTCATG
ACGTCGTATTATACCCGCCATGGAA GGTACGGCGCTATCATGTACTCATG
10S-l-Oligo-39 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-40 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-41 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-42 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-43 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-44 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-45 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-46 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-47 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-48 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-49 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-50 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-51 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-52 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-53 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-54 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-55 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-56 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-57 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-58 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
TGCTTAATTTACGACCGATGCTGCG GGTACGGCGCTATCATGTACTCATG
TCCATAGATTTCTCCGTGAGTCTTT GGTACGGCGCTATCATGTACTCATG
GTGCCGCAGACATTGCATACGATAT GGTACGGCGCTATCATGTACTCATG
GCAGGTCCTAACCCGCAACCATTTA GGTACGGCGCTATCATGTACTCATG
TGCACCGTTCATATGTTATCGGGAC GGTACGGCGCTATCATGTACTCATG
AGAGACTTACACCCGTAGACGTCGG GGTACGGCGCTATCATGTACTCATG
ATAAAAGAAACCCTCCGCATTGTGT GGTACGGCGCTATCATGTACTCATG
GGTCCCATCCGAGCAGATTTGACTC GGTACGGCGCTATCATGTACTCATG
ATGAGCTGTCTCGAACCGAAGGCAC GGTACGGCGCTATCATGTACTCATG
TCGGGCGGTTCAACTTACTGGTAGA GGTACGGCGCTATCATGTACTCATG
GGGGAAATAACGGATGCGCTCTTGA GGTACGGCGCTATCATGTACTCATG
ACTTCTTCTCGGTCGCATGAGGCTG GGTACGGCGCTATCATGTACTCATG
GGATACATATACGCTCGTCGGGACT GGTACGGCGCTATCATGTACTCATG
CCGGGAAGTGTCATAACTTGAAGCG GGTACGGCGCTATCATGTACTCATG
CTCAGCCTGCCTCGCTTCTGATATT GGTACGGCGCTATCATGTACTCATG
AGGGCCAAGTCGACCTAGATGGCTA GGTACGGCGCTATCATGTACTCATG
GGTAGGGCTACTGTTATCCTCCGTC GGTACGGCGCTATCATGTACTCATG
CGTACGGCTGGAGAGCTGTATGTGG GGTACGGCGCTATCATGTACTCATG
ACAGGTTGTATTACTTCGCGCCTTG GGTACGGCGCTATCATGTACTCATG
CTGGGCTCATTACAAGTGTTGCATA GGTACGGCGCTATCATGTACTCATG
10S-l-Oligo-59 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-60 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-61 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-62 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-63 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-64 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-65 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-66 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-67 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-68 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-69 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-70 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-71 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-72 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-73 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-74 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-75 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-76 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-77 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-78 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
CTAAGTGGCGCCGATTGTTTGTCCA GGTACGGCGCTATCATGTACTCATG
IA IA I 111 GG GA GAGA GGTACGGCGCTATCATGTACTCATG
GCAATTTGCGCTTGTTCGGCATAGC GGTACGGCGCTATCATGTACTCATG
GAGTCGAATATCCACCACCGTATGG GGTACGGCGCTATCATGTACTCATG
TTGTGGTTTGGGTCCTCAGAGGAGA GGTACGGCGCTATCATGTACTCATG
GGTACCTAGTCTCGTAATCATAGGA GGTACGGCGCTATCATGTACTCATG
GCGGCATGATCTACCTTAAAGCTTG GGTACGGCGCTATCATGTACTCATG
CCGGCGCAGAAGTTTGAACGAAAAG GGTACGGCGCTATCATGTACTCATG
ATGCACTATTTTACGTATCCCGTGC GGTACGGCGCTATCATGTACTCATG
GATAGGGTGACTGCTTTCGCGTACA GGTACGGCGCTATCATGTACTCATG
TATCTGGTAGACATCTCGGCACAGA GGTACGGCGCTATCATGTACTCATG
TCGGGGTGCAATAATCACTAGTGCT GGTACGGCGCTATCATGTACTCATG
TAGTTCTGGCTATACACACTTCGGG GGTACGGCGCTATCATGTACTCATG
GCATAGAGTTACCCGATGGATTCGA GGTACGGCGCTATCATGTACTCATG
GTTCATGGTACAGGCTTCTTTACGG GGTACGGCGCTATCATGTACTCATG
GA I GGG GG I 11IGAG IA GGTACGGCGCTATCATGTACTCATG
ATTATTCGTGACCCAACTCATCAGG GGTACGGCGCTATCATGTACTCATG
CTGAATGGTGAATAATGCGTTCGCC GGTACGGCGCTATCATGTACTCATG
GCTATTAGTTGCTACCCCAAGAATC GGTACGGCGCTATCATGTACTCATG
AGAAAGTCTTGGATACACGGCCGGG GGTACGGCGCTATCATGTACTCATG
10S-l-Oligo-79 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-80 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-81 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-82 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-83 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-84 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-85 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-86 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-87 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-88 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-89 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-90 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-91 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-92 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-93 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-94 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-95 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-96 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-97 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
10S-l-Oligo-98 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
GTGTGTTCCTATGCACAATTTCATA GGTACGGCGCTATCATGTACTCATG
TACATGGTAGGGGTCTCCGAACCGT GGTACGGCGCTATCATGTACTCATG
TAGGGATAACTTTCCTCCCACTTGG GGTACGGCGCTATCATGTACTCATG
TCTGGTGTCTCACCCATGGGATGTC GGTACGGCGCTATCATGTACTCATG
1AACGA N CI G GGGA 111 G GGTACGGCGCTATCATGTACTCATG
CGAGCCTGGTTAGCGCCTACAAGAG GGTACGGCGCTATCATGTACTCATG
CGTAGTAAGATATGTAGTCCACGTC GGTACGGCGCTATCATGTACTCATG
TGTTAGTTGCCCCATATCTTTACGC GGTACGGCGCTATCATGTACTCATG
GCTGGATTGTGATTGTCCGGATCCG GGTACGGCGCTATCATGTACTCATG
GGGAGGACTGCGGTTCAGCTTACAA GGTACGGCGCTATCATGTACTCATG
GCGTAGGTCTAGTTCAGATTCTATA GGTACGGCGCTATCATGTACTCATG
GTCTACGTGGTTCTATACCATTCGG GGTACGGCGCTATCATGTACTCATG
AGGCTTTACTACAATGCGTGGGCTC GGTACGGCGCTATCATGTACTCATG
AGCTTGCTGTATGGGTCATGTTCCT GGTACGGCGCTATCATGTACTCATG
TGCTCTAAAGACGCGAGGACTACCT GGTACGGCGCTATCATGTACTCATG
TGTACATGTCATACTCAAGGCTTTA GGTACGGCGCTATCATGTACTCATG
TTGACATGTACGCCATTTGGGTCGC GGTACGGCGCTATCATGTACTCATG
GCAATTCAGTACGATCGTGTAGCGG GGTACGGCGCTATCATGTACTCATG
CGCTGTCCAAAGGTTCTTCGTAACG GGTACGGCGCTATCATGTACTCATG
TTAGACGAGCAGGTTTCTTGCCTAT GGTACGGCGCTATCATGTACTCATG
10S-l-Oligo-99 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-100 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-101 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-102 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-103 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-104 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-105 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-106 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-107 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-108 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-109 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
lOS-l-Oligo-110 Biotin-C6- AGATTCTATAAACTGTGCGGTCCTT NNNNNN
TCGTTTGGAGCCGTTCACACATGAA GGTACGGCGCTATCATGTACTCATG
CTGATCAACTTGCGCCCAGCGTTAT GGTACGGCGCTATCATGTACTCATG
GACGA IG I IG G I 11I GA IACGA GGTACGGCGCTATCATGTACTCATG
GGGTAGTCGTGAGGTGAACTCTTCC GGTACGGCGCTATCATGTACTCATG
AGCCATTTTACGATTCTATTCGATG GGTACGGCGCTATCATGTACTCATG
GTGGTTTATATAATCCCACCTCCTA GGTACGGCGCTATCATGTACTCATG
GCGAAGAACATCCCGGCATTTCATG GGTACGGCGCTATCATGTACTCATG
GCTGGGACAATGCCGAAAACTCTTC GGTACGGCGCTATCATGTACTCATG
ATTCCGTACCAACCCGCGTCTTAGA GGTACGGCGCTATCATGTACTCATG
CTGCAGGAGGCTCTAATGCACTCAA GGTACGGCGCTATCATGTACTCATG
GCGTTCAGCATTCATTACGTCTCAC GGTACGGCGCTATCATGTACTCATG
GCTGAGGAAGCCCAATGTTCAGTAC GGTACGGCGCTATCATGTACTCATG
Table 9. Listing of the 110 combinations of peptide-HLA Binding Molecules and
the respective Labels, 1OS and 2OS DNA-barcodes, that were used to encode
the given specificity of all Detection Molecules applied in experiments 3-6.
In the table, HLA code Ά 1' refers to HLA-A010 1 . HLA code Ά 2' refers to HLA-A0201 .
HLA code 'A3' refers to HLA-A0301 . HLA code Ά 11' refers to HLA-A1 10 1 . HLA code
Ά 24' refers to HLA-A2402. HLA code 7' refers to HLA-B0702.
HLA10S Barcode 20S Barcode Peptide Sequence
code
1 A 1B 1 A 1 CMV pp65 YSE YSEHPTFTSQY
2 A 1B2 A 1 CMV pp50 VTE VTEHDTLLY
3 A 1B3 A 1 FLU BP-VSD VSDGGPNLY
4 A 1B4 A 11 EBV-EBNA4 AVFDRKSDAK
5 A 1B5 A 11 HCMV pp65 GPISGHVLK
6 A 1B6 A 11 VP1 DLQGLVLDY
7 A 1B7 A 11 VP1 VLGRKMTPK
8 A 1B8 A 11 VP1 VTLRKRWVK
9 A 1B9 A 11 VP1 LVLDYQTEY
10 A 1B 10 A 11 VP1 GQEKTVYPK
11 A2B1 A 11 VP1 VTFQSNQQDK
12 A2B2 A 11 VP1 LKGPQKASQK
13 A2B3 A 11 VP1 NVASVPKLLVK
14 A2B4 A 11 VP1 TSNWYTYTY
15 A2B5 A 11 VP1 LVLDYQTEYPK
16 A2B6 A 11 VP1 TLRKRWVKNPY
17 A2B7 A 11 VP1 AVTFQSNQQDK
18 A2B8 A 11 VP1 PLKGPQKASQK
19 A2B9 A2 VP1 RIYEGSEQL
20 A2B1 0 A 11 VP1 SLFSNLMPK
2 1 A3B1 A2 VP1 KLLVKGGVEV
22 A3B2 A 11 VP1 SLINVHYWDMK
23 A3B3 A2 HPV E6 29-38 TIHDIILECV
24 A3B4 A2 FLU MP 58-66 GIL GILGFVFTL
25 A3B5 A2 EBV LMP2 CLG CLGGLLTMV
26 A3B6 A2 EBV BMF1 GLC GLCTLVAML
27 A3B7 A2 EBV LMP2 FLY FLYALALLL
28 A3B8 A2 CMV pp65 NLV NLVPMVATV
29 A3B9 A2 EBV BRLF1 YVL YVLDHLIVV
30 A3B1 0 A2 HPV E7 11-20 YMLDLQPETT
3 1 A4B1 A2 CMV IE1 VLE VLEETSVML
32 A4B2 A2 VP1 GCCPNVASV
33 A4B3 A2 VP1 SITQIELYL
34 A4B4 A2 VP1 LQMWEAISV
35 A4B5 A2 VP1 AISVKTEVV
36 A4B6 A2 VP1 KMTPKNQGL
37 A4B7 A2 VP1 TVLQFSNTL
38 A4B8 A2 VP1 GLFISCADI
39 A4B9 A2 VP1 LLVKGGVEVL
40 A4B1 0 A2 VP1 ELYLNPRMGV
4 1 A5B1 A2 VP1 NLPAYSVARV
42 A5B2 A2 VP1 TLQMWEAISV
43 A5B3 A2 VP1 QMWEAISVKT
44 A5B4 A2 VP1 VVGISSLINV
45 A5B5 A2 VP1 SLINVHYWDM
46 A5B6 A2 VP1 HMFAIGGEPL
47 A5B7 A2 VP1 FAIGGEPLDL
48 A5B8 A2 VP1 NLINSLFSNL
49 A5B9 A2 VP1 FLFKTSGKMAL
50 A5B1 0 A2 VP1 ALHGLPRYFNV
5 1 A6B1 A2 VP1 NLINSLFSNLM
52 A6B2 A2 VP1 FLDKFGQEKTV
53 A6B3 A2 VP1 VKGGVEVLSV
54 A6B4 A24 HCMV 248-256 AYAQKIFKIL
55 A6B5 A24 EBV LMP2 IYVLVMLVL
56 A6B6 A24 EBV BRLF1 TYPVLEEMF
57 A6B7 A24 EBV BMLF1 DYNFVKQLF
58 A6B8 A3 CMV pp150 TTV TTVYPPSSTAK
59 A6B9 A3 FLU NP 265-273 ILR ILRGSVAHK
60 A6B1 0 A3 EBV EBNA 3a RLR RLRAEAQVK
6 1 A 1B 1 1 A3 CMV pp150 TVY TVYPPSSTAK
62 A 1B 12 A3 EBV BRLF1 148-56 RVR RVRAYTYSK
63 A 1B 13 A3 VP1 ASVPKLLVK
64 A 1B14 A3 VP1 CCPNVASVPK
65 A 1B 15 A3 VP1 ITIETVLGR
66 A 1B 16 A3 VP1 NTLTTVLLD
67 A 1B 17 A3 VP1 ALHGLPRYF
68 A 1B 18 A3 VP1 VASVPKLLVK
69 A 1B 19 A3 VP1 VSGQPMEGK
70 A 1B20 A3 VP1 KASSTCKTPK
7 1 A2B1 1 A3 VP1 KTPKRQCIPK
72 A2B1 2 A3 VP1 YTYTYDLQPK
73 A2B1 3 A3 VP1 PITIETVLGR
74 A2B14 B7 VP1 SVARVSLPM
75 A2B1 5 A3 VP1 NSLFSNLMPK
76 A2B1 6 A3 VP1 KVSGQPMEGK
77 A2B1 7 A3 VP1 TVYPKPSVAP
78 A2B1 8 A3 VP1 SLINVHYWDMK
79 A2B1 9 A3 VP1 GVEVLSVVT
80 A2B20 A3 VP1 PLDLQGLVL
8 1 A3B1 1 A3 VP1 GLDPQAKAK
82 A3B1 2 A3 VP1 EVWCPDPSK
83 A3B1 3 A3 VP1 ADIVGFLFK
84 A3B14 A3 VP1 KTSGKMALH
85 A3B1 5 A3 VP1 KMALHGLPR
86 A3B1 6 A3 VP1 RYFNVTLRK
87 A3B1 7 A3 VP1 TLRKRWVKN
88 A3B1 8 B7 CMV pp65 TPR TPRVTGGGAM
89 A3B1 9 B7 CMV pp65 RPH-L RPHERNGFTV
90 A3B20 B7 EBV EBNA RPP RPPIFIRLL
9 1 A4B1 1 B7 VP1 KPGCCPNVA
92 A4B1 2 B7 VP1 QPIKENLPA
93 A4B1 3 B7 VP1 LPRYFNVTL
94 A4B14 B7 VP1 MPKVSGQPM
95 A4B1 5 B7 VP1 YPKPSVAPA
96 A4B1 6 B7 VP1 KPSVAPAAV
97 A4B1 7 B7 VP1 APLKGPQKA
98 A4B1 8 B7 VP1 APKRKASSTC
99 A4B1 9 B7 VP1 SVARVSLPML
100 A4B20 B7 VP1 YPKTTNGGPI
101 A5B1 1 B7 VP1 YPKPSVAPAA
102 A5B1 2 B7 VP1 KPGCCPNVASV
103 A5B1 3 B7 VP1 NPRMGVNSPDL
104 A5B14 B7 VP1 LPAYSVARVSL
105 A5B1 5 B7 VP1 TPTVLQFSNTL
106 A5B1 6 B7 VP1 LPRYFNVTLRK
107 A5B1 7 B7 VP1 YPVVNLINSLF
108 A5B1 8 B7 VP1 YPKPSVAPAAV
109 A5B1 9 B7 VP1 KPSVAPAAVTF
110 A5B20 B7 VP1 APKRKASST
Table 10: The PCR Master mix applied prior to sequencing of DNA-barcodes
associated with sorted cells. The forward and reverse primer included adaptors
for the sequencing reaction (A-key and P 1-key respectively). Moreover the
forward primer carried a sample-identification barcode (table 12 and 13). The
template was drawn from the residual fluid ( 10-1 9 ul) containing the sorted cells.
Nuclease free H2O was added to a final volume of 50 ul per PCR
Component Volume per sample (µ Ι)
Master mix 25
Forward primer (5 µΜ) 3 (300nM)
Reverse primer (5 µΜ) 3 (300nM)
Template 10-19
Nuclease free H20 0-9
Total 50
Table 11 : The thermal profile applied for amplification of DNA-barcodes
associated with sorted cells. 36 cycles were applied if > 1 ,000 cells were sorted
while 38 cycles were applied if < 1 ,000 cells were sorted.
Temperature { °C) Time No. of cycles
- 95 10 min 1
- 95 30 s
- 60 45 s 36-38
- 72 30 s
- 72 4 min 1
4
Table 12: Forward and reverse primers applied for amplification of enriched
Detection Ivlolecules prior to sequencing. Primers carry Ion Torrent adaptors, A-
key and P 1-key. Moreover the forward primer encodes a unique sample-ID
barcode (6xN). Compatible with the 1OS Label system (F1 =forward primer,
R 1=reverse primer)
Table 13: Forward and reverse primers applied for amplification of enriched
Detection Ivlolecules prior to sequencing. Primers carry Ion Torrent adaptors, A-
key and P 1-key. Moreover the forward primer encodes a unique sample-ID
barcode. A-key 2OS-F1 - 1 - 15 have a 6xN sample-ID barcode region (applied in
experiment 4 and 6) while A-key 2OS-F1 - 16-40 have a 8xN sample-ID and a
2xN spacer (used in all other experiments applying the 2OS system).
Compatible with the 2OS Label system (F1 =forward primer, R 1=reverse primer)
6N 2N
Primer name Forward primer region region 8N region spacer
A-Key 20S-F1-1 GAAGTTCCAGCCAGCGTC CTGGGG
A-Key 20S-F1-2 GAAGTTCCAGCCAGCGTC CTCCAC
A-Key 20S-F1-3 GAAGTTCCAGCCAGCGTC CTTACC
A-Key 20S-F1-4 GAAGTTCCAGCCAGCGTC TGGCAG
A-Key 20S-F1-5 GAAGTTCCAGCCAGCGTC TGAGTA
A-Key 20S-F1-6 GAAGTTCCAGCCAGCGTC ATTCAG
A-Key 20S-F1-7 GAAGTTCCAGCCAGCGTC TGAGCT
A-Key 20S-F1-8 GAAGTTCCAGCCAGCGTC GGCGTG
A-Key 20S-F1-9 GAAGTTCCAGCCAGCGTC AAATTG
A-Key 2OS-F1-10 GAAGTTCCAGCCAGCGTC GCTGAC
A-Key 20S-F1-11 GAAGTTCCAGCCAGCGTC TTCTTA
A-Key 20S-F1-12 GAAGTTCCAGCCAGCGTC TGGTGG
A-Key 20S-F1-13 GAAGTTCCAGCCAGCGTC GCAGTC
A-Key 20S-F1-14 GAAGTTCCAGCCAGCGTC TCGTGA
A-Key 20S-F1-15 GAAGTTCCAGCCAGCGTC TACAGT
A-Key 20S-F1-16 GAAGTTCCAGCCAGCGTC TTGCGTTA TG
A-Key 20S-F1-17 GAAGTTCCAGCCAGCGTC CGAGCGAG TG
A-Key 20S-F1-18 GAAGTTCCAGCCAGCGTC CGACTCTG TG
A-Key 20S-F1-19 GAAGTTCCAGCCAGCGTC ATCCGTCC TG
A-Key 2OS-F1-20 GAAGTTCCAGCCAGCGTC TTAAACGA TG
A-Key 20S-F1-21 GAAGTTCCAGCCAGCGTC IAG I 111 TG
A-Key 20S-F1-22 GAAGTTCCAGCCAGCGTC CACATGTA TG
A-Key 20S-F1-23 GAAGTTCCAGCCAGCGTC GATAGCCA TG
A-Key 20S-F1-24 GAAGTTCCAGCCAGCGTC ACCTGTTA TG
A-Key 20S-F1-25 GAAGTTCCAGCCAGCGTC TGCGAATT TG
A-Key 20S-F1-26 GAAGTTCCAGCCAGCGTC GTACATTT TG
A-Key 20S-F1-27 GAAGTTCCAGCCAGCGTC CTATTGCA TG
A-Key 20S-F1-28 GAAGTTCCAGCCAGCGTC ACGATACA TG
A-Key 20S-F1-29 GAAGTTCCAGCCAGCGTC CTTAGCGC TG
A-Key 2OS-F1-30 GAAGTTCCAGCCAGCGTC CGGAAACC TG
A-Key 20S-F1-31 GAAGTTCCAGCCAGCGTC GATGTTGG TG
A-Key 20S-F1-32 GAAGTTCCAGCCAGCGTC ATCGGCGT TG
A-Key 20S-F1-33 GAAGTTCCAGCCAGCGTC TAGTACGA TG
A-Key 20S-F1-34 GAAGTTCCAGCCAGCGTC GACGTGAT TG
A-Key 20S-F1-35 GAAGTTCCAGCCAGCGTC TGAGCCAA TG
A-Key 20S-F1-36 GAAGTTCCAGCCAGCGTC CCTCGCAG TG
A-Key 20S-F1-37 GAAGTTCCAGCCAGCGTC AGATCCAG TG
A-Key 20S-F1-38 GAAGTTCCAGCCAGCGTC TTGGCTGA TG
A-Key 20S-F1-39 GAAGTTCCAGCCAGCGTC GACCGCTA TG
A-Key 2OS-F1-40 GAAGTTCCAGCCAGCGTC GAGCTTAA TG
A-Key 20S-F1-41 GAAGTTCCAGCCAGCGTC GGACTGGT TG
A-Key 20S-F1-42 GAAGTTCCAGCCAGCGTC TGGGAGTC TG
A-Key 20S-F1-43 GAAGTTCCAGCCAGCGTC GCGATGGC TG
A-Key 20S-F1-44 GAAGTTCCAGCCAGCGTC ACTTGGTT TG
A-Key 20S-F1-45 GAAGTTCCAGCCAGCGTC ATACTCAT TG
A-Key 20S-F1-46 GAAGTTCCAGCCAGCGTC TAGTGTCC TG
A-Key 20S-F1-47 GAAGTTCCAGCCAGCGTC GCATATAA TG
A-Key 20S-F1-48 GAAGTTCCAGCCAGCGTC GGCGATTG TG
A-Key 20S-F1-49 GAAGTTCCAGCCAGCGTC GGGCTGTA TG
A-Key 2OS-F1-50 GAAGTTCCAGCCAGCGTC CGCTATTT TG
A-Key 20S-F1-51 GAAGTTCCAGCCAGCGTC GTACTGCA TG
A-Key 20S-F1-52 GAAGTTCCAGCCAGCGTC TGTCTATG TG
A-Key 20S-F1-53 GAAGTTCCAGCCAGCGTC CGAATCAC TG
A-Key 20S-F1-54 GAAGTTCCAGCCAGCGTC CGTCCTAA TG
A-Key 20S-F1-55 GAAGTTCCAGCCAGCGTC ACAAATGG TG
A-Key 20S-F1-56 GAAGTTCCAGCCAGCGTC TCTACTTT TG
A-Key 20S-F1-57 GAAGTTCCAGCCAGCGTC AATTCGAG TG
A-Key 20S-F1-58 GAAGTTCCAGCCAGCGTC GAACTCGG TG
A-Key 20S-F1-59 GAAGTTCCAGCCAGCGTC GCGGACGC TG
A-Key 2OS-F1-60 GAAGTTCCAGCCAGCGTC CTTGTCCA TG
A-Key 20S-F1-61 GAAGTTCCAGCCAGCGTC GTCGCGGT TG
A-Key 20S-F1-62 GAAGTTCCAGCCAGCGTC CAGGTCGT TG
A-Key 20S-F1-63 GAAGTTCCAGCCAGCGTC TCTCATCC TG
A-Key 20S-F1-64 GAAGTTCCAGCCAGCGTC GCTTCGTG TG
A-Key 20S-F1-65 GAAGTTCCAGCCAGCGTC CGTGATAA TG
A-Key 20S-F1-66 GAAGTTCCAGCCAGCGTC TTGCTCAC TG
A-Key 20S-F1-67 GAAGTTCCAGCCAGCGTC CGCTCTCC TG
A-Key 20S-F1-68 GAAGTTCCAGCCAGCGTC ATTCTACT TG
A-Key 20S-F1-69 GAAGTTCCAGCCAGCGTC AAGGCGTT TG
A-Key 2OS-F1-70 GAAGTTCCAGCCAGCGTC GCGGGATT TG
Primer name Ion Torrent region (A Key)
A-Key 20S-F1-1 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-2 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-3 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-4 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-5 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-6 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-7 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-8 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-9 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 2OS-F1-10 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-11 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-12 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-13 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-14 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-15 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-16 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-17 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-18 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-19 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 2OS-F1-20 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-21 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-22 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-23 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-24 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-25 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-26 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-27 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-28 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-29 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 2OS-F1-30 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-31 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-32 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-33 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-34 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-35 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-36 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-37 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-38 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-39 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 2OS-F1-40 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-41 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-42 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-43 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-44 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-45 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-46 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-47 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-48 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-49 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 2OS-F1-50 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-51 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-52 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-53 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-54 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-55 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-56 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-57 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-58 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-59 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 2OS-F1-60 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-61 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-62 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-63 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-64 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-65 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-66 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-67 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-68 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 20S-F1-69 CCATCTCATCCCTGCGTGTCTCCGACTCAG
A-Key 2OS-F1-70 CCATCTCATCCCTGCGTGTCTCCGACTCAG
Table 14: Listing of the 175 combinations of peptide-HLA Binding Molecules
and the respective 2OS DNA-barcodes that were used to encode the given
specificity of all Detection Molecules applied in experiments 7 . 168 of the
peptide-ligands are associated with melanoma while the remaining 7 are
different virus specific peptides. All are HLA-A0201 peptide antigens.
Barcode HLA
20S allele Peptide Sequence
A7B1 HLA-A0201 707-AP RVAALARDAP
A7B2 HLA-A0201 ATIC (AICRT) RLDFNLI RV
A7B3 HLA-A0201 ATIC (AICRT) MVYDLYKTL
A7B4 HLA-A0201 BA46 (MFG E8) NLFETPVEA
A7B5 HLA-A0201 BA46 (MFG E8) GLQHWVPEL
A7B6 HLA-A0201 Bcl-2 PLFDFSWLSL
A7B7 HLA-A0201 Bcl-2 WLSLKTLLSL
A7B8 HLA-A0201 Bcl-xL YLNDHLEPWI
A7B9 HLA-A0201 BING-4 CQWG RLWQL
A7B1 0 HLA-A0201 B-RAF LATEKSRWSG
A7B1 1 HLA-A0201 cyclophilin B (Cyp-B) VLEGMEVV
A7B1 2 HLA-A0201 Cadherin 3/P-cadherin FILPVLGAV
A7B1 3 HLA-A0201 Cadherin 3/P-cadherin FIIENLKAA

A9B8 HLA-A0201 hsp70 LLDVAPLSL
A9B9 HLA-A0201 MAG E-A1 0 GLYDGMEHL
A9B1 0 HLA-A0201 MAG E-A2 LVHFLLLKY
A9B1 1 HLA-A0201 MAG E-A2 LVQENYLEY
A9B1 2 HLA-A0201 MAG E-A2 YLQLVFGI EV
A9B1 3 HLA-A0201 MAG E-A2 KMVELVHFL
A9B1 4 HLA-A0201 MAG E-A3 LVFG IELMEV
A9B1 5 HLA-A0201 MAG E-A4 GVYDGREHTV
A9B1 6 HLA-A0201 MAGE-A1 YLEYRQVPV
A9B1 7 HLA-A0201 MAG E-A8 GLMDVQI PT
A9B1 8 HLA-A0201 MAG E-A8 KVAELVRFL
A9B1 9 HLA-A0201 MAG E-A9 ALSVMGVYV
A9B20 HLA-A0201 MAG E-C2 ALKDVEERV
A9B21 HLA-A0201 MAG E-C2 LLFGLALI EV
A9B22 HLA-A0201 MAG E-C2 VIWEVLNAV
A9B23 HLA-A0201 MAG E-C2 TLDEKVAELV
A9B24 HLA-A0201 MAG E-C2 KVLEFLAKL
A 10B1 HLA-A0201 MAG E-A3 KVAELVHFL
A 10B2 HLA-A0201 MC1 R TILLGI FFL
A 10B3 HLA-A0201 Melan-A / MART-1 ELAG IG ILTV
A 10B4 HLA-A0201 Melan-A / MART-1 ILTVILGVL
A 10B5 HLA-A0201 Meloe-1 TLNDECWPA
A 10B6 HLA-A0201 MG50 CMHLLLEAV
A 10B7 HLA-A0201 MG50 VLSVNVPDV
A 10B8 HLA-A0201 NY-ESO-1 / LAG E-2 QLSLLMWIT
A 10B9 HLA-A0201 NY-ESO-1 / LAG E-2 SLLMW ITQCFL
A 10B1 0 HLA-A0201 P Polypeptide IMLCLIAAV
A 10B1 1 HLA-A0201 p53 VVPCEPPEV
A 10B1 2 HLA-A0201 p53 KTCPVQLWV
A 10B1 3 HLA-A0201 p53 RMPEAAPPV
A 10B1 4 HLA-A0201 p53 LLPENNVLSPV
A 10B1 5 HLA-A0201 p53 KLCPVQLWV
A 10B1 6 HLA-A0201 p53 SMPPPGTRV
A 10B1 7 HLA-A0201 p53 LLG RNSFEV
A 10B1 8 HLA-A0201 p53 GLAPPQHLI RV
A 10B1 9 HLA-A0201 p53 SLPPPGTRV
A 10B20 HLA-A0201 p53 YLGSYGFRL
A 10B21 HLA-A0201 PGK1 IIGGGMAFT
A 10B22 HLA-A0201 PRAME ALYVDSLFFL
A 10B23 HLA-A0201 PRAME SLLQHLIGL
A 10B24 HLA-A0201 SOX1 0 SAWISKPPGV
A 11B 1 HLA-A0201 PRAME SLYSFPEPEA
A 11B2 HLA-A0201 PRAME VLDGLDVLL
A B3 HLA-A0201 PRDX5 LLLDDLLVSI
A 11B4 HLA-A0201 NY-ESO-1 / LAG E-2 SLLMWITQC
A 11B5 HLA-A0201 RAB38 / NY-MEL-1 VLHWDPETV
A 11B6 HLA-A0201 RAGE-1 LKLSGVVRL
A 11B7 HLA-A0201 RAGE-1 PLPPARNGGL
A 11B8 HLA-A0201 Replication protein A YLMDTSGKV
A 11B9 HLA-A0201 SART-3 LLQAEAPRL
A 11B 10 HLA-A0201 SART-3 RLAEYQAYI
A 11B 11 HLA-A0201 secernin 1 KMDAEHPEL
A 11B 12 HLA-A0201 SOX10 AWISKPPGV
A 11B 13 HLA-A0201 SSX-2 RLQG ISPKI
A 11B 14 HLA-A0201 SSX-2 KASEKIFYV
A 11B 15 HLA-A0201 STAT1-alpha/3 KLQELNYNL
A 11B 16 HLA-A0201 STEAP1 FLYTLLREV
A 11B 17 HLA-A0201 STEAP1 LLLGTIHAL
A 11B 18 HLA-A0201 STEAP1 MIAVFLPIV
A 11B 19 HLA-A0201 Survivin LMLG EFLKL
A 11B20 HLA-A0201 Survivin ELTLGEFLKL
A 11B21 HLA-A0201 Survivin TLPPAWQPFL
A 11B22 HLA-A0201 TAG-1 SLGWLFLLL
A 11B23 HLA-A0201 Telomerase RLFFYRKSV
A 11B24 HLA-A0201 TRP-2 VYDFFVWLHY
A 12B1 HLA-A0201 NY-ESO-1 / LAG E-2 SLLMWITQA
A 12B2 HLA-A0201 Telomerase RLVDDFLLV
A 12B3 HLA-A0201 Telomerase ILAKFLHWL
A 12B4 HLA-A0201 Topoisomerase II FLYDDNQRV
A 12B5 HLA-A0201 TRAG-3 ILLRDAGLV
A 12B6 HLA-A0201 TRP-2 FVWLHYYSV
A 12B7 HLA-A0201 TRP-2 SLDDYNHLV
A 12B8 HLA-A0201 TRP-2 TLDSQVMSL
A 12B9 HLA-A0201 TRP-2 SVYDFFVWL
A 12B1 0 HLA-A0201 TRP2-6b ATTNILEHY
A 12B1 1 HLA-A0201 tyrosinase CLLWSFQTSA
A 12B1 2 HLA-A0201 tyrosinase MLLAVLYCL
A 12B1 3 HLA-A0201 tyrosinase YMDGTMSQV
A 12B1 4 HLA-A0201 XBP-1 LLSGQPASA
A 12B1 5 HLA-A0201 MG50 LLLEAVPAV
A 12B1 6 HLA-A0201 MG50 TLKCDCEIL
A 12B1 7 HLA-A0201 MG50 WLPKILGEV
A 12B1 8 HLA-A0201 MG50 RLG PTLMCL
A 12B1 9 HLA-A0201 Meloe-2 RCPPKPPLA
A 12B20 HLA-A0201 PRDX5 AMAPIKVRL
A 12B21 HLA-A0201 cyclin B 1 ILI DWLVQV
A 2B22 HLA-A0201 Melan-A / MART-1 EAAG IG ILTV
A 2B23 HLA-A0201 adipophilin SVASTITGV
A 2B24 HLA-A0201 alpha-actinin-4 FIASNGVKLV
A 13B1 HLA-A0201 Meloe-2 RLPPKPPLA
A 3B2 HLA-A0201 CDKN1 A LMAGCIQEA
A 3B3 HLA-A0201 CDKN1 A GLGLPKLYL
A 3B4 HLA-A0201 CDKN1 A FAW ERVRGL
A 13B5 HLA-A0201 CLP (coactosin-like protein) NLVRDDGSAV
A 13B6 HLA-A0201 CLP (coactosin-like protein) RLFAFVRFT
A 13B7 HLA-A0201 CLP (coactosin-like protein) VVQNFAKEFV
A 13B8 HLA-A0201 c-MET YVDPVITSI
A 13B9 HLA-A0201 CYP1 B 1 WLQYFPNPV
A 13B 0 HLA-A0201 IMP-3 NLSSAEVVV
A 13B1 1 HLA-A0201 IMP-3 RLLVPTQFV
A 13B 2 HLA-A0201 KIF20A LLSDDDVVV
A 13B 3 HLA-A0201 KIF20A CIAEQYHTV
A 13B 4 HLA-A0201 KIF20A AQPDTAPLPV
A 13B 5 HLA-A0201 MAG E-A1 0 SLLKFLAKV
A 13B 6 HLA-A0201 MAG E-A1 2 FLWG PRALV
A 13B 7 HLA-A0201 MAG E-C2 FLAKLNNTV
A 13B 8 HLA-A0201 Melan-A / MART-1 AAG IG ILTV
A 13B 9 HLA-A0201 Survivin QMFFCFKEL
A 3B20 HLA-A0201 Telomerase LLTSRLRFI
A 13B21 HLA-A0201 TYMS LMALPPCHAL
A 3B22 HLA-A0201 FLU MP 58-66 GIL GILGFVFTL
A 3B23 HLA-A0201 EBV LMP2 CLG CLGGLLTMV
A 3B24 HLA-A0201 EBV BMF1 GLC GLCTLVAML
A 4B1 HLA-A0201 cyclin D 1 LLGATCMFV
A 4B2 HLA-A0201 HIV pol TPRVTGGGAM
A 4B3 HLA-A0201 EBV LMP2 FLY FLYALALLL
A 4B4 HLA-A0201 CMV pp65 NLV NLVPMVATV
A 4B5 HLA-A0201 EBV BRLF1 YVL YVLDHLIVV
A 4B6 HLA-A0201 BAP31 KLDVGNAEV
A 4B7 HLA-A0201 CMV IE1 VLE VLEETSVML
Example 20
This is an example where the Sample is a whole blood sample. Instead of being a mix
of two PBMC donor materials as described in e.g. example 3 it is a mix of two whole
blood samples. Except for the sample preparation the example is performed as
example 3
Thus, the Linker is a dextrane conjugate with streptavidin and fluorocrome (PE
Dextramer backbone from Immudex ApS).
The Binding Molecules are peptide-MHC (pMHC) complexes. In this example a panel
of 110 labeled pMHC-multimers, constituting a library of Detection Molecules, are
tested. Apart from 26 virus epitopes that are commonly found in healthy donors
(derived from EBV, CMV, FLU and HPV), is included a number of polyomavirus capsid
protein (VPI)-derived epitopes that has previously led to detection of T cells in healthy
donors.
110 different Labels are generated as example 3 . Detection Molecules are synthetized
as in example 3 .
Sample, whole blood, was incubated with an amount of a library of detection molecules
as described in example 3 .
The cell-bound detection molecules are separated from the non-cell bound detection
molecules as described in example3.
FACS isolated cells were subjected to PCR amplification of the oligonucleotide label
associated with the detection molecules bound to cells. Subsequent extensive
sequencing of PCR products revealed the identity of Detection Molecules that bound to
the T cells present in the sample.
1. Sample preparation. The cell samples used in this experiment are obtained by
mixing whole blood from two different donors to obtain a cell sample where a
number of T-cell specificities are known prior to the experiment. Thus, the
sensitivity of the method as well as the relevance of the results obtained in the
experiment can be evaluated at the end of the experiment, by comparison with
data obtained previously, using other methods but cell samples prepared from
the same donors.
a .Acquiring sample: Blood is obtained from the Danish Blood Bank.
b. Modifying sample:
i . Blood is drawn into BD Vacutainer® Plus Plastic K2EDTA Tubes
according to manufacturer's protocol.
ii. Anti-coagulated blood samples are diluted 1: 1 in RPMI (RPMI
1640, GlutaMAX, 25mM Hepes; gibco-Life technologies).
iii. The samples used in the experiment are obtained by mixing
blood from a donor (e.g. BC260) with 5% of the T cells specific
for HLA-B7/CMV pp65 TPR into blood from a donor (e.g. BC262)
without HLA-B7/CMV pp65 TPR specific T cells in fivefold
dilutions, creating seven samples (with 5%, 1%, 0.2%, 0.04%,
0.008%, 0.0016% and 0.00032% HLA-B7/CMV pp65 TPR-
specific T cells). The CMV pp65 TPR negative sample
preparation instead has a population of HLA-A1 1/EBV-EBNA4
specific T cells
iv. The remaining of the example is as for example 3.
2 . Linker preparation: The linker used in this example is dextrane conjugate with
streptavidin and fluorocrome (PE Dextramer backbone from Immudex) as
described in 1.
3 . Binding molecules preparation: The 110 different Binding Molecules are
prepared as in example 3 .
4 . Label preparation: The 110 different DNA oligo Labels are prepared as in
example 3 .
5 . Detection molecules preparation: 110 different Detection Molecules are
prepared as in example 3 .
6 . Incubation of sample and detection molecules:
a . Amount of sample: 0,2mL anti-coagulated blood diluted 1: 1 in RPMI.
b.Amount of detection molecule: As for e.g. example 3 .
c . Conditions: Sample is incubated with dasatinib (50nM final
concentration), 30 min, 37°C. Subsequently, sample and Detection
Molecule is mixed and incubated as e.g. example 3 .
7 . Enrichment of detection molecules with desired characteristics: Detection
Molecules are isolated with their associated cells by FACS as described in
example 3 .
8 . Identification of enriched detection molecule: By identifying the Label (in this
Example, the oligonucleotide label), the pMHCs that bound separated cells can
be identified. Therefore, the oligonucleotide labels that were comprised within
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the Detection Molecule that were recovered with the cells, were sequenced.
This allowed the identification of pMHCs that bound cells of the cell sample.
Labels associated with FACS isolated cells are sequenced as described in
example 3 .
Example 2 1
This is an example where the Sample is mononuclear cells derived from bone marrow
(BM MNCs). Instead of being a mix of two PBMC donor materials as described in
example 3 it is a mix of two whole blood samples. Except for the sample preparation
the example is performed as example 3 .
Thus, the Linker is a dextrane conjugate with streptavidin and fluorocrome (PE
Dextramer backbone from Immudex).
The Binding Molecules are peptide-MHC (pMHC) complexes. In this example a panel
of 110 labeled pMHC-multimers, constituting a library of Detection Molecules, are
tested. Apart from 26 virus epitopes that are commonly found in healthy donors
(derived from EBV, CMV, FLU and HPV), is included a number of polyomavirus capsid
protein (VPI)-derived epitopes that has previously led to detection of T cells in healthy
donors.
110 different Labels are generated as in example 3 . Detection Molecules are
synthetized as in example 3 .
Sample, whole blood, was incubated with an amount of a library of detection molecules
as described in example 3 .
The cell-bound detection molecules are separated from the non-cell bound detection
molecules as described in example 3 .
FACS isolated cells were subjected to PCR amplification of the oligonucleotide label
associated with the detection molecules bound to cells. Subsequent extensive
sequencing of PCR products revealed the identity of Detection Molecules that bound to
the T cells present in the sample.
1. Sample preparation. The cell samples used in this experiment was obtained by
mixing bone marrow from two different donors to obtain a cell sample where a
number of T-cell specificities were known prior to the experiment. Thus, the
sensitivity of the method as well as the relevance of the results obtained in the
experiment could be evaluated at the end of the experiment, by comparison
with data obtained previously, using other methods but cell samples prepared
from the same donors.
a . Acquiring sample: Collect bone marrow from the upper iliac crest or the
sternum by using an aspiration needle.
b. Modifying sample:
i . Dilute aspirated human bone marrow at a ratio of 7:1 with buffer
(phosphate buffered saline (PBS), pH 7.2, and 2 mM EDTA),
e.g., dilute 30 mL of bone marrow with 5 mL of buffer to a final
volume of 35 mL.
ii. Pass cells through a 100 µηι filter to remove bone fragments and
cell clumps.
iii. Carefully layer 3 5 mL of diluted cell suspension over 15 mL of
Ficoll-Paque in a 5 0 mL conical tube. Centrifuge at 445xg for 3 5
minutes at 2 0 °C in a swinging bucket rotor without brake.
Aspirate the upper layer leaving the mononuclear cell layer
undisturbed at the interphase. Carefully transfer the BM MNCs at
the interphase to a new 5 0 mL conical tube. Wash cells by
adding up to 4 0 mL of buffer, mix gently and centrifuge at 300xg
for 10 minutes at 2 0 °C. Carefully remove supernatant
completely. For removal of platelets, resuspend the cell pellet in
5 0 mL of buffer and centrifuge at 200xg for 10-15 minutes at 2 0
°C. Carefully remove the supernatant completely. Resuspend
cell pellet in 5 mL buffer for downstream applications.
iv. The samples used in the experiment is obtained by mixing BM
MNCs from a donor (e.g. BC260) with 5% of the T cells specific
for HLA-B7/CMV pp65 TPR into BM MNCs from a donor (e.g.
BC262) without HLA-B7/CMV pp65 TPR specific T cells in
fivefold dilutions, creating seven samples (with 5%, 1%, 0.2%,
0.04%, 0.008%, 0.001 6% and 0.00032% HLA-B7/CMV pp65
TPR-specific T cells). The CMV pp65 TPR negative BM MNC
preparation instead has a population of HLA-A1 1/EBV-EBNA4
specific T cells.
v. The remaining of the example is as for example 3 .
Linker preparation: The linker used in this example is dextrane conjugate with
streptavidin and fluorocrome (PE Dextramer backbone from Immudex) as
described in 1.
Binding molecules preparation: The 110 different Binding Molecules are
prepared as in example 3 .
Label preparation: The 110 different DNA oligo Labels are prepared as in
example 3 .
Detection molecules preparation: 110 different Detection Molecules are
prepared as in example 3 .
Incubation of sample and detection molecules:
a .Amount of sample: 0,2mL anti-coagulated blood diluted 1: 1 in RPMI.
b.Amount of detection molecule: As for example 3 .
c . Conditions: Sample is incubated with dasatinib (50nM final
concentration), 30 min, 37°C. Subsequently, sample and Detection
Molecule is mixed and incubated as e.g. example 3 .
Enrichment of detection molecules with desired characteristics: Detection
Molecules are isolated with their associated cells by FACS as described in
example 3 .
Identification of enriched detection molecule: By identifying the Label (in this
Example, the oligonucleotide label), the pMHCs that bound separated cells can
be identified. Therefore, the oligonucleotide labels that were comprised within
the Detection Molecule that were recovered with the cells, were sequenced.
This allowed the identification of pMHCs that bound cells of the cell sample.
Labels associated with FACS isolated cells are sequenced as described in
example 3 .
Example 60
This is an example where the binding molecules (BM) are MHC-like antigen-presenting
molecules such as e.g. CD1 a , CD1 b, CD1 c and CD1 d .
The Linker used in this example is dextran conjugate with streptavidin and fluorocrome
(PE Dextramer backbone from Immudex), the label used is a DNA oligonucleotide and
the Sample is PBMC's.
Isolation and identification of detection molecules capable of binding to cells of the cell
sample is done by FACS of cells with PE labeled dextran conjugate, and the identity
and amount of associated labels are determined by DNA sequencing.
1. Sample preparation.
The sample used in this example can be any type of cell sample, for example one
PBMC sample from a human being, as described in Example 1.
2 . Linker preparation:
The linker used in this experiment is a dextran molecule, prepared as described in
Example 1.
3 . Binding molecules preparation
a . Synthesis: CD1 a , CD1 b, CD1c and CD1d is produced as described by
Khurana A , et.al, J Vis Exp. 2007; (10): 556. and as performed
by a person skilled in the art.
b. Modification: CD1 a , CD1b, CD1c and CD1d is loaded with 15 potential
lipid antigens (GMM, glucose monomycolate; Sulfolipid,
diacylated sulfoglycolipid; PIM's, phosphatidylinositol
mannosides; Man- LAM, mannosylated lipoarabinomannan;
MPM, mannosyl-b1 -phosphomycoketide; MPP, mannosyl-b1 -
phosphoheptaprenol; DDM, dideoxymycobactin; GSL-1 , a-
glucoronsylceramide; GalDAG, a-galactosyldiacylglycerol;
LPG, lipophosphoglycan; PI, phosphatidylinositol; PG,
phosphatidylglycerol; PE, phosphatidylethanolamine; iGb3,
isoglobotrihexosylceramide; Alpha-GC, a-galactosylceramide).
Lipids are dissolved to 2 mg/mL in DMSO, heated to 50 °C for
2 min and diluted further 1: 1 0 in PBS+ 0,1% Tween20. Lipids
are mixed individually with the four different CD1 molecules
giving rise to 4x1 5 = 60 combinations. Briefly 10 uL 1 ug/uL
CD1 protein is mixed with 2 uL 0,2 mg mL lipid in PBS+ 0,1%
Tween20+1 0% DMSO. Load lipids into CD1 4h at 30 ° .
c . Purification: The CD1 a-lipid, CD1b-lipid, CD1c-lipid and CD1d-lipid
complexes are not purified further.
4 . Label preparation: Labels as described in example 3 are used.
a . Synthesis: The first 60 Labels in table 8 are used.
b. Modification: no further
c . Purification: no further
5 . Detection molecules preparation
a . Synthesis: The detection molecules are prepared as in example 3 except
that the 60 different CD1 and lipid combinations are mixed with
60 individual DNA oligonucleotide labels (labels 1-60 from
table 8).
b. Modification: no further modifications
c . Purification: no further
6 . Incubation of sample and detection molecules
The sample and detection molecules of step 1 and 5 , respectively, are mixed
and incubated as described in Example 3 .
7 . Enrichment of detection molecules with desired characteristic: Cells positive for
PE fluorochrome on the Linker is isolated by FACS as described in example 3 .
8 . Identification of enriched detection molecule: The detection molecules
recovered in step 7 are identified by sequencing, as described in Example 3 .
Example 6 1
This is an example where the binding molecules (BM) are MHC class I I proteins.
The Linker used in this example is dextran conjugate with streptavidin and fluorocrome
(PE Dextramer backbone from Immudex), the label used is a DNA oligonucleotide and
the Sample is PBMC's.
Isolation and identification of detection molecules capable of binding to cells of the cell
sample is done by FACS of cells with PE labeled dextran conjugate, and the identity
and amount of associated labels are determined by DNA sequencing.
1. Sample preparation: The sample used in this example can be any type of cell
sample, for example one PBMC sample from a human being, as described in
Example 1.
2 . Linker preparation: The linker used in this experiment is a dextran molecule,
prepared as described in Example 1.
3 . Binding molecules preparation
a . Synthesis: MHC class I I protein in the form of biotinylated monomers are
obtained from The NIH Tetramer Core Facility, at Emory
University, US. The following eight MHC Class I I monomers
are used (DPB1 * 04:01 C. tetani TT 948-968
FNNFTVSFWLRVPKVSASHLE, DPB1 * 04:01 human MAGE3
243-258 KKLLTQHFVQENYLEY, DPB1 * 04:01 human
oxytocinase 272-284 KKYFAATQFEPLA, DPB1 * 04:01
human CLIP 87-1 0 1 PVSKMRMATPLLMQA, DPB1 * 04:01
human CTAG1 157-1 70 SLLMWITQCFLPVF, DPB1 * 04:01
HIV env 3 1-45 TEKLWVTVYYGVPVW, DQB1 * 03:02 human
CLIP 87-1 0 1 PVSKMRMATPLLMQA, DQB1 * 03:02 human
FcR2 104-1 19 QDLELSWNLNGLQADL
b. Modification: Monomers are obtained ready folded and biotinylated from
The NIH Tetramer Core Facility
c . Purification: No further modification
4 . Label preparation
a . Synthesis: The first 8 labels from Table 8 are used
b. Modification: No further
c . Purification: No further
5 . Detection molecules preparation
a . Synthesis: The detection molecules are prepared as in example 3 except
that the 8 different MHC class I I molecules are are combined
with 8 different DNA oligonucleotide labels as described in
example 3 .
b. Modification: No further
c . Purification: No further
6 . Incubation of sample and detection molecules: The sample and detection
molecules of step 1 and 5 , respectively, are mixed and incubated as described
in Example 3 .
7 . Enrichment of detection molecules with desired characteristics: Cells positive
for PE fluorochrome on the Linker is isolated by FACS as described in example
5 .
8 . Identification of enriched detection molecule: The detection molecules
recovered in step 7 are identified by sequencing, as described in Example 3 .
Example 79
In this example, 20 different pMHC complexes (e.g. corresponding to 20 known cancer
epitopes) are used as binding molecules, the linker is dextran-streptavidin-PE
conjugate, and 20 different DNA oligonucleotides are used as labels.
The detection of detection molecules capable of binding to cells of the sample, is by
immobilization on an array of anti-sense DNA oligonucleotides.
20 different pMHC complexes (all A*02-01 , but each of the 20 complexes carrying one
specific peptide epitope commonly found in cancer patients) (e.g epitopes from
antigens such as WT-1 , survivin, and NY-ESO-1) are prepared using standard
procedures, and as described in other examples above. The pMHC complexes are
preferably mono-biotinylated.
Dextran-streptavidin-PE conjugate is used as linker, as described in several examples
above. PE is a strong fluorochrome, and a given conjugate carries e.g. 1-3 PE
molecules.
The labels are 20 different DNA oligonucleotides of different sequences, of
approximately 50 nt in length. The oligonucleotides are biotinylated at one terminus.
Detection molecules are generated by mixing the dextran-streptavidin-PE conjugate
with the 20 different biotinylated pMHC complexes and the 20 different biotinylated
DNA oligonucleotides from above, using standard conditions, as described in several
examples above. This leads to generation of 20 detection molecules, each of which
carries a specific pMHC complex and a specific DNA label.
Whole blood from e.g. a cancer patient is then mixed with the detection molecules
generated immediately above, and incubated for 15 minutes. Then the cells are spun
down and supernatant removed, and the centrifugation and resuspension repeated 0-3
times. Finally, the cells are resuspended in an appropriate binding buffer that allows
specific hybridization of complementary DNA strands.
After incubation and washing the solution of cells and detection molecules is applied to
an array, comprising 20 different anti-sense DNA oligos, each of which is confined to a
specific area in the array. In other words, each of the 20 different anti-sense DNA
oligonucleotides are located in a small area of the array - the array therefore consists
of 20 areas each of which comprise antisense oligonucleotides of a given sequence.
Each of these 20 anti-sense DNA oligonucleotides comprise a sequence of 10-1 5 nt
that is complementary to the DNA label of one of the 20 detection molecules.
Therefore, cells that are bound by a certain detection molecule will become
immobilized to the array, through hybridization between the DNA oligonucleotide label
of said certain detection molecule and the anti-sense DNA oligonucleotide of the array
at that position. The hybridization conditions may be adjusted so that hybridization
between just one detection moleule and one anti-sense DNA leads to inefficient
immobilization of the corresponding cell, whereas hybridization of several detection
moleules to several anti-sense DNA leads to efficient immobilization of the
corresponding cell.
As a result, the cells bound by a certain kind of detection molecules (i.e. bound to a
certain specificity of detection molecule) will become immobilized to one of the 20
areas of the array, defined by the sequence of the detection molecule bound to the cell
and the position in the array of the antisense DNA oligonucleotide that is
complementary to said detection molecule's label. Several cells, each bound by a large
number of detection molecules, may become immobilized in a certain area of the array.
Because of the fluorescent PE molecules attached to the detection molecule, this will
give rise to a fluororescent signal from this area of the array. Moreover, at higher
resolution (using a microscope) it will be possible to count the number of cells
immobilized in the specific area of the array, and finally, the fluorescence of each cell
and therefore the relative number of detection molecules bound to each cell, may be
determined. See the figure below showing an example where the cell sample
comprises two cell specificities that are bound by detection molecules; one of the
specificities are represented by 12 cells, the other is represented by 5 cells. In figure
17 , hatched areas represent fluorescent light above a certain threshold.
In this example, the fluid cell sample could be of any kind (e.g. synovial fluid, blood,
bone marrow, environmental sample (e.g. comprising bacterial cells, in which case the
binding molecules could be antibodies binding to proteins of different bacterial
surfaces), etc.
The number of different detection molecules could be expanded to much larger
numbers, e.g. 100, 1.000 or 10.000.
Rather than having the detection molecules carry the fluorescent molecules directly, a
system of primary and secondary antibodies and a corresponding staining system
could be used, like standard secondary labelling systems, in order to increase the
signal strength.
Example 80
In this example, the labels used are DNA oligonucleotides of different length. The
identity of the individual label is based on its mass, by either mass spectrometry or
differential migration in a gel electrophoresis analysis.
1. Sample preparation.
Blood comprising different kinds of blood cells is drawn from a person, and used
directly in the incubation, step E below. Alternatively, any type of sample described in
the examples above can be used.
3 . Binding molecules preparation
The binding molecules used in this study are 10 different antibodies, recognizing 10
different cell differentiation markers (CDs) respectively, namely CD3, CD4, CD8, CD16,
CD56, * * . Each of these are commercially available.
4 . Label preparation
10 DNA oligonucleotides of length 50 nt, 100 nt, 150 nt, 200 nt, 250 nt, 300 nt, 350 nt,
400 nt, 450 nt, and 500 nt, respectively, with a terminal N-succinimidyl ester moiety are
prepared by standard means.
5 . Detection molecules preparation
Each of the 10 antibodies mentioned under (B) are incubated in appropriate buffer (e.g.
PBS pH 8) together with one of the 10 oligonucleotides mentioned in step (C) above,
allowing the N-succinimidyl ester to react with free amines on the surface of the
antibody, to form a covalent link between the antibody and the oligonucleotide. In this
way, 10 detection molecules are generated, each of which comprise one specific
antibody (e.g. anti-CD3 antibody) and one specific oligonucleotide (e.g. 50 nt DNA
oligo).
6 . Incubation of sample and detection molecules
The sample of step (A) is incubated with the 10 detection molecules under appropriate
conditions (e.g. appropriate buffer, e.g. Tris pH 7,5 is added, or the oligonucleotides
from step (D) in e.g. PBS pH 8 is simply mixed with sample without further addition of
buffer. Incubation can be at 0 , 4 , 10, 20, 30, or 40 degrees celcius.
7 . Isolating bound and unbound detection molecules
The incubation mixture of step (E) is centrifuged, to recover all cells of the sample.
Supernatant is removed, the cells resuspended and buffer added. Centrifugation is
repeated 1-3 times, and the cells finally resuspended. The suspension of cells will
contain detection molecules that are capable of binding to one or more cells. Thus, the
detection molecules of the suspension are representative of the distribution of
receptors on the cell surface of the cells of the original sample.
8 . Determining the identity and amount of the recovered detection molecules.
1 µ Ι_ of the mixture of cells and bound detection molecules are transferred to a 100 µ Ι_
PCR reaction comprising forward and reverse primers that can anneal to each of the
10 oligonucleotide labels described in step (C) above, and comprising all other
components for an efficient PCR reaction. The PCR reaction is performed under
standard conditions, and aliquots are taken out after 25, 30 and 35 cycles are
performed.
The PCR product is applied to a gel capable of resolving the individual oligonucleotide
fragments (e.g. a 2.5% agarose gel), and electrophoresis is performed. Once the
fastest moving product (corresponding to the 50 nt oligonucleotide) has migrated about
¾ of the gel length, eletrophoresis is terminated. The position of a band in the gel
reflects its size and therefore identifies the corresponding oligonucleotide label; the
uppermost band represents the largest fragment (500 nt), and the lowermost band
represents the smallest fragment (50 nt). The intensity of each of the 10 bands,
corresponding to each of the 10 different oligonucleotide fragments, is indicative of the
relative amount recovered of each oligonucleotide label and therefore, of each
detection molecule.
Example 8 1
This example is as example 80, except that the labels used here are PNA fragments
rather than DNA oligonucleotides, and the identity of the labels of the recovered
detection molecules are determined by mass spectrometry analysis rather than gel
electrophoresis.
Sample and binding molecules are as described in example 80.
Labels are prepared as follows. 10 different PNAs are prepared, of different size (e.g.
comprising 5 , 7 , 9 , 11, 13 , 15 , 17 , 19 , 2 1, and 23 bases). During synthesis, N-
succinimidyl ester is introduced at one of the PNA fragment. Further, also during its
synthesis, a disulfide bond (S-S) is introduced between the ester and the rest of the
PNA fragment. Thus, in the label a disulfide bond links the N-succinimidyl ester with the
remainder of the PNA fragment.
Detection molecules are prepared as in example 80, except that the PNA labels are
used instead of the DNA oligonucleotide labels of example 80. Each of the resulting 10
detection molecules therefore consists of a specific binding molecule (a specific
antibody, e.g. CD3) and a specific PNA label (e.g. PNA comprising 5 bases).
Isolation of detection molecules capable of binding to cells of the sample is done by
centrifugation as decribed in example 80, and the final cell suspension thus contains
cells plus detection molecules capable of binding to cells of the sample.
Finally, the identity and amount of the recovered detection molecules is determined in
the following way: First, the PNA labels are cleaved off from the detection molecules
(and therefore, released from the cells that the detection molecule is bound to) by
addition of DTT, which cleaves the disulfide bond. The cells are spun down by
centrifugation, and the supernatant (comprising the relased PNA labels but not the
cells) is then subjected to a mass spectrometry analysis.
The mass spectrometry analysis will reveal the relative amount of each of the 10 PNA
labels (corresponding to the relative amount of each of the 10 detection molecules
recovered by centrifugation of the cells).
Example 82
This example is as example 8 1 , except that the labels used here are peptide fragments
rather than PNA fragments
Labels are prepared as follows. 10 different peptides are prepared, of different size
(e.g. comprising 5 , 7 , 9 , 11, 13 , 15 , 17 , 19 , 2 1 , and 23 amino acids). During synthesis,
N-succinimidyl ester is introduced at one of the peptide fragment. Further, also during
its synthesis, a disulfide bond (S-S) is introduced between the ester and the rest of the
peptide fragment. Thus, in the label a disulfide bond links the N-succinimidyl ester with
the remainder of the peptide fragment.
Detection molecules are prepared as in example 8 1 , except that the peptide labels are
used instead of the PNA labels of example 8 1. Each of the resulting 10 detection
molecules therefore consist of a specific binding molecule (a specific antibody, e.g.
CD3) and a specific peptide label (e.g. peptide comprising 5 amino acids).
The mass spectrometry analysis will reveal the relative amount of each of the 10
peptide labels (corresponding to the relative amount of each of the 10 detection
molecules recovered by centrifugation of the cells).
Example 120
This is an example where the samples are three buffy coats (BC's), the Linker is PE
and streptavidin conjugated dextran, and the Binding Molecules are biotinylated
peptide-MHC (pMHC) complexes. The Labels are synthetic oligonucleotides modified
with a terminal biotin capture-tag. The labels are combined oligonucleotide label arising
by annealing an A oligonucleotide (modified with biotin) to a partially complimentary B
oligonucleotide label followed by enzymatic DNA polymerase extension of Oligo A and
Oligo B to create a fully double stranded label.
The Detection Molecules are created by combining biotinylated pMHC and labels in the
form of biotin-modified oligonucleotide onto a streptavidin-modified dextran linker. The
detection molecule further contained a fluorochrome (PE). 30 different Detection
Molecules are generated wherein the individual detection molecules containing
different pMHC are encoded by corresponding individual oligonucleotide labels. Two
versions (Set 1 and Set 2 , see table x) of each of the 30 different Detection Molecules
are created in the way that all Detection molecules are generated in two forms with
different labels. Three samples, PBMC's, were incubated with an amount of mixed
Detection Molecules.
In this example CD8+ T cell-bound Detection Molecules are separated from the non-
cell bound Detection Molecules by capture of CD8+ T cells using anti CD8-coated
magnetic Dynabeads. Magnetic bead-isolated CD8-positive T cells are subjected to
PCR amplification of associated Label and the PCR product is analyzed as a read of
the oligonucleotide label associated with the detection molecules bound to the isolated
cells thus revealing the identity of detection molecules bound to the T cells present in
the sample.
1. Sample preparation.
a . Acquiring sample: The cell sample used in this experiment is obtained by
preparing PBMC's from blood drawn from three donors (D1 3 1 ,
D149 and D158) that, by conventional MHC-multimer staining,
are characterized for their specific T cells towards a number of
virus antigens.
b. Modifying sample: The PBMC's are prepared as described in example 1.
Linker preparation: The Linker is PE and streptavidin conjugated dextran
(Dextramer from Immudex) which is prepared as in example 1.
Binding molecules preparation: Binding Molecules are biotinylated pMHC
complexes with peptide/HLA combination as described in table below
Label preparation: Label is generated as described in example 4 except that
this example only 2x60 labels are used (See table above)
Detection molecules preparation
a . Synthesis
According to table below transfer the required volume Dextran
conjugate to an Eppendorf tube. Centrifuge ( 10.000 g , 10 min,
4°C).
Transfer the supernatant containing dextrane conjugate without
precipitates to 2*30 wells on two plates.
In a 96 well format add the 2x30 Label oligos in 2:1 molar
concentration to PE-Dextramer conjugate.
IV. Mix well and incubate 30 min, 4°C.
Thaw pMHC binding molecules on ice, dilute to 100 µg/mL in
PBS and centrifuge (2000 g , 5 minutes, 18°C).
Transfer the pMHC monomers to wells of the 96 well plate
according to the above table to allow the combination of pMHC
with labeled linker.
VI Mix well and incubate 30 minutes at r.t. and PBS subsequently.
Detection molecule preparation
Concentration
Dextran conjugate i Ί 0 -8Μ
Oligo table 54.25 Ί 0 -8Μ
Detection
molecules/samples
Number of Detection molecules
Number of samples m
Assembling Label and Linker Volumes needed
1.-Transfer Dextran to Eppendorf
tube and centrifuge 10000g,5min,4C µ Ι
2:Transfer the supernatant to wells
on a plate according to setup µ Ι/well
3:Add oligo labels to wells according
to setup, Mix and incubate 30min,4C µ Ι/well
Preparation of binding molecules:
1: Thaw pMHC monomers on ice
2:Dilute monomers in PBS
to 100iig/ml = 2µ
Vtotal needed per pMHC per plate 40 µ Ι/pMHC
Preparation of Detection Molecules
7; Centrifuge pMHC monomers
2000g, 10min 18C.
2: Transfer supernatant to the 96well
plate µ Ι/well
(To the Dextran -MHC control is an
equal volume of PBS added)
3: Mix well and incubate 30min at T
4: Add PBS µ Ι/well
5: Store at 4C
Vtotal in each well 60,0
a . Modification: No further
b. Purification: No further
Incubation of sample and detection molecules
a . Amount of sample: 2 million PBMC's per sample
b.Amount of detection molecule: According to table below. Each donor
sample is incubated with 4 different amounts of Detection Molecule
c . Conditions:
i . PBMC's are thawed in 10 ml RPMI-1 0% FCS and washed twice
in 2 mL RPMI-1 0% FCS. Cells are then washed in 2 mL PBS w.
0.5%BSA, 100µg/ml Herring DNA, 2mM EDTA. (All washing of
cells in this experiment refers to centrifuge for 5min at 800g to
collect cells followed by discarding of wash buffer)
ii. Resuspend cells in 500 µ Ι PBS w. 0.5%BSA, 100µg/ml Herring
DNA, 2mM EDTA to a concentration 20million/ml.
iii. Add 25 µ Ι 1 µΜ Dasatinib and incubate 30 min at 37 ° (Final
Dasatinib cone. 50 nM).
iv. Centrifuge Detection Molecules (2000 g , 5 minutes, 18°C)
v. Add 166,5 µ Ι 10µΜ biotin to an Eppendorf tube.
Pool 25 µ Ι of each Detection Molecule from each of the two sets
into the Eppendorf tube (Detection Molecule library) Vtot =
1666,5µ Ι which is enough for 3 donors in 4 concentrations.
Centrifuge the library of Detection Molecules (10000g, 10min)
and transfer 1550µ Ι to a new tube avoiding aggregates.
Transfer from new tube to 5ml tubes according to setup/volumes
below.
To all twelve tubes add 0ΟµΙ cells (2 million cells) of the
respective donors, to a VTot in each sample of 300µ Ι. Incubate
15 minutes at 37°C.
Wash cells twice in 2 ml PBS w. 0.5%BSA, 10C^g/ml Herring
DNA, 2mM EDTA (Centrifuge 5min at 800g)
Sample/Detect 3µ Ι 1,5µ Ι 0,75 µ Ι 0,375 µ Ι
Mol
D131 S 1 : 200 µ Ι S2: 100µ Ι S3: 50µ Ι S4: 25µ Ι
D149 S5: 200 µ Ι S6: 100µ Ι S7: 50µ Ι S8: 25µ Ι
D158 S9: 200 µ Ι S 10 : 100µ Ι S 11: 50µ Ι S 12 : 25µ Ι
PBS w.
0.5%BSA,
100µg/ml Herring
DNA, 2mM EDTA
D131 S 1 : ΟµΙ S2: 100µ Ι S3: 150µ Ι S4: 175µ Ι
D149 S5: ΟµΙ S6: 100µ Ι S7: 150µ Ι S8: 175µ Ι
D158 S9: ΟµΙ S 10 : 100µ Ι S 11: 150µ Ι S 12: 175µ Ι
ichment of detection molecules with desired characteristics
a .Apply: In this example Detection Molecules are isolated by capturing
CD8+ cells using anti CD8 antibody coated magnetic beads
(DYNABEADS CD8, # 147D, Life Technologies). Detection molecules
associated with captured CD8+ cells are isolated. Dynabeads used
according to manufacturer's protocol.
i . Briefly; Dynabeads are vortex >30sec and transfer θµΐ/ ηιρΐβ =
600 µ Ι to a 5ml tube and add 1 ml PBS + 0.1%BSA + 2mM
EDTA. Re-suspended dynabeads are placed in magnet 1 min,
supernatant is discarded and dynabeads are re-suspended in
600µ Ι PBS + 0.1%BSA + 2mM EDTA.
ii. To all samples add 50µ Ι washed beads + 950µ Ι Isolation buffer
=> Vtot = 1 ml. Incubate 20 min 4C on a tilting plate.
b. Wash:
i . Place tubes in magnet (Dynal, Life Technologies) for 2 min and
carefully remove supernatant
ii. Wash twice: Add 2 ml PBS + 0.1%BSA + 2mM EDTA, vortex,
place in magnet 2 min, remove supernatant.
iii. Re-suspend beads in 500 µ Ι PBS w. 0.5%BSA, 100µg/ml Herring
DNA, 2mM EDTA, transfer to Eppendorf tubes.
iv. Centrifuge tubes 5 min at 5000g, remove supernatant final
volume app. 20µ Ι -> Store at -80C or store on ice at 4C O.N for
PCR
c . Separate: Is done during washing.
8 . Identification of enriched detection molecule: Separated Detection Molecules
are analyzed by PCR amplification of the attached labels followed by
sequencing of the PCR products to reveal the identity of isolated detection
molecules and thus the identity of those antigens for which specific T cells were
present in the sample. The PCR amplification and sequencing of PCR product
is done as for example 3 using the same sets of primers and the same
sequencing service and sequencing de-convolution service.
Example 121
This is an example where the samples are PBMC's prepared as three buffy coats
(BC's), the Linker is PE and streptavidin conjugated dextran, and the Binding
Molecules are biotinylated peptide-MHC (pMHC) complexes. The Labels are synthetic
oligonucleotides modified with a terminal biotin capture-tag.
In this example CD8+ T cell-bound Detection Molecules are separated from non-cell
bound Detection Molecules by capture of CD8+ T cells by magnetic labeling of CD8+
cells with CD8 MicroBeads (CD8 MicroBeads, human, # 130-045-201 , Miltenyi,
Germany). Magnetic bead-isolated CD8-positive T cells are subjected to PCR
amplification of associated Label (as described in example 3) and the PCR product is
analyzed as a read of the oligonucleotide label associated with the detection molecules
bound to the isolated cells thus revealing the identity of detection molecules bound to
the T cells present in the sample (as example 3).
1. Sample preparation. The samples are PBMC's from three donor materials
prepared as described in example 3 .
2 . Linker preparation: The Linker is PE and streptavidin conjugated dextran
(Dextramer from Immudex) which is prepared as in example 1.
3 . Binding molecules preparation: Binding Molecules are biotinylated pMHC
complexes with peptide/HLA combination as described in example 3 .
4 . Label preparation: Labels are biotin modified DNA oligonucleotides as
described in example 3 .
5 . Detection molecules preparation: Detection Molecules are prepared by
combining 110 aliquots of Linker with individual Labels followed by adding
pMHC Binding Molecules as described in Example 3 .
6 . Incubation of sample and detection molecules: PBMC's are mixed with the 110
member library of Detection Molecules as described in example 3 .
7 . Enrichment of detection molecules with desired characteristics:
a .Apply: In this example Detection Molecules are isolated by capturing
CD8+ cells using anti CD8 antibody coated magnetic beads
(CD8 MicroBeads, human, # 130-045-201 , Miltenyi, Germany).
Detection molecules associated with captured CD8+ cells are
isolated. CD8 MicroBeads are used according to
manufacturer's protocol. Briefly;
i . Centrifuge cell suspensions at 300xg for 10 minutes. Aspirate
supernatant completely.
ii. Resuspend cell pellets in 80 µ of buffer (phosphate-buffered
saline (PBS), pH 7.2, 0.5% bovine serum albumin (BSA), and 2
mM EDTA).
iii. Add 20 µ of CD8 MicroBeads. Mix well and incubate for 15
minutes in the refrigerator (2-8)
iv. Wash cells by adding 1- 2 mL of buffer and centrifuge at 300xg
for 10 minutes. Aspirate supernatant completely. Resuspend
cells in 500 µ of buffer.
v. Place an MS column (Miltenyi, Germany) in the magnetic field of
a OctoMACS column stand Separator. Prepare column by
rinsing with 500 µ Ι_ of buffer:
vi. Apply cell suspension onto the column. Collect unlabeled cells
that pass through and wash column with 500 µ Ι_ of buffer. Collect
total effluent; this is the unlabeled cell fraction. Perform washing
steps by adding buffer three times. Only add new buffer when
the column reservoir is empty.
vii. Remove column from the separator and place it on a suitable
collection tube.
viii. Pipette 1 mL of buffer onto the column.
ix. Immediately flush out the magnetically labeled cells by firmly
pushing the plunger into the column.
x . Centrifuge tubes 5 min at 500g, remove supernatant. The final
volume of app. 20µ Ι containing collected CD8+ cells and their
associated Detection Molecules are store at -80C for later
analysis.
Identification of enriched detection molecule: Separated cells and their
associated Detection Molecules are analyzed by PCR amplification of the
attached labels followed by sequencing of the PCR products to reveal the
identity of isolated Detection Molecules and thus the identity of those antigens
for which specific T cells were present in the sample. The identification is done
as for example 3 .
Example 122
This is an example where the samples are PBMC's prepared as three buffy coats
(BC's), the Linker is PE and streptavidin conjugated dextran, and the Binding
Molecules are biotinylated peptide-MHC (pMHC) complexes. The Labels are synthetic
oligonucleotides modified with a terminal biotin capture-tag.
In this example, though, all cells and their bound Detection Molecules are first
separated, by centrifugation, from the supernatant containing Detection Molecules not
bound to cells. Secondly, remaining Detection Molecules are captured by their PE
modification on the Linker using anti PE MicroBeads (anti PE MicroBeads, # 130-048-
801 , Miltenyi, Germany). Magnetic bead-isolated cells are subjected to PCR
amplification of Detection-Molecule associated Labels (as described in example 3 ) and
the PCR product is analyzed as a read of the oligonucleotide label associated with the
detection molecules bound to the isolated cells thus revealing the identity of detection
molecules bound to the T cells present in the sample as in example 3 .
1 . Sample preparation. The samples are PBMC's from three donor materials
prepared as described in example 3 .
2 . Linker preparation: The Linker is PE and streptavidin conjugated dextran
(Dextramer from Immudex) which is prepared as in example 1 .
3 . Binding molecules preparation: Binding Molecules are biotinylated pMHC
complexes with peptide/HLA combination as described in example 3 .
4 . Label preparation: Labels are biotin modified DNA oligonucleotides as
described in example 3 .
5 . Detection molecules preparation: Detection Molecules are prepared by
combining 1 1 0 aliquots of Linker with individual Labels followed by adding
pMHC Binding Molecules as described in Example 3 .
6 . Incubation of sample and detection molecules: PBMC's are mixed with the 1 1 0
member library of Detection Molecules as described in example 3 .
7 . Enrichment of detection molecules with desired characteristics
a .Apply: In this example Detection Molecules are isolated by centrifugation
separation of cells and their bound Detection Molecules from
the supernatant containing Detection Molecules not bound to
cells followed by magnetic capture of cells with bound PE-
labeled Detection Molecules thereby separating from cells
without bound PE-labeled Detection Molecules using anti PE
MicroBeads (anti PE MicroBeads, # 1 30-048-801 , Miltenyi,
Germany). MicroBeads are used according to manufacturer's
protocol. Briefly;
i . Centrifuge cell suspensions at 300xg for 1 0 minutes. Aspirate
supernatant completely
ii. Wash cells twice by adding 2 mL of buffer (phosphate-buffered
saline (PBS), pH 7.2, 0.5% bovine serum albumin (BSA), and 2
mM EDTA) and centrifuge at 300 x g for 1 0 minutes. Aspirate
supernatant completely.
iii. Resuspend cell pellets in 80 µ Ι_ of buffer.
iv. Add 20 µ Ι_ of anti PE MicroBeads. Mix well and incubate for 15
minutes in the refrigerator (2-8)
v. Wash cells by adding 1- 2 mL of buffer and centrifuge at 300xg
for 10 minutes. Aspirate supernatant completely. Resuspend
cells in 500 µ Ι_ of buffer.
vi. Place an MS column (Miltenyi, Germany) in the magnetic field of
a OctoMACS column stand Separator. Prepare column by
rinsing with 500 µ Ι_ of buffer:
vii. Apply cell suspension onto the column. Collect unlabeled cells
that pass through and wash column with 500 µ Ι_ of buffer. Collect
total effluent; this is the unlabeled cell fraction. Perform washing
steps by adding buffer three times. Only add new buffer when
the column reservoir is empty.
viii. Remove column from the separator and place it on a suitable
collection tube.
ix. Pipette 1 mL of buffer onto the column.
x . Immediately flush out the magnetically labeled cells by firmly
pushing the plunger into the column.
xi. Centrifuge tubes 5 min at 500g, remove supernatant. The final
volume of app. 20µ Ι containing collected CD8+ cells and their
associated Detection Molecules are store at -80C for later
analysis.
Identification of enriched detection molecule: Separated cells and their
associated Detection Molecules are analyzed by PCR amplification of the
attached labels followed by sequencing of the PCR products to reveal the
identity of isolated Detection Molecules and thus the identity of those antigens
for which specific T cells were present in the sample. The identification is done
as for e.g. example 6 .
Example 123
This is an example where the samples are PBMC's prepared as three buffy coats
(BC's), the Linker is PE and streptavidin conjugated dextran, and the Binding
Molecules are biotinylated peptide-MHC (pMHC) complexes. The Labels are synthetic
oligonucleotides modified with a terminal biotin capture-tag.
In this example, cells and their bound Detection Molecules are separated, by
centrifugation, from the supernatant containing Detection Molecules not bound to cells.
The DNA oligonucleotide Labels on Detection Molecules associated with captured cells
are subjected to PCR amplification (as example 3 ) and the PCR product is analyzed as
a read of the oligonucleotide label associated with the detection molecules bound to
the isolated cells thus revealing the identity of detection molecules bound to the T cells
present in the sample (as example 3).
Sample preparation. The samples are PBMC's from three donor materials
prepared as described in example 3 .
Linker preparation: The Linker is PE and streptavidin conjugated dextran
(Dextramer from Immudex) which is prepared as in example 1 .
Binding molecules preparation: Binding Molecules are biotinylated pMHC
complexes with peptide/HLA combination as described in example 3 .
Label preparation: Labels are biotin modified DNA oligonucleotides as
described in example 3 .
Detection molecules preparation: Detection Molecules are prepared by
combining 1 1 0 aliquots of Linker with individual Labels followed by adding
pMHC Binding Molecules as described in Example 3 .
Incubation of sample and detection molecules: PBMC's are mixed with the 1 1 0
member library of Detection Molecules as described in example 3 .
Enrichment of detection molecules with desired characteristics
b.Apply: Detection Molecules are isolated by centrifugation-separation of
cells and their bound Detection Molecules from the
supernatant containing Detection Molecules not bound to cells.
Briefly;
i . Centrifuge cell suspensions at 300xg for 1 0 minutes. Aspirate
supernatant completely.
ii. Wash cells twice by adding 2 mL of buffer (phosphate-buffered
saline (PBS), pH 7.2, 0.5% bovine serum albumin (BSA), and 2
mM EDTA) and centrifuge at 300 x g for 1 0 minutes.
iii. Aspirate supernatant completely. The final volume of app. 20µ Ι
containing collected cells and their associated Detection
Molecules are store at -80C for later analysis.
8 . Identification of enriched Detection Molecule: Separated cells and their
associated Detection Molecules are analyzed by PCR amplification of the
attached labels followed by sequencing of the PCR products to reveal the
identity of isolated Detection Molecules and thus the identity of those antigens
for which specific T cells were present in the sample. The identification is done
as for example 3 .
Example 124
This is an example where the samples are PBMC's prepared as three buffy coats
(BC's), the Linker is PE and streptavidin conjugated dextran, and the Binding
Molecules are biotinylated peptide-MHC (pMHC) complexes. The Labels are synthetic
oligonucleotides modified with a terminal biotin capture-tag.
In this example, INFy producing cells and their bound Detection Molecules are
separated from Detection Molecules not bound to INFy producing cells by magnetic
labeling and capture of INFy producing cells using the MicroBead based INFy
Secretion Assay (INFy Secretion Assay, # 130-054-201 , Miltenyi, Germany). Magnetic
bead-isolated INFg producing cells are subjected to PCR amplification of associated
DNA oligonucleotide Label (as described in example 3) and the PCR product is
analyzed as a read of the oligonucleotide label associated with the detection molecules
bound to the isolated cells thus revealing the identity of detection molecules bound to
the INFy producing cells present in the sample (as example 3).
1. Sample preparation. The samples are PBMC's from three donor materials
prepared as described in example 3 .
2 . Linker preparation: The Linker is PE and streptavidin conjugated dextran
(Dextramer from Immudex) which is prepared as in example 1.
3 . Binding molecules preparation: Binding Molecules are biotinylated pMHC
complexes with peptide/HLA combination as described in example 3 .
4 . Label preparation: Labels are biotin modified DNA oligonucleotides as
described in example 3 .
Detection molecules preparation: Detection Molecules are prepared by
combining 110 aliquots of Linker with individual Labels followed by adding
pMHC Binding Molecules as described in Example 3 .
Incubation of sample and detection molecules: PBMC's are mixed with the 110
member library of Detection Molecules as described in example 3 .
Enrichment of detection molecules with desired characteristics
i . Apply: In this example Detection Molecules are isolated by
capturing INF γ producing cells using anti INF γ catch antibody in
combination with anti INF ydetection antibody. All reagents and
procedures as described by Miltenyi (INF γ Secretion Assay, #
130-054-201 , Miltenyi, Germany). Finally INFy producing cells
are captured using anti PE Microbeads.
ii. Centrifuge tubes 5 min at 500g, remove supernatant. The final
volume of app. 20µ Ι containing collected INFy producing cells
and their associated Detection Molecules are store at -80C for
later analysis.
Identification of enriched detection molecule: Separated cells and their
associated Detection Molecules are analyzed by PCR amplification of the
attached labels followed by sequencing of the PCR products to reveal the
identity of isolated Detection Molecules and thus the identity of those antigens
for which specific T cells were present in the sample. The identification is done
as for example 3 .
ITEMS SET # 1
A method comprising the following steps:
a. Combining at least one cell with at least one detection molecule, where
the detection molecule comprises a binding molecule (BM), a linker (Li),
and a label (La);
b. Allowing the detection molecules to recognize and bind cells through
their binding molecule entity;
c. Detecting or isolating pairs of cell-detection molecule complexes formed
in step (b);
d. Identifying detection molecules capable of binding to a cell in step (b).
2 . The method of item 1 where the binding molecule (BM) is a peptide-MHC complex,
an antibody or an oligonucleotide.
3 . The method of item 1 or 2 where the label (La) is an antibody, a nucleic acid, a
particle comprising an electronic or electromagnetic signal, or a particle comprising
a radio signal.
4 . The method of any of items 1-3 where the linker (Li) is a streptavidin,
polysaccharide, dextran, peptide, or carbon-based polymer.
5 . The method of any of items 1-4 where step c is carried out by immobilization of the
cell-detection molecule pairs
6 . The method of item 5 where said immobilization is by precipitating cells by
centrifugation, immunoprecipitation of the cells optionally involving centrifugation, or
any other means that precipitates the cells, leading to co-precipitation of detection
molecules bound to cells.
7 . The method of item 6 where said immobilization is by binding one or more cells to a
bead, particle or surface, or any other means that immobilizes said one or more
cells, leading to co-immobilization of the detection molecules bound to said one or
more cells.
8 . The method of any of items 5-7 where said immobilization involves the use of an
antibody or other molecule, capable of specifically binding a subset of cells
9 . The method of item 8 where said antibody or other molecule specifically recognizes
the T cell receptor (TCR) or the CD4 or CD8 proteins of T cells.
10 . The method of any of the preceding items where a label uniquely identifies
individual detection molecules or identifies specific subsets of detection molecules
11. The method of any of the preceding items where the Label is an oligonucleotide.
The method of any of the preceding items where the binding molecule is a pMHC
complex, an antibody or an oligonucleotide aptamer.
The method of any of the preceding items where the linker is a dextran molecule,
polysaccharide, oligonucleotide, streptavidin, peptide, carbon-based molecule,
carbohydrate or an organic molecule.
A multimeric major histocompatibility complex (MHC) comprising
a . two or more MHC's linked by a backbone molecule; and
b. at least one nucleic acid molecule linked to said backbone, wherein said
nucleic acid molecule comprises a central stretch of nucleic acids (barcode
region) designed to be amplified by e.g. PCR.
The multimeric major histocompatibility complex according to item 14, wherein the
backbone molecule is selected from the group consisting of polysaccharides, such
as glucans such as dextran, a streptavidin or a streptavidin multimer.
The multimeric major histocompatibility complex according to item 14 or 15,
wherein the MHC's are coupled to the backbone through a streptavidin-biotin
binding, streptavidin-avidin.
The multimeric major histocompatibility complex according to any of the preceding
items, wherein the MHC's are linked to the backbone via the MHC heavy chain.
The multimeric major histocompatibility complex (MHC) according to any of the
preceding items, wherein the MHC is artificially assembled.
The multimeric major histocompatibility complex (MHC) according to any of the
preceding items, composed of at least four MHC's, such as at least eight, such as
at least ten, 2-30, 2-20, such as 2-1 0 or such as 4-1 0 MHC's.
The multimeric major histocompatibility complex (MHC) according to any of the
preceding items, wherein the at least one nucleic acid molecule is composed of at
least a 5' first primer region, a central region (barcode region), and a 3' second
primer region.
The multimeric major histocompatibility complex (MHC) according to any of the
preceding items, wherein the at least one nucleic acid molecule has a length in the
range 20-100 nucleotides, such as 30-100, such as 30-80, such as 30-50
nucleotides.
The multimeric major histocompatibility complex (MHC) according to any of the
preceding items, wherein the at least one nucleic acid molecule is linked to said
backbone via a streptavidin-biotin binding and/or streptavidina-avidin binding.
The multimeric major histocompatibility complex (MHC) according to any of the
preceding items, wherein the at least one nucleic acid molecule comprises or
consists of DNA, RNA, and/or artificial nucleotides such as PLA or LNA.
The multimeric major histocompatibility complex (MHC) according to any of the
preceding items, wherein the MHC is selected from the group consisting of class I
MHC, a class I I MHC, a CD1 , or a MHC-like molecule.
The multimeric major histocompatibility complex (MHC) according to any of the
preceding items, wherein the backbone further comprises one or more linked
fluorescent labels.
A composition comprising a subset of multimeric major histocompatibility
complexes (MHC's) according to any of items 14-25, wherein each set of MHC's
has a different peptide decisive for T cell recognition and a unique "barcode" region
in the DNA molecule.
The composition according to item 26, wherein the primer regions in the DNA
molecule are identical for each set of MHC's.
A) The composition according to item 26 or 27, comprising at least 10 different sets
of MHC's such as at least 100, such as at least 500, at least 1000, at least 5000,
such as in the range 10-50000, such as 10-1000 or such as 50-500 sets of MHC's.
B) A kit of parts comprising
a . a composition according to any of items 26 to 28; and
b. one or more sets of primers for amplifying the nucleic acid molecules.
A method for detecting antigen responsive cells in a sample comprising:
i) providing one or more multimeric major histocompatibility complexes (MHC's)
according to any of items 1- 12 or a composition according to any of items 14-16; ii)
contacting said multimeric MHC's with said sample; and detecting binding of the
multimeric MHC's to said antigen responsive cells, thereby detecting cells
responsive to an antigen present in a set of MHC's, wherein said binding is
detected by amplifying the barcode region of said nucleic acid molecule linked to
the one or more MHC's.
The method according to item 29, wherein unbound MHC's are removed before
amplification, e.g. by washing and/or spinning.
The method according to item 29 or 30, wherein the sample is a blood sample,
such as an peripheral blood sample, a blood derived sample, a tissue biopsy or
another body fluid, such as spinal fluid, or saliva.
The method according to any of items 29-31 , wherein said sample has been
obtained from a mammal, such as a human, mouse, pigs, and/or horses.
The method according to any of item 30-32, wherein the method further comprises
cell sorting by e.g. flow cytometry such as FACS.
The method according to any of items 29-33, wherein said binding detection
includes comparing measured values to a reference level, e.g. a negative control
and/or total level of response.
The method according to any of item 29-34, wherein said amplification is PCR such
as QPCR.
The method according to any of items 29-35, wherein the detection of barcode
regions includes sequencing of said region such as deep sequencing or next
generation sequencing.
Use of a multimeric major histocompatibility complex (MHC) according to any of
items 14-25 or a composition according to any of items 26-29 for the detecting of
antigen responsive cells in a sample.
Use of a multimeric major histocompatibility complex (MHC) according to any of
items 14-25 or a composition according to any of items 26-29 in the diagnosis of
diseases or conditions, preferably cancer and/or infectious diseases.
Use of a multimeric major histocompatibility complex (MHC) according to any of
items 14-25 or a composition according to any of items 26-29 in the development of
immune-therapeutics.
Use of a multimeric major histocompatibility complex (MHC) according to any of
items 14-25 or a composition according to any of items 26-29 in the development of
vaccines.
Use of a multimeric major histocompatibility complex (MHC) according to any of
items 14-25 or a composition according to any of items 26-29 for the identification
of epitopes.
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ITEMS SET #2
1. A detection molecule comprising
a . at least one binding molecule (BM),
b. at least one linker (Li), and
c . at least one label (La).
A cell-detection molecule complex comprising
a .At least one detection molecule comprising a binding molecule (BM),
linker (Li) and a label (La), and
b. at least one cell.
A composition comprising two or more different detection molecules, or two or
more sets of different detection molecules, each detection molecule comprising
at least one binding molecule (BM), at least one linker (Li) and at least one label
(La),
wherein each of the two or more detection molecules, or two or more sets of
detection molecules, comprises a label which is unique to and specific for the
binding molecule of each of said two or more different detection molecules.
The composition according to item 3 , said composition comprising 2 to
1,000,000 different detection molecules, such as 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11, 12 ,
13 , 14, 15, 16 , 17, 18 , 19 , 20, 2 1, 22, 23, 24, 25, 26, 27, 28, 29, 30, 3 1 , 32, 33,
34, 35, 36, 37, 38, 39, 40 different detection molecules or sets of different
detection molecules; for example 1-3, 3-5, 5-10, 10-15, 15-20, 20-25, 25-30, 30-
35, 35-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-1 00, 100-1 10, 110-1 20, 120-
130, 130-140, 140-1 50, 150-175, 175-200, 200-250, 250-300, 300-400, 400-
500, 500-600, 600-700, 700-800, 800-900, 900-1000, 1000-1500, 1500-2000,
2000-3000, 3000-4000, 4000-5000, 5000-7500, 7500-10,000, 10,000-20,000,
20,000-50,000, 50,000-100,000, 100,000-200,000, 200,000-500,000, 500,000-
1,000,000 different detection molecules, or sets of different detection
molecules.
The detection molecule according to any of the preceding items, wherein said
binding molecule is capable of specifically associating with, recognizing and/or
binding to a structure belonging to or associated with an entity in a sample,
such as a target structure.
The detection molecule according to any of the preceding items, wherein said
binding molecule associates with, recognizes and/or binds to a marker molecule
specific for a given cell or cell type.
The detection molecule according to any of the preceding items, wherein said
binding molecule is capable of specifically associating with, recognizing and/or
binding to a specific cell type, such as selected from the group consisting of
immune cells, lymphocytes, monocytes, dendritic cells, T-cells, B-cells, NK
cells, CD4+ T cells, CD8+ T cells, αβ T cells, invariant γ δ T cells, antigen-
specific T-cells, cells comprising TCRs, cells comprising BCRs, a specific
cancer cell
The detection molecule according to any of the preceding items, wherein said
binding molecule is capable of specifically associating with, recognizing and/or
binding to a target specifically associated with an organ selected from the group
consisting of lymph nodes, kidney, liver, skin, brain, heart, muscles, bone
marrow, skin, skeleton, lungs, the respiratory tract, spleen, thymus, pancreas,
exocrine glands, bladder, endocrine glands, reproduction organs including the
phallopian tubes, eye, ear, vascular system, the gastroinstestinal tract including
small intestines, colon, rectum, canalis analis and prostate gland.
The detection molecule according to any of the preceding items, wherein said
binding molecule is peptide-based or protein-based.
The detection molecule according to any of the preceding items, wherein said
binding molecule is an anti-target molecule capable of specifically associating
with, recognizing and/or binding to a predetermined target structure.
The detection molecule according to any of the preceding items, wherein said
binding molecule is an anti-target-molecule.
The detection molecule according to any of the preceding items, wherein said
binding molecule is selected from the group consisting of an antibody, an
antibody mimetic, an antibody-like molecule, a peptide, an oligonucleotide, a
peptide aptamer, a nucleic acid aptamer, a DNA aptamer, an RNA aptamer, an
XNA aptamer, a ligand, a natural ligand, a variant or fragment of a natural
ligands, a synthetic ligand and a small organic molecule.
The detection molecule according to any of the preceding items, wherein said
antibody mimetic is selected from the group consisting of affibody molecules,
affilinns, affimers, affitins, alphabodies, anticalins, avimers, DARPins, fynomers,
Kunitz domain peptides and monobodies.
The detection molecule according to any of the preceding items, wherein said
binding molecule is an antibody selected from the group consisting of a
monoclonal antibody, a polyclonal antibody, a bi-specific antibody, an antibody
like molecule, a Fc-molecule, a KIR-molecule, a ScFv and a Fab.
The detection molecule according to any of the preceding items, wherein said
binding molecule is a peptide of 1-100 amino acid residues without tertiary
structure.
The detection molecule according to any of the preceding items, wherein said
binding molecule is a MHC molecule or MHC complex.
The detection molecule according to any of the preceding items, wherein said
binding molecule is a MHC class I complex.
The detection molecule according to any of the preceding items, wherein said
binding molecule is a MHC class I I complex.
The detection molecule according to any of the preceding items, wherein said
binding molecule is a MHC-like molecule.
The detection molecule according to any of the preceding items, wherein said
binding molecule is CD1 , wherein said CD1 is selected from the group
consisting of CD1 CD1a, CD1 b, CD1c, CD1d and CD1 e.
The detection molecule according to any of the preceding items, wherein said
binding molecule is a MHC Class l-like proteins; including MIC A , MIC B, CD1d,
HLA E, HLA F, HLA G, HLA H, ULBP-1 , ULBP-2, and ULBP-3.
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is a cell-surface target.
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is an intracellular target.
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is a receptor, such as a cell-surface receptor, an
intracellular receptor, a soluble receptor or an extracellular receptor.
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is a T-cell receptor.
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is a B-cell receptor.
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is CD4 of T cells.
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is CD8 of T cells.
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is CD20 of B cells.
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is selected from the group consisting of cancer
cell markers, developmental markers, cell cycle markers, proliferation markers,
activation markers, hormones, hormone receptors, intracellular markers, cluster
of differentiation (CD), cell surface markers, cytokines and cytokine receptors.
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is selected from the group consisting of CD2,
CD3, CD4, CD5, CD8, CD9, CD27, CD28, CD30, CD69, CD1 34 (OX40),
CD137 (4-1 BB), CD147, CDw1 50 (SLAM), CD152 (CTLA-4), CD1 53 (CD30L),
CD40L (CD1 54), NKG2D, ICOS, HVEM, HLA Class II, PD-1 , Fas (CD95), FasL,
CD40, CD48, CD58, CD70, CD72, B7.1 (CD80), B7.2 (CD86), B7RP-1 , B7-H3,
PD-L1 , PD-L2, CD134L, CD137L, ICOSL, LIGHT CD1 6 , NKp30, NKp44,
NKp46, NKp80, 2B4, KIR, LIR, CD94/NKG2A, CD94/NKG2C, LFA-1 ,
CD1 1a/1 8 , CD54 (ICAM-1 ) , CD1 06 (VCAM), CD49a,b,c,d,e,f/CD29 (VLA-4),
CD1 1a, CD14, CD15, CD19, CD25, CD30, CD37, CD49a, CD49e, CD56,
CD27, CD28, CD45, CD45RA, CD45RO, CD45RB, CCR7, CCR5, CD62L,
CD75, CD94, CD99, CD1 07b, CD1 09, CD1 52, CD1 53, CD154, CD160, CD161 ,
CD1 78, CDw1 97, CDw21 7 , Cd229, CD245, CD247 and Foxp3.
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is a cytokine selected from the group consisting
of TNFa, ΤΝ , TNF, IFNa, Ι Ν , IFNy, IL-1 , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-
8 , IL-9, IL-10, IL-1 0-20, IL-20-30, IL-30, IL-31 , IL-32, IL-33, IL-34, IL-35, IL-36,
IL-37, IL-38, IL-39, IL-40, NFKB , chemokines including CC chemokines (CCL1
to CCL-28), CXC chemokines (CXCL1 to CXCL17) C chemokines (XCL-1 and -
2) and CX3X chemokines (CX3CL1 ) .
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is a cancer cell marker selected from the group
consisting of HER2, CA125, Tyrosinase, Melanoma-associated antigen
(MAGE), abnormal products of Ras or p53, Carcinoembryonic antigen, Muc-1 ,
Epithelial tumor antigen, Carbonic Anhydrase, VEGFR, EGFR, TRAIL and
RANKL.
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is a stem cell marker selected from the group
consisting of Stro-1 , CD146, CD105, CD44, c-kit, Oct4, Sox-2, Klf4, EphB,
Nestin and TWIST-1 .
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is a developmental marker selected from the
group consisting of Nanog, Oct4, Sox2, TEKT-1 , NANOS, c-kit, Sox9, Notch,
Msx1 , Msx2 and Coll .
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is a proliferation marker selected from the group
consisting of CyclinA, CyclinB, PCNA, PC1 0 , p53, Mdm2, Cyclin D, Cyclin E,
Rb, ARF and HDM2.
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is an activation marker selected from the group
consisting of CD28, Tbet, Eomes, Blimp, Bcl-6, CD27, MHC-II, TNF, IFN, Fizzl ,
ARG1 and CCL22R.
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is an hormone selected from the group consisting
of estrogen, PTH, ADH, T3, ANP, Epinephrine, Norepinephrine, Cortisol,
Corticosterone, Aldosterone, Progestin, EPO, Leptin, Insulin, Glucagon, T4,
ACTH, FSH, oxytocin and Calcitriol.
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is an hormone receptor selected from the group
consisting of EstrogenR (ER), GLP-1 R, Thyroid receptor, Leptin receptor,
Epinephrine receptor, Insulin receptor and Glucagon receptor.
The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is a cluster of differentiation (CD) molecule
selected from the group consisting of CD1-10, CD10-20, CD20-30, CD30-40,
CD40-50, CD50-1 00, CD1 00-200, CD200-300 and CD300-364.
4 1. The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is an intracellular marker selected from the group
consisting of Cyclins, Cytokines and organelle markers (for example Apg12,
Syntaxin, PAF-46, Histones, Early endosome antigen, clathrin, tubulins, PAF49,
FTCD).
42. The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is selected from the group consisting of CD1 ,
CD1a, CD1 b, CD1c, CD1d, and MR1 .
43. The detection molecule according to any of the preceding items, wherein the
target of the binding molecule is selected from the group consisting of targets
included in Table 4 of the examples.
44. The detection molecule according to any of the preceding items, wherein said
binding molecule is a surface-molecule receptor to a cytokine receptor selected
from the group consisting of interleukins and TNF-like molecules.
45. The detection molecule according to any of the preceding items, wherein said
label is any molecule, atom or signal the identity of which can be determined.
46. The detection molecule according to any of the preceding items, wherein said
label is unique to and/or specifies the binding molecule or a group of binding
molecules.
47. The detection molecule according to any of the preceding items, wherein said
detection molecule comprises one label.
48. The detection molecule according to any of the preceding items, wherein said
detection molecule comprises more than one label.
49. The detection molecule according to any of the preceding items, wherein said
detection molecule comprises two or more labels, such as 3 labels, 4 labels, 5
labels, 6 labels, 7 labels, 8 labels, 9 labels, 10 labels, 11, 12 , 13 , 14 , 15 , 16 , 17 ,
18, 19 , 20, 20-25, 25-30, 30-40, 40-50, 50-75, 75-1 00 labels.
50. The detection molecule according to any of the preceding items, wherein said
detection molecule comprises two or more labels and each of said labels are
identical to each other.
5 1 . The detection molecule according to any of the preceding items, wherein said
detection molecule comprises two or more labels and at least two of said labels
are different.
52. The detection molecule according to any of the preceding items, wherein said
label is attached to the linker of the detection molecule.
53. The detection molecule according to any of the preceding items, wherein said
label is attached to the binding molecule of the detection molecule.
54. The detection molecule according to any of the preceding items, wherein said
label comprises a connector molecule (attachment molecule) for attachment to
the detection molecule.
55. The detection molecule according to any of the preceding items, wherein said
label is a nucleic acid label.
56. The detection molecule according to any of the preceding items, wherein said
label is a nucleic acid label selected from the group consisting of a DNA label,
an RNA label, and an artificial nucleic acid label.
57. The detection molecule according to any of the preceding items, wherein said
label is a nucleic acid label comprising one or more nucleotides individually
derived from one or more of DNA, RNA, and an artificial nucleic acid.
58. The detection molecule according to any of the preceding items, wherein said
artificial nucleic acid is selected from the group consisting of XNA, LNA, PNA,
GNA, TNA, HNA, CeNA, and morpholino-nucleic acids.
59. The detection molecule according to any of the preceding items, wherein said
label is a DNA label.
60. The detection molecule according to any of the preceding items, wherein said
nucleic acid label comprises 1 to 1,000,000 nucleic acids, such as 1, 2 , 3 , 4 , 5 ,
6 , 7 , 8 , 9 , 10, 11, 12, 13, 14, 15, 16 , 17, 18 , 19, 20, 2 1, 22, 23, 24, 25, 26, 27,
28, 29, 30, 3 1, 32, 33, 34, 35, 36, 37, 38, 39, 40 nucleic acids; for example 1-3,
3-5, 5-1 0 , 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-50, 50-60, 60-70, 70-
80, 80-90, 90-1 00, 100-1 10, 110-1 20, 120-1 30, 130-140, 140-150, 150-1 75,
175-200, 200-250, 250-300, 300-400, 400-500, 500-600, 600-700, 700-800,
800-900, 900-1 000, 1000-1500, 1500-2000, 2000-3000, 3000-4000, 4000-
5000, 5000-7500, 7500-10,000, 10,000-1 00,000, 100,000-1 ,000,000 nucleic
acids.
6 1 . The detection molecule according to any of the preceding items, wherein said
label is a nucleic acid label comprising one or more of
a . barcode region,
b. 5' first primer region (forward)
c . 3' second primer region (reverse),
d . random nucleotide region,
e.connector molecule
f . stability-increasing components
g . short nucleotide linkers in between any of the above-mentioned
components
h . adaptors for sequencing
i . annealing region
62. The detection molecule according to any of the preceding items, wherein said
label is a nucleic acid label comprising at least a barcode region.
The detection molecule according to any of the preceding items, wherein said
label is a nucleic acid label comprising at least a barcode region, wherein said
barcode region comprises a sequence of consecutive nucleic acids.
The detection molecule according to any of the preceding items, wherein the
barcode region of said nucleic acid comprises 1-3, 3-5, 5-1 0 , 10-15, 15-20, 20-
25, 25-30, 30-35, 35-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-1 00, 100-1 10,
110-1 20, 120-1 30, 130-140, 140-1 50, 150-1 75, 175-200, 200-250, 250-300,
300-400, 400-500, 500-600, 600-700, 700-800, 800-900, 900-1000 nucleic
acids.
The detection molecule according to any of the preceding items, wherein said
barcode region comprises or consists of 5-1 0 , 10-15, 15-20, 20-25, 25-30, 30-
40, 40-45, 45-50 nucleic acids.
The detection molecule according to any of the preceding items, wherein said
label is a nucleic acid label comprising at least a 3' primer region, a barcode
region, and a 5' primer region.
The detection molecule according to any of the preceding items, wherein said
label is a nucleic acid label comprising at least a 3' primer region, a barcode
region, and a 5' primer region, wherein said barcode region is designed to be
amplified by e.g. PCR and identified by e.g. sequencing.
The detection molecule according to any of the preceding items, wherein the
primer regions of said nucleic acid label are identical for subsets of detection
molecules comprising different labels.
The detection molecule according to any of the preceding items, wherein said
label is a nucleic acid label comprising a connector molecule which is able to
interact with a component on the linker and/or binding molecule of the detection
molecule.
The detection molecule according to any of the preceding items, wherein said
nucleic acid label comprises a connector molecule which is biotin.
7 1 . The detection molecule according to any of the preceding items, wherein said
nucleic acid label comprises a random nucleotide region comprising 3-20
nucleotides, such as 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10, 11, 12 , 13,1 4,1 5 , 16 , 17, 18 , 19 or
20 nt.
72. The detection molecule according to any of the preceding items, wherein said
nucleic acid label comprises one or more stability-increasing components, such
as HEG or TEG.
73. The detection molecule according to any of the preceding items, wherein a
sample identifying sequence is attached to the nucleic acid label such as by
attachment to one of the primers capable of binding to the primer regions of the
nucleic acid label.
74. The detection molecule according to any of the preceding items, wherein said
label is a peptide label.
75. The detection molecule according to any of the preceding items, wherein said
peptide label comprises a stretch of consecutive amino acid residues (coding
region).
76. The detection molecule according to any of the preceding items, wherein said
peptide label comprises a stretch of consecutive amino acid residues (coding
region) and a protease cleavage site.
77. The detection molecule according to any of the preceding items, wherein said
peptide label comprises a stretch of consecutive amino acid residues (coding
region) and a protease cleavage site.
78. The detection molecule according to any of the preceding items, wherein said
protease cleavage site in said peptide label is located proximal to the linker that
connects the label to the binding molecule.
79. The detection molecule according to any of the preceding items, wherein said
peptide label comprising a protease cleavage site allows for cleavage of the
stretch of consecutive amino acid residues (coding region) and release thereof
from the detection molecule.
80. The detection molecule according to any of the preceding items, wherein said
label is a peptide label comprising 2 or more consecutive amino acids, such as
2-3 , 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10, 10-1 1, 11-12, 12-13, 13-14, 14-1 5 , 15-16,
16-17, 17-18, 18-1 9 , 19-20, 20-21 , 21-22, 22-23, 23-24, 24-25, 25-26, 26-27,
27-28, 28-29, 29-30, 30-31 , 3 1-32, 32-33, 33-34, 34-35, 35-36, 36-37, 37-38,
38-39, 39-40, 40-45, 45-50, 50-55, 55-60, 60-65, 65-70,70-75, 75-80, 80-85,
85-90, 90-95, 95-1 00, 100-1 10 , 110-120, 120-1 30, 130-140, 140-150, 150-160,
160-1 70,170-1 80, 180-190, 190-200, 200-225, 225-250, 250-275, 275-300,
300-350, 350-400, 400-450, 450-500, 500-600, 600-700, 700-800, 800-900,
900-1 000, 1000-1 500, 1500-2000, or more than 2000, consecutive amino acids.
8 1 . The detection molecule according to any of the preceding items, wherein said
peptide label comprises proteinogenic and/or non-proteinogenic amino acids.
82. The detection molecule according to any of the preceding items, wherein said
label is a fluorescent label (fluorophore label).
83. The detection molecule according to any of the preceding items, wherein said
label is a fluorescent label selected from the group consisting of fluorescein
isothiocyanate (FITC), fluorescein (Flu) derivates, rhodamine,
tetramethylrhodamine, phycoerythrin, R-phycoerythrin (RPE), allophycoerythrin,
phycocyanin, allophycocyanin, o-phthaldehyde, fluorescamine; 2-(4'-
maleimidylanilino)naphthalene-6- sulfonic acid; 5-((((2-
iodoacetyl)amino)ethyl)amino) naphthalene-1 -sulfonic acid; Pyrene-1-butanoic
acid; AlexaFluor 350 (7-amino-6-sulfonic acid-4-methyl coumarin-3-acetic acid);
AMCA (7-amino-4-methyl coumarin-3-acetic acid); 7-hydroxy-4-methyl
coumarin-3-acetic acid; Marina Blue (6,8-difluoro-7-hydroxy-4-methyl coumarin-
3-acetic acid); 7-dimethylamino-coumarin-4-acetic acid; Fluorescamin-N-butyl
amine adduct; 7-hydroxy-coumarine-3-carboxylic acid; CascadeBlue (pyrene-
trisulphonic acid acetyl azide); Cascade Yellow; Pacific Blue (6,8 difluoro-7-
hydroxy coumarin-3-carboxylic acid); 7-diethylamino-coumarin-3-carboxylic
acid; N-(((4-azidobenzoyl)amino)ethyl)- 4-amino-3,6-disulfo-1 ,8-naphthalimide;
Alexa Fluor 430; 3-perylenedodecanoic acid; 8-hydroxypyrene-1 ,3,6-trisulfonic
acid; 12-(N-(7-nitrobenz-2-oxa-1 ,3- diazol-4-yl)amino)dodecanoic acid; Ν ,Ν'-
dimethyl-N- (iodoacetyl)-N'-(7-nitrobenz-2- oxa-1 ,3-diazol-4-yl)ethylenediamine;
Oregon Green 488 (difluoro carboxy fluorescein); 5-iodoacetamidofluorescein;
propidium iodide-DNA adduct; Carboxy fluorescein; 5- or 6-carboxyfluorescein;
6-(fluorescein)-5-(and 6)-carboxamido hexanoic acid; Texas Red, Princeton
Red, Green fluorescent protein (GFP) and analogues thereof; PerCP;
AlexaFluor®(AF), AF405, AF488,AF500, AF514, AF532, AF546, AF555,
AF568, AF594, AF610, AF633, AF635, AF647, AF680, AF700, AF710, AF750,
AF800; Quantum Dot based dyes, Qdot®525, Qdot®565, Qdot®585,
Qdot®605, Qdot®655, Qdot®705, Qdot®800; DyLight™ Dyes (Pierce) (DL);
DL549, DL649, DL680, DL800; Cy-Dyes, Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7;
Fluorescent Proteins, RPE, PerCp, APC, Green fluorescent proteins; GFP and
GFP derivated mutant proteins; BFP,CFP, YFP, DsRed, T 1, Dimer2,
mRFP1 ,MBanana, mOrange, dTomato, tdTomato, mTangerine, mStrawberry,
mCherry; Tandem dyes, RPE-Cy5, RPE-Cy5.5, RPE-Cy7, RPE-AlexaFluor®
tandem conjugates; RPE-Alexa61 0 , RPE-TxRed, APC-Aleca600, APC-
Alexa610, APC-Alexa750, APC-Cy5 and APC-Cy5.5.
84. The detection molecule according to any of the preceding items, wherein said
label is a phosphorescence label.
85. The detection molecule according to any of the preceding items, wherein said
label is a bioluminescence label or chemoluminescence label.
86. The detection molecule according to any of the preceding items, wherein said
chemoluminiscence label is selected from luminol, isoluminol, acridinium esters,
acridinium salt, theromatic acridinium ester, 1,2-dioxetanes, oxalate ester,
imidazole and pyridopyridazines.
87. The detection molecule according to any of the preceding items, wherein said
bioluminiscence label is selected from the group luciferin, luciferase and
aequorin.
88. The detection molecule according to any of the preceding items, wherein said
label is an enzymatic label.
89. The detection molecule according to any of the preceding items, wherein said
label is an enzymatic label, wherein the enzyme catalyze a reaction between
chemicals in the near environment of the labeling molecules, which results in
one or more of producing a light signal (chemi-luminescence) and precipitation
of chromophor dyes.
90. The detection molecule according to any of the preceding items, wherein said
label is an enzymatic label selected from peroxidases, malate dehydrogenase,
staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol
dehydrogenase, alpha-glycerophosphate, dehydrogenase, triose phosphate
isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase,
glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-
6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase.
9 1 . The detection molecule according to any of the preceding items, wherein said
label is an enzymatic label selected from horse radish peroxidase (HRP),
alkaline phosphatase (AP), beta-galactosidase (GAL), glucose-6-phosphate
dehydrogenase, beta-N-acetylglucosaminidase, β-glucuronidase, invertase,
Xanthine Oxidase, firefly luciferase and glucose oxidase (GO).
92. The detection molecule according to any of the preceding items, wherein said
label is capable of reflection of light, such as gold, plastic, glass, polystyrene
and pollen.
93. The detection molecule according to any of the preceding items, wherein said
label is capable of capable of absorption of light, such as a chromophore or a
dye.
94. The detection molecule according to any of the preceding items, wherein said
label is capable of emission of light after excitation, such as a fluorochrome.
95. The detection molecule according to any of the preceding items, wherein said
label is a nanoparticle label.
96. The detection molecule according to any of the preceding items, wherein said
label is an element.
97. The detection molecule according to any of the preceding items, wherein said
label is selected from the group consisting of heavy metal labels, isotope labels,
radiolabels, radionuclide, stable isotopes, chains of isotopes and single atoms.
98. The detection molecule according to any of the preceding items, wherein said
label is a single atom selected from the group consisting of zinc (Zn), iron (Fe),
magnesium (Mg), any of the lanthanides (Ln) including La, Ce, Pr, Nd, Pm, Sm,
Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb and Lu; scandium (Sc) and yttrium (Y).
99. The detection molecule according to any of the preceding items, wherein said
radioactivity labels comprises incorporated isotopes of iodide, cobalt, selenium,
tritium and/or phosphor.
100. The detection molecule according to any of the preceding items, wherein
said label is a DNA fluorescing stain, such as Propidium iodide, Hoechst stain,
DAPI, DraQ5 or Acridine orange.
101 . The detection molecule according to any of the preceding items, wherein
said label comprises a nucleic acid label and at least a second label.
102. The detection molecule according to any of the preceding items, wherein
said label comprises a nucleic acid label and at least a second label according
to any of the preceding items.
103. The detection molecule according to any of the preceding items, wherein
said label comprises a nucleic acid label and a fluorophore label.
104. The detection molecule according to any of the preceding items, wherein
said label comprises one type of label.
105. The detection molecule according to any of the preceding items, wherein
said label comprises more than one type of label, such as comprising 2 types of
labels, for example comprising 3 types of labels, such as comprising 4 types of
labels, for example comprising 5 types of labels.
106. The detection molecule according to any of the preceding items, wherein
said linker is a molecular entity and/or bond that connects the binding molecule
and the label.
107. The detection molecule according to any of the preceding items, wherein
one or more of the binding molecules are covalently associated with the one or
more linkers.
108. The detection molecule according to any of the preceding items, wherein
one or more of the binding molecules are non-covalently associated with the
one or more linkers.
109. The detection molecule according to any of the preceding items, wherein
one or more labels are covalently associated with the one or more linkers.
110 . The detection molecule according to any of the preceding items, wherein
one or more of labels are non-covalently associated with the one or more
linkers.
111. The detection molecule according to any of the preceding items, wherein
the one or more labels and/or one or more binding molecules are associated
with a molecule in the one or more linkers, such as a connector molecule, a
sugar residue, a protein, an antibody, a DNA, an aptamer, reactive groups,
nucleophilic group, electrophilic groups, radicals, or conjugated double bonds.
112 . The detection molecule according to any of the preceding items, wherein
the one or more linkers comprises one or more multimerization domains.
113. The detection molecule according to any of the preceding items, wherein
the one or more linkers comprises one or more scaffolds.
114. The detection molecule according to any of the preceding items, wherein
the one or more linkers comprises one or more connectors.
115 . The detection molecule according to any of the preceding items, wherein
the one or more multimerization domains comprises at least one scaffold and at
least one connector.
116 . The detection molecule according to any of the preceding items, wherein
the binding molecule and/or the label is attached to the linker via a streptavidin-
biotin linkage.
117 . The detection molecule according to any of the preceding items, wherein
the one or more linkers comprise one or more optionally substituted organic
molecules.
118 . The detection molecule according to any of the preceding items, wherein
the optionally substituted organic molecule comprises one or more
functionalized cyclic structures.
119 . The detection molecule according to any of the preceding items, wherein
the one or more functionalized cyclic structures comprises one or more
benzene rings.
120. The detection molecule according to any of the preceding items, wherein
the optionally substituted organic molecule comprises a scaffold molecule
comprising at least three reactive groups, or at least three sites suitable for non-
covalent attachment.
12 1 . The detection molecule according to any of the preceding items, wherein
the one or more linkers comprises one or more biological cells and/or cell-like
structures, such as antigen presenting cells or dendritic cells.
122. The detection molecule according to any of the preceding items, wherein
the one or more linkers comprises one or more membranes.
123. The detection molecule according to any of the preceding items, wherein
the one or more membranes comprises liposomes or micelles.
124. The detection molecule according to any of the preceding items, wherein
the one or more linkers comprises one or more polymers such as one or more
synthetic polymers.
125. The detection molecule according to any of the preceding items, wherein
reactive groups involved in forming an association between the multimerization
domain and the binding molecule are located on glutamate or aspartate
residues, or on a vinyl sulfone activated dextran.
126. The detection molecule according to any of the preceding items, wherein
the one or more linker polymers are selected from the group consisting of
polysaccharides.
127. The detection molecule according to any of the preceding items, wherein
the linker comprises one or more dextran moieties.
128. The detection molecule according to any of the preceding items, wherein
the one or more dextran moieties are covalently attached to one or more
binding molecules.
129. The detection molecule according to any of the preceding items, wherein
the one or more dextran moieties are non-covalently attached to one or more
binding molecules.
130. The detection molecule according to any of the preceding items, wherein
the one or more dextran moieties are covalently attached to one or more labels.
13 1 . The detection molecule according to any of the preceding items, wherein
the one or more dextran moieties are non-covalently attached to one or more
labels.
132. The detection molecule according to any of the preceding items, wherein
reactive groups of the multimerization domains include hydroxyls of
polysaccharides such as dextrans.
133. The detection molecule according to any of the preceding items, wherein
the one or more linker dextran moieties are modified.
134. The detection molecule according to any of the preceding items, wherein
the one or more linker dextran moieties are activated.
135. The detection molecule according to any of the preceding items, wherein
the one or more linker dextran moieties are activated by reaction of the dextran
hydroxyls with divinyl sulfon.
136. The detection molecule according to any of the preceding items, wherein
dextran is activated by a multistep reaction that results in the decoration of the
dextran with maleimide groups.
137. The detection molecule according to any of the preceding items, wherein
the one or more linker dextran moieties comprises one or more amino-dextrans.
138. The detection molecule according to any of the preceding items, wherein
the one or more linker dextran moieties comprises one or more amino-dextrans
modified with divinyl sulfone.
139. The detection molecule according to any of the preceding items, wherein
the one or more linker dextran moieties comprises one or more dextrans with a
molecular weight of from 1,000 to 50,000, such as from 1,000 to 5,000, for
example 5,000 to 10,000, such as from 10,000 to 15,000, for example 15,000 to
20,000, such as from 20,000 to 25,000, for example 25,000 to 30,000, such as
from 30,000 to 35,000, for example 35,000 to 40,000, such as from 40,000 to
45,000, for example 45,000 to 50,000.
140. The detection molecule according to any of the preceding items, wherein
the one or more linker dextran moieties comprises one or more dextrans with a
molecular weight of from 50,000 to 150,000, such as from 50,000 to 60,000, for
example 60,000 to 70,000, such as from 70,000 to 80,000, for example 80,000
to 90,000, such as from 90,000 to 100,000, for example 100,000 to 110,000,
such as from 110,000 to 120,000, for example 120,000 to 130,000, such as
from 130,000 to 140,000, for example 140,000 to 150,000.
141 . The detection molecule according to any of the preceding items, wherein
the one or more linker dextran moieties comprises one or more dextrans with a
molecular weight of from 150,000-270,000 such as from 150,000 to 160,000, for
example 160,000 to 170,000, such as from 170,000 to 180,000, for example
180,000 to 190,000, such as from 190,000 to 200,000, for example 200,000 to
2 10,000, such as from 2 10,000 to 220,000, for example 220,000 to 230,000,
such as from 230,000 to 240,000, for example 240,000 to 250,000, such as
from 250,000 to 260,000, for example 260,000 to 270,000, such as from
270,000 to 280,000, for example 280,000 to 290,000, such as from 290,000 to
300,000, for example 300,000 to 3 10,000 such as from 3 10,000 to 320,000, for
example 320,000 to 330,000 such as from 330,000 to 340,000, for example
340,000 to 350,000 such as from 350,000 to 360,000, for example 360,000 to
370,000 such as from 370,000 to 380,000, for example 380,000 to 390,000,
such as from 390,000 to 400,000.
142. The detection molecule according to any of the preceding items, wherein
the one or more linker dextran moieties are linear.
143. The detection molecule according to any of the preceding items, wherein
the one or more linker dextran moieties are branched.
144. The detection molecule according to any of the preceding items, wherein
the one or more linkers comprises a carboxy methyl dextran and/or a dextran
polyaldehyde and/or a carboxymethyl dextran lactone and/or a cyclodextrin.
145. The detection molecule according to any of the preceding items, wherein
the one or more linker synthetic polymers are selected from the group
consisting of PNA, polyamide and PEG.
146. The detection molecule according to any of the preceding items, wherein
the one or more linkers comprises one or more entities selected from the group
consisting of an IgG domain, a coiled-coil polypeptide structure, a DNA duplex,
a nucleic acid duplex, PNA-PNA, PNA-DNA, DNA-RNA.
147. The detection molecule according to any of the preceding items, wherein
the one or more linkers, such as one or more multimerization domains,
comprises one or more avidins, such as one or more streptavidins.
148. The detection molecule according to any of the preceding items, wherein
the one or more streptavidins comprises one or more tetrameric streptavidin
variants.
149. The detection molecule according to any of the preceding items, wherein
the one or more streptavidins comprises one or more monomeric streptavidin
variants.
150. The detection molecule according to any of the preceding items, wherein
the one or more linkers comprises an antibody.
15 1 . The detection molecule according to any of the preceding items, wherein
the linker antibody is selected from the group consisting of polyclonal antibody,
monoclonal antibody, IgA, IgG, IgM, IgD, IgE, lgG1 , lgG2, lgG3, lgG4, lgA1 ,
lgA2, lgM1 , lgM2, humanized antibody, humanized monoclonal antibody,
chimeric antibody, mouse antibody, rat antibody, rabbit antibody, human
antibody, camel antibody, sheep antibody, engineered human antibody,
epitope-focused antibody, agonist antibody, antagonist antibody, neutralizing
antibody, naturally-occurring antibody, isolated antibody, monovalent antibody,
bispecific antibody, trispecific antibody, multispecific antibody, heteroconjugate
antibody, immunoconjugates, immunoliposomes, labeled antibody, antibody
fragment, domain antibody, nanobody, minibody, maxibody, diabody, fusion
antibody.
152. The detection molecule according to any of the preceding items, wherein
the detection molecule comprises one or more organic molecules selected from
the group consisting of small organic scaffold molecules, small organic
molecules, steroids, peptides, aromatic organic molecules, monocyclic
structures, functionalized or substituted benzene rings, dicyclic structures,
polycyclic structures, aliphatic molecules, monocyclic molecules, dicyclic
molecules, polycyclic molecules.
153. The detection molecule according to any of the preceding items, wherein
the detection molecule comprises one or more monomeric molecules able to
polymerize; one or more biological polymers such as one or more proteins; one
or more small molecule scaffolds; one or more supramolecular structure(s) such
as one or more nanoclusters; and/or one or more protein complexes.
154. The detection molecule according to any of the preceding items, wherein
the linker of the detection molecule comprises one or more beads.
155. The detection molecule according to any of the preceding items, wherein
the linker is a bead coated with streptavidin, such as streptavidin monomers or
tetramers, and the one or more binding molecules are biotinylated.
156. The detection molecule according to any of the preceding items, wherein
the linker is a bead coated with polysaccharide, such as a polysaccharide
comprising dextran moieties.
157. The detection molecule according to any of the preceding items, wherein
the one or more beads are selected from the groups consisting of beads that
carry electrophilic groups e.g. divinyl sulfone activated polysaccharide,
polystyrene beads that have been functionalized with tosyl-activated esters,
magnetic polystyrene beads functionalized with tosyl-activated esters, and
beads where binding molecules have been covalently immobilized to these by
reaction of nucleophiles comprised within the binding molecules with the
electrophiles of the beads.
58. The detection molecule according to any of the preceding items, wherein
the one or more beads is selected from the groups consisting of sepharose
beads, sephacryl beads, polystyrene beads, agarose beads, polysaccharide
beads, polycarbamate beads and any other kind of beads that can be
suspended in an aqueous buffer.
59. The detection molecule according to any of the preceding items, wherein
the linker comprises one or more compounds selected from the group
consisting of agarose, sepharose, resin beads, glass beads, pore-glass beads,
glass particles coated with a hydrophobic polymer, chitosan-coated beads, SH
beads, latex beads ,spherical latex beads, allele-type beads, SPA bead, PEG-
based resins, PEG-coated bead, PEG-encapsulated bead, polystyrene beads,
magnetic polystyrene beads, glutathione agarose beads, magnetic bead,
paramagnetic beads, protein A and/or protein G sepharose beads, activated
carboxylic acid bead, macroscopic beads, microscopic beads, insoluble resin
beads, silica-based resins, cellulosic resins, cross-linked agarose beads,
polystyrene beads, cross-linked polyacrylamide resins, beads with iron cores,
metal beads, dynabeads, Polymethylmethacrylate beads activated with NHS,
streptavidin-agarose beads, polypropylene, polyethylene, dextran, nylon,
amylases, natural and modified celluloses, nitrocellulose, polyacrylamides,
gabbros, magnetite, polymers, oligomers, non-repeating moieties, polyethylene
glycol (PEG), monomethoxy-PEG, mono-(Ci-Ci 0)alkoxy-PEG, aryloxy-PEG,
poly-(N-vinyl pyrrolidone)PEG, tresyl monomethoxy PEG, PEG
propionaldehyde, bis-succinimidyl carbonate PEG, polystyrene bead
crosslinked with divinylbenzene, propylene glycol homopolymers, a
polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g.,
glycerol), polyvinyl alcohol, dextran, aminodextran, carbohydrate-based
polymers, cross-linked dextran beads, polysaccharide beads, polycarbamate
beads, divinyl sulfone activated polysaccharide, polystyrene beads that have
been functionalized with tosyl-activated esters, magnetic polystyrene beads
functionalized with tosyl-activated esters, streptavidin beads, streptaivdin-
monomer coated beads, streptaivdin-tetramer coated beads, Streptavidin
Coated Compel Magnetic beads, avidin coated beads, dextramer coated beads,
divinyl sulfone-activated dextran, Carboxylate-modified bead, amine-modified
beads, antibody coated beads, cellulose beads, grafted co-poly beads, poly-
acrylamide beads, dimethylacrylamide beads optionally crosslinked with N-N'-
bis-acryloylethylenediamine, hollow fiber membranes, fluorescent beads,
collagen-agarose beads, gelatin beads, collagen-gelatin beads, collagen-
fibronectin-gelatin beads, collagen beads, chitosan beads, collagen-chitosan
beads, protein-based beads, hydrogel beads, hemicellulose, alkyl cellulose,
hydroxyalkyl cellulose, carboxymethylcellulose, sulfoethylcellulose, starch,
xylan, amylopectine, chondroitin, hyarulonate, heparin, guar, xanthan, mannan,
galactomannan, chitin and chitosan.
. The detection molecule according to any of the preceding items, wherein
the multimerization domain comprises one or more beads further comprises a
linker moiety.
. The detection molecule according to any of the preceding items, wherein
the multimerization domain comprises one or more beads comprising a linker
moiety which is a flexible linker, a rigid linker, a water-soluble linker or a
cleavable linker.
. The detection molecule according to any of the preceding items, wherein
the one or more linkers comprises a dimerization domain.
163. The detection molecule according to any of the preceding items, wherein
the one or more linkers comprises a trimerization domain.
164. The detection molecule according to any of the preceding items, wherein
the one or more linkers comprises a tetramerization domain.
165. The detection molecule according to any of the preceding items, wherein
the one or more linkers comprises a pentamerization domain.
166. The detection molecule according to any of the preceding items, wherein
the pentamerization domain comprises a coiled-coil polypeptide structure.
167. The detection molecule according to any of the preceding items, wherein
the one or more linkers comprises a hexamerization domain, such as a
hexamerization domain comprises three IgG domains.
168. The detection molecule according to any of the preceding items, wherein
the one or more linkers comprises a polyamide and/or a polyethylene glycol
and/or a polysaccharide and/or a sepharose.
169. The detection molecule according to any of the preceding items, wherein
the one or more linkers have a molecular weight of less than 1,000 Da.
170. The detection molecule according to any of the preceding items, wherein
the one or more linkers have a molecular weight of from 1,000 Da to preferably
less than 10,000 Da.
17 1 . The detection molecule according to any of the preceding items, wherein
the one or more linkers have a molecular weight of from 10,000 Da to
preferably less than 100,000 Da.
172. The detection molecule according to any of the preceding items, wherein
the one or more linkers have a molecular weight of from 100,000 Da to
preferably less than 1,000,000 Da.
173. The detection molecule according to any of the preceding items, wherein
the one or more linkers have a molecular weight of more than 1,000,000 Da.
174. The detection molecule according to any of the preceding items further
comprising one or more scaffolds, carriers, connectors and/or linkers selected
from the group consisting of streptavidin (SA) and avidin and derivatives
thereof, biotin, immunoglobulins, antibodies (monoclonal, polyclonal, and
recombinant), antibody fragments and derivatives thereof, leucine zipper
domain of AP-1 (jun and fos), hexa-his (metal chelate moiety), hexa-hat GST
(glutathione S-tranferase) glutathione affinity, Calmodulin-binding peptide
(CBP), Strep-tag, Cellulose Binding Domain, Maltose Binding Protein, S-
Peptide Tag, Chitin Binding Tag, Immuno-reactive Epitopes, Epitope Tags,
E2Tag, HA Epitope Tag, Myc Epitope, FLAG Epitope, AU1 and AU5 Epitopes,
Glu-Glu Epitope, KT3 Epitope, IRS Epitope, Btag Epitope, Protein Kinase-C
Epitope, VSV Epitope, lectins that mediate binding to a diversity of compounds,
including carbohydrates, lipids and proteins, e.g. Con A (Canavalia ensiformis)
or WGA (wheat germ agglutinin) and tetranectin or Protein A or G (antibody
affinity).
175. The detection molecule according to any of the preceding items, wherein
the binding molecule and/or the label comprises a connector molecule, such as
biotin, and the linker comprises a connector such as streptavidin or another
avidin connector.
176. The detection molecule according to any of the preceding items, wherein
the binding molecule is linked to at least one of the one or more multimerization
domains by a non-covalent linker moiety, such as natural dimerization or
protein-protein interactions.
177. The detection molecule according to any of the preceding items, wherein
the binding molecule is linked to at least one of the one or more multimerization
domains by a protein-protein interaction selected from the group consisting of
Fos/Jun interactions, Acid/Base coiled coil structure based interactions,
antibody/antigen interactions, polynucleotide-polynucleotide interactions,
synthetic molecule-synthetic molecule interactions and protein-small molecule
interactions.
178. The detection molecule according to any of the preceding items, wherein
the binding molecule is linked to at least one of the one or more multimerization
domains by natural dimerization selected from the group consisting of antigen-
antibody pairs, DNA-DNA interactions, natural interactions, biotin and
streptavidin.
179. The detection molecule according to any of the preceding items, wherein
the detection molecule further comprises an enzyme capable of catalysing the
transfer of a cell surface moiety (e.g. a peptide fragment or 'peptide tag') from a
cell surface protein to the binding molecule of the detection molecule, when
said surface moiety binds to the binding molecule.
180. The detection molecule according to any of the preceding items,
comprising
a . a monomeric or a multimeric major histocompatibility complex (MHC)
molecule, such as a monomeric or multimeric peptide MHC complex,
b. a linker comprising a multimerization domain and optionally one or more
connectors, and
c . a nucleic acid label.
18 1 . The detection molecule according to any of the preceding items,
comprising
a . a monomeric or a multimeric major histocompatibility complex (MHC)
molecule, such as a monomeric or multimeric peptide MHC complex,
b. a linker comprising a multimerization domain and optionally one or more
connectors, and
c . a peptide label.
182. The detection molecule according to any of the preceding items,
comprising
a . CD1 , wherein said CD1 is selected from the group consisting of CD1
CD1 a , CD1 b, CD1c, CD1d and CD1 e,
b. a linker comprising a multimerization domain and optionally one or more
connectors, and
c . a nucleic acid label.
183. The detection molecule according to any of the preceding items,
comprising
a . an anti-target molecule capable of associating with, recognizing and/or
binding to a predetermined marker molecule (or target) on a cell type,
wherein said marker molecule is specific for a certain cell type
b. a linker (Li) comprising a multimerization domain and optionally one or
more connectors, and
c . a nucleic acid label.
184. The detection molecule according to any of the preceding items, wherein
said linker comprising a multimerization domain and optionally one or more
connectors is a dextran optionally comprising streptavidin or avidin, and said
binding molecule and/or label optionally comprises biotin.
185. A kit of parts comprising
a . One or more detection molecules according to any of the preceding
items, and
b. one or more additional components.
186. The kit of parts according to any of the preceding items, wherein said one
or more additional components comprise reagents for detecting and/or
amplifying the label of the detection molecule.
187. The kit of parts according to any of the preceding items, wherein said one
or more additional components comprise reagents for detecting and/or
amplifying the nucleic acid label of the detection molecule.
188. The kit of parts according to any of the preceding items, wherein said
reagents for detecting the nucleic acid label of the detection molecule
comprises one or more primer sets capable of amplifying the nucleic acid label.
189. A detection method comprising the steps of
a . Combining a sample with at least one detection molecule; wherein the
detection molecule comprises a binding molecule (BM), a linker (Li), and
a label (La) according to any of the preceding items; and wherein said
sample comprises at least one cell and/or entity,
b. Incubating the at least one detection molecule and the sample;
c . Isolating and/or detecting the at least one detection molecule of step b),
and
d . Optionally determining the identity of the at least one detection molecule
of step c).
190. The detection method according to any of the preceding items, wherein in
step b) the one or more detection molecules are allowed to associate with,
recognize, and/or bind to said at least one cell and/or entity through their
binding molecule.
19 1 . The detection method according to any of the preceding items, wherein in
step c) and d) said detection molecule is comprised in a cell-detection molecule
complex or an entity-detection molecule complex.
192. The detection method according to any of the preceding items, wherein in
step c) and d) said detection molecule is not comprised in a cell-detection
molecule complex or an entity-detection molecule complex.
193. The detection method according to any of the preceding items, wherein in
step c) and d) said detection molecule is no longer comprised in a cell-detection
molecule complex or an entity-detection molecule complex, wherein said
detection molecule has previously interacted with a cell-detection molecule
complex or an entity-detection molecule complex.
194. The detection method according to any of the preceding items, wherein
said cell-detection molecule complexes comprises a cell, such as an immune
cell, associated with or bound to a detection molecule having a binding
molecule specific for the immune cell.
195. The detection method according to any of the preceding items, wherein
step c) comprises isolating and detecting the at least one detection molecule.
196. The detection method according to any of the preceding items, wherein
step c) comprises first isolating and then detecting the at least one detection
molecule.
197. The detection method according to any of the preceding items, wherein
step c) comprises detecting the at least one detection molecule.
198. The detection method according to any of the preceding items, wherein
step c) comprises isolating the at least one detection molecule.
199. The detection method according to any of the preceding items, wherein
step c) comprises first detecting and then isolating the at least one detection
molecule.
200. The detection method according to any of the preceding items, wherein in
step c) isolating comprises flow cytometry and/or FACS sorting
201 . The detection method according to any of the preceding items, wherein in
step c) isolating comprises one or more steps of washing, centrifugation and/or
precipitation.
202. The detection method according to any of the preceding items, wherein in
step c) isolating comprises one or more steps of filtration.
203. The detection method according to any of the preceding items, wherein in
step c) isolating comprises one or more steps of application on an affinity
column.
204. The detection method according to any of the preceding items, wherein in
step c) isolating comprises sorting of cell populations based on the functional
response to a stimuli (responsive or non-responsive population), such as
cytokine secretion, phosphorylation, calcium release.
205. The detection method according to any of the preceding items, wherein in
step c) isolating comprises sorting of cell populations based on phenotype, such
as by linking a certain set of phenotypic characteristics to the antigen-
responsiveness.
206. The detection method according to any of the preceding items, wherein in
step c) isolating comprises immobilization of the detection molecule and/or cell-
detection molecule complexes.
207. The detection method according to any of the preceding items, wherein
said immobilization of the cell-detection molecule complexes comprises
precipitating cells, such as by centrifugation, by immunoprecipitation, or any
other means that precipitates the cells.
208. The detection method according to any of the preceding items, wherein
said immobilization of the cell-detection molecule complexes comprises binding
the cell-detection molecule complexes to a bead, a particle, another surface, an
antibody or an MHC complex.
209. The detection method according to any of the preceding items, wherein
said immobilization of the detection molecule and/or cell-detection molecule
complexes comprises hybridization onto an array.
2 10 . The detection method according to any of the preceding items, wherein
said immobilization of the detection molecule and/or cell-detection molecule
complexes by hybridization onto an array comprises a nucleic acid/nucleic acid-
interaction between the nucleic acid label of the detection molecule and an
antisense nucleic acid sequence in the array.
. The detection method according to any of the preceding items, wherein
said immobilization of the detection molecule and/or cell-detection molecule
complexes by hybridization onto an array comprises a DNA/DNA-interaction
between the DNA label of the detection molecule and an antisense DNA in the
array.
. The detection method according to any of the preceding items, wherein
said detecting in step c) and/or determining the identity in step d) comprises
one or more steps of adding primary antibodies that bind to the immobilized
detection molecule and/or cell-detection molecule complexes and detecting said
primary antibodies directly wherein the primary antibody is labelled, or indirectly
by adding labelled secondary antibodies.
. The detection method according to any of the preceding items, wherein
said detecting in step c) and/or determining the identity in step d) comprises
one or more steps of detecting the immobilized detection molecule and/or cell-
detection molecule complexes by monitoring read-out from a second label such
as a fluorophore.
. The detection method according to any of the preceding items, wherein
said detecting in step c) and/or determining the identity in step d) comprises
one or more steps of determining the identity of said label.
. The detection method according to any of the preceding items, wherein
said detecting in step c) and/or determining the identity in step d) comprises
interaction between 'coating DNA' on the cell surface and the DNA label of the
detection molecule.
216. The detection method according to any of the preceding items, wherein
said detecting in step c) and/or determining the identity in step d) comprises
protease cleavage of the peptide label of the detection molecule.
217. The detection method according to any of the preceding items, wherein
said detecting in step c) and/or determining the identity in step d) comprises
transfer of a cell surface moiety to the detection molecule (e.g. a 'peptide tag').
218. The detection method according to any of the preceding items, wherein
said detecting in step c) and/or determining the identity in step d) comprises
detection of the label based on the physical characteristics of the label,
including mass, sequence, charge, volume, size, dimensions, fluorescence,
absorption, emission, NMR spectra and others.
219. The detection method according to any of the preceding items, wherein
said detecting in step c) and/or determining the identity in step d) comprises
amplification of the label.
220. The detection method according to any of the preceding items, wherein
said detecting in step c) and/or determining the identity in step d) comprises
sequencing of the label (e.g. DNA sequencing, peptide sequencing).
221 . The detection method according to any of the preceding items, wherein
said detecting in step c) and/or determining the identity in step d) comprises
amplification of the barcode sequence of a nucleic acid label by PCR and/or
sequencing of the barcode sequence.
222. The detection method according to any of the preceding items, wherein
said sequencing comprises deep sequencing or next generation sequencing.
223. The detection method according to any of the preceding items, wherein
said detecting in step c) and/or determining the identity in step d) comprises
mass spectrometry.
224. The detection method according to any of the preceding items, wherein
said detecting in step c) and/or determining the identity in step d) comprises
one or more of gel electrophoresis, gel filtration, PAGE, column fractionation,
PCR and QPCR.
225. The detection method according to any of the preceding items, said
method further comprising one or more steps of providing a sample, preferably
a sample comprising at least one entity and/or at least one cell.
226. The detection method according to any of the preceding items, said
method further comprising one or more steps of pre-treatment of the sample,
and/or pre-treatment of cells of the sample.
227. The detection method according to any of the preceding items, said
method further comprising one or more steps of separating unbound detection
molecules from cell- or entity-detection molecule complexes.
228. The detection method according to any of the preceding items, said
method further comprising one or more steps of removing unbound detection
molecules by washing and/or centrifuging.
229. The detection method according to any of the preceding items, said
method further comprising one or more steps of single-cell sorting and
sequencing.
230. The detection method according to any of the preceding items, said
method further comprising one or more steps of single-cell T cell sorting of and
single-cell TCR sequencing.
231 . The detection method according to any of the preceding items, wherein
said sample comprises one or more cells.
232. The detection method according to any of the preceding items, wherein
said sample comprises at least one cell and/or entity to which the binding
molecule of the detection molecule is able to associate with, recognize and/or
bind.
233. The detection method according to any of the preceding items, wherein
said sample is selected from the group consisting of a solid sample, a fluid
sample, a semifluid sample, a liquid sample, a solubilised sample and a sample
comprising dissociated cells of a solid sample.
234. The detection method according to any of the preceding items, wherein
said sample is selected from the group consisting of a biofilm, a biopsy, a
surgical sample, a tissue sample, a microarray-fixed sample, a section such as
a fresh section, a frozen section and a FFPE section.
235. The detection method according to any of the previous items, wherein
said sample is selected from the group consisting of blood, whole blood,
plasma, serum, Peripheral blood mononuclear cells (PBMC), human PBMN
(HPBMC), buffy coat, synovial fluid, bone marrow, cerebrospinal fluid, saliva,
lymph fluid, seminal fluid, urine, stool, exudate, transdermal exudates,
pharyngeal exudates, nasal secretions, sputum, sweat, bronchoalveolar lavage,
tracheal aspirations, fluid from joints, vitreous fluid, vaginal or urethral
secretions or semen.
236. The detection method according to any of the previous items, wherein
said sample comprises cell populations isolated from a fluid, a semifluid sample
or a solid sample.
237. The detection method according to any of the previous items, wherein
said cell is selected from the group consisting of immune cells, lymphocytes,
monocytes, dendritic cells, T-cells, B-cells and NK cells
238. The detection method according to any of the previous items, wherein
said cell is a T-cell, such as a T cell selected from the group consisting of CD4+
T cells, CD8+ T cells, αβ T cells and invariant γ δ T cells.
239. The detection method according to any of the previous items, wherein
said cell is an antigen-specific T-cell or antigen-responsive T cell.
240. The detection method according to any of the previous items, wherein
said cell comprises T-cell receptors.
241 . The detection method according to any of the previous items, wherein
said cell is a cancer cell.
242. The detection method according to any of the previous items, wherein
said sample is derived from an organ selected from the group consisting of
lymph nodes, kidney, liver, skin, brain, heart, muscles, bone marrow, skin,
skeleton, lungs, the respiratory tract, spleen, thymus, pancreas, exocrine
glands, bladder, endocrine glands, reproduction organs including the phallopian
tubes, eye, ear, vascular system, the gastroinstestinal tract including small
intestines, colon, rectum, canalis analis and prostate gland.
243. The detection method according to any of the previous items, wherein the
surface of sample cells is coated with proteases capable of cleaving a peptide
label, for example by adding antibody-protease conjugates where the antibody
recognizes a particular cell surface structure.
244. The detection method according to any of the previous items, wherein the
surface of sample cells is coated with DNA oligonucletides ("coating DNA"), for
example by adding antibody-DNA conjugates where the antibody recognizes a
particular cell surface structure.
245. A method for detecting antigen-specific T cells in a sample, said method
comprising providing a detection molecule and a detection method according to
any of the preceding items.
246. A method for detecting specific cells in a sample, said method
comprising providing a detection molecule and a detection method according to
any of the preceding items.
247. A method for diagnosing a disease, said method comprising providing a
detection molecule and a detection method according to any of the preceding
items.
248. A method for diagnosing a disease according to the previous items,
wherein said disease is selected from the group consisting of cancer,
Cancerous diseases, infectious diseases, Infectious diseases caused by virus,
Infectious diseases caused by bacteria, Infectious diseases caused by fungus,
Parasitic diseases, Allergic diseases, Transplantation-related diseases and
Autoimmune and inflammatory diseases.
249. A method for detecting the presence and/or abundance of a certain cell or
cell type in a sample, said method comprising providing a detection molecule
and a detection method according to any of the preceding items, wherein said
detection molecule comprises a binding molecule capable of associating
specifically with the cell or cell type in said sample
250. A method for investigating the binding characteristics of a certain cell or
cell type in a sample, said method comprising providing a detection molecule
and a detection method according to any of the preceding items, wherein said
detection molecule comprises a binding molecule capable of associating
specifically with a known target.
251 . A method for the identification of epitopes comprising providing a
detection molecule and a detection method according to any of the preceding
items
252. A method for vaccine development comprising providing a detection
molecule and a detection method according to any of the preceding items.
253. A method for measuring immune reactivity after vaccination comprising
providing a detection molecule and a detection method according to any of the
preceding items.
. A method for development of immune-therapeutics comprising providing
a detection molecule and a detection method according to any of the preceding
items.
Claims
1. A detection molecule comprising
a . at least one binding molecule (BM),
b. at least one linker (Li), and
c . at least one label (La).
2 . A composition comprising two or more different detection molecules, or two or
more sets of different detection molecules, each detection molecule comprising
at least one binding molecule (BM), at least one linker (Li) and at least one label
(La),
wherein each of the two or more detection molecules, or two or more sets of
detection molecules, comprises a label which is unique to and specific for the
binding molecule of each of said two or more different detection molecules.
3 . The detection molecule according to the preceding claims, wherein said label is
selected from the group consisting of a DNA label, a nucleic acid label, an RNA
label, an artificial nucleic acid label, a peptide label, a fluorescent label, heavy
metal labels, isotope labels, radiolabels, radionuclide, stable isotopes, chains of
isotopes and single atoms.
4 . The detection molecule according to any of the preceding claims, wherein said
label is a nucleic acid label comprising at least a barcode region and optionally
one or more of
a . 5' first primer region (forward)
b. 3' second primer region (reverse),
c . random nucleotide region,
d . connector molecule
e. stability-increasing components
f . short nucleotide linkers in between any of the above-mentioned
components
g . adaptors for sequencing
h . annealing region
5 . The detection molecule according to any of the preceding claims, wherein said
binding molecule associates with, recognizes and/or binds to a marker molecule
specific for a given cell or cell type.
The detection molecule according to the preceding claims, wherein said binding
molecule associates with, recognizes and/or binds to a marker molecule
specific for an immune cell, such as an immune cell selected from the group
consisting of lymphocytes, monocytes, dendritic cells, T-cells, B-cells, NK cells,
CD4+ T cells, CD8+ T cells, αβ T cells, invariant γ δ T cells, and antigen-specific
T-cells.
The detection molecule according to the preceding claims, wherein said binding
molecule associates with, recognizes and/or binds to a cluster of differentiation
molecule.
The detection molecule according to claim 7 , wherein said cluster of
differentiation molecule is selected from the group consisting of CD1-1 0 , CD1 0-
20, CD20-30, CD30-40, CD40-50, CD50-100, CD1 00-200, CD200-300 and
CD300-364.
The detection molecule according to the preceding claims, wherein said binding
molecule is selected from the group consisting of an antibody, an antibody
mimetic, an antibody-like molecule, a peptide, an oligonucleotide, a peptide
aptamer, a nucleic acid aptamer, a DNA aptamer, an RNA aptamer, an XNA
aptamer, a ligand, a natural ligand, a variant or fragment of a natural ligands, a
synthetic ligand and a small organic molecule.
10 . The detection molecule according to the preceding claims, wherein said binding
molecule is a MHC complex.
11. The detection molecule according to the preceding claims, wherein said binding
molecule is a MHC-like molecule.
12. The detection molecule according to the preceding claims, wherein said binding
molecule is CD1 , wherein said CD1 is selected from the group consisting of
CD1 CD1a, CD1b, CD1c, CD1d and CD1e.
13. The detection molecule according to any of the preceding claims, wherein said
linker is a molecular entity and/or bond that connects the binding molecule and
the label.
14. The detection molecule according to any of the preceding claims, wherein said
linker comprises one or more multimerization domains and optionally one or
more connector molecules.
15. The detection molecule according to claim 14, wherein said multimerization
domain comprises polysaccharides such as dextrans.
16. The detection molecule according to claim 14-15, wherein said connector
molecule comprises streptavidin and/or avidin.
17 . The detection molecule according to any of the preceding claims, wherein said
binding molecule and/or label comprises biotin.
18. The detection molecule according to any of the preceding claims comprising
a .An anti-CD molecule, which specifically associates with, recognizes
and/or binds to a cluster of differentiation molecule,
b. a linker comprising a multimerization domain and optionally one or more
connectors, and
c . a nucleic acid label.
19 . The detection molecule according to any of the preceding claims comprising
a . CD1 , wherein said CD1 is selected from the group consisting of CD1
CD1 a , CD1 b, CD1c, CD1d and CD1 e,
b. a linker comprising a multimerization domain and optionally one or more
connectors, and
c . a nucleic acid label.
20. A detection method comprising the steps of
a . Combining a sample with at least one detection molecule; wherein the
detection molecule comprises a binding molecule (BM), a linker (Li), and
a label (La) according to any of the preceding claims; and wherein said
sample comprises at least one cell and/or entity,
b. Incubating the at least one detection molecule and the sample;
c . Isolating and/or detecting the at least one detection molecule of step b),
and
d . Optionally determining the identity of the at least one detection molecule
of step c).
2 1. The detection method according to claim 20, wherein in step c) isolating
comprises one or more methods selected from flow cytometry, FACS sorting,
washing, centrifugation, precipitation, filtration, affinity column, sorting of cell
populations based on the functional response to a stimuli, sorting of cell
populations based on phenotype and immobilization of the detection molecule
and/or cell-detection molecule complexes.
22. The detection method according to claim 2 1 , wherein said immobilization of the
detection molecule and/or cell-detection molecule complexes comprises
hybridization onto an array.
23. The detection method according to claim 22, wherein said hybridization onto an
array comprises a nucleic acid/nucleic acid-interaction between the nucleic acid
label of the detection molecule and an antisense nucleic acid sequence in the
array.
24. The detection method according to claim 23, further comprising one or more
steps of adding primary antibodies that bind to the immobilized detection
molecule and/or cell-detection molecule complexes and detecting said primary
antibodies directly wherein the primary antibody is labelled, or indirectly by
adding labelled secondary antibodies.
25. The detection molecule according to any of the preceding claims, wherein said
detecting in step c) and/or determining the identity in step d) comprises one or
more steps of amplification of the label, sequencing of the label (e.g. DNA
sequencing, peptide sequencing), mass spectrometry, gel electrophoresis, gel
filtration, PAGE, column fractionation, PCR and QPCR.
26. The detection method according to any of the preceding claims, said method
further comprising one or more steps of single-cell sorting and sequencing.
27. The detection method according to claim 26, comprising one or more steps of
single-cell T cell sorting of and single-cell TCR sequencing.
28. The detection method according to any of the preceding claims, wherein said
sample is selected from the group consisting of a biofilm, a biopsy, a surgical
sample, a tissue sample, a microarray-fixed sample, a section such as a fresh
section, a frozen section, a FFPE section, blood, whole blood, plasma, serum,
Peripheral blood mononuclear cells (PBMC), human PBMN (HPBMC), buffy
coat, synovial fluid, bone marrow, cerebrospinal fluid, saliva, lymph fluid,
seminal fluid, urine, stool, exudate, transdermal exudates, pharyngeal
exudates, nasal secretions, sputum, sweat, bronchoalveolar lavage, tracheal
aspirations, fluid from joints, vitreous fluid, vaginal or urethral secretions and
semen.
29. A method for detecting specific cells in a sample, said method comprising
providing a detection molecule and a detection method according to any of the
preceding items.
30. A multimeric major histocompatibility complex (MHC) comprising
- two or more MHC molecules linked by a backbone molecule; and
- at least one nucleic acid molecule linked to said backbone, wherein said nucleic
acid molecule comprises a central stretch of nucleic acids (barcode region)
designed to be amplified by e.g. PCR.
3 1. The multimeric major histocompatibility complex according to claim 30, wherein
the backbone molecule is selected from the group consisting of
polysaccharides, such as glucans such as dextran, a streptavidin or a
streptamer multimer.
32. The multimeric major histocompatibility complex according to claim 30 or 3 1,
wherein the MHC molecules are coupled to the backbone through a
streptavidin-biotin binding and/or streptavidin-avidin and/or via the MHC heavy
chain and/or via light chain (B2M).
33. The multimeric major histocompatibility complex (MHC) according to any of the
preceding claims, wherein said multimeric MHC is composed of at least four
MHC molecules, such as at least eight, such as at least ten, 2-30, 2-20, such as
2-1 0 , such as 4-1 0 or such as 15-30 MHC molecules.
34. The multimeric major histocompatibility complex (MHC) according to any of the
preceding claims, wherein the at least one nucleic acid molecule is composed
of at least a 5' first primer region, a central region (barcode region), and a 3'
second primer region.
35. The multimeric major histocompatibility complex (MHC) according to any of the
preceding claims, wherein the at least one nucleic acid molecule has a length in
the range 20-200 nucleotides, such as 20-150, such as 20-100 , such as 30-
100, such as 30-80, such as 30-50 nucleotides.
36. The multimeric major histocompatibility complex (MHC) according to any of the
preceding claims, wherein the at least one nucleic acid molecule is linked to
said backbone via a streptavidin-biotin binding and/or streptavidin-avidin
binding.
37. The multimeric major histocompatibility complex (MHC) according to any of the
preceding claims, wherein the at least one nucleic acid molecule comprises or
consists of DNA, RNA, and/or artificial nucleotides such as PNA or LNA.
38. The multimeric major histocompatibility complex (MHC) according to any of the
preceding claims, wherein the MHC is selected from the group comprising class
I MHC, a class I I MHC, a CD1 , or other MHC-like molecules.
39. The multimeric major histocompatibility complex (MHC) according to any of the
preceding claims, wherein the backbone further comprises one or more linked
fluorescent labels and/or His-tags, and/or metalion tags, and/or other selectable
tags or labels.
40. A composition comprising:
i . a subset of multimeric major histocompatibility complexes (MHC molecules)
according to any of claims 30-39, wherein each subset of MHC molecules
has a different peptide decisive for T cell recognition and
ii. a nucleic acid molecule comprising a central stretch of nucleic acids
(barcode region).
4 1. The composition according to claim 40, comprising at least 10 different subsets
of MHC molecules such as at least 100, such as at least 500, at least 1000, at
least 5000, such as in the range 10-100000, such as 10-50000, such as 10-
1000 or such as 50-500 sets of MHC molecules.
42. A method for detecting antigen responsive cells in a sample comprising:
i) providing one or more multimeric major histocompatibility complexes
(MHC molecules) according to any of claims 30-39 or a composition
according to any of claims 40-41 ;
ii) contacting said multimeric MHC molecules with said sample; and
iii) detecting binding of the multimeric MHC molecules to said antigen
responsive cells, thereby detecting cells responsive to an antigen
present in a set of MHC molecules, wherein said binding is detected by
amplifying the barcode region of said nucleic acid molecule linked to the
one or more MHC molecules through the backbone molecule.
43. The method according to claim 42, wherein the sample is a blood sample, such
as a peripheral blood sample, a blood derived sample, a tissue sample or body
fluid, such as spinal fluid, or saliva.
44. The method according to any of claims 42-43, wherein said sample has been
obtained from a mammal, such as a human, mouse, pigs, and/or horses.
45. The method according to any of claim 42-44, wherein the method further
comprises cell selection by e.g. flow cytometry such as FACS, magnetic-bead
based selection, size-exclusion, gradient centrifugation, column attachment or
gel-filtration.
46. The method according to any of claims 42-45, wherein said binding detection
includes comparing measured values to a reference level, e.g. a negative
control and/or total level of response.
47. The method according to any of claim 42-46, wherein said amplification is PCR
such as QPCR.
48. The method according to any of claims 42-47, wherein the detection of barcode
regions includes sequencing of said barcode region, by deep sequencing, high-
throughput sequencing or next generation sequencing, or detection of said
barcode region by QPCR,
49. Use of a multimeric major histocompatibility complex (MHC) according to any of
claims 30-39 or a composition according to any of claims 40-41 for the
detecting of antigen responsive cells in a sample.
50. Use of a multimeric major histocompatibility complex (MHC) according to any of
claims 30-39 or a composition according to any of claims 40-41 in the diagnosis
of diseases or conditions, preferably cancer and/or infectious diseases.
5 1. Use of a multimeric major histocompatibility complex (MHC) according to any of
claims 30-39 or a composition according to any of claims 40-41 in the
development of immune-therapeutics, and/or development of vaccines, and/or
identification of epitopes.





















